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1.1 | Introduction 
Revolutionary insights of the human microbiome, the conglomeration of microorganisms 
that stably occupy an expansive array of anatomical locations of the human body, have 
certified the phenomenon as an integral component of human biology. As progress has 
been made in elucidating the various factors of influence that the microbiome imposes on 
human health, it has become apparent that modulation of the community structure and 
functional activity of the microbiome is an essential step in utilizing these microbes as an 
element of intervention in healthcare. Advancement in understanding of how the 
microbiome is manipulated is accordingly of great interest and importance. 
1.2 | Methods 
Physical activity is a recently emergent prospective modulator of the human intestinal 
microbiome. This development in microbiome-host interaction presents great potential, but 
has presently been investigated in limited depth. To expand the understanding of this 
biological dynamic we engaged the subject with focus on metabolic function of the 
microbiome, utilising advanced computation methods and molecular technologies. Our 
approach has sought to address multiple aspects of exercise induced microbiome alteration, 
and accordingly was conducted with randomized control trials and prospective observa-




1.3 | Results 
This work describes further evidence that physical exercise has a role in directing the 
community structure and metabolic activity of the gut microbiome. Our inspection of 
professional athletes, whose prolonged engagement in rigorous exercise grants perspective 
of the extreme end of the spectrum of physical activity, revealed a divergent microbiome 
from that of more sedentary controls. Metabolic pathways from the athletes were 
configured to offer enhanced energy recovery from the intestinal environment. Quantified 
metabolomic phenotyping of this system similarly revealed that the athlete microbiome had 
a favourable profile of SCFA enrichment. 
 Examination of structured short-term exercise on exercise naïve individuals revealed 
subtle alterations of the microbiome, both in terms of phylogenetic composition and 
metabolic output. In our investigation it was also observed for the first time that supple-
mentation of whey protein resulted in an alteration of the virome. Further sequencing of the 
supplement itself revealed a highly similar viral composition to the participants, suggesting 
that whey protein, a widely used supplement, is directly transmitting virus particles. 
To explore the implementation of exercise as a supportive intervention for health 
conditions related to the GI system, patients with inflammatory bowel disease (IBD) were 
recruited for a short-term exercise intervention study. While minimal changes in the 
composition of the IBD patients’ gut microbiome were identified, the patients were shown 
to undergo the treatment without insult to, or perturbation of their disease state. This 
important finding illustrates that sufferers of IBD can engage in physical exercise, reaping 





Elucidation of the longitudinal effects of exercise on the gut microbiome was 
achieved through the examination of two individuals engaging in exercise over the course 
of six months. Through this N of 1 style of study, resources were concentrated on the two 
participants, enabling the acquisition of much greater detail on the proposed question. Here 
again, it was observed that while the participants were rewarded with improvements in 
health parameters, changes of the gut microbiome were subtle. 
Complementing the impressive results produced from initial investigations of pro-
fessional athletes, effort was put forth to apply advanced computational approaches to the 
previously generated data in order to advance understanding of the athlete microbiome. A 
novel algorithm designed to predict adherence to healthy dietary habits based on 
metabolomic profiling was used to better define dietary influence on the metabolomic 
dynamics of the gut environment. Separately, a computational modelling method centred 
on Flux Balance Analysis generated models of microbial metabolic exchange within the 
athletes and corresponding controls.  
1.4 | Conclusions 
The findings supporting this thesis have immediate relevance in the area of athleticism, 
with implications for professional athletes and individuals casually engaged in exercise. 
There is further impetus provided for continued investigation of the athlete microbiome, the 
influence of prolonged periods of exercise on populations with low fitness levels, and the 
impact of dietary supplement derived microbe transmission. 
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Chapter 1  
―― 
INTRODUCTION AND BACKGROUND 
1.1 | Abstract 
The human enteric microbiome has been identified as having key roles in health and 
numerous diseases. Comprised of trillions of microbial cells and viral particles, the 
microbiome represents a bioactive ecosystem of exceedingly high complexity. Investigation 
of the importance of enteric microbes has progressed through culture dependant (e.g. 
media-based methods) and molecular (e.g. genetic sequencing and metabolomic analysis) 
techniques. The latter have become increasingly popular and evolved from being used for 
taxonomic identification of microbiota to elucidation of functional capacity (sequencing) 
and metabolic activity (metabolomics). 
The following chapter provides details of this thesis; the core rationale behind it, 
outcomes of its course, and an outline of its structure. Following this description, an 
overview of the metabolic capabilities of the gut microbiome will be presented in the 
context of health and disease. 
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1.4 | Introduction 
Microbial communities are ubiquitously integrated with the physical world we oc-
cupy, and indeed, are intricately linked to our corporeal forms [1-10]. Comprised of 
numerous phylogenetic lineages, such as protozoa [11-16], fungi [17-20], viruses [21-24], and 
prokaryota [25-29], these microbiome communities exist in complex ecological states, with 
widely varying capacities of function [29-34]. While the influences of these microbial 
systems are intently studied in diverse research areas, such as food [7, 35], agriculture [36], 
and ecology [37], all with profound implications, the microbiome as it pertains to human 
health has gained immense momentum as an area of research. Underlying the human 
microbiome is recognition that the microbial communities integrated throughout the human 
body act as important factors in metabolic function, essentially operating as previously 
unknown organs [38-43]. Unlike the mammalian components of the human body, the 
microbiome can be modified to achieve specific health aims. Specifically, the use of 
pharmaceuticals [44-46], pre- and probiotics [47-49], diet [50-55], and exercise [56-61] can be 
utilised to alter the composition and function of the microbiome. The latter of which, 
exercise, has particular importance in this regard due to the numerous benefits exerted by 
the behaviour on its own, such as with brain function [62], immunity [63], and metabolism 
[64, 65]. To this end, the current chapter and the thesis it introduces outlines advances made 
towards interaction of exercise and the human gut microbiome. 
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1.5 | Purpose of research 
The primary aim of this thesis is to elaborate on the understanding of the human gut 
microbiome in its relation to physical activity and diet. In particular, the effort of 
investigating the diet and exercise—microbiome paradigm has been driven by the utilization of 
computationally centred practices and methodologies. As with many areas of the 
microbiome, advances in high-throughput technologies (e.g. shotgun metagenomic 
sequencing) have enabled researchers to probe inquiries with unprecedented depth, while 
simultaneously creating a bottleneck with the volume of data generated. As such, 
navigation of complex high-volume data has become a limiting factor in the perpetuation of 
research (i.e. drawing evidence for hypotheses, disseminating results, and laying 
groundwork for the generation of further inquiries). 
1.6 | Thesis structure 
The final portions of this chapter will establish the base knowledge underpinning this 
thesis, describing the current relevant information related to the interaction of the human 
gut microbiome and host physiology. Specific attention is given to the microbiome of the 
gastrointestinal system and its relation to physical activity (i.e. exercise). 
Prior to description of experimental work in chapters 3-8, materials and methods 
utilised throughout the course of this PhD are outlined in chapter 2. Beginning with chapter 
3, the first such investigation within this thesis of professional athletes is presented. Here, 
via combined metabolomic and metagenomic analysis, the functional capacity of the elite 
athlete gut microbiome was presented for the first time. Chapter 4 continues the exploration 
of the elite athlete microbiome with the application of a novel mathematical tool for dietary 
analysis based on urine metabolomic profile with the professional athlete cohort and 
accompanying controls. Similarly, chapter 5 applies the flux balance analysis (FBA) 
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metabolomic modelling approach to the original high-throughput sequencing data 
generated from the elite athletes. 
 Beginning with chapter 6, the focus of this thesis shifts from the investigation of 
professional athletes to exercise naïve individuals. Chapter 6, the first such entry, describes 
an intervention study in unfit, but otherwise healthy adults. Here, participants were subject 
to treatment of a structured exercise regime, whey protein supplementation, or both. The 
study revealed modest influence of exercise on the gut microbiome, however for the first 
time, reported that viral particles in whey protein transfer to humans via consumption. 
Chapter 7 continues in this vein with an exercise intervention in adult patients with 
inflammatory bowel disease. In this chapter, it is revealed that short –term exercise confers 
no insult to disease state or composition of gut microbiome in IBD patients, while still 
granting the well documented positive influence of physical activity on health. Concluding 
the description of experimental efforts, chapter 8 details an n of 1 type study in which two 
individuals were prospectively examined over the course of 6 months. With this approach 
resources were focused on the two participants, granting more elaborate assessment of 
longitudinal influences of moderate intensity self-structured exercise. Finally, chapter 9 
concludes this thesis, with discussion of the cumulative implications of previous chapters, 
and consideration of future directions.  
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1.7 | The human microbiome as it relates to metabolic function and health 
It has been established that communities of microorganisms, microbiomes, reside on 
or within nearly every physical substrate on our planet (and associated artificial satellites) 
[1-10]. The importance of the microbiome as an integral component of the human biological 
system has become clear, not only to microbiologists, but to clinicians and the general 
public. Encompassing multiple divisions of the tree of life such as protozoa [11-16], fungi 
[17-20], viruses [21-24], and prokaryota [25-29], microbiomes consist of compositions of 
microorganisms in various ecological structures and functional capacities [29-34]. 
Comprehension of the microbiome’s vast influence on human health has become 
formidably wide. Accordingly, the ever expansive sum of such information presents a 
continuously growing hurdle in the field for those involved in the field to overcome. The 
remainder of this chapter aims to offer essential background to the human microbiome, 
providing overview of microbiomes delineated by human anatomy within the framework 
of microbe-host metabolic interaction. 
1.7.1 | Membership 
Within the context of human health, protozoa have historically been regarded as 
opportunistic parasites, acting as agents of disease [14, 16, 66-69]. Notable examples of 
protists implicated in morbidity include Giardia, Entamoeba histolytica, and Cryptosporidium 
[16, 66-68]. A feature common to infections with these organisms is invasion of the 
gastrointestinal (GI) mucosa, resulting in diarrhoea. Inconsistencies in the development and 
presentation of symptoms in response to infection, along with disagreement on phylogenet-
ic classification of the organisms, have led to an incomplete acceptance of the etiological role 
of the protozoa in disease. In contrast, there is evidence for a protective role of a commensal 
protist, Tritrichomonas musculis (T. musculis) in murine models [14, 15]. Intestinal coloniza-
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tion of non-human animals with T. musculis produced a host-protective immunological 
response, which attenuated the deleterious effects of a challenge with Salmonella [15]. 
The fungal microbiome, or mycobiome, like that of the protozoan contribution to the 
microbiome, is incompletely understood. As shortcomings of the selective nature of culture-
dependent methods for taxonomic profiling were relocated to the past for prokaryotic 
organisms with the revolution of 16S sequencing, the fungal counterpart of the 16S rRNA 
gene, the internal transcribed spacers (ITS) rRNA gene loci have received less attention in 
terms of supporting sequence analysis software, and databases [19, 70]. Although the 
catalogue of taxonomic members of the human mycobiome is still expanding, the role of 
Candida species in health has been relatively well characterised. While present at various 
anatomical sites as a stable constituent of the human microbiome, aberrations in Candida 
abundance and morphology increase pathogenicity of the organism, which, regardless of 
immunocompetency can result in infection with widely varying virulence [18-20, 32, 71]. 
Within the GI tract, pathogenicity of Candida has been shown, in part, to be regulated by 
Lactobacillus species. Although the precise mechanism remains unknown, it is evident that 
some lactobacilli suppress Candida through host epithelial immunomodulation and 
competition for epithelial adherence [48, 72-74]. Advantageously reducing competition for 
proliferation at the epithelium, lactobacilli interfere with hyphal formation of Candida with 
the production of SCFAs and exopolysaccharides (EPS) [72, 74]. 
Viral infections are a significant cause of human disease and morbidity [22, 23, 75]. 
Despite the challenges viruses pose to health, it has become evident that bacteriophage, 
virus particles that target bacteria, have a beneficial role in the microbiome. Indeed, these 
viruses that attack bacteria may be harnessed for therapeutic use. Bacteriophage are both 
highly efficient and specific. Each virus will typically infect only a small number of bacterial 
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strains. Elimination of bacterial cells occurs via lysis, resulting from propagation of viral 
particles within the infected cell. Publically disclosed in 1915, the discovery of bacterio-
phage preceded that of antibiotic drugs by over a decade [76-78]. Despite this, therapeutic 
use of bacteriophage has historically been overshadowed by antibiotics. A revival of interest 
in bacteriophage therapy has been driven by the emergence of antibiotic resistance and 
limitations in novel antibiotic discovery [30, 79-82]. In addition to the therapeutic potential 
of bacteriophage, the viruses integrally influence the larger microbial community through 
transmission of genetic material between hosts (e.g. antibiotic-resistance genes), and 
lowering host density via lysis [83]. 
Each known component of the microbiome presents specific challenges in its inves-
tigation and role in human health. Bacteria, however, are understood as the predominate 
drivers of the microbiome, and thus, are the focal point of microbiome research [25-27, 29, 
84]. 
1.7.2 | Womb to Tomb 
Present from birth to death, an individual’s microbiome maintains a constant pres-
ence as a chimeric organ [39, 40, 43, 85]. Seeding of this microbial system occurs at the 
beginning of life with birth, via transmission of a mother’s microbiome to her infant during 
the birthing process [86-90]. Influenced by direct environmental transmission, a delivered 
infant will inherit either the mother’s vaginal and faecal microbiota as it passes through the 
birthing canal, or the skin microbiota during caesarean delivery [86-88]. Either route of 
delivery imposes prolonged multi-faceted effects on the infant [91, 92]. Vaginal birth confers 
a microbiome of the mother’s urogenital system which has undergone specific alterations 
throughout the pregnancy that are conducive to the development of robust and functional 
immune and GI systems of the infant [89]. Alternatively, numerous deleterious health 
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effects for infants delivered by caesarean section have been identified. Immediate influences 
upon the infant include increased risk of exposure to antibiotic resistant bacteria from the 
mother’s skin [87]. Long-term insults to health arising from caesarean delivery include 
greater risk of developing obesity, sensitivity to food and inhalant allergens, and asthma 
[91-95]. In light of increasing awareness of potential negative health effects associated with 
caesarean delivery, an experimental procedure of vaginal seeding has been developed to 
simulate the microbial exposures present in vaginal birth via administration of vaginal 
swabs to newly-delivered infants [96]. Implementing vaginal seeding is an issue of 
contention, and many clinical practitioners are wary of the intervention prior to elaborate 
investigation of its effects [97, 98]. 
Throughout infancy, an individual’s core microbiome is continuously influenced by 
the mother and environment. Whether nourished by the mother’s natural breast milk or 
formula, the infant microbiome continues to be moulded through supplied nutrition. In this 
regard, a positive health bias towards biological ‘tradition’ persists, as both the process of 
breast feeding and breast milk itself, convey health benefits superior to formula [89, 99, 100]. 
Progressing through infancy the microbiome goes through highly variable changes, 
beginning to stabilize at approximately 2 years of age. Flux of the microbiome during this 
period is attributed to numerous factors, including dietary variations (e.g. milk vs. solid 
food), immunological development, introduction to novel microbes, and antibiotic exposure 
[87, 89, 90, 100-102]. 
Through the transition from infancy to childhood, and onto adulthood, the microbi-
ome of an individual stabilizes, while still being influenced by drug exposure [29, 44, 45, 
103, 104], physical activity [57-61, 105-110], the environment [3], and diet [21, 49, 53] 
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(discussed more elaborately in proceeding sections) [111, 112]. The microbiome changes 
again with old age [50, 113, 114], and again finally with death [115, 116]. 
1.8 | The Human Body – a Microbiome Perspective 
Microbial communities take form within any accessible area of a host’s body. The 
defined niches with stable communities in humans and other mammals are currently 
generalized to the respiratory system [20, 117-120], nasal [25, 121, 122] and oral cavities [17, 
25, 26, 123], skin [22, 25, 26, 75, 88, 124-128], vagina and urinary tract [25, 87, 88, 96, 129-131], 
and gastro-intestinal system [21, 25-27, 29, 40, 43, 84, 85, 87]. For each of these unique 
communities, varied technical challenges and health related prospects are present.  




Figure 1.1 | Demonstration of key microbiota and metabolites of the human microbiome, 
delineated according to human physiology.  (A) The skin, (B) oral cavity, (C) respiratory 
tract, (D) urogenital system, (E) and gastrointestinal tract are each highlighted with 
examples of microbiota (Taxa) and relevant metabolic activity (Metab). Beneficial 
associations to host health are denoted as (+), while negative associations are (-).  
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1.8.1 | The Skin 
Comprising a relatively vast space (~1.8 m2 for an adult human) with an equally ex-
pansive range of subsystems defined by folds, crevices, pH, secretion profiles, and 
environmental exposures, the skin supports highly varied microbial communities 
functioning in diverse ecological constraints (see Figure 1.1 A) [125, 132, 133]. 
Ecological partitioning of the skin microbiome is further defined by elementary bio-
logical traits of the host. Microbial composition at specific anatomical locations coordinates 
with gender [132, 134, 135]. Topical sampling of hand palms demonstrates greater diversity 
of bacterial taxa in women than men, with specific taxa differentially abundant between the 
two sexes [134, 135]. Similar results have been presented for other body sites, such as the 
thigh and torso [132, 134]. Expectedly, cohabitation of sexually active partners results in a 
shared skin microbiome that accurately matches couples 86% of the time [134]. Ancestral 
host genetics have also been demonstrated to influence the composition of the skin 
microbiome. Male participants of diverse ethnic backgrounds, all dwelling in a single 
geographic location, were shown to have microbial differences specific to ethnicity [136]. 
Despite such associations with the skin microbiome, ancestral genetics have been shown to 
exert negligible influence on the gut microbiome, where instead other factors, such as 
environment, play a more profound role in the form and function of the microbial 
community [137]. Microbiome structure also corresponds with age, with diversity 
increasing towards its peak in adulthood, before sharply declining with elderhood [132, 
138]. Guidance of skin microbiome composition is not limited to host biology, but also 
subject to extrinsic factors. 
Continuous environmental interaction leaves the skin communities as our most ex-
posed microbiome. Environmental factors shown to be influential include: hygiene routines, 
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topical medication and cosmetic use, and residential environment (e.g. rural vs. urban) [125, 
126, 132, 135, 139]. Despite the vulnerability to external perturbations, an individual’s skin 
microbiome maintains a consistent core structure [140]. Primary constituents of this stable 
inner-community are residential commensal taxa which perform homeostatic functions and 
act as a barrier against transient and potentially pathogenic species, subsequently 
maintaining a role in a variety of cutaneous conditions [128, 138, 140, 141]. Among these 
residential members are strains of Propionibacterium acnes (P. acnes), Malassezia, and 
Staphylococcus epidermidis (S. epidermidis) [138, 140, 142, 143]. Lipophilic, P. acnes and species 
of Malassezia proliferate in sebaceous gland rich body sites, such as the face and back [125, 
138, 142]. The rich pool of triglycerides found in sebum are hydrolysed by microbiota to 
produce fatty acids which assist in bacterial adherence and maintaining an acidic pH [138, 
144]. Such low pH environmental conditions reinforce the presence of lipophilic commen-
sals, while simultaneously inhibiting colonization by potentially pathogenic strains of 
Staphylococcus aureus and Staphylococcus pyogenes (S. aureus and S. pyogenes, respectively) 
[138, 145]. P. acnes additionally contributes to suppression of methicillin-resistant S. aureus 
through glycerol fermentation to short-chain fatty acids (SCFA), particularly so with 
propionic acid which also inhibits growth of Escherichia coli and Candida albicans [74, 141, 
145]. Despite its contribution to homeostasis of the skin, P. acnes, as its name suggests, plays 
a clear role in the condition of acne. 
1.8.2 | The Mouth 
The oral cavity provides a rich landscape wherein microbes establish a well-defined 
ecosystem (see Figure 1.1 B). Structure morphology and tissue type of the human mouth 
offers a variety of microbial habitats, further delineated by conditions of oxygenation, pH, 
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and nutrient availability [146, 147]. Control of the oral microbiome is mediated in concert by 
factors derived both by host and microbiota [146, 148-150]. 
Immunological training by microbiota seeded early in life defines the distinction 
between the commensal core and transient pathogens, wherein selected commensals create 
biological barriers with biofilm formation, alterations of pH and oxygen levels, and 
production of growth interfering molecules [148, 150, 151]. Bacteriocins, i.e., small peptide 
molecules including lantibiotics and microcins, are one such vehicle of microbial-derived 
molecular regulation of community composition within the mouth (and other microbial 
systems) [150]. Underlying mechanisms coordinating this antagonistic inter-microbe 
regulation of community structure remain unresolved, however its complexity is 
highlighted by findings of at least 1,169 putative lantibiotic gene clusters within the oral 
metagenomes defined by the Human Microbiome Project (HMP) [152].  
Complementing microbial influences, the host exerts an array of modulating effects 
upon the oral cavity. Prominently featured throughout this environment, saliva, is 
comprehensively understood for moistening the mouth and aiding in the mastication, 
swallowing, and digestion of food. Saliva also provides an essential nutrient source for 
microbiota, containing complex molecules such as glycoproteins (e.g. mucins) [146, 148, 153, 
154]. Similarly, saliva-derived proline-rich glycoproteins contribute to pellicle formation on 
mouth surfaces, immobilizing microbiota through their adherence to the structures [146, 
148]. Bioactive compounds found within saliva also include potent factors that inhibit 
growth or otherwise modify the microbial complex’s activity within the mouth. For 
example, bacterial growth is curbed by lysozyme mediated cell lysis and interference of 
glucose metabolism with lactoperoxidase catalysed conversion of hydrogen peroxide and 
thiocyanate to hypothiocyanite [146, 148]. 
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Sustaining a balanced oral microbiome purportedly results in numerous local and 
systemic health benefits. Nitric oxide (NO) is an important cellular signalling molecule, 
crucially involved with various physiological functions: metabolism, nerve function, and 
cardiovascular function. Key oral microbiome constituents have demonstrated the ability to 
reduce dietary nitrates to nitrite [42, 148, 154]. Converted nitrite is deposited into saliva, 
which is ingested after oral cavity circulation, leading to NO conversion and the subsequent 
transmission to tissues across the body [42, 154]. Countering the potential health benefits of 
bacterial nitrite supplementation, the compound may stimulate cancer development 
through formation of carcinogenic N-nitrosamines [42]. Posing similar risk of carcinogene-
sis, acetaldehyde is converted from ethanol by oral bacteria [154]. 
Dysfunction of the oral microbiome contributes directly to dental diseases; the most 
widely recognized such condition being tooth decay or dental caries. Caries formation 
begins with bacterial fermentation of carbohydrates to organic acids, resulting in localised 
pH reduction and subsequent tooth demineralization [146, 148, 151, 154]. Once the site has 
been acidified, the affected environment becomes increasingly hospitable to bacteria that 
are tolerant of low pH conditions, thus stimulating proliferation of destructive communi-
ties, and worsening of the condition [146, 148, 154]. While Streptococcus mutans is implicated 
as an integral component of tooth decay, it is evident that no single perpetrating organism is 
the causative agent, and instead polymicrobial activity drives the condition, with diverse 
actors from genera such as Actinomyces, Slackia, Propionibacterium, and Lactobacillus [151]. 
Periodontal disease is similarly notorious and well-understood for its influence by 
microbiota. Prolonged biofilm formation at the interface of gingival tissue and the tooth 
surface leads to accumulation of pathogenic bacteria that exacerbate inflammation through 
secretion of cytotoxic compounds such as lipopolysaccharides (LPS) [148, 154]. Resultant 
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bleeding from the inflammation provides a source of iron from heme, a molecule utilized by 
pathogenic microbes (e.g. Porphyromonas gingivalis) [148, 154]. Without disruption, the 
dysbiotic periodontal microbial community thrives, and with enhanced immunological 
antagonisation of the gingival tissue, contributes to induction of a dysregulated inflamma-
tory response, permanently damaging connective tissue and bone [148, 154]. 
Despite long-standing associations between oral health and microorganisms, and 
increasing understanding of such associations with advances of genetic sequencing and 
metabolomic technologies, a great deal more remains to be investigated within the oral 
microbiome. 
1.8.3 | The Nose and Respiratory System 
The human lung has long been considered a sterile biological system unless challenged with 
disease. Awareness of the microbiome has led to revision of this perception, and general 
acceptance of the respiratory microbiome (see Figure 1.1 C). 
Under conditions of general health, the lung environment reflects many characteris-
tics of the mouth and nose interiors: moderate thermal stability, high oxygen availability, 
mucosa-lined internal surfaces, and a continuous influx of environmental microbes. Despite 
being similarly well-suited for thriving microbial activity as the respiratory system 
openings, modern investigation of respiratory-related microbes deeper in the system 
projects a healthy lung microbiome with low phylogenetic diversity [155-157]. Simplicity of 
the lung microbiome is most notable in comparison to the oral cavity, which acts as a major 
channel for microbiota translocation with microaspiration of aerosolized material from the 
upper respiratory tract and direct migration along the oropharynx mucosa [157, 158].  
While many human microbial communities exhibit high levels of diversity when 
healthy, presenting associations between disease and reduced diversity, the respiratory 
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microbiome deviates from this trend and is indicated to be more susceptible to malignancy 
when complexity of its composition increases [25, 148, 157, 159, 160]. This is observed as far 
up in the respiratory system as the nasal cavity, with elevated diversity of the inner nostril 
associated with number of allergies [134]. Conversely, postsurgical outcome of sinus 
surgery is better with more diverse sinonasal microbiomes, suggesting an unpredictable 
relationship between upper respiratory tract microbial diversity and health [161].  
Association between heightened lung microbiome complexity and compromised 
pulmonary health has been demonstrated with asthma, an inflammatory disease [20, 119, 
121, 160, 162]. Aligned with much of microbiome-health interaction, evidence supports 
early life microbial exposures as critically influential on respiratory health. Strong 
epidemiological associations assert an increased risk of inflammatory respiratory disease 
with caesarean birth, and reduced risk from diverse antigen presentation (i.e. rural and 
farm exposures) [93, 94, 163, 164]. Mechanistic detail of the microbial role in asthma remains 
undescribed, however associations have been made between a deviation from the typical 
predominance of Bacteroidetes members (e.g. species of Prevotella) to those of Proteobacteria 
(e.g. Haemophilus species) [119, 165, 166]. Intriguingly, Proteobacteria are a predominant 
component of the skin microbiome, suggesting detrimental transposition of skin associated 
microbiota into the lungs [134, 138]. Similarly, analysis of fungal contributions to the 
pulmonary microbiome implicates the presence of Malassezia species in asthma [167]. This 
particular fungal species is more prominently known as a factor in atopic and seborrhoeic 
dermatitis, further supporting a role of deleterious skin microbiota cross-over in asthma 
[143]. It remains to be determined whether translocation of undesirable microbiota 
exacerbates the disease, or rather, the condition establishes a dysfunctional environment 
that is more conducive to infiltration of foreign microbes. 
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Although elaborate understanding of the respiratory microbiome’s general func-
tionality is lacking, evidence has been presented for alterations of the asthmatic lung 
microbiome composition within the context of corticosteroid treatment [162, 166]. Patients 
with asthma either resistant or sensitive to corticosteroid treatment both demonstrated 
compositional derangements in comparison to controls, with reduced Bacteroidetes 
abundance, and increased levels of Proteobacteria and Actinobacteria species [162]. 
Additionally, host-derived peripheral blood monocytes from the lungs of corticosteroid 
resistant patients had inhibited corticosteroid response when co-cultured with an isolate of 
Haemophilus parainfluenzae, a potential pathogen associated with asthma [162]. 
Although initial findings of the respiratory microbiome are promising, future devel-
opments face significant challenges. While other body sites are highly accessible for 
sampling with topical swabbing or secretion collection, acquiring samples from the lung is 
considerably more complicated. Not only is advanced training necessary to safely reach the 
tissue of the lower respiratory tract, but contamination risk throughout the respiratory 
system becomes exceedingly high when attempting to sample from specific pulmonary sites 
[155, 156, 158, 168]. 
1.8.4 | The Vagina and Urinary Tract 
The female urogenital microbiome maintains a paramount health role, seeding the 
microbiome of infants passing through the birth canal. Contribution of the mother’s 
urogenital microbiome during vaginal birth (or skin with caesarean delivery) on the 
establishment of an individual’s microbiome marks a critical stage of biological develop-
ment, with potentially life-long influences on asthma and allergy susceptibility, obesity, and 
neurocognitive development [90, 91, 169-171]. 
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Highlighted by its epidemiological influence, substantial effort has been put towards 
characterisation of vaginal microbial components and associated metabolic function (see 
Figure 1.1D). Similarly to the lungs, the healthy vaginal microbiome is characterized as 
maintaining low microbial diversity, however Lactobacillus species dominate its composition 
[25, 131, 172]. Disruptions to the healthy vaginal microbiome’s stable low-complexity are 
linked to severity of cervical intra-epithelial neoplasia (CIN) and bacterial vaginosis (BV), of 
which the latter presents increased risk of sexually transmitted infection acquisition, pelvic 
inflammatory disease, and preterm birth [129, 173-178]. 
Lactobacillus dominance of the vaginal microbiome appears to be unique in humans 
when compared to other animals (>70% and ~1%, respectively) [179]. In response to this 
anomaly, several theories have been proposed for the Lactobacillus-centric human vaginal 
microbiome: conserved common function of vaginal microorganisms that in humans 
happens to be fulfilled by Lactobacillus species, and such microbes adapting to starch rich 
diets that are typical of humans [179]. The diet hypothesis further suggests that high 
glycogen concentrations found within the human vaginal tract reflect dietary carbohydrate 
catabolism which is facilitated by abundant salivary amylase levels. 
Irrespective of evolutionary basis, thriving lactobacilli growth is fostered in the vag-
inal environment by glycoprotein and mucin rich genital fluid and high levels of glycogen 
and α-amylase, of which the latter increases energy availability of glycogen through its by-
products [179-181]. With Lactobacillus proliferation, oestrogen mediated pH of the vagina is 
further acidified by microbial-derived lactic acid, which is metabolized from glycogen 
through anaerobic glycolysis [182-187]. Low pH (~3.5) and high lactic acid concentrations 
contribute in conjunction with cervicovaginal fluid, a highly effective antimicrobial and 
antiviral medium, to stabilization of the vaginal environment [185, 187]. With BV, when 
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vaginal pH rises (>4.5) and microbial composition shifts away from lactobacilli to 
Gardnerella species, lactic acid levels drop and a more prominent SCFA profile develops 
[185]. While SCFAs are generally observed to bestow health benefits, particularly in the gut, 
within the vaginal tract an undesirable pro-inflammatory response appears to be induced 
by acetate and butyrate [55, 74, 128, 141, 185, 188]. 
The vaginal microbiome’s dichotomous state between Lactobacillus and Gardnerella 
dominance appears to considerably influence the efficacy of microbicide HIV prevention 
therapy [129]. Tenofovir microbicide gel was 59.2% effective in HIV infection prevention for 
Lactobacillus dominant vaginal communities, while the Gardnerella based BV microbiome 
had a prevention rate of 18% [129]. Controlled doses of tenofovir administered to patients 
with either Gardnerella or Lactobacillus oriented microbiomes showed significantly lower 
concentrations of the drug in Gardnerella dominated vaginal communities, and indeed, drug 
concentration negatively correlated with Gardnerella abundance [129]. In vitro analysis 
demonstrated that Gardnerella and other BV associated microbes efficiently metabolised the 
drug through a cleavage of an oxy-methylphosphonic acid side-chain of the compound 
[129].  
The male urogenital tract microbiome has received less attention; however budding 
investigation of the subject suggests health-relevant microbial activity within this system. 
Circumcision significantly modifies microbial composition of the coronal sulci of the penis, 
decreasing the total microbial load, including anaerobic taxa putatively associated with BV 
[189, 190]. Reduced HIV infection rates have independently been associated with 
circumcision, however the underlying factors of this protective effect are unknown [191]. 
Characterization of the penile microbiome suggests that microbial modulations from 
circumcision reduce epithelial immune activity, subsequently reducing HIV presentation to 
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the immune system [189-191]. Although the human urogenital microbiome has already 
begun to yield promising insights to a variety of important aspects of health, there 
continues to be numerous questions that remain unanswered. 
1.8.5 | The Gut 
Of the microbial communities delineated by human physiology, the consortium of 
prokaryotes, viruses, Archaea, and eukaryotes found within the gastrointestinal (GI) system 
have been investigated with the greatest intensity, subsequently yielding the most elaborate 
insights of microbial contributions to health and disease (see Figure 1.1 E) [12, 21, 27, 29]. 
Present knowledge of microbial introduction to the GI tract dictates uni-directional 
passage of microbiota within ingested material. Microbes are transported along the GI 
system, following a gradient of community complexity that peaks in the colon [192-194]. 
Once established, the gut microbiome is subject to influence from a growing number of 
known factors, both from the host and other microbial cohabitants. Perhaps most 
profoundly affecting this community is host diet, supplying microbes and the arsenal of 
nutrients that contribute to the microbiome’s function and proliferation [53, 55, 102, 195, 
196]. Plant-based complex carbohydrates, which intestinal microbiota process with enzymes 
that are absent from the human host, keenly exemplify dietary influence on the microbiome 
[55, 196, 197]. Through metabolism of these polysaccharides, microbial fermentation yields 
SCFAs, compounds with a broad range of purportedly profound effects on the host [55, 196, 
197]. 
Host-derived metabolites, similarly to dietary constituents, are utilized by the mi-
crobiome [196, 198-201]. Examples highlighting this host-microbe interaction include: bile 
acids (BA), which upon metabolization by bacteria, engage in complex host-microbe 
signalling cascades, and intestinal mucins, compounds utilized by mucin specialists (e.g. 
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Akkermansia muciniphila), providing protective properties to the host [38, 196, 198-201]. In 
addition to drugs explicitly affecting microorganisms, i.e. antibiotics, other medications 
demonstrate profound microbial interactions, affecting microbes and pharmacokinetics of 
the drugs [200, 202-205]. An in vitro screen of more than 1000 pharmaceutical compounds 
against core representative strains of gut bacteria, demonstrated that growth of at least one 
strain was inhibited by 24% of compounds intended to target human cells [205]. The type II 
diabetes drug metformin has separately been implicated in altering both composition and 
function of human intestinal microbiota, moulding a microbiome with an enrichment of 
SCFA metabolism genes and faecal concentrations of propionate and butyrate [204]. Specific 
microbial metabolic interaction with metformin however, remains to be elucidated.  
Indeed, drugs of intoxication (e.g. alcohol and cannabis) are indicated as having mi-
crobiome interactions, although such insights are sparse and often limited to non-human 
animal models [46, 104, 206-209]. An exception to the limited reporting on recreational drug 
use and the microbiome is the profiling of the gut microbiome of chronic cannabis users 
[208]. It was demonstrated that in comparison to controls, chronic cannabis users had a 13-
fold reduction in the Prevotella:Bacteroides ratio. Lower Prevotella abundance was further 
associated with poor cognition test performance and reduced mitochondrial ATP 
production [208]. 
Host behaviour, specifically physical exercise, is also recognized as an integral factor 
in modulation of the intestinal microbiome’s composition and function [57-61, 105-110]. 
Illustrating the influence of the extremes of exercise, professional athletes have been shown 
to harbour a gut microbiome, that in addition to having high compositional diversity of 
microbial taxa, contains a gene profile with robust potential for environmental energy 
capture [57, 58]. Specifically with the cohort of professional rugby players, in comparison to 
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age matched controls with similar BMI to represent the range of body composition in the 
athletes, a substantial increase in metabolic pathways with potential for health benefit, and 
a unique profile of faecal metabolites were observed. The pathways, which, given levels of 
expression matching their abundance offer opportunity for health modulation, ranged from 
organic cofactor and antibiotic biosynthesis to degradation and biosynthesis of carbohy-
drates. The latter of which could potentially result in an increased capacity for energy 
utilisation by the microbiome [57]. Metabolomic profiling of the athlete gut microbiome 
revealed elevated levels of SCFAs, metabolites with wide health implications (detailed 
further below) and association to a lean body composition [210]. The faecal metabolome of 
these athletes also presented elevated levels of trimethylamine-N-oxide (TMAO), a 
compound that has been associated with cardiovascular disease and atherosclerosis, 
although these negative associations have been disputed due the occurrence of high levels 
of TMAO in populations with low occurrence of cardiovascular disease [211]. Examining 
the microbiome of high-performance bicyclists, it was shown that the genus of Prevotella 
was significantly associated with reported time of exercising, while transcriptional levels of 
Methanobrevibacter smithii products were upregulated, particularly so for methanogenesis 
genes [60]. Investigation of amateur half-marathon runners demonstrated that through the 
course of high-intensity running, significant changes occurred in certain taxa (e.g. 
Coriobacteriaceae) and metabolites within the gut environment [61]. Intriguingly, the 
introduction of exercise as a novel stimulus appears to elicit more subtle changes in the gut 
microbiome. After undergoing a short period (8 weeks) of moderate-intensity exercise, 
healthy but inactive adults were shown to have only minor changes in the composition of 
their gut microbiome [59]. A separate analysis of a combination of lean and obese 
individuals undergoing a period of structured exercise conversely asserted that concentra-
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tions of faecal SCFAs increased in lean participants following exercise, while an obesity 
dependant shift in microbial diversity was present after exercise, and dissipated after a 
washout period [56]. Taken together, there still remains work to be done in understanding 
the mechanisms underlying the interaction of exercise and the gut microbiome. 
Gut microbiome analysis is predominantly carried out on the terminal end of the GI 
tract with the large intestine. Focus on the large intestine results from the relative ease and 
reliability by which gut specimens can be non-invasively acquired as stool samples. These 
samples importantly provide accurate representation of the intestinal microbiome as 
excreted samples retain microbial cells and metabolites from the lumen and mucosa, 
however, without exact recapitulation of the intestine’s various sub-sites [192, 193, 212]. 
From these samples, understanding of the gut microbiome has advanced through 
utilization of culture-dependant methodologies, to microbial taxonomic characterization 
with 16S rRNA gene sequencing, and on to the functional potential of the microbiome, 
progressing in stride with advancements in genetic sequencing and metabolomic 
technologies [25, 28, 54, 57, 213]. 
These collective analyses have revealed numerous roles for the gut microbiome in a 
broad range of disease states. Early sequencing based studies of the intestinal microbiome 
presented an influence of the microbiome in obesity, first with mice and later with humans 
[28, 214]. This early work paved the way for numerous other proposed health insults 
resulting from undesirable intestinal microbiota composition or function, ranging from 
diabetes and inflammatory bowel disease to psychiatric disorder and cancer [24, 215-222]. 
While initial contemporary gut microbiome research presented microbiota taxonomically, 
which drastically limits potential understanding of microbial influence on disease, shotgun 
metagenomic sequencing and metabolomic analysis strategies place the microbiome within 
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a framework of genetic pathways and metabolic products, enabling more elaborate 
investigations of mechanistic interactions between host and microbe [38, 46, 57, 213, 223]. 
1.9 | Systemic Implication of the Gut Microbiome in Health and Disease 
The GI tract acts as the primary site for the uptake and metabolic processing of nutrients, 
and subsequent systemic allocations of such products. As the human body’s central portal, 
the gut plays substantial role in health regulation. Gut microbiome investigation supports a 
similarly crucial role of intestinal microbes in health maintenance and modulation of 
various disease states, compounding with native biology of the host intestinal system. 
Microbial contributions to this health dynamic are mediated by numerous metabolic 
modalities operating independently or in concert. The most prominent metabolic circuit is 
at the interface of the microbiome and ingested nutrients, wherein microbiota utilize host 
diet to proliferate and produce metabolites that integrate with host cell metabolism (see 
Figure 1.2) [29, 43, 53, 195, 196, 224, 225]. 
1.9.1 | Short-chain fatty acids 
Of microbially produced metabolites influencing the host, SCFAs have demonstrat-
ed immense contribution to host biology, both locally within the intestinal system and 
distally with hepatic, neurological, and immunological function [55, 188, 225-229]. As 
previously noted, microbial SCFA generation occurs through polysaccharide utilization. 
Although the primary substrate for production of these compounds, it has also been 
demonstrated that gut microbiota have the capacity to convert butyrate from the 
metabolism of protein [225, 230-232]. Primary SCFA biosynthesis from polysaccharides is 
facilitated by various gut microbiota, employing a diverse repertoire of metabolic and 
enzymatic capacities [55, 225, 233]. Acetate, the SCFA generally found in the highest 
concentrations of intestinal SCFA profiling, can be derived from pyruvate metabolism, 
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following the Wood-Ljungdahl pathway or acetyl-coA synthesis [55, 225, 233]. Propionate is 
produced via two known processes involving sugar fermentation pathways, the succinate 
and propanediol pathways [55, 225]. Carbohydrate-derived propionate predominantly 
occurs through the succinate pathway, utilizes hexose and pentose sugars (e.g. glucose and 
ribose, respectively), and is dependent on vitamin B12 for complete conversion of succinate 
to propionate [225]. Propionate biosynthesis mediated by the propanediol pathway uses 
deoxy sugars fucose and rhamnose as the main reactants, however lactate conversion to 
lactaldehyde by Lactobacillus buchneri can feed generation of 1,2-propanediol [225]. Butyrate, 
the third most common SCFA, is most frequently formed through glycolysis of carbohy-
drates in which two acetyl-CoA molecules are combined to acetoacetyl-CoA, which is then 
reduced to butyryl-CoA [55, 225]. Final formation of butyrate within this metabolic scheme 
is carried out through two known pathways; butyryl-CoA: acetate CoA-transferase or 
phosphotransbutyrylase and butyrate kinase [55, 225].  
  




Figure 1.2 | Host-microbe metabolic interaction.  
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Figure 1.2 continued | A simplified demonstration of the metabolic interactions between 
host and microbiome. The cross-section of the small intestine illustrates the metabolic 
exchange between the intestine and two taxonomic representatives (Prevotella spp. and F. 
prausnitzii). Polysaccharides act as an example of dietary substrate utilized by the 
microbiota for the production of SCFA (butyrate and acetate). Similarly, host-derived 
substrate in the form of lactate presented with excretion of mucin from the intestine can be 
used by the microbiota. Within the example, acetate can either be absorbed by the intestine 
and subsequently the blood stream where systematic influences take place, or converted to 
butyrate, exerting localized effect on intestinal epithelial cells.  
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Upon excretion from microbial cells, SCFAs entering the intestinal environment are 
utilized by colonocytes as an energy source or pass into broader circulation via the portal 
vein [55, 225]. Acting locally on colonocytes, butyrate is incorporated into luminal cells 
through diffusion or direct transport mediated by the Na(+)-coupled transporter SLC5A8 
[55, 234]. Butyrate within colonocytes contributes to energy production through conversion 
of the compound to acetyl-CoA, or alternatively will inhibit histone deacetylase (HDAC) 
activity [55, 234, 235]. HDAC inhibition occurs within colorectal cancer cells, wherein 
glucose is preferentially used as an energy source, leading to butyrate accumulation and the 
subsequent action upon HDAC which results in a cascade of effect on cell proliferation, 
differentiation, and apoptosis [55, 234, 235]. 
Upon entering wider circulation through the portal vein, propionate is primarily 
metabolized in the liver while acetate is more broadly circulated, for example, crossing the 
blood-brain barrier where it may influence satiety through action on the hypothalamus 
[227]. Demonstrated in mice, gut-derived acetate and propionate have separately been 
suggested to influence asthma [55, 236, 237]. While regulatory T cell activity is enhanced by 
acetate inhibition of histone deacetylase 9 (HDAC9), resulting in suppression of environ-
mental allergen hypersensitivity, propionate affects lung dendritic cells dampening 
promotion of T helper type 2 cell driven inflammation while leaving the cells’ phagocytic 
ability intact [55, 117, 236-238]. 
Of particular relevance to this thesis, SCFAs have been shown to be detected by 
metabolomic profiling in higher concentrations within the gut of athletes when compared to 
controls. Our work with elite athletes demonstrated that an enrichment of SCFAs is present 
in the intestinal environment of the athletes when compared to controls [57]. Separately it 
was shown that lean individuals undergoing a short-term exercise intervention had 
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increased levels of SCFAs in response to the treatment [56]. This intriguingly suggests that 
physical fitness may foster an environment within the gut that, likely in conjunction with 
dietary changes associated with increased exercise, is more conducive to the production of 
SCFAs 
1.9.2 | Bile acids 
With similarly profound implications as SCFAs, bile acids (BA) are shown to be at the 
centre of a metabolic interplay between host and microbe [53, 198, 199, 202, 204, 239-241]. 
Following post-meal metabolic cues, bile released from the canalicular membrane of 
hepatocytes enters the intestinal system. Primary BAs, cholic acid and chenodeoxycholic 
acid, are converted from cholesterol and conjugated to taurine or glycine, and within 
context of host physiology, are utilized as detergents to allow intestinal absorption of 
dietary lipids and fat-soluble vitamins [239, 241, 242]. 
Microbial bile salt hydrolase (BSH) facilitates conjugated bile acid (CBA) hydrolysis, 
reverting the compounds back to BAs which permits small intestine reabsorption or 
additional metabolic processing [241, 242]. Unconjugated and glycine-conjugated BA 
absorption by passive diffusion and active transport creates a circulating pool of BAs, 
establishing continuous bioavailability of the compounds [240-242]. As detergents, BAs 
have the capacity to disrupt the lipid membrane of bacterial cells, subsequently exerting 
considerable influence on the structure of the microbiome. Microbes accordingly employ 
myriad strategies to circumvent the antimicrobial action of BAs, such as outer membrane 
lipid and protein modifications [241, 242]. In conjunction with BA resistance, microbiota 
exploit their ability to alter BA hydrophobicity through modification of the compounds, 
permitting either evasion of destruction or an inhospitable environment for competing 
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organisms [241, 242]. Microbial-BA activity impacting host health has consequentially 
begun to be elucidated.  
Microbial BSH driven hydrolysis of CBAs to unconjugated primary BAs enables 
subsequent conversion to secondary BAs deoxycholic acid and lithocholic acid (DCA and 
LCA, respectively) [241, 242]. DCA in particular, accumulates in the enterohepatic BA pool. 
Relatively high concentrations of DCA result from intestinal diffusion and hepatic reuptake 
conduced by the compound’s hydrophobicity, and the human liver’s inability to 
rehydroxylate DCA [241]. 
Obesity is a health condition with demonstrated influence by BAs, for example die-
tary insult to weight-gain and glycaemic control was ameliorated with intervention of BA 
binding resins [243]. Anatomical influence on BA Roux-en-Y gastric bypass surgery has 
intriguingly been shown to also have an effect on BAs, with serum concentrations raised in 
individuals that have undergone the procedure when compared to obese and severely 
obese controls, suggesting that anatomical manipulation of the procedure modifies the 
dynamics of the BA pool [244, 245]. The fat and protein enriched ‘Western’ diet that 
contributes to obesity development modifies not only gut microbiome composition but also 
microbial BA pool contributions [53, 196, 214, 216, 240]. 
Among the numerous detrimental effects of obesity, evidence supports microbial 
derived DCA as a potent tumour promoter, contributing to development of hepatocellular 
carcinoma and the colorectal cancer precursor colorectal adenomas [53, 240, 246-248]. 
Although mechanistic detail in the human gut is limited, DCA-driven hepatocellular 
carcinoma in mice is suggested to result from the compound’s provocation of the 
senescence-associated secretory phenotype (SASP) in hepatic stellate cells [247]. SASP is 
characterized by broad alterations in gene expression and secretory profile, which affect 
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neighbouring cells through numerous factors: release of cytokines (e.g. IL-1α and -β), 
insulin-like growth factor binding proteins, nitric oxide and reactive oxygen species, and 
potentially the glycoprotein, fibronectin [247, 249]. Influence of DCA on colorectal 
tumorigenesis is proposed to mediate derangement of epidermal growth factor receptor-
mitogen activated protein kinase (EGFR-MAPK) regulation, specifically with DCA 
preventing degradation of EGFR through calcium signalling of MAPK [246]. Within this 
valuable framework established around the interaction of gut microbes and BAs, a wide 
range of metabolic facets remain to be elucidated. There continue to be poorly understood 
aspects of the roles BAs have on microbial function and ecology, and indeed, the influences 
of microbial-derived BAs on host health. Furthermore, the dynamics of BA-microbiome-
host interaction are only a small component of the numerous bioactive compounds within 
the gut environment, highlighting the vast areas of the microbiome that still require 
investigation.  
Chapter 1 39 
 
 
1.10 | Conclusions and Outlook 
Examination of microbiome-host interaction has defined an integral role of microbiota in 
health and disease. The challenge now lies in comprehensive elucidation of the underlying 
mechanisms. Metabolic phenotyping and identification of the microbial metabolites 
interacting with the host will be pivotal to this challenge. With robust characterization of 
metabolic activity within the various microbiomes of the human body, progress can be 
made in the development of defined microbial cultures (probiotics) and substrates 
conducive to selective growth or function of microbes (prebiotics) for health enhancement. 
In short, there is need and opportunity for the imaginative deployment of metabolic 
phenotyping within the field of microbiome research. 
1.11 | Hypothesis 
The research of this thesis is directed towards expanding the understanding of physical 
exercise as an agent in the modification of the gut microbiome, particularly in how the 
microbiome pertains to health. This goal encompasses the profiling of intestinal microbiota, 
both in terms of taxonomy and metabolic function, within the context of various degrees of 
exercise intensity, and human populations.  
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The specific hypotheses of this thesis are as follows: 
1. The athlete microbiome exhibits unique characteristics, including functional adapta-
tions to the dietary and energetic extremes associated to the demands of high-
performance sport. 
2. Identifiable changes occur in the composition and function of the gut microbiome in 
response to exercise and/or protein supplementation as novel stimuli. 
3. Computational based investigations can be utilized to elucidate additional details of 
the microbiome dynamics in athletic populations. 
4. Exercise can be used by inflammatory bowel disease patients without detrimental 
impact on their intestinal microbiome. 
5. Prolonged engagement in physical activity results in pronounced alterations of the 
gut microbiome. 
1.12 | Objective 
The objectives of this thesis are as follows: 
1. Describe the taxonomic and metabolic potential profiles for the gut microbiome of 
high-performance athletes. 
2. Identify alterations in the gut microbiome of exercise naïve individuals in specific 
response to physical exercise, whey protein supplementation, or both. 
3. Assess the viability of exercise as an adjunct treatment in physically inactive in-
flammatory bowel disease patients. 
4. Evaluate the influence of moderate intensity exercise on the microbiome longitudi-
nally over the course of 6 months. 
5. Determine the effectiveness of elucidating additional details of gut microbiome 
dynamics with computational modelling strategies. 
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Chapter 2  
―― 
MATERIALS AND METHODS 
The following chapter outlines the general materials and methods that were practiced in the 
experimental portions of this thesis. Any deviations or additional approaches have been 
described in corresponding chapters. 
2.1 | Ethical approval 
Investigations that focused on, or otherwise included human participants (chapters 3 - 8) 
were appropriately conducted under guidelines defined by the Helsinki Declaration. In all 
such studies, ethical approval was formally sanctioned by the Clinical Ethics Committee of 
the Cork Teaching Hospitals (CREC). All study participants provided written informed 
consent prior to commencement of the various studies. An adapted version of the American 
College of Sports Medicine’s safe participation questionnaire was utilized to ensure 
participant safety during the course of the exercise intervention studies (chapters 6 and 7) 
[1]. 
2.2 | Study compliance and withdrawal 
Exercise program compliance (chapters 6 and 7) was monitored remotely by the investiga-
tors using the FitLinxx® activity monitoring system (Shelton, Connecticut, USA). All 
volunteers were provided with a unique identification number for the FitLinxx® physical 
activity recording system and were required to login and record all activities undertaken at 
the Mardyke Arena gymnasium during the intervention period. Using this tracking system, 
compliance with the prescribed exercise program was monitored by the investigators. 
Similarly, the quantity of aerobic and resistance training performed by participants was 
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compiled. The Fitlinxx® software program enables accurate recording of the duration and 
frequency of training, and provides an estimate of energy expenditure during aerobic 
exercise. The facility’s Fitlinxx® software and hardware was maintained and re-calibrated 
prior to commencement of the study. Volunteers noted not to be complying with the 
exercise regime for more than 7 consecutive days were withdrawn from participation. 
2.3 | Participant data collection 
2.3.1 | Diet & nutrition 
In all studies, recruited volunteers were asked to maintain typical dietary habits throughout 
the observation periods. For chapters 3, 4, 5, 6, and 8, dietary data from participants was 
collected by means of a 146-item food frequency questionnaire (FFQ). The FFQ was an 
adapted version of the questionnaire used in the UK arm of the European Prospective 
Investigation into Cancer (EPIC) study [2], which was based on the original Willet FFQ [3]. 
Participants were asked to record their usual pattern of dietary intake over the duration of 
observation. 
2.3.2 | Physical activity 
Healthy individuals compared to athletes as controls for high-performance athleticism for 
studies described in chapters 3-5, were assessed for physical activity levels using an 
adapted version of the EPIC-Norfolk questionnaire [4]. Baseline physical activity levels of 
volunteers (chapters 6, 7 and 8) were characterized using the long form of the International 
Physical Activity Questionnaire (IPAQ) [5]. This self-reported questionnaire provided an 
estimate of the physical activity patterns of participants including an estimation of the time 
spent engaged in physical activity (walking, moderate, and vigorous activity) and the 
metabolic equivalents of task (MET) minutes and kilocalories expended per week by 
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physical activity. To prevent injury from unaccustomed vigorous exercise, a sub-maximal 
assessment of peak aerobic capacity was used in intervention studies (chapters 6 and 7). 
Baseline and post-intervention levels of cardio-respiratory fitness were measured using a 
validated sub-maximal fitness test [6]. The Rockport one-mile walk test was performed in a 
standardized temperature environment at the indoor running track of the Mardyke Arena, 
University College Cork, Ireland. This test was used to estimate maximal oxygen uptake 
(VO2max). 
2.3.3 | Body composition 
Dual Energy X-ray Absorptiometry (DEXA) was used to assess body composition change in 
the volunteers from all cohorts. A GE Healthcare Lunar iDXA machine (Madison, 
Wisconsin, USA) at the Bone Densitometry Unit, Cork University Hospital, Ireland was 
used. The enCORE software (V.13.4, 2010) analysed body composition using a three-
compartment body composition model (Fat mass, bone mass, lean tissue). Volunteers were 
scanned post-voiding and dressed in light clothing, with metal-wear removed where 
present. Quality control analysis was performed on the iDXA machine before use on each 
measurement day. 
2.3.4 | Inflammatory cytokine measurement 
Blood samples (4 ml) from participants were collected in serum separator clot activator 
blood collection tubes (Greiner Bio-One, Stonehouse, United Kingdom; reference no. 
454071). The blood samples were allowed to rest upright on the laboratory bench for 30 min 
before centrifugation was performed at 1,000 × g for 20 min at room temperature. 
Approximately 2 ml of supernatant sera was then harvested by pipette, frozen, and stored 
at −80°C in polypropylene cryogenic vials. At a later date, following a complete thaw, 
resting levels of proinflammatory cytokines were measured using a mesoscale discovery 
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(MSD) platform (Meso Scale Discovery, Rockville, MD). The MSD system is an electrochem-
iluminescence-based solid-phase multiplex assay. An ultrasensitive human 
proinflammatory I, V-Plex immunoassay panel containing interleukin-6 (IL-6), IL-8, IL-10, 
tumour necrosis factor alpha (TNF-α), and gamma interferon was used to measure serum 
cytokine levels. All such cytokines were measured in chapter 6, while gamma interferon 
was not measured in chapters 7 and 8. Samples were diluted 1:2 according to the 
manufacturer’s protocol. The lower limit of detection was <1 pg/ml for all assays. All 
plasma samples were measured in duplicate, and the mean cytokine concentration of the 
duplicates (in picograms per millilitre) was used for analysis. 
2.4 | Exercise intervention 
Combined aerobic and resistance training (chapters 6 and 7) was performed at the Mardyke 
Arena gymnasium at University College Cork, Ireland, where all exercise sessions took 
place. Participants undergoing exercise intervention were instructed to adhere to the 
assigned exercise program and to avoid additional moderate to vigorous physical activity 
outside of that prescribed. Participants were instructed to train 3-times per week for the 8-
week intervention periods. Participants were familiarized with the format of the required 
training program during a 90-minute induction session with designated gym instructors. 
This induction included demonstration of all aerobic and resistance training equipment 
allowing the opportunity to ask questions if required. Resistance training machines were 
customized for individual differences in range of motion and the participants were 
observed using all machines with instructor feedback and correction. For resistance 
machines, 1 repetition maximum (1RM) values were calculated using standardized methods 
[7]. 
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The outline of the exercise sessions was as follows: After a 5-minute warm-up on the 
treadmill (brisk walking at approximately 4km/hour, modified Borg rating of perceived 
exertion (RPE) scale: 3-5/10) [8], participants underwent aerobic training of moderate 
intensity (modified Borg RPE: 5-7/10). To encourage compliance with the prescribed RPE 
scales, volunteers were reminded of the desired intensities on each of their weekly exercise 
training programs. The duration of aerobic exercise progressed on a weekly basis but 
remained of moderate intensity. Initially, aerobic exercise lasted approximately 18 minutes 
and by week 8 of the intervention period, aerobic exercise increased to approximately 32 
minutes depending on the type of aerobic activity chosen by the volunteer. To allow variety 
and to maintain interest participants were provided with a choice of aerobic activities, 
including treadmill jogging/running, use of a cross-trainer device (with no added 
resistance), use of a stepper machine, and stationary cycling (with mild resistance). The 
duration for each of these activities was calculated based on the 2011 Compendium of 
Physical Activities [9] to ensure similar levels of energy expenditure across all activities. 
Participants were instructed not to change between aerobic exercises within a given training 
session. 
Upon completion of aerobic activity, participants undertook machine-based re-
sistance training. In summary, participants were required to perform a minimum of 3 sets of 
8 repetitions on 7-different resistance machines (three upper body, three lower body, one 
core muscle exercise). The allowed resistance machine options were as follows: for the 
upper body, shoulder press, chest press, lateral pulldowns, and seated rowing; for the lower 
body, leg extension, leg curl, gluteal kick-back, and leg press; for the core muscles, 
abdominal curls and torso rotation. A minimum limit of 3 sets of 8 repetitions was 
instituted, with a maximum limit of 3 sets of 12 repetitions. Starting weights were calculated 
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at induction to correspond to 70% of the individual’s one-repetition maximum (1RM) value. 
Resistance training was progressive, with the aim of increasing the resistance weight by 
15% to 20% over an 8-week period. Free-weight use was not permitted. 
2.5 | Extraction and sequencing of faecal microbiome DNA 
2.5.1 | Processing of faecal samples 
DNA was extracted from the donated fresh faecal samples received at the Teagasc 
Moorepark research facility using a QIAmp DNA stool minikit (Qiagen, Crawley, West 
Sussex, United Kingdom) [10]. Samples were provided by participants as partial 
evacuations into sterile containers and, when not immediately transported for DNA 
extraction, were held at 4°C for no more than 12 h. Samples were prepared for DNA 
extraction by manual homogenization of a portion of the sample representing all 
microenvironments (i.e., core and external surface) of the faeces. The provided manufactur-
er’s protocol was used with modification whereby a zirconia bead (Stratech Scientific) cell 
disruption bead-beating step (performed three times for 30 s each time) was introduced in 
order to enhance homogenization of the extraction material. DNA extracts and the 
remaining faecal samples were subsequently stored at −80°C until they were prepared for 
sequencing. 
2.5.2 | Metagenomic library preparation and sequencing 
Metagenomic library preparation was performed with the Illumina Nextera XT DNA 
Library Preparation Kit (cat. no. FC-131-1096, Illumina Inc., USA) in explicit accordance 
with the manufacturer’s protocol (15031942, Illumina). Normalisation of samples to the 
recommended 0.2 ng/μL per individual library was carried out with the ThermoFisher 
Qubit 2.0 Flurometric Quantitation system (ThermoFisher Scientific), using a combination of 
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broad-range and high-sensitivity assay kits as appropriate (cat. nos. Q32850 and Q32851 
respectively, ThermoFisher Scientific). Tagmentation—the combined cleavage of sample 
DNA into fragments and application of universal overhang ‘tag’—and amplification of 
DNA fragments was carried out with the G-STORM GS1 thermal cycler system (G-Storm 
Ltd. UK), using the thermal cycler programs provided by the Nextera XT protocol 
(15031942, Illumina). Following the combined enzymatic fragmentation and adapter 
sequence tagging—tagmentation—and the subsequent amplification of the tagmented 
DNA, libraries were purified with the AMPure magnetic bead system at a ratio of 1:1.8 
(DNA:AMPure) (cat. no. 9A63880, Beckman Coulter). Subsequently, libraries were assessed 
for appropriate fragment size on the Agilent 2100 Bioanalyzer system (cat. no. G2939BA, 
Agilent Technologies), utilizing the accompanying Agilent DNA 1000 chip-assay kit (cat. 
no. 5067-1504, Agilent Technologies). With the libraries passing quality and fragment length 
requirements, the library preparation was continued on through library normalization, 
which was met with an additional assessment of suitable molar concentrations (~2 nM) with 
the KAPA Library Quantification Kit (KK4824, Kapabiosystems) run on a Roche Light-
Cycler 480 (Roche Applied Science). Samples from the various studies were combined in 
equimolar concentration (2nM) pools for prior to sequencing. 
Sequencing data used in chapters 3 – 5 were generated from the Illumina HiSeq 2500 
(chemistry V.4.0) next generation sequencing (NGS) platform by Eurofins Genetic Services 
Ltd. (Ebersberg, Germany), while such data for chapter 6 was provided with the same 
instrument but by Beckman Coulter Genomics Inc. (Danvers, MA U.S.). NGS data for 
chapters 7 and 8 were produced at the Teagasc sequencing facility (Cork, Ireland) on the 
Illumina NextSeq 500 (chemistry V.2.0). Further specific details are outlined in the 
appropriate chapters. 
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2.6 | Bioinformatic processing of microbial sequencing data 
Processing of metagenomic FASTQ sequence files proceeded with the removal of human-
derived contaminant sequences with NCBI Best Match Tagger (BMTagger) software (Fig. 
2.1), while trimming and removal of duplicate reads or of reads of substandard quality were 
performed with Picard and SAM tools. Functional profiling of high-quality processed reads 
was facilitated by use of the Human Microbiome Project (HMP) Unified Metabolic Analysis 
Network (HUMAnN2) pipeline [11]. Models of microbial metabolic pathways produced by 
HUMAnN2 were derived from the MetaCyc database [12] and were the basis for analyses 
performed on microbial metabolic profiling. Version 0.5.0 of HUMAnN2 was used in 
chapters 3-5, while a later edition, version 0.99 was used in subsequent chapters. 
Taxonomic profiles were generated from the sequencing data using a combination of 
Metagenomic Phylogenetic Analysis (MetaPhlA2, V.2.0), Kaiju (V.1.5.0) [13] and Kraken 
(V.0.10.6) software packages [14, 15]. Additionally, for the comparison of sequencing 
approaches presented in chapter 3, the software tool GraPhlAn (V.0.9.7) was used to 
construct phylogenetic trees [16].  




Figure 2.1 | Comparison of sequences from all studies. Quantification of sequencing reads 
yielded from all studies included in this thesis. (A) Raw FASTQ reads and (B) the outlying 
relatively high numbers of FASTQ reads. (C) FASTQ reads removed due to mapping to the 
human genome and (D) such reads that were particularly high.  
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2.7 | Metabolomic phenotyping 
2.7.1 | Sample preparation 
Faecal and urine samples donated by participants were stored at the Teagasc Moorepark 
research facility at -80○C before being shipped on dry ice for metabolomic analysis at the 
Centre for Computational and Systems Medicine in Imperial College London. 
Frozen urine samples (-80○C) were thawed, vortexed and then centrifuged at 1600 × 
g for 10 minutes to remove particulates and precipitated proteins. Urine samples were 
prepared for metabolic profiling analysis by reversed phase (RP) and hydrophilic 
interaction chromatography (HILIC) ultra performance liquid chromatography – mass 
spectrometry (UPLC-MS) as follows: 200 μl of supernatant was diluted (1:1) with high 
purity (HPLC grade) water, vortexed, centrifuged at 2700 × g for 20 minutes and aliquoted 
for HILIC and RP methods. Quality control (QC) samples were prepared by pooling 50 µl 
volumes of each sample. During the analysis, the samples were maintained at 4oC in the 
autosampler. For 1H NMR spectroscopy, 540 μL of urine samples were mixed with 60 μL of 
phosphate buffer (pH 7.4, 80% D2O) containing 1 mM of the internal standard, 3-
(trimethylsilyl)-[[2,2,3,3,-2H4]]-propionic acid (TSP) and 2mM sodium azide (Na3N), as 
described previously.[17] 
Frozen faecal samples (-80oC) underwent x2 freeze thaw cycles to lyse the cells. After 
thoroughly defrosting, 100mg of homogenised sample was placed in a microtube containing 
250 μl of 25% acetonitrile (1 ACN : 3 H2O), 2mM sodium azide and ~0.05g 1mm Zirconia 
beads. The microtubes underwent 10 seconds in a Biospec bead beater. Samples were then 
centrifuged at 16000 x g for 20 mins. Following this the faecal water supernatant was 
centrifuged through centrifuge tube filters (cellulose acetate membrane, pore size 0.22 μm) 
to remove any remaining particular matter. The centrifuge tube filters were washed prior to 
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use three times with 25% acetonitrile. The resulting faecal water was prepared for metabolic 
profiling analysis by HILIC and bile acid profiling UPLC-MS as follows: 150ul of faecal 
water was diluted 3:1 with acetonitrile. Samples were vortexed and incubated at -20oC for 1 
hour. Following this, samples were centrifuged at 4oC at 16000 x g for 1 hour. Quality 
control (QC) samples were prepared by pooling 20 µl volumes of each faecal water sample 
and then preparing as above. For 1H nuclear magnetic resonance (NMR) spectroscopy, 50 μl 
of the filtered faecal water was added to a Pyrex glass tube, which was placed under 
Nitrogen gas flow for 30 mins or until all the liquid had evaporated. The dried sample was 
reconstituted with 540 μl of D2O and 60 μl of phosphate buffer solution as described above. 
The solution was mixed and sonicated for 5 minutes before undergoing further centrifuga-
tion at 14000 RPM for 10 mins before 600 μl supernatant was transferred to a NMR tube for 
1H-NMR spectral acquisition. 
Faecal samples from participants in studies described in chapters 3-6 were prepared 
for targeted analysis of short-chain fatty acids (SCFA) using gas chromatography – mass 
spectrometry (GC-MS) as previously described.[18] In brief, 100mg of thawed faecal sample 
was suspended in 1ml of water with 0.5% phosphoric acid. After acidification, samples 
were vortexed for 2 min and centrifuged for 10 min at 16000 x g. 1ml of the resulting faecal 
water supernatant was added to 1 ml of ethyl acetate for 2 min and then centrifuged for 10 
min at 16000 x g. Prior to analysis, a 600ul volume of the organic phase was transferred into 
a silanised vial with 4-methyl valeric acid added as the internal standard (IS) at a final 
concentration of 500uM. Samples were analysed in a random order with QCs every ten 
samples. Calibration curves of the measured SCFA were derived through analysis of 
duplicate dilution series of the purchased chemical standards at the beginning and end of 
the run. 
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2.7.2 | LC-MS Metabolic profiling analysis 
Reversed-phased (RP), HILIC and bile acid UPLC-MS metabolic profiling experiments were 
performed using a Waters Acquity Ultra Performance LC system (Waters, Milford, MA, 
USA) coupled to Xevo G2 Q-TOF mass spectrometer (Waters, Milford, MA, USA) with an 
electrospray source. Samples were analysed in a random order, with QCs every ten 
samples. 
Urine samples were first analysed using UPLC-MS, with a RP chromatographic method 
with both positive and negative MS ionisation modes. Secondly, to separate and detect 
more polar molecules, a HILIC chromatographic stage was used with positive MS 
ionisation modes. Faecal water samples underwent analysis using HILIC, and for samples 
used in chapters 3-5, bile acid profiling chromatographic methods in positive and negative 
ionisation modes respectively. 
HILIC, Reversed-Phase and bile acid profiling liquid chromatographic separation 
was performed as previously described.[19, 20] Mass spectrometry was performed with the 
following settings: capillary and cone voltages were set at 1.5 kV and 30 V, respectively. The 
desolvation gas was set to 1000 L/hr at a temperature of 600°C; the cone gas was set to 50 
L/hr and the source temperature was set to 120°C. For mass accuracy a lock-spray interface 
was used with leucine enkephalin [[556.27741 Da ([[M+H]]+), 554.2615 Da ([[M-H]]-)]] 
solution used as the lock mass at a concentration of 2000 ng/ml and at a flow rate of 15 
µl/min. 
2.7.3 | 1H-NMR Metabolic profiling analysis 
1H-NMR spectroscopy was performed on the aqueous phase extracts at 300 K on a Bruker 
600 MHz spectrometer (Bruker Biospin, Germany) using the following standard one-
dimensional pulse sequence: RD – gz1 – 90° – t1 – 90° – tm – gz2 – 90° – ACQ.[17] The 
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relaxation delay (RD) was set at 4 s, 90° represents the applied 90° radio frequency pulse, 
interpulse delay (t1) was set to an interval of 4 μs, mixing time (tm) was 10 ms, magnetic 
field gradients (gz1 and gz2) were applied for 1 ms and the acquisition period (AQA) was 2.7 
s. Water suppression was achieved through irradiation of the water signal during RD and 
tm. For the urine samples, each spectrum was acquired using 4 dummy scans followed by 32 
scans while faecal spectrum were acquired using 256 scans and 4 dummy scans and 
collected into 64K data points. A spectral width of 12 000Hz was used for all the samples. 
Prior to Fourier transformation, the FIDs were multiplied by an exponential function 
corresponding to a line broadening of 0.3 Hz. 
2.7.4 | GC-MS SCFA targeted analysis 
For samples used in chapters 3-6, the GC-MS targeted SCFA analysis was conducted on an 
Agilent 7890B GC system, coupled to an Agilent 5977A mass selective detector (Agilent 
Technologies, USA). The analysis was performed to detect levels of the SCFAs acetate, 
propionate, butyrate, valerate, isobutyrate, isovalerate, according to a previously described 
method.[18] The detector was operated in selected ion monitoring (SIM) mode (electron 
energy 70 eV), scanning the selected characteristic target ion for each measured SCFA 
(acetate, propionate, butyrate, valerate, isobutyrate, and isovalerate), at the corresponding 
retention times. Retention times were confirmed prior to analysis through analysis of 
authentic SCFAs in full scan mode. 
2.7.5 | LC-MS data treatment 
The raw mass spectrometric data acquired were pre-processed using xcms in R and the 
centwave peak picking methods were used to detect chromatographic peaks.[21] The xcms-
centwave parameters were dataset specific. Feature grouping across samples was 
performed using the ‘nearest’ method within xcms. Peak filling, MinFrac (0.5) and CV (0.3) 
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filters were applied to the features. Data was normalised using median fold change 
normalisation using the median data set as the reference.[22] 
2.7.6 | 1H-NMR data treatment 
1H-NMR spectra were automatically corrected for phase and baseline distortions and 
referenced to the TSP singlet at δ 0.0 using TopSpin 3.1 software. Spectra were then 
digitized into 20,000 data points at a resolution of 0.0005ppm using an in-house MATLAB 
R2014a (Mathworks) script. Subsequently, spectral regions corresponding to the internal 
standard (δ -0.5 to 0.5) and water (δ 4.6 to 5) peaks were removed. In addition, urea (δ 5.4 to 
6.3) was removed from the urinary spectra. All spectra were normalised using median fold 
change normalisation using the median spectrum as the reference.[22]  
2.7.7 | GC-MS data treatment 
GC-MS data was processed using MassHunter Quantitative Analysis (Agilent Technolo-
gies) software. Extracted ion chromatograms of the target ion selected for each SCFA were 
integrated and the peak area was normalised to the internal standard (4-methyl valeric acid) 
to correct for variability in the instrument response. Calibration curves were constructed by 
plotting the internal standard normalised area of authentic SCFA standards against the 
corresponding known SCFA concentrations and used to calculate the measured concentra-
tions of SCFAs in the analysed samples. 
2.7.8 | Metabolite ID 
Confirmation of metabolite identities in the NMR data was obtained using 1D 1H NMR 
sequence with water pre-saturation and 2D NMR experiments such as J-Resolved 
spectroscopy, 1H-1H TOtal Correlation SpectroscopY (TOCSY), 1H-1H COrrelation 
SpectroscopY (COSY), 1H-13C Hetero-nuclear Single Quantum Coherence (HSQC) and 1H-
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13C Hetero-nuclear Multiple-Bond Correlation (HMBC) spectroscopy. In addition, statistical 
tools such as SubseT Optimization by Reference Matching (STORM) and Statistical TOtal 
Correlation SpectroscopY (STOCSY) were also applied. Confirmation of metabolites 
identities in the LC-MS data was obtained using Tandem MS (MS/MS) on selected target 
ions with an energy ramp 5-20eV to produce product ions. 
Metabolite identification was characterized by a level of assignment (LoA) score that 
describes how the identification was made.[23] The levels used were as follows: LoA 1: 
Identified compound, confirmed by comparison to an authentic chemical reference. LoA 2: 
MS/MS precursor and product ions or 1D+2D NMR chemical shifts and multiplicity match 
to a reference database or literature to putatively annotate compound. LoA 3: Chemical shift 
(δ) and multiplicity matches a reference database to tentatively assign the compound. 
2.8 | Quantification and statistical analysis 
2.8.1 | Power analysis and sample size 
For chapters related to examination of the athlete microbiome (chapters 3-5), sample size 
was defined by the number of players within the athletic team (n = 40). As the entire team 
was recruited, a number controls not less than the athletes were included for comparison (n 
= 46). Post hoc power analysis, was performed in R using the power.t.test function in the 
base stats package for pairwise comparisons, while pwr.anova.test from the pwr package 
was used for comparisons of 2 or more groups [24]. For the study described in chapter 3, at 
the given outcome standard deviation (σ) of 2.7%, effect size (𝛿) of 4.5%, significance level of 
5%, and minimum sample size (n) of 23, power was calculated at 99.9% for the measure-
ment of Shannon’s alpha diversity index. For comparison, 𝛿 of 10% with the same σ, 
provides power of ~1 with a group size of 7. Comparing alpha diversity between all groups 
with a significance of 5%, and 𝛿 of 52% (given as ANOVA F value), power of 95.1% was 
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calculated with a group size of 20. The intervention studies described in chapters 6 and 7 
had more explicit experimental aims, and accordingly utilised methods to determine 
appropriate sample sizes. For chapter 6, an estimation of required sample size was 
calculated with Mead’s resource equation, yielding a minimum total sample size of 75 
participants for the 3 interventions. Retrospective power analysis of this study illustrated 
that the detection of an 8.6% change in alpha diversity for the group size of 17 and 
significance level of 5% was powered at 12% for paired analysis. Balanced one-way analysis 
of variance power calculation on all 3 intervention groups showed that the effect size of 
61%, with significance level of 5% was powered at 97% for the group size used (n = 17), 
while a power level of ~1 would be reached at 54 participants per group. Sample size for the 
study presented in chapter 7 was calculated to detect a 2% body fat percentage reduction 
with a two-sided significance level of 5% and 80% power, resulting in a minimum of 7 
control patients and 14 patients in the exercise group. Additionally, analysis of alpha 
diversity showed that the testing of the microbiome was powered at 29% for a significance 
level of 5% and effect size 5% Due to the nature of the N of 1 style study presented in 
chapter 8, statistical power calculations were inappropriate. 
2.8.2 | Clinical data 
Statistical analysis of participants’ clinical measures (chapters 6 - 8) was carried out using 
the Statistical Package for the Social Sciences V.23 (SPSS, Inc., Chicago, Illinois). Due to the 
predominance of non-normally distributed data, nonparametric analyses were performed to 
compare clinical and demographic variables between experimental groups (chapters 6 and 
7). Clinical data are presented as medians and interquartile ranges (IQR), unless stated 
otherwise. Between-group differences in baseline, follow-up, and post intervention changes 
(Δ) in clinical and demographic data were compared using the Kruskal-Wallis test. For 
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significantly different results, a Mann-Whitney U test was performed to determine the 
groups between which this difference applied. Where stated, the Wilcoxon signed-rank test 
was used to compare baseline and post intervention values within intervention groups. A 
type I error rate of ≤0.05 was considered significant in all cases. 
2.8.3 | Microbiome analysis 
Statistical analysis of microbiome data was conducted within the R statistical programing 
environment (V.3.2.2 for chapter 3 and V.3.3.2 for all other chapters). As with clinical 
variables, the predominance of non-normally distributed data from microbiome measure-
ments was accommodated with the use of nonparametric statistical tests. Statistical 
variation of measures between 3 or more groups was carried out with the Kruskal-Wallis H 
test with compareGroups (V.2.0), while pairwise comparisons were performed with the 
Wilcoxon signed-rank test unless otherwise noted. Correlations of variables were done with 
Spearman’s rank test. Correction of P values relating to microbiome and metabolomic 
analysis was performed using the Benjamini-Hochberg false-discovery rate (FDR) [25] in the 
base stats package in R. 
Beta diversity, the measurement of variable diversity as it is defined by habitat type 
(i.e. experimental group), was assessed with the Bray-Curtis index of dissimilarity using a 
combination of principal coordinate analysis (PCoA) and non-metric multidimensional 
scaling (NMDS), both performed with the vegan R package (V.2.4-3) [26-29]. Statistical 
assessment of dissimilarity matrices (Bray-Curtis) derived from microbial data was 
facilitated with permutational multivariate analysis of variance (PERMANOVA) tests as 
implemented by the adonis2 function in the vegan package. Identification of statistically 
relevant taxonomic features was performed with the analysis of composition 
of microbiomes (ANCOM) test as implemented in the R package of the same name (V.1.1-3) 
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[30]. Detection of underlying features of metabolic pathways in chapters 5 and 6 was 
performed with unsupervised cross-validated partial-least-squares–discriminant analysis 
(PLS-DA) and the KODAMA algorithm from the R package of the same name (V.1.4) [31]. 
Diversity measurements of microbiome variables (e.g. species and metabolic pathways) 
defined by site (i.e. participant),alpha diversity, and calculations of relative abundances 
were also performed with the vegan package [27]. Relative-abundance data were generated 
separately for identified species within each phylogenetic domain (e.g., Bacteria). 
 For metabolomic analysis, the resulting 1H-NMR and LC-MS data sets were 
imported into MatLab to conduct multivariate statistical analysis. Data were centred and 
scaled to account for the repeated-measures design and then modelled using partial-least-
squares–discriminant analysis (PLS-DA) with Monte Carlo cross-validation (MCCV) [32]. 
The fit and predictability of the models obtained were determined and expressed as R2 and 
Q2 values, respectively. 
2.8.4 | Metabonomic Statistical and Bioinformatics Analysis 
The resulting 1H-NMR and LC-MS data sets were imported into SIMCA 14.1 (Umetrics) to 
conduct multivariate statistical analysis. Principal Component Analysis (PCA), followed by 
an Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) was performed to 
examine the data sets and to observe clustering in the results according to the predefined 
classes. The OPLS-DA models in the current study were established based on one PLS 
component and one orthogonal component. Unit variance scaling was applied to 1H-NMR 
data, Pareto scaling was applied to MS data. The fit and predictability of the models 
obtained was determined by the R2Y and Q2Y values, respectively. 
Significant metabolites were obtained from LC-MS OPLS-DA models through divi-
sion of the regression coefficients by the jack-knife interval standard error to give an 
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estimate of the t-statistic. Variables with a t-statistic ≥ 1.96 (z-score, corresponding to the 
97.5 percentile) were considered significant. Significant metabolites were obtained from 1H-
NMR OPLS-DA models after investigating correlations with correlation coefficients values 
higher than 0.4. 
Univariate statistical analysis was used to examine the SCFA data set. The data was 
not normally distributed; hence the Mann-Whitney U test was performed to examine 
differences between classes. 
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Chapter 3  
―― 
THE MICROBIOME OF PROFESSIONAL ATHLETES DIFFERS FROM THAT OF CONTROLS 
NOT ONLY IN COMPOSITION BUT PARTICULARLY AT THE FUNCTIONAL METABOLIC 
LEVEL 
3.1 | Abstract 
It is evident that the gut microbiome, and therefore, factors driving its composition and 
activity, both influence human metabolic, immunological, and developmental processes. 
We previously reported that extreme physical activity and associated dietary adaptations, 
are associated with changes in faecal microbial diversity and composition relative to that of 
individuals with a more sedentary lifestyle. Here we address the impact of these factors on 
the functionality/metabolic activity of the gut microbiota in athletes, which reveals even 
greater separation between exercise and a more sedentary state. Athletes had relative 
increases in pathways (e.g. amino acid and antibiotic biosynthesis and carbohydrate 
metabolism) and faecal metabolites (e.g. microbial produced short chain fatty acids [SCFAs] 
acetate, propionate, and butyrate) associated with enhanced muscle turnover and overall 
health when compared to control groups. Differences in faecal microbiota between athletes 
and less active controls show even greater separation in metagenomic and metabolomics 
dynamics than at compositional levels, and provide added insight into the diet-exercise-gut 
microbiota paradigm.  
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3.2 | Introduction 
Regular exercise challenges systemic homeostasis resulting in a breadth of multi-
organ molecular and physiological responses, including many that centre on immunity, 
metabolism and the microbiome-gut-brain axis [1-5]. Exercise exhibits systemic and end-
organ anti-inflammatory effects, as well as contributing to more efficient carbohydrate 
metabolism, in addition to trophic effects at the level of the central nervous system [6, 7]. In 
fact, increasing physical activity offers an effective treatment and preventative strategy for 
many chronic conditions in which the gut microbiome has been implicated [8-10]. 
Conversely, a sedentary lifestyle is a major contributing factor to morbidity in developed 
Western society and is associated with heightened risk of numerous diseases of affluence, such 
as obesity, diabetes, asthma, and cardiovascular disease [11-14]. Recent evidence supports 
an influential role for the gut microbiome in these diseases [15-23]. 
 The concept that regular exercise and sustained levels of increased physical activity 
foster or assist the maintenance of a preferential intestinal microbiome has recently gained 
momentum and interest [24-29]. Previously, using 16S rRNA amplicon sequencing, we 
demonstrated taxonomic differences in gut microbiota between an elite athlete cohort of 
international-level rugby players and a group of age-matched high (>28 kg/m2) and low (<25 
kg/m2) BMI controls [26]. This analysis illustrated a significantly greater intestinal microbial 
diversity amongst the athletes compared to both control groups. This taxonomic diversity 
significantly correlated with exercise and dietary protein consumption. However, the 
possibility existed that these differences did not equate to differences at a functional level. 
Here, we re-examine the microbiome in these participants by whole metagenome shotgun 
sequencing to provide deeper insight into taxonomic composition and metabolic potential 
and by complementary metabolic phenotyping analyses of host- and microbial-derived 
Chapter 3 87 
 
 
(urine and faecal respectively) metabolic profiles. This analysis shows that the differences in 
the gut microbiota between athletes and controls is even more pronounced at the functional 
metabolic level than at the compositional level as previously reported, and provides further 
rationale for prospective controlled studies to unravel the relationship between diet, 
exercise and the gut microbiome. 
3.3 | Study objective 
It is evident that the gut microbiota and factors that influence its composition and 
activity influence human metabolic, immunological, and developmental processes. We 
previously reported that extreme physical activity with associated dietary adaptations, such 
as that pursued by professional athletes, is associated with changes in faecal microbial 
diversity and composition relative to that of individuals with a more sedentary lifestyle. 
Here we address the impact of these factors on the functionality/metabolic activity of the 
microbiota which reveals even greater separation between exercise and a more sedentary 
state. 
3.4 | Methods 
3.4.1 | Study population 
Elite professional male athletes (n = 40) and healthy controls (n = 46) matched for age 
and gender were enrolled in 2011 as previously described in the study [26]. Due to the 
range of physiques within a rugby team (player position dictates need for a variety of 
physical constitutions, i.e. forward players tend to have larger BMI values than backs, often 
in the overweight/obese range) the recruited control cohort was subdivided into two 
groups. In order to more completely include control participants, the BMI parameter for 
group inclusion was adjusted to BMI ≤ 25.2 and BMI ≥ 26.5 for the low BMI and high BMI 
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groups respectively. Approval for this study was granted by the Cork Clinical Research 
Ethics Committee. 
3.4.2 | Acquisition of clinical, exercise and dietary data 
Self-reported dietary intake information was accommodated by a research nutrition-
ist within the parameters of a food frequency questionnaire (FFQ) in conjunction with a 
photographic food atlas as per the initial investigation [26]. Fasting blood samples were 
collected and analysed at the Mercy University Hospital clinical laboratories, Cork. As the 
athletes were involved in a rigorous training camp we needed to assess the physical activity 
levels of both control groups. To determine this we used an adapted version of the EPIC-
Norfolk questionnaire [30]. Creatine kinase levels were used as a proxy for level of physical 
activity across all groups. 
3.4.3 | Preparation of Metagenomic libraries 
DNA derived from faecal samples was extracted and purified using the QIAmp 
DNA Stool Mini Kit (cat. no. 51504) prior to storage at -80°C. DNA libraries were prepared 
with the Nextera XT DNA Library Kit (cat. no. FC-131-1096) prior to processing on the 
Illumina HiSeq 2500 sequencing platform (refer to section 2.5 for further detail). 
3.4.4 | Metagenomic statistical and bioinformatic analysis 
Delivered raw FASTQ sequence files were quality checked as follows: contaminating 
sequences of human origin were first removed through the NCBI Best Match Tagger 
(BMTagger). Poor quality and duplicate read removal, as well as trimming was implement-
ed using a combination of SAM and Picard tools. Processing of raw sequence data produced 
a total of 2,803,449,392 filtered reads with a mean read count of 32,598,248.74 (± 10,639,447 
SD) per each of the 86 samples. These refined reads were then subjected to functional 
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profiling by the most recent iteration of the Human Microbiome Project (HMP) Unified 
Metabolic Analysis Network (HUMAnN2 V.0.5.0) pipeline [31]. The functional profiling 
performed by HUMAnN2 composed tabulated files of microbial metabolic pathway 
abundance and coverage derived from the Metacyc database [32]. Microbial pathway data 
was statistically analysed in the R software environment (V.3.2.2) (for further details see 
section 2.6) [33]. The GraPhlAn software tool was used to construct the circular phylogenet-
ic trees that provided the basis for comparison of taxonomic profiles generated from 
original 16S sequencing and the shotgun metagenomic sequencing introduced in this 
present chapter. All presented p values were corrected for multiple comparisons using the 
Benjamini-Hochberg False Discovery Rate (pFDR) method [34]. 
3.4.5 | Metabolic profiling 
Urine and faecal samples were prepared for metabonomic analysis as previously 
described [35, 36]. Utilising established methods, urine samples underwent 1H-NMR, 
reversed-phased (RP) and hydrophilic interaction chromatography (HILIC) profiling 
experiments. Faecal samples underwent 1H-NMR, hydrophilic interaction chromatography 
(HILIC) and bile acid UPLC-MS profiling experiments and GC-MS targeted SCFA analysis 
[36-38]. 
After data pre-processing,[39] the resulting 1H-NMR and LC-MS data sets were im-
ported into SIMCA 14.1 (Umetrics) to conduct multivariate statistical analysis. Principal 
Component Analysis (PCA), followed by Orthogonal Partial Least Squares Discriminant 
Analysis (OPLS-DA) was performed to examine the data sets and to observe clustering in 
the results according to the predefined classes. The OPLS-DA models in the current study 
were established based on one PLS component and one orthogonal component. Unit 
variance scaling was applied to 1H-NMR data, Pareto scaling was applied to MS data. The 
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fit and predictability of the models obtained was determined by the R2Y and Q2Y values, 
respectively. Significant metabolites were obtained from LC-MS OPLS-DA models through 
division of the regression coefficients by the jack-knife interval standard error to give an 
estimate of the t-statistic. Variables with a t-statistic ≥ 1.96 (z-score, corresponding to the 
97.5 percentile) were considered significant. Significant metabolites were obtained from 1H-
NMR OPLS-DA models after investigating correlations with correlation coefficients values 
higher than 0.4. Univariate statistical analysis (Mann-Whitney U test) was used to examine 
the SCFA data set. P-values were adjusted for multiple testing using the Benjamini-
Hochberg False Discovery Rate (pFDR) method. Confirmation of metabolite identities in the 
NMR data was obtained using 1D 1H NMR and 2D 1H-1H NMR and 1H-13C NMR 
experiments. In addition, statistical tools such as SubseT Optimization by Reference 
Matching (STORM) and Statistical TOtal Correlation SpectroscopY (STOCSY) were also 
applied [40, 41]. Confirmation of metabolites identities in the LC-MS data was obtained 
using Tandem MS (MS/MS) on selected target ions. 
Metabolite identification was characterized by a level of assignment (LoA) score that 
describes how the identification was made [42]. The levels used were as follows: LoA 1: 
Identified compound, confirmed by comparison to an authentic chemical reference. LoA 2: 
MS/MS precursor and product ions or 1D+2D NMR chemical shifts and multiplicity match 
to a reference database or literature to putatively annotate compound. LoA 3: Chemical shift 
(δ) and multiplicity matches a reference database to tentatively assign the compound. (For 
further details see sections 2.7-2.8).  
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3.5 | Results 
The study groups were comprised of professional male athletes (n = 40) and healthy 
controls (n = 46) [26]. To better represent the variability of BMI in the athletes, controls were 
classified as either low BMI (n = 22, BMI ≤ 25.2) or high BMI (n = 24, BMI ≥ 26.5). Participants 
made no report of gastrointestinal (GI) distress or alterations of GI transit time throughout 
the course of the initial study. 
3.5.1 | Functional structure of the enteric microbiome correlates with athletic state 
Functional metagenomic analysis of faecal samples allowed for the prediction of the 
operational potential of each individual’s microbiota. In total, 19,300 taxonomically linked 
metabolic pathways were identified in at least one individual. Comparison of phylogenetic 
constructions derived from the 16S rRNA amplicon data of our previous study and the 
functional data of this present report revealed a greater level of identification at higher 
levels of taxonomy (e.g. phylum) for 16S sequences,[26] while the metagenomic data had 
greater fidelity and superior resolution of lower levels of taxonomy (e.g. species) (Figure 
3.1). Consistent with previous results, the microbiota of the athletes were significantly more 
diverse than that of both the low and high BMI control groups at the functional level (Figure 
3.2A). Furthermore, our previous findings of an enrichment of Akkermansia in athletes was 
corroborated by the presence of significantly higher proportions of metabolic pathways 
associated with this genus in athletes when compared to high BMI controls (p < 0.001). 
Correlation analysis revealed that, of the total 19,300 pathways, 98 were significantly altered 
between the three cohorts (p < 0.05) (Supplementary Table 3.1, see appendix A). Subse-
quently, large-scale functional dissimilarity between athletes and controls was determined, 
and distinct patterns of pathway composition between groups were revealed (Supplemen-
tary Figure 3.1A). This functional distinction remained true whether applied to total 
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pathway data or to the statistically significant subset of pathways (Supplementary Figure 
3.1B). Correlation of pathways present in at least one member from both cohorts further 
exemplified the uniformity of the athletes and the division between the athletes and control 
groups (Supplementary Figure 3.1C). Separation according to group membership was 
further illustrated through Principal Coordinate Analysis (PCoA), with statistical support of 
the significant separation between the athletes and both control groups (p < 0.05) (Figure 
3.2B). This was also the case for the statistically significant subset of pathways (Supplemen-
tary Figure 3.1D). Principal Component Analysis (PCA) supplemented with a 
Correspondence Analysis (CA) and k-Nearest Neighbour (k-NN) semi-supervised learning 
approach cast further light (i.e. visualization of robustly defined class associations of 
specific individuals within the groups) on the clustering of participants within and between 
cohorts (Supplementary Figure 3.1E). 
  




Figure 3.1 | Comparison of phylogenetic constructions from metagenomic and 16S rRNA 
gene sequencing sourced from all participants. Phylogenetic trees derived from (A) 
metagenomic sequencing and (B) 16S rRNA amplicon sequencing. Taxonomic levels are 
assigned from centre out with kingdom level assignment in centre and strain level 
assignment in outer most ring. Dark blue radial highlights correspond to poorly identified 
taxonomies (i.e. ‘unknown’ and ‘unassigned’ database entries). Number of assignments at 
each level of phylogeny is displayed below the respective graph. Taxonomic trees derived 
from the two sequencing approaches illustrate an advantage of metagenomic sequencing in 
the number of predictions of lower taxonomic levels and the frequency of full identification 
of taxa, while 16S rRNA sequencing grants greater insight of high level phylogenies within 
the population.  
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Figure 3.2 | Group-wise comparison of microbial metagenomic and metabolomic 
profiles. (A) Alpha diversity for metabolic pathways from all three groups presented as 
Shannon diversity index. Pathway diversity is increased in the athlete group when 
compared to low BMI and high BMI controls. Diversity measures are statistically significant 
between high BMI controls and athletes (p < 0.049), with statistical significance between all 
groups (Kruskal Wallis p < 0.05). (B) Principal coordinate analysis (PCoA) of Bray-Curtis 
compiled distance matrix illustrates beta diversity of all microbial metabolic pathway 
relative abundances between the three groups. Ordination of the pathways between the 
groups shows significant variation from one another (Adonis PERMANOVA p < 0.05). (C & 
D) Cross validated orthogonal partial least squares regression discriminant analysis (OPLS-
DA) of full Nuclear Magnetic Resonance (1H-NMR) spectra from urine (R2Y=0.86, 
Q2Y=0.60)(C) and faecal water (R2Y=0.86, Q2Y=0.52)(D) samples. OPLS-DA displays robust 
separation between the detected metabolic profiles of athletes and controls. Models are 
comprised of 1 predictive (tcv[1]) and 1 orthogonal (tocv[1]) principal component.  
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Pathways exhibiting statistically significant variation between the athletes and both 
control groups were organised according to MetaCyc metabolic pathway hierarchy 
classification (34 metabolic categories), highlighting a number of differences (Figure 3.3A, 
Supplementary Table 3.2 located in Appendix A). Distinct clustering patterns were 
observed within each cohort, with the high BMI control group having the lowest average 
abundance scores across 31 metabolic pathway categories (the exceptions being Vitamin 
Biosynthesis (VB), Lipid Biosynthesis (LB), and Amino Acid Biosynthesis (AAB) categories). 
The athlete group had the highest mean abundance across 29 of the 34 metabolic categories 
(e.g. Carbohydrate Biosynthesis [CB], Cofactor Biosynthesis [CfB], and Energy Metabolism 
[EM]) (Supplementary Table 3.2, Appendix A). Numerous statistically significant (p < 0.05) 
associations were identified between pathway abundances and serum Creatine Kinase—an 
enzymatic marker of muscle activity (CK, IU/L), total bilirubin (IU/L) and dietary 
macronutrient intake of protein (g/day), fibre (g/day), carbohydrates (g/day), sugars (g/day), 
starch (g/day), fat (g/day), and total energy (KJ/day) (Figure 3.3B). Each group was 
represented by distinct association profiles of the correlation between clinical measurements 
and metagenomic pathways. Dietary factors, sugars and other carbohydrates, as well as 
energy intake, provide the majority of the correlation for the control groups whereas the 
athlete group was predominantly correlated with CK, total bilirubin, and total energy 
intake. Of the total number of metabolic pathways with associations to the clinical data 
from all three groups (10,760; data not shown), relevant pathways related to the production 
of secondary metabolites, co-factors, and SCFAs were identified (e.g. biotin biosynthesis 
and pyruvate fermentation to butanoate). 
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Figure 3.3 | Group variation of microbial metabolic function and associations between 
pathways and clinical and dietary variables. (A) Mean relative abundance values of 
statistically significant (Kruskal Wallis p < 0.05) metabolic pathways binned according to 
categories of metabolic function. The relative abundance values of each group (columns) 
and statistically detected pathways (rows) demonstrates variability in the metabolic 
potential of microbial communities from the separate groups. (B) Number of metabolic 
pathways significantly (Benjamini-Hochberg corrected p < 0.05) correlated with dietary 
constituents and blood serum metabolites. The relatively large number of significant 
associations between metabolic pathways and clinical measurements are presented as 
counts of associations for the three groups, and illustrates variation in the potential 
influence of different factors on the microbiome of participants in the separate groups. 
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3.5.2 | Distinct differences between host and microbial metabolites in athletes and 
controls 
A combination of multi-platform metabolic phenotyping and multivariate analysis 
based on Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) was used to 
compare urinary and faecal samples from athletes and controls. The cross-validated (CV) 
OPLS-DA models show strong differences between athletes and controls in urine samples 
by proton nuclear magnetic resonance (1H-NMR) analysis (R2Y=0.86, Q2Y=0.60, Figure 3.2C), 
hydrophilic interaction ultra-performance liquid chromatography mass spectroscopy 
(HILIC UPLC-MS) positive mode analysis (R2Y=0.85, Q2Y=0.74, Supplementary Figure 3.2A) 
and reverse phase ultra-performance liquid chromatography mass spectroscopy (RP UPLC-
MS) in both positive and negative mode analysis (R2Y=0.83, Q2Y=0.73, and R2Y=0.83, 
Q2Y=0.67, Supplementary Figure 3.2B and 3.2C respectively). Likewise, the CV-OPLS-DA 
models comparing faecal samples, although weaker than the urine models, reveal 
significant differences between athletes and controls by 1H-NMR analysis (R2Y=0.86, 
Q2Y=0.52, Figure 3.2D) and HILIC UPLC-MS positive mode analysis (R2Y=0.65, Q2Y=0.34, 
Supplementary Figure 3.2D). 
The loadings of the pairwise OPLS-DA models were used to identify metabolites 
discriminating between the two classes. Athletes’ 1H-NMR metabolic phenotypes were 
characterised by higher levels of trimethylamine-N-oxide (TMAO), L-carnitine, dimethyl-
glycine, O-acetyl carnitine, proline betaine, creatinine, acetoacetate, 3-hydroxy-isovaleric 
acid, acetone, N-methylnicotinate, N-methylnicotinamide, phenylacetylglutamine (PAG) 
and 3-methylhistidine in urine samples and higher levels of propionate, acetate, butyrate, 
trimethylamine (TMA), lysine, and methylamine in faecal samples, relative to controls. 
Beta-alanine betaine was higher in both faecal and urine samples of athletes. Athletes were 
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further characterised by lower levels of glycerate, allantoin and succinate and lower levels 
of glycine and tyrosine relative to controls in urine and faecal samples, respectively 
(Supplementary Table 3.3). 
While numerous metabolites discriminated significantly between athletes and con-
trols with RP UPLC-MS positive (490) and negative (434) modes for urine, as well as with 
HILIC UPLC-MS positive mode for urine (196) and faecal water (3), key metabolites were 
structurally identified using the strategy described below. UPLC-MS analyses revealed 
higher urinary excretion of N-formylanthranilic acid, hydantoin-5-propionic acid, 3-
Carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), CMPF glucuronide, trimeta-
phosphoric acid, acetylcarnitine - C2, propionylcarnitine - C3, isobutyrylcarnitine – C4, 2-
Methylbutyroylcarnitine - C5, Hexanoylcarnitine - C6, C9:1-carnitine, L-valine, nicotinuric 
acid, 4-pyridoxic acid and creatinine in athletes relative to controls. Levels of glutamine, 7-
methylxanthine, imidazoleacetic acid, isoquinoline / quinolone were lower in athletes’ 
urinary samples relative to controls. Additionally, 16 unknown glucuronides were lower in 
the athlete samples (Supplementary Table 3.4). 
SCFA levels in faeces measured by targeted GC-MS showed significantly higher lev-
els of acetate, propionate, butyrate ( all with p < 0.001) and valerate (p = 0.011) in athletes 
relative to controls. Isobutyrate and isovalerate did not differ significantly between the 
groups (Figure 3.4B, Supplementary Table 3.5). Furthermore, concentrations of propionate 
strongly correlated to protein intake while butyrate was shown to have a strong association 
with intake of dietary fibre (Supplementary Table 3.6).  




Figure 3.4 | Athletes display a profile of Short Chain Fatty Acids that alters from that of the 
controls. (A) Heat map of bacterial taxa (family, genus, and species level) that correlate with 
faecal short-chain fatty acid levels using Spearman’s correlation. Cool colours represent 
positive correlations; hot colours represent negative correlations (r). All taxa shown had a 
correlation p-value < 0.01. Those marked * represent correlations with a pFDR < 0.01 after 
Benjamini-Hochberg multiple testing corrections. (B) Median concentrations of GC-MS 
derived faecal short chain fatty acid. Quantitative analysis of SCFAs in faecal samples 
shows significant increase in measured concentrations of acetate, propionate, butyrate, and 
valerate in athletes. Error bars represent 95% confidence intervals. * Data statistically 
significant (p < 0.05 after Benjamini-Hochberg corrections). (C) Quantification of statistically 
relevant correlations of metabolic pathways to GC-MS derived faecal SCFA concentrations 
(μM). Athletes consistently present great numbers of significant associations between 
pathways and SCFA concentrations.  
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3.5.3 | Correlating metabonomic and metagenomic results 
Correlation analysis between targeted measurements of SCFAs and taxonomic data 
from 16S rRNA sequencing revealed a number of correlations that remained significant 
following correction; Roseburia was positively correlated with acetate (p = 0.004) and 
butyrate (p = 0.018) while Family XIII Incertae Sedis was positively correlated with 
isobutyrate (p < 0.001), isovaleric acid (p < 0.001) and valeric acid (p = 0.008) (Figure 3.4A, 
Supplementary Table 3.7). 
SCFAs were also correlated with pathway relative abundances, with all SCFAs asso-
ciating with considerably more pathways in the athletes versus the controls (Figure 3.4C). 
Multiple statistically significant (7,948) (p < 0.05) correlations between the metabolic 
pathways and SCFAs were identified (Supplementary Table 3.8, refer to Appendix A). Two 
distinct blocks of proportionately discriminant correlations were observed with isobutyric 
and isovaleric acids, which were more abundant in the athletes while acetic and butyric 
acids were more proportionately abundant in controls. Correlations of the SCFA 
concentrations to pathways related to fermentation, biosynthesis, or modification of fatty 
acids were identified among the numerous other associations (see supplementary Table 3.8 
for complete list). Additional correlations of metabolic pathways against well-identified 
metabolites detected from both faecal water (Figure 3.5A and 3.5C) and urine (Figure 3.5B 
and 3.5D) presented numerous significant associations (6,186 and 13,412, respectively; p < 
0.05, data not shown) (). It was also observed that 16 genera correlated with 12 metabolites 
(Supplementary Table 3.9).  




Figure 3.5 | Distinctive association profiles of metabolic pathways to metabolites in 
athletes and controls. (A) Significant correlations of faecal water derived metabolites and 
metabolic pathways, represented by number of correlations for each metabolite. (B) Urine 
metabolites significantly correlated to pathways and displayed as number of correlations. 
(C) Significant correlations shown in (A) displayed as proportions of total associations. (D) 
Correlations presented in (B) given as proportions of total associations. All panels illustrate 
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3.6 | Discussion 
The results confirm enhancement of microbial diversity in athletes compared with 
controls. Supporting previous insights into the beneficial influence of physical exercise and 
associated diet on the compositional structure of the gut microbiota [25, 26, 43], this study 
has extended the paradigm to include links between physical fitness and the functional 
potential of the gut microbiota and its metabolites. It must be conceded that some athletes, 
although fit, may not necessarily be more healthy [44]. 
Athletes have an increased abundance of pathways that—giving an equivalent 
amount of expression activity—could be exploited by the host for potential health benefit, 
including biosynthesis of organic cofactors and antibiotics, as well as carbohydrate 
degradation and secondary metabolite metabolism compared to both control groups [45]. 
Furthermore, athletes have an enriched profile of SCFAs, previously associated with 
numerous health benefits and a lean phenotype [46-48]. While interpretation of SCFA data 
can be difficult as levels represent a combination of SCFA production and host-absorption 
rates, it is notable that as previously presented, the athletes’ diet maintained significantly 
higher quantities of fibre intake [26]. This, along with an increased number of detected 
SCFA pathways in the athletes would be conducive to an enhanced rate of SCFA 
production [49]. 
It was noted that athletes excreted proportionately higher levels of the metabolite 
TMAO, an end product metabolite of dietary protein degradation. Elevated TMAO has 
been observed in patients with cardiovascular disease and atherosclerosis, highlighting a 
potential downside to increased protein intake [15-17, 22, 50]. However, TMAO is also 
found in high levels in the urine of Japanese populations [51], who do not have high risk for 
CVD. Similarly to these populations, the athletes’ diet contained a significantly greater 
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proportion of fish. Our current understanding of the implications of this result remains 
limited and requires elaboration in future studies. Furthermore, pathway abundance in a 
metagenome merely reflects functional potential and not necessarily increased expression in 
situ. 
Variance of metagenomic composition between athletes and controls was exempli-
fied with unique pathway-pathway correlations between the two groups. Analysis of 
categorically arranged pathway abundances within the separate cohorts provided 
additional insight into the previously described dichotomy between the microbiota of 
athletes and high BMI controls. The two groups displayed distinct structures of functional 
capacity, separately oriented to operate under the different physiological milieu of the two 
groups. Notably, from a functional perspective, the microbiota of the low BMI group was 
more similar to the athletes. The low BMI controls were generally engaged in a modestly 
active-lifestyle, reflected by their leanness and increased levels of CK. It is speculative but 
not implausible, that moderate improvements in physical activity, for overweight and obese 
individuals may confer the beneficial metabolic functions observed within the athlete 
microbiome. 
Dietary contributions to the functional composition of the enteric microbial system 
are also evident in our study. The relative abundances of pathways related to fundamental 
metabolic function—amino acid biosynthesis, vitamin biosynthesis, and lipid biosynthe-
sis—were higher on average within the high BMI control group when compared to the 
athlete group. The mechanisms behind these differences are unclear and might reflect 
chronic adaptation of the athlete gut microbiome; possibly due to a reduced reliance on the 
corresponding biosynthetic capacities of their gut microbiota. On the contrary, the athlete 
microbiome presents a functional capacity that is primed for tissue repair and to harness 
104 
The microbiome of professional athletes differs from that of controls not only in composition but 
particularly at the functional metabolic level  
 
 
energy from the diet with increased capacity for carbohydrate, cell structure and nucleotide 
biosynthesis, reflecting the significant energy demands and high cell-turnover evident in 
elite sport. 
Remarkably, our examination of pathway correlation to dietary macronutrients and 
plasma CK, as a biomarker of exercise [52], is suggestive of an impact of physical activity 
upon the utilization of dietary nutrients by the microbiota of the gut. Comparing athletes to 
both high and low BMI controls, a greater number of pathways correlating to specific 
macronutrients with the controls suggests a shift in the dynamics of these varied metabolic 
functions. The impact of the athletes’ increased protein intake compared to both control 
groups was evident in the metabolomic phenotyping results. By-products of dietary protein 
metabolism (mostly by microbes) including TMAO, carnitines, trimethylamine, 3-Carboxy-
4-methyl-5-propyl-2-furanpropionic acid, and 3-hydroxy-isovaleric acid are all elevated in 
the athlete cohort. Of particular interest is 3-hydroxy-isovaleric acid (potentially from egg 
consumption) which has been demonstrated to have efficacy for inhibiting muscle wasting 
when used in conjunction of physical exercise [53]. The compound is also commonly used 
as a supplement by athletes to increase exercise-induced gains in muscle size, muscle 
strength, and lean body mass, reduce exercise-induced muscle damage, and speed recovery 
from high-intensity exercise [54]. Numerous metabolites associated with muscle turnover—
creatine, 3-methylhistidine, and L-valine—and host metabolism—carnitine—are elevated in 
the athlete groups. Metabolites derived from vitamins and recovery supplements common 
in professional sports, including glutamine, lysine, 4-pyridoxic acid, and nicotinamide, are 
also raised in the athlete group. 
It is notable that PAG—a microbial conversion product of phenylalanine—has been 
associated with a lean phenotype, and is increased in the athletes [55]. Furthermore, PAG 
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positively correlates with the genus Erysipelotrichaceae Incertae Sedis, which we have 
previously noted to be present in relatively higher proportions in the athlete group 
compared to both control groups. PAG is the strongest biomarker post bariatric surgery, 
where it is associated with an increase in the relative proportions of Proteobacteria as 
observed here in the athlete group. Within the SCFAs, two distinct clusters were observed; 
acetic acid, propionic acid and butyric acid correlate with dietary contributors (fibre and 
protein), while isobutyric acid, isovaleric acid and valeric acid correlate with microbial 
diversity. The same clusters are observed when correlating with individual taxa, in support 
of previously observed links between SCFAs and numerous metabolic benefits and a lean 
phenotype [46-48]. 
Our on-going work in this area with non-athletes engaging in a structured exercise 
regime looks to further explore components of the exercise and diet-microbiome paradigm, 
which, along with the present study may inform the design of exercise and fitness 
programs, including diet design in the context of optimizing microbiota functionality for 
both athletes and the general population. 
  
106 
The microbiome of professional athletes differs from that of controls not only in composition but 
particularly at the functional metabolic level  
 
 
3.7 | References 
[1] A. Harkin, Muscling in on depression, N Engl J Med 371 (24) (2014) 2333-4. 
[2] F. B. Benatti, B. K. Pedersen, Exercise as an anti-inflammatory therapy for rheumatic 
diseases-myokine regulation, Nat Rev Rheumatol 11 (2) (2015) 86-97. 
[3] J. A. Hawley, A. Krook, Metabolism: One step forward for exercise, Nat Rev Endocrinol 12 
(1) (2016) 7-8. 
[4] L. Hoffman-Goetz, N. Pervaiz, N. Packer, J. Guan, Freewheel training decreases pro- and 
increases anti-inflammatory cytokine expression in mouse intestinal lymphocytes, Brain 
Behav Immun 24 (7) (2010) 1105-15. 
[5] W. Barton, F. Shanahan, P. D. Cotter, O. O'Sullivan, The metabolic role of the microbiota, 
Clinical Liver Disease 5 (4) (2015) 91-93. 
[6] K. L. Szuhany, M. Bugatti, M. W. Otto, A meta-analytic review of the effects of exercise on 
brain-derived neurotrophic factor, J Psychiatr Res 60 (2015) 56-64. 
[7] S. M. Ryan, Y. M. Nolan, Neuroinflammation negatively affects adult hippocampal 
neurogenesis and cognition: can exercise compensate?, Neurosci Biobehav Rev 61 (2016) 
121-31. 
[8] E. Johannesson, M. Simren, H. Strid, A. Bajor, R. Sadik, Physical activity improves 
symptoms in irritable bowel syndrome: a randomized controlled trial, Am J Gastroenterol 
106 (5) (2011) 915-22. 
[9] T. E. Robsahm, B. Aagnes, A. Hjartaker, H. Langseth, F. I. Bray, I. K. Larsen, Body mass 
index, physical activity, and colorectal cancer by anatomical subsites: a systematic review 
and meta-analysis of cohort studies, Eur J Cancer Prev 22 (6) (2013) 492-505. 
[10] L. Schwingshackl, B. Missbach, S. Dias, J. Konig, G. Hoffmann, Impact of different training 
modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a 
systematic review and network meta-analysis, Diabetologia 57 (9) (2014) 1789-97. 
[11] A. Biswas, P. I. Oh, G. E. Faulkner, R. R. Bajaj, M. A. Silver, M. S. Mitchell, D. A. Alter, 
Sedentary time and its association with risk for disease incidence, mortality, and 
hospitalization in adults: a systematic review and meta-analysis, Ann Intern Med 162 (2) 
(2015) 123-32. 
[12] R. V. Same, D. I. Feldman, N. Shah, S. S. Martin, M. Al Rifai, M. J. Blaha, G. Graham, H. 
M. Ahmed, Relationship Between Sedentary Behavior and Cardiovascular Risk, Curr Cardiol 
Rep 18 (1) (2016) 6. 
[13] E. G. Wilmot, C. L. Edwardson, F. A. Achana, M. J. Davies, T. Gorely, L. J. Gray, K. 
Khunti, T. Yates, S. J. Biddle, Sedentary time in adults and the association with diabetes, 
cardiovascular disease and death: systematic review and meta-analysis, Diabetologia 55 (11) 
(2012) 2895-905. 
Chapter 3 107 
 
 
[14] Y. C. Chen, Y. K. Tu, K. C. Huang, P. C. Chen, D. C. Chu, Y. L. Lee, Pathway from central 
obesity to childhood asthma. Physical fitness and sedentary time are leading factors, Am J 
Respir Crit Care Med 189 (10) (2014) 1194-203. 
[15] R. A. Koeth, Z. Wang, B. S. Levison, J. A. Buffa, E. Org, B. T. Sheehy, E. B. Britt, X. Fu, Y. 
Wu, L. Li, J. D. Smith, J. A. DiDonato, J. Chen, H. Li, G. D. Wu, J. D. Lewis, M. Warrier, J. 
M. Brown, R. M. Krauss, W. H. Tang, F. D. Bushman, A. J. Lusis, S. L. Hazen, Intestinal 
microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis, Nat 
Med 19 (5) (2013) 576-85. 
[16] W. H. W. Tang, Z. E. Wang, B. S. Levison, R. A. Koeth, E. B. Britt, X. M. Fu, Y. P. Wu, S. 
L. Hazen, Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk, 
New England Journal of Medicine 368 (17) (2013) 1575-1584. 
[17] W. H. W. Tang, S. L. Hazen, Microbiome, trimethylamine N-oxide, and cardiometabolic 
disease, Translational Research (2016)  
[18] A. Woting, N. Pfeiffer, G. Loh, S. Klaus, M. Blaut, Clostridium ramosum promotes high-fat 
diet-induced obesity in gnotobiotic mouse models, MBio 5 (5) (2014) e01530-14. 
[19] K. M. Utzschneider, M. Kratz, C. J. Damman, M. Hullar, Mechanisms linking the gut 
microbiome and glucose metabolism., The Journal of clinical endocrinology and metabolism 
101 (4) (2016) jc20154251. 
[20] P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, J. I. Gordon, An 
obesity-associated gut microbiome with increased capacity for energy harvest, Nature 444 
(7122) (2006) 1027-31. 
[21] N. C. Williams, M. A. Johnson, D. E. Shaw, I. Spendlove, J. Vulevic, G. R. Sharpe, K. A. 
Hunter, A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced 
bronchoconstriction and markers of airway inflammation, Br J Nutr 116 (5) (2016) 798-804. 
[22] Z. Wang, E. Klipfell, B. J. Bennett, R. Koeth, B. S. Levison, B. Dugar, A. E. Feldstein, E. B. 
Britt, X. Fu, Y. M. Chung, Y. Wu, P. Schauer, J. D. Smith, H. Allayee, W. H. Tang, J. A. 
DiDonato, A. J. Lusis, S. L. Hazen, Gut flora metabolism of phosphatidylcholine promotes 
cardiovascular disease, Nature 472 (7341) (2011) 57-63. 
[23] A. Zhernakova, A. Kurilshikov, M. J. Bonder, E. F. Tigchelaar, M. Schirmer, T. Vatanen, Z. 
Mujagic, A. V. Vila, G. Falony, S. Vieira-Silva, J. Wang, F. Imhann, E. Brandsma, S. A. 
Jankipersadsing, M. Joossens, M. C. Cenit, P. Deelen, M. A. Swertz, s. LifeLines cohort, R. 
K. Weersma, E. J. Feskens, M. G. Netea, D. Gevers, D. Jonkers, L. Franke, Y. S. Aulchenko, 
C. Huttenhower, J. Raes, M. H. Hofker, R. J. Xavier, C. Wijmenga, J. Fu, Population-based 
metagenomics analysis reveals markers for gut microbiome composition and diversity, 
Science 352 (6285) (2016) 565-9. 
[24] O. Cronin, M. G. Molloy, F. Shanahan, Exercise, fitness, and the gut, Curr Opin 
Gastroenterol 32 (2) (2016) 67-73. 
108 
The microbiome of professional athletes differs from that of controls not only in composition but 
particularly at the functional metabolic level  
 
 
[25] M. Estaki, J. Pither, P. Baumeister, J. P. Little, S. K. Gill, S. Ghosh, Z. Ahmadi-Vand, K. R. 
Marsden, D. L. Gibson, Cardiorespiratory fitness as a predictor of intestinal microbial 
diversity and distinct metagenomic functions, Microbiome 4 (1) (2016) 42. 
[26] S. F. Clarke, E. F. Murphy, O. O'Sullivan, A. J. Lucey, M. Humphreys, A. Hogan, P. Hayes, 
M. O'Reilly, I. B. Jeffery, R. Wood-Martin, D. M. Kerins, E. Quigley, R. P. Ross, P. W. 
O'Toole, M. G. Molloy, E. Falvey, F. Shanahan, P. D. Cotter, Exercise and associated dietary 
extremes impact on gut microbial diversity, Gut 63 (12) (2014) 1913-20. 
[27] O. O'Sullivan, O. Cronin, S. F. Clarke, E. F. Murphy, M. G. Molloy, F. Shanahan, P. D. 
Cotter, Exercise and the microbiota, Gut Microbes 6 (2) (2015) 131-6. 
[28] O. Cronin, O. O'Sullivan, W. Barton, P. D. Cotter, M. G. Molloy, F. Shanahan, Gut 
microbiota: implications for sports and exercise medicine, Br J Sports Med (2017)  
[29] A. Rankin, C. O’Donavon, S. M. Madigan, O. O’Sullivan, P. D. Cotter, ‘Microbes in sport’ –
The potential role of the gut microbiota in athlete health and performance, British Journal of 
Sports Medicine (2017) bjsports-2016-097227. 
[30] N. J. Wareham, R. W. Jakes, K. L. Rennie, J. Mitchell, S. Hennings, N. E. Day, Validity and 
repeatability of the EPIC-Norfolk Physical Activity Questionnaire, International Journal of 
Epidemiology 31 (1) (2002) 168-74. 
[31] S. Abubucker, N. Segata, J. Goll, A. M. Schubert, J. Izard, B. L. Cantarel, B. Rodriguez-
Mueller, J. Zucker, M. Thiagarajan, B. Henrissat, O. White, S. T. Kelley, B. Methe, P. D. 
Schloss, D. Gevers, M. Mitreva, C. Huttenhower, Metabolic reconstruction for metagenomic 
data and its application to the human microbiome, PLoS Comput Biol 8 (6) (2012) e1002358. 
[32] R. Caspi, T. Altman, R. Billington, K. Dreher, H. Foerster, C. A. Fulcher, T. A. Holland, I. 
M. Keseler, A. Kothari, A. Kubo, M. Krummenacker, M. Latendresse, L. A. Mueller, Q. 
Ong, S. Paley, P. Subhraveti, D. S. Weaver, D. Weerasinghe, P. Zhang, P. D. Karp, The 
MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of 
Pathway/Genome Databases, Nucleic Acids Res 42 (Database issue) (2014) D459-71. 
[33] R Development Core Team, R: A Language and Environment for Statistical Computing (R 
Foundation for Statistical Computing, Vienna, 2012), URL: http:// www. R-project. org 
(2015)  
[34] Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate - a Practical and Powerful 
Approach to Multiple Testing, Journal of the Royal Statistical Society Series B-
Methodological 57 (1) (1995) 289-300. 
[35] A. C. Dona, B. Jimenez, H. Schafer, E. Humpfer, M. Spraul, M. R. Lewis, J. T. Pearce, E. 
Holmes, J. C. Lindon, J. K. Nicholson, Precision high-throughput proton NMR spectroscopy 
of human urine, serum, and plasma for large-scale metabolic phenotyping, Anal Chem 86 
(19) (2014) 9887-94. 
Chapter 3 109 
 
 
[36] R. Garcia-Villalba, J. A. Gimenez-Bastida, M. T. Garcia-Conesa, F. A. Tomas-Barberan, J. 
Carlos Espin, M. Larrosa, Alternative method for gas chromatography-mass spectrometry 
analysis of short-chain fatty acids in faecal samples, J Sep Sci 35 (15) (2012) 1906-13. 
[37] E. J. Want, I. D. Wilson, H. Gika, G. Theodoridis, R. S. Plumb, J. Shockcor, E. Holmes, J. K. 
Nicholson, Global metabolic profiling procedures for urine using UPLC-MS, Nat Protoc 5 
(6) (2010) 1005-18. 
[38] M. H. Sarafian, M. R. Lewis, A. Pechlivanis, S. Ralphs, M. J. McPhail, V. C. Patel, M. E. 
Dumas, E. Holmes, J. K. Nicholson, Bile acid profiling and quantification in biofluids using 
ultra-performance liquid chromatography tandem mass spectrometry, Anal Chem 87 (19) 
(2015) 9662-70. 
[39] K. A. Veselkov, L. K. Vingara, P. Masson, S. L. Robinette, E. Want, J. V. Li, R. H. Barton, 
C. Boursier-Neyret, B. Walther, T. M. Ebbels, I. Pelczer, E. Holmes, J. C. Lindon, J. K. 
Nicholson, Optimized preprocessing of ultra-performance liquid chromatography/mass 
spectrometry urinary metabolic profiles for improved information recovery, Anal Chem 83 
(15) (2011) 5864-72. 
[40] J. M. Posma, I. Garcia-Perez, M. De Iorio, J. C. Lindon, P. Elliott, E. Holmes, T. M. Ebbels, 
J. K. Nicholson, Subset optimization by reference matching (STORM): an optimized 
statistical approach for recovery of metabolic biomarker structural information from 1H 
NMR spectra of biofluids, Anal Chem 84 (24) (2012) 10694-701. 
[41] O. Cloarec, M. E. Dumas, A. Craig, R. H. Barton, J. Trygg, J. Hudson, C. Blancher, D. 
Gauguier, J. C. Lindon, E. Holmes, J. Nicholson, Statistical total correlation spectroscopy: an 
exploratory approach for latent biomarker identification from metabolic 1H NMR data sets, 
Anal Chem 77 (5) (2005) 1282-9. 
[42] L. W. Sumner, A. Amberg, D. Barrett, M. H. Beale, R. Beger, C. A. Daykin, T. W. Fan, O. 
Fiehn, R. Goodacre, J. L. Griffin, T. Hankemeier, N. Hardy, J. Harnly, R. Higashi, J. Kopka, 
A. N. Lane, J. C. Lindon, P. Marriott, A. W. Nicholls, M. D. Reily, J. J. Thaden, M. R. Viant, 
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working 
Group (CAWG) Metabolomics Standards Initiative (MSI), Metabolomics 3 (3) (2007) 211-
221. 
[43] B. A. Petriz, A. P. Castro, J. A. Almeida, C. P. Gomes, G. R. Fernandes, R. H. Kruger, R. W. 
Pereira, O. L. Franco, Exercise induction of gut microbiota modifications in obese, non-obese 
and hypertensive rats, BMC Genomics 15 (1) (2014) 511. 
[44] P. B. Maffetone, P. B. Laursen, Athletes: Fit but Unhealthy?, Sports Med Open 2 (1) (2016) 
24. 
[45] H. J. Flint, K. P. Scott, S. H. Duncan, P. Louis, E. Forano, Microbial degradation of complex 
carbohydrates in the gut, Gut Microbes 3 (4) (2012) 289-306. 
110 
The microbiome of professional athletes differs from that of controls not only in composition but 
particularly at the functional metabolic level  
 
 
[46] A. Koh, F. De Vadder, P. Kovatcheva-Datchary, F. Backhed, From Dietary Fiber to Host 
Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites, Cell 165 (6) (2016) 1332-
1345. 
[47] V. K. Ridaura, J. J. Faith, F. E. Rey, J. Cheng, A. E. Duncan, A. L. Kau, N. W. Griffin, V. 
Lombard, B. Henrissat, J. R. Bain, M. J. Muehlbauer, O. Ilkayeva, C. F. Semenkovich, K. 
Funai, D. K. Hayashi, B. J. Lyle, M. C. Martini, L. K. Ursell, J. C. Clemente, W. Van 
Treuren, W. A. Walters, R. Knight, C. B. Newgard, A. C. Heath, J. I. Gordon, Gut microbiota 
from twins discordant for obesity modulate metabolism in mice, Science 341 (6150) (2013) 
1241214. 
[48] H. M. Hamer, D. M. Jonkers, A. Bast, S. A. Vanhoutvin, M. A. Fischer, A. Kodde, F. J. 
Troost, K. Venema, R. J. Brummer, Butyrate modulates oxidative stress in the colonic 
mucosa of healthy humans, Clin Nutr 28 (1) (2009) 88-93. 
[49] G. den Besten, K. van Eunen, A. K. Groen, K. Venema, D. J. Reijngoud, B. M. Bakker, The 
role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy 
metabolism, J Lipid Res 54 (9) (2013) 2325-40. 
[50] B. J. Bennett, T. Q. de Aguiar Vallim, Z. Wang, D. M. Shih, Y. Meng, J. Gregory, H. 
Allayee, R. Lee, M. Graham, R. Crooke, P. A. Edwards, S. L. Hazen, A. J. Lusis, 
Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex 
genetic and dietary regulation, Cell Metab 17 (1) (2013) 49-60. 
[51] E. Holmes, R. L. Loo, J. Stamler, M. Bictash, I. K. Yap, Q. Chan, T. Ebbels, M. De Iorio, I. 
J. Brown, K. A. Veselkov, M. L. Daviglus, H. Kesteloot, H. Ueshima, L. Zhao, J. K. 
Nicholson, P. Elliott, Human metabolic phenotype diversity and its association with diet and 
blood pressure, Nature 453 (7193) (2008) 396-400. 
[52] P. Brancaccio, F. M. Limongelli, N. Maffulli, Monitoring of serum enzymes in sport, Br J 
Sports Med 40 (2) (2006) 96-7. 
[53] S. L. Stratton, A. Bogusiewicz, M. M. Mock, N. I. Mock, A. M. Wells, D. M. Mock, 
Lymphocyte propionyl-CoA carboxylase and its activation by biotin are sensitive indicators 
of marginal biotin deficiency in humans, Am J Clin Nutr 84 (2) (2006) 384-8. 
[54] G. J. Wilson, J. M. Wilson, A. H. Manninen, Effects of beta-hydroxy-beta-methylbutyrate 
(HMB) on exercise performance and body composition across varying levels of age, sex, and 
training experience: A review, Nutr Metab (Lond) 5 (2008) 1. 
[55] E. Holmes, J. V. Li, T. Athanasiou, H. Ashrafian, J. K. Nicholson, Understanding the role of 
gut microbiome-host metabolic signal disruption in health and disease, Trends Microbiol 19 
(7) (2011) 349-59.  
Chapter 3 111 
 
 
3.8 | Supplementary Content 
 
Supplementary Figure 3.1 | Comparison of metabolic pathway composition between 
groups. Comparative correlation plots of total metabolic pathways (A) pathways of 
statistical significance (B) and pathways of which each is represented in at least one subject 
from each group (C). The respective subsets of metabolic pathways are correlated separately 
for the athlete group (left and bottom) and all controls (right and top), after which the 
correlation plots are merged. The joined correlation plots illustrate distinct dynamics of 
pathway interrelation between athletes and controls. (D) Principal coordinate analysis 
(PCoA) of Bray-Curtis compiled distance matrix of the 98 significant pathway relative 
abundances. Groups show significant variation from one another (Adonis PERMANOVA P 
<.001). (E) Semi-supervised learning supplemented Principal Component Analysis (PCA-
CA-kNN) of total pathway abundance values from all three groups. Outliers were detected 
through deviation of the defined grouping structure. 
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Supplementary Figure 3.2 | OPLS-DA cross-validated scores plots comparing athletes to 
controls. Models are comprised of 1 predictive (tcv[1]) and 1 orthogonal (tocv[1]) principal 
component. (A) UPLC-MS (HILIC, positive mode) urine sample analysis (R2Y=0.85, 
Q2Y=0.74), (B) UPLC-MS (reversed phase, positive mode) urine sample analysis (R2Y=0.83, 
Q2Y=0.73), (C) UPLC-MS (reversed phase, negative mode) urine sample analysis (R2Y=0.83, 
Q2Y=0.67), (D) UPLC-MS (HILIC, positive mode) faecal sample analysis (R2Y=0.65, 
Q2Y=0.34). Models are comprised of 1 predictive (tcv[1]) and 1 orthogonal (tocv[1]) 
principal component. 
 
Supplementary Table 3.1 | Statistically significant metagenomic pathways. Pathways 
found to be statistically significant between the athlete group and both low and high BMI 
control groups. See appendix A. 
 
Supplementary Table 3.2 | Significant pathways organised according to MetaCyc 
metabolic classification. Pathways of statistical significance were organised into metabolic 
classes according to the MetaCyc database. See appendix A 




1H chemical shift δ (multiplicity) a 
[Linked with STOCSY / TOCSY] LoAb Association Biofluid 
TMAO 3.27 (s) 1 ↑ Urine 
L-Carnitine 3.23 (s), 2.45 (dd), 3.43 (m) 1 ↑ Urine 
Dimethylglycine 2.93 (s), 3.72 (s) 1 ↑ Urine 
O-Acetyl Carnitine 3.19 (s), 2.15 (s) 2 ↑ Urine 
Proline Betaine 3.30 (s), 3.11 (s) 2 ↑ Urine 
Creatinine 3.05 (s), 4.06 (s) 2 ↑ Urine 
Acetoacetate 2.29 (s), 3.45 (s) 2 ↑ Urine 
3-hydroxy-isovaleric acid 1.27 (s), 2.37 (s) 2 ↑ Urine 
Acetone 2.24 (s) 2 ↑ Urine 
N-methylnicotinate 4.44 (s), 8.84 (d), 9.12 (s), 8.10 (t) 2 ↑ Urine 
N-methylnicotinamide 
4.486 (s), 8.19 (t), 8.90 (d), 8.96 (d), 
9.29 (s) 
2 ↑ Urine 
Phenylacetylglutamine 
(PAG) 
2.11 (m), 2.27 (m), 3.67 (m), 4.19 (m), 
7.36 (t), 7.43 (t) 
2 ↑ Urine 
3-Methylhistidine 
3.32 (dd), 3.34 (dd), 3.76 (s), 3.98 (dd), 
7.16 (s), 8.27 (s) 
2 ↑ Urine 
Beta alanine betaine  
(3-N-trimethyl-
aminoproprionic acid)* 
3.12 (s) - ↑ Urine 
Unknown B 6.67 (d) - ↑ Urine 
Unknown C 2.90 (t), 4.42 (s), 4.43 (d) - ↑ Urine 
Unknown D 2.13 (d) - ↑ Urine 
Glycerate 3.70(m), 3.87 (dd) 1 ↓ Urine 
Allantoin 5.39 (s) 1 ↓ Urine 
Succinate 2.41 (s) 1 ↓ Urine 
Propionate 1.06 (t), 2.19 (q) 2 ↑ Faeces 
Acetate 1.92 (s) 2 ↑ Faeces 
Butyrate 0.90 (t), 1.56 (m), 2.16 (t) 2 ↑ Faeces 
Trimethylamine 2.88 (s) 1 ↑ Faeces 
Lysine 1.46 (m), 1.73 (q), 3.02 (t) 1 ↑ Faeces 
Methylamine 2.60 (s) 1 ↑ Faeces 
Beta alanine betaine  3.12 (s) - ↑ Faeces 
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1H chemical shift δ (multiplicity) a 
[Linked with STOCSY / TOCSY] LoAb Association Biofluid 
(3-N-trimethyl-
aminoproprionic acid)* 
Unknown E** 4.43 (d), 5.49 (d) 3 ↑ Faeces 
Glycine 3.56 (s) 2 ↓ Faeces 
Tyrosine 
6.91 (d), 7.20 (d), 3.94 (dd), 3.06 (dd), 
3.20 (dd) 
2 ↓ Faeces 
*Tentative identification under the process of spiking the standard.  
**overlapping region – multiple candidate saccharides 
aMultiplicity key is as follows: s=singlet, d=doublet, t=triplet, q=quartet, dd=doublet of doublets, 
m=multiplet. 
bThe Level of Assignment (LoA) used for the molecules identified by NMR are LoA 1: Identified 
compound, confirmed by adding the authentic chemical compound to the urine samples (spike-in 
experiments). LoA 2: 1H and 13C NMR chemical shifts and their multiplicity matched to database or 
literature to putatively annotate compound. LoA 3: 1H NMR chemical shifts and their multiplicity 
matched to database or literature to putatively annotate compound. 
 
Supplementary Table 3.3 | List of significantly associated metabolites whose excretion 
discriminates between athletes and controls when using 1H-NMR metabolic profiling 
models of urine (Figure 3.2C) and faecal water (Figure 3.2D). Lists the metabolite name, 
significant chemical shift values and multiplicity, LoA and direction of association (↑ 
indicates higher excretion in the athletes group, ↓ indicates lower excretion in the athletes 
group) for urine and faecal biofluids.  







MSMS product ions  
(5-20eV) RT LoA Association 
N-formylanthranilic 
acid 
RP - 164.034 120.04, 136.04, 92.05 4.52 2 ↑ 
Hydantoin-5-
propionic acid 





RP - 239.091 195.10, 151.11 6.16 2 ↑ 
CMPF glucuronide x1 
RP - - 
Aglycone: CMPF 
(239.09 – see above) 
- * ↑ 
Trimetaphosphoric 
acid 
RP - 238.891 96.96, 220.90, 78.96 0.42 2 ↑ 
Glucuronide x1 RP - - Aglycone: 239.09 - * ↑ 
Acetylcarnitine - C2 RP + 204.125 145.05, 85.03 0.85 2 ↑ 
Propionylcarnitine - 
C3 
RP + 218.139 159.07, 85.03 1.99 2 ↑ 
(Iso)Butyrylcarnitine - 
C4 
RP + 232.155 173.08. 85.03 2.83 2 ↑ 
2-
Methyl-
butyroylcarnitine - C5 
RP + 246.171 187.10, 85.03 3.60 2 ↑ 
C9:1-carnitine RP + 300.217 241.14, 139.11, 85.03 5.32 2 ↑ 
L-Valine RP + 118.086 72.08 2.43 2 ↑ 




HILIC + 260.185 201.11, 85.03 5.72 2 ↑ 
4-Pyridoxic acid HILIC + 184.062 166.05, 148.04, 138.06 1.14 2 ↑ 
Creatinine HILIC + 114.067 87.06 6.49 2 ↑ 
Glutamine 
RP - 145.061 
127.05, 102.95, 
101.94, 128.04, 84.05, 
109.04 
2.89 2 ↓ 
Unknown 
glucuronides x9 






- * ↓ 
7-Methylxanthine RP + 167.059 124.05, 150.03, 142.06 1.98 2 ↓ 
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MSMS product ions  
(5-20eV) RT LoA Association 
Imidazoleacetic acid RP + 127.051 81.05 0.67 2 ↓ 
Isoquinoline / 
quinoline 
RP + 130.065 103.06 4.79 2 ↓ 
Unknown 
glucuronides x7 





- * ↓ 
The Level of Assignment (LoA) used for the molecules identified by MS are LoA 1: Identified 
compound, confirmed by comparison to an authentic chemical reference. LoA 2: MS/MS spectrum 
matched to database or literature to putatively annotate compound. 
*Glucuronides characterised by a neutral loss of 176.03 Da (loss of monodehydrated glucuronic acid) 
in positive and negative modes. Further characterised by 175 m/z (anhydrous glucuronic acid) + 113 
m/z (fragment of glucuronic acid) product ions in negative mode. If unable to unambiguously 
identify resulting aglycone, aglycone m/z stated. 
 
Supplementary Table 3.4 | List of significantly associated metabolites whose excretion 
discriminates between athletes and controls when using LC-MS metabolic profiling 
models of urine (Supplementary Figure 3.2A-D). Lists the metabolite name, liquid 
chromatography (LC)- platform, mass charge ratio (m/z), MSMS fragments, retention time 
(RT), level of assignment (LoA) and direction of association (↑ indicates higher excretion in 
the athletes group, ↓ indicates lower excretion in the athletes group) in urine.  




Supplementary Table 3.5 | Short Chain Fatty Acid concentrations and statistical. 
analysis. Concentrations of SCFAs detected in faecal water samples. Statistical testing was 
performed on concentrations, comparing the athlete and control group. 
 
Supplementary Table 3.6 | Short Chain Fatty Acid correlation with diet and diversity. 
SCFA concentrations correlated to measures of gut microbial diversity and participant 
dietary and body composition measurements.  
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p value pFDR 
Rikenellaceae   
 
    
 
    
 
  
Verrucomicrobia   
 
    
 
    
 
  
Desulfovibrionaceae   
 
    
 




Incertae Sedis   
 
    
 
    
 
  
Enterobacteriaceae   
 
    
 
    
 
  
Anaerotruncus   
 
    
 
    
 
  
Catabacter   
 
    
 
    
 
  
(Uncultured)   
 
    
 
    
 
  
Roseburia 0.53 0 0.004 0.4 0.001 0.109 0.48 0 0.018 
Ruminococcus 0.35 0.005 0.21   
 
    
 
  
Veillonellaceae   
 
  0.34 0.006 0.205   
 
  
Streptococcus   
 
  0.36 0.004 0.183   
 
  
Streptoccaceae   
 
  0.42 0.001 0.109 0.34 0.006 0.248 
Lactobacillus   
 
  0.41 0.001 0.109   
 
  
Lactobacillaceae   
 
  0.41 0.001 0.109   
 
  
Pseudodubutyrivibrio   
 
    
 
  0.32 0.01 0.308 
    
 
    
 
    
 
  
Victivallis   
 
  -0.38 0.002 0.138   
 
  
Lentisphaerae   
 
  -0.38 0.002 0.138 -0.33 0.009 0.297 
Faecalibacterium   
 
    
 
    
 
  
RF3   
 
  -0.37 0.003 0.142 -0.33 0.008 0.272 
Akkermansia   
 
    
 
  -0.35 0.005 0.23 
Akkermansiaceae -0.32 0.01 0.276 -0.35 0.005 0.183 -0.38 0.002 0.135 
Supplementary Table 3.7 (Part A)  
Chapter 3 119 
 
 
          













p value pFDR 
Rikenellaceae 0.33 0.009 0.295   
 
    
 
  
Verrucomicrobia 0.37 0.003 0.147 0.4 0.001 0.109   
 
  




Incertae Sedis 0.6 0 0 0.58 0 0 0.51 0 0.008 
Enterobacteriaceae 0.33 0.007 0.272 0.34 0.006 0.248 0.3 0.019 0.401 
Anaerotruncus 0.4 0.001 0.109 0.41 0.001 0.109 0.41 0.001 0.109 
Catabacter 0.39 0.001 0.119 0.38 0.002 0.138 0.42 0.001 0.109 
(Uncultured) 0.35 0.005 0.211 0.34 0.007 0.253   
 
  
Roseburia   
 
    
 
    
 
  
Ruminococcus   
 
    
 
    
 
  
Veillonellaceae   
 
    
 
    
 
  
Streptococcus   
 
    
 
    
 
  
Streptoccaceae   
 
    
 
    
 
  
Lactobacillus   
 
    
 
    
 
  
Lactobacillaceae   
 
    
 
    
 
  
Pseudodubutyrivibrio   
 
    
 
    
 
  
    
 
    
 
    
 
  
Victivallis   
 
    
 
    
 
  
Lentisphaerae   
 
    
 
    
 
  
Faecalibacterium   
 
    
 
  -0.38 0.002 0.138 
RF3   
 
    
 
    
 
  
Akkermansia   
 
    
 
    
 
  
Akkermansiaceae                   
Supplementary Table 3.7 (Part B) | Short Chain Fatty Acid correlation with taxa. 
Statistically significant correlations between faecal water derived concentrations of SCFAs 
and 16S identified gut bacteria. 
 
Supplementary Table 3.8 | Short Chain Fatty Acid correlation with metagenomic 
pathways. List of statistically significant correlations between faecal water derived 
concentrations of SCFAs and metagenomic pathways. See appendix A. 
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Supplementary Table 3.9 | Correlation of gut bacterial taxa with metabolites. Statistically 
significant correlations of metabolites derived from both urine and faecal water to genera of 
gut microbiota 
.
Erys ipelotrichaceae_Incertae_Sedis Acetoacetate 8.27E-05 4.14E-01 1.32E-03
Howardel la Glycerate 4.08E-04 -3.75E-01 6.52E-03
Anaerotruncus PAG 6.82E-04 3.61E-01 1.09E-02
Erys ipelotrichaceae_Incertae_Sedis PAG 1.48E-03 3.39E-01 1.19E-02
Parasutterel la N.methylnicotinamide 7.82E-04 3.58E-01 1.25E-02
Succinivibrio O.Acetyl .Carnitine 8.47E-04 3.55E-01 1.35E-02
Succinivibrio TMAO 1.95E-03 3.31E-01 1.56E-02
Erys ipelotrichaceae_Incertae_Sedis O.Acetyl .Carnitine 3.59E-03 3.13E-01 1.92E-02
Erys ipelotrichaceae_Incertae_Sedis Unkown.A..3.12. 5.38E-03 2.99E-01 2.15E-02
Phascolarctobacterium L.Carnitine 2.10E-03 3.29E-01 2.24E-02
Phascolarctobacterium N.methylnicotinamide 2.80E-03 3.20E-01 2.24E-02
Erys ipelotrichaceae_Incertae_Sedis TMAO 7.36E-03 2.89E-01 2.35E-02
Lactobaci l lus O.Acetyl .Carnitine 1.53E-03 3.38E-01 2.45E-02
Escherichia_higel la Glycerate 1.54E-03 -3.38E-01 2.46E-02
Phascolarctobacterium Glycerate 7.10E-03 -2.90E-01 2.85E-02
Phascolarctobacterium Acetoacetate 7.12E-03 2.90E-01 2.85E-02
Escherichia_higel la O.Acetyl .Carnitine 4.14E-03 3.08E-01 3.32E-02
Parasutterel la Creatinine 4.91E-03 3.02E-01 3.93E-02
Succinivibrio L.Carnitine 8.42E-03 2.84E-01 4.49E-02
Anaerotruncus Acetoacetate 5.66E-03 2.98E-01 4.52E-02
Escherichia_higel la X3.OH.Isovaleric.acid 8.80E-03 2.83E-01 4.69E-02
Mogibacterium Acetoacetate 6.51E-03 2.93E-01 5.97E-02
Mogibacterium PAG 7.47E-03 2.88E-01 5.97E-02
Catabacter Prol ine.Betaine 4.06E-03 3.09E-01 6.50E-02
Coriobacteriaceae_bacterium_WAL_18889 TMAO 5.28E-03 3.00E-01 8.44E-02
Clostridium O.Acetyl .Carnitine 5.82E-03 2.97E-01 8.76E-02
Ruminococcus Acetone 5.48E-03 2.99E-01 8.77E-02
Al l i sonel la L.Carnitine 6.41E-03 2.93E-01 9.43E-02
Bacteroides O.Acetyl .Carnitine 8.04E-03 -2.86E-01 9.91E-02
Turicibacter Prol ine.Betaine 6.89E-03 -2.91E-01 1.10E-01
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Chapter 6  
―― 
A PROSPECTIVE METAGENOMIC AND METABOLOMIC ANALYSIS OF THE IMPACT OF 
EXERCISE AND/OR WHEY PROTEIN SUPPLEMENTATION ON THE GUT MICROBIOME 
OF SEDENTARY ADULTS 
6.1 | Abstract 
Many components of modern living exert influence on the resident intestinal microbiota of 
humans with resultant impact on host health. For example, exercise-associated changes in 
gut microbial diversity, composition, and functional profiles have been described in cross-
sectional studies of habitual athletes. However, this relationship is compounded by changes 
in diet that coincide with exercise such as dietary and supplementary protein consumption. 
To determine whether increasing physical activity and/or increased protein intake 
modulates gut microbial composition and function, we prospectively challenged healthy 
but sedentary adults with a short-term exercise regime, with and without concurrent daily 
whey protein consumption. Metagenomic and metabolomic-based assessments demonstrat-
ed modest changes in gut microbial composition and function following increases in 
physical activity. Significant changes in the diversity of the gut virome were evident in 
participants receiving daily whey protein supplementation. Results indicate that improved 
body composition with exercise is not dependent on major changes in gut microbial 
diversity.  
Chapter 6 197 
 
 
In addition to the author, the original material subject of this chapter was contributed to 
accordingly: 
Clinical work: Dr. Owen Cronin, 
Metabolomic processing and data analysis: Dr. Nicholas C. Penney, Dr. Isabel Garcia 
Perez, & Professor Elaine Holmes 
 
Presented material has been published at the time of this thesis’ submission. 
 
A Prospective Metagenomic and Metabolomic Analysis of the Impact of Exercise and/or Whey 
Protein Supplementation on the Gut Microbiome of Sedentary Adults. 
 
Owen Cronin,1,2*∧ Wiley Barton,1,2,3∧ Peter Skuse,3 Nicholas C. Penney,4,5 Isabel Garcia-
Perez,4 Eileen F. Murphy,6 Trevor Woods,7 Helena Nugent,2 Aine Fanning,1 Silvia Melgar,1 
Eanna C. Falvey,2,8 Elaine Holmes,4 Paul D. Cotter,2,3 Orla O’Sullivan,2,3 Michael G. Molloy,1,2 
Fergus Shanahan.1,2  
 
1 APC Microbiome Ireland, National University of Ireland, Cork, T12 YT20, Ireland. 
2 Department of Medicine, National University of Ireland, Cork, T12 DC4A, Ireland. 
3 Teagasc Food Research Centre, Moorepark, Fermoy, P61 C996, Cork, Ireland. 
4 Section of Biomolecular Medicine, Division of Computational Systems Medicine, 
Department of Surgery and Cancer, Imperial College London, SW7 2AZ, United Kingdom. 
5 Division of Surgery, Department of Surgery and Cancer, Imperial College London, SW7 
2AZ, United Kingdom. 
6 Alimentary Health Ltd., Cork Airport Business Park, Cork, T12 N84F, Ireland. 
7 Human Performance Laboratory, Department of Sport and Physical Activity, National 
University of Ireland, Cork, T12 N1FK, Ireland. 
8 Department of Sports Medicine, Sports Surgery Clinic, Northwood, Santry, Dublin 9, D09 
C523, Ireland.  
198 
A Prospective Metagenomic and Metabolomic Analysis of the Impact of Exercise and/or Whey Protein 
Supplementation on the Gut Microbiome of Sedentary Adults  
 
 
6.2 | Introduction 
Most of the elements of human lifestyle and environment influence the composition or 
function of the gut microbiome [1, 2]. Indeed, the microbiome has been viewed as a 
transducer of nutrient and other environmental signals for the host [3]. Therefore, several 
investigators have begun to explore whether a sedentary lifestyle, or more specifically, 
exercise and fitness, is associated with changes in the gut microbiota [4-7]. This has been 
assessed in cross-sectional studies of habitual exercisers [8-10] and professional athletes [10-
12] in addition to experimental models. 
 In elite athletes, distinct compositional and functional microbial characteristics are 
evident in the gut including increased α-diversity, enhanced microbial production of short-
chain fatty acids, and greater metabolic capacity [11, 12]. These microbial features positively 
correlate with the athletes’ levels of physical activity, in addition to the quantity of dietary 
protein consumed. In many professional sporting disciplines, as well as amateur sport, 
intentional protein supplementation (e.g. whey protein) provides a sizeable proportion of 
athletes’ daily protein intake [12]. 
 Evidence from animal studies highlights the potential for taxonomic manipulation of 
colonic microbiota following exercise interventions, both with and without concurrent 
dietary alterations [6, 13, 14]. Previously, we have proposed several mechanisms by which 
exercise and resultant fitness may directly influence the gut microbiota including effects on 
gastro-intestinal transit time [15], a known driver of gut microbial diversity [16, 17]. It 
appears that physical activity initiated in the juvenile period of development demonstrates 
a greater potential for fostering a preferential microbiota than exercise commenced in 
adulthood [6, 18]. 
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However, in humans the relationship between exercise and alterations in the microbiome is 
compounded by changes in dietary consumption that often accompany physical activity e.g. 
increased protein supplement intake. 
 Building on previous work [11, 12], the present study sought to interrogate 
correlations between the gut microbiome and levels of physical activity and protein 
consumption. To do so, using a combination of next generation shotgun sequencing and 
metabolomic analysis, we prospectively examined the impact of exercise, with and without 
whey protein supplementation, on the adult human gut microbiome. We report that 8-
weeks of combined aerobic and resistance training lead to modest alterations in the 
composition and activity of the gut microbiome of sedentary individuals. Participants 
consuming daily whey protein did experience a marked increase in the diversity of their gut 
virome following 8-weeks of oral supplementation. 
6.3 | Materials and Methods 
6.3.1 | Experimental models and subject details 
A description of the human study model used here is outlined in Results under “Study 
overview” and in figure 6.1. Male and female volunteers were enrolled. The Cork Clinical 
Research Ethics Committee (CREC) approved the study before it commenced. Recruitment 
and assignment of interventions are outlined in detail below. 
6.3.2 | Study recruitment and safe participation 
Male and female participants, aged between 18 and 40 years (inclusive) were recruited via 
online, e-mail and poster advertisement of the study details. This information was 
circulated to the study institutions (University College Cork and Cork University Hospital) 
and local businesses in Cork City, Ireland. Participants were informed that free gymnasium 
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membership would be supplied for the study period. Interested individuals contacted 
researchers via the study telephone line and were screened initially for inclusion criteria 
(see Table 6.1 in the supplemental material). Baseline levels of physical activity were 
assessed using the International Physical Activity Questionnaire short form [19]. If 
appropriate, a subsequent screening visit at the study site was arranged for further 
assessment of the exclusion criteria. Safe participation in the exercise program was ensured 
by medical screening of all participants using an adapted version of the safe participation 
questionnaire of the American College of Sports Medicine [20]. 
6.3.3 | Intervention group allocation 
Eligible volunteers were randomized into 2 intervention groups, namely, an exercise-only 
group (E group) and an exercise plus daily whey protein supplementation group (EP 
group) (Figure 6.1). A separate parallel group consuming whey protein supplementation 
alone (P group) was included in the study as a control. Participants in the P group were 
instructed to maintain their usual levels of light physical activity. To encourage recruitment 
to the control group, volunteers were offered an exercise program at a later date but were 
not followed extensively during that period. All participants were observed and their 
responses measured for 8 weeks (n = 30 for each group). 
6.3.4 | Combined exercise intervention 
Combined aerobic and resistance training was performed at the Mardyke Arena gymnasi-
um at University College Cork, Ireland. All exercise sessions took place at this venue. 
Volunteers in the P group were asked to maintain usual levels of physical inactivity for the 
8-week period. Participants in the E and EP groups were instructed to adhere to the 
assigned exercise program and to avoid additional (moderate to vigorous) physical activity 
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outside that prescribed. Details of the structured exercise intervention are presented in 
section 2.4. Compliance and withdrawal from the study 
Compliance with the prescribed exercise program was monitored remotely by the 
investigators using a FitLinxx activity monitoring system (Activelinxx, Shelton, CT), and is 
further outlined in section 2.2. This activity monitoring system was used to record the 
quantity of aerobic and resistance training performed by participants (supplementary table 
6.4). 
Participants noted to have not complied with the exercise regime for more than 7 
consecutive days were withdrawn from the study. Individuals requiring antibiotics during 
the intervention period were also withdrawn from the study, as were participants not 
complying with whey protein intake requirement in the EP and P groups. 
6.3.5 | Measurement visits  
Measurement visits took place at 2 sites: Cork University Hospital and the Mardyke Arena, 
University College Cork. Baseline measurement was conducted within the 4 days prior to 
the commencement of the intervention period and once more after the 8-week intervention. 
Participants were asked to refrain from the use of alcohol and medication and moderate to 
vigorous physical activity for at least 24 h prior to measurement. To minimize potential 
effects of diurnal variation, measurement visits took place between 7:00 a.m. and 10:30 a.m. 
Initially, participants attended the Department of Medicine research facility at Cork 
University Hospital and sat restfully in a quiet environment. Participants proceeded to 
participate in measurement of clinical variables, e.g., recording of weight, blood pressure, 
and heart rate, before undergoing phlebotomy by a trained nurse using universal 
precautions. Approximately 16 ml of venous blood was withdrawn. Plasma and serum 
samples were transported immediately to the clinic laboratories at the Mercy University 
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Hospital, Cork. Standardized laboratory techniques were employed for the measurement of 
haematology and biochemistry indices. Following phlebotomy, individuals underwent a 
total body dual-energy X-ray absorptiometry (DEXA) scan to assess body composition 
(refer to section 2.3.3 for further detail). When possible, volunteers were asked to provide 
fresh urine and faecal samples, which were transported at room temperature to the Teagasc 
Food Research Centre, Moorepark, Fermoy, Co. Cork, where DNA extraction took place in 
accordance with the procedures outlined in section 2.5.1. Following completion of the body 
composition assessment, participants proceeded to the indoor track at the Mardyke Arena 
gymnasium to undergo a submaximal cardiorespiratory fitness assessment as described in 
section 2.3.2. 
6.3.6 | Inflammatory cytokine measurement 
Blood samples (4 ml) from participants were collected in serum separator clot activator 
blood collection tubes (Greiner Bio-One, Stonehouse, United Kingdom; reference no. 
454071). Serum C reactive protein (CRP) was measured. Additionally, resting levels of 
proinflammatory cytokines interleukin-6 (IL-6), IL-8, IL-10, tumour necrosis factor alpha 
(TNF-α), and gamma interferon were measured using a mesoscale discovery (MSD) 
platform. Further description of blood sample preparation and immunoassay are presented 
in section 2.3.4. Samples from all 3 intervention groups were dispersed across each MSD 
plate.  
6.3.7 | Dietary data collection 
Dietary data were collected by means of a 146-item food frequency questionnaire (FFQ) as 
described in section 2.3.1 and outlined previously [12]. Participants were asked to record 
their usual pattern of dietary intake over the previous 8 weeks. Completed FFQs were 
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coded and dietary data were visualized with correspondence analysis using the ade4 
package [21] in the R programing environment (V.3.3.2). 
6.3.8 | DNA extraction and metagenomic sequencing of faecal microbiome and 
whey protein supplement 
DNA was extracted from the donated fresh faecal samples received at the Teagasc 
Moorepark research facility and prepared for shotgun metagenomic sequencing as detailed 
in section 2.5. A total of 8 equimolar library pools of samples were made prior to shipping 
of the pools on dry ice for sequencing on an Illumina Hiseq 2500 (chemistry V.4.0) 
sequencing platform (Beckman Coulter, Inc.; Genomics Inc., Danvers, MA). High-
throughput sequencing was performed using the high-output run mode for 2 × 125-bp 
paired-end reads with the addition of a PhiX library (1%) to estimate sequence quality. A 
sample of the whey protein used in the study and a sample of an oat-based nutritional 
supplement used as a control were both processed in a manner identical to that used with 
the faecal samples for the extraction of microbial DNA and preparation of metagenomic 
libraries. Sequencing of the supplement libraries was performed using an Illumina MiSeq 
(chemistry V.3.0) platform in high-output run mode for 2 × 300-bp paired-end reads 
(Teagasc sequencing facility). 
6.3.9 | Bioinformatic processing of microbial metagenomic sequencing 
Metagenomic FASTQ sequence files were processed according to section 2.6. Models of 
microbial metabolic pathways produced by HUMAnN2 were derived from the MetaCyc 
database [22] and were the basis for analyses performed on microbial metabolic profiling. 
Taxonomic profiling was facilitated by use of the Kraken taxonomy assignment software 
tool (V.0.10.6) [23]. 
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6.3.10 | Metabolomic sample preparation 
Samples of urine and faeces were stored at −80°C prior to analysis. Metabolomic processing 
proceeded as described in sections 2.7 and 2.8.4. 
6.3.11 | Quantification and statistical analysis 
Statistical analysis was carried out using the Statistical Package for the Social Sciences V.23 
(SPSS, Inc., Chicago, Illinois) and the R statistical programing environment (V.3.3.2). Due to 
the predominance of non-normally distributed data, nonparametric analyses were 
performed to compare baseline clinical and demographic variables between groups. 
Similarly, nonparametric statistical tests were employed in the analysis of microbiome and 
metabolomics data. Clinical data are presented as medians and interquartile ranges (IQR), 
unless stated otherwise. Between-group differences in baseline, follow-up, and postinter-
vention changes (Δ) in clinical and demographic data were compared using the Kruskal-
Wallis test. For significantly different results, a Mann-Whitney U test was performed to 
determine the groups between which this difference applied. Where stated, the Wilcoxon 
signed-rank test was used to compare baseline and postintervention values within 
intervention groups. A type I error rate of ≤0.05 was considered significant in all cases. 
Correction of P values relating to microbiome and metabolomic analysis was performed 
using the Benjamini-Hochberg false-discovery rate (FDR) [24] in the base stats package in R. 
Statistical assessment of dissimilarity matrices (Bray-Curtis) derived from microbial data 
was facilitated with the adonis2 function in the vegan R package (V.2.4-3) [25]. Identifica-
tion of statistically relevant taxonomic features was performed with the analysis 
of composition of microbiomes (ANCOM) test as implemented in the R package of the same 
name (V.1.1-3) [26]. Detection of underlying features of metabolic pathways was performed 
with unsupervised cross-validated partial-least-squares–discriminant analysis (PLS-DA) 
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and the KODAMA algorithm from the R package of the same name (V.1.4) [27]. Measure-
ments of alpha diversity and calculations of relative abundances were also performed with 
the vegan package. Relative-abundance data were generated separately for identified 
species within each phylogenetic domain (e.g., Bacteria). 
For metabolomic analysis, the resulting 1H-NMR and LC-MS data sets were import-
ed into MatLab to conduct multivariate statistical analysis. Data were centred and scaled to 
account for the repeated-measures design and then modelled using partial-least-squares–
discriminant analysis (PLS-DA) with Monte Carlo cross-validation (MCCV) [28]. The fit and 
predictability of the models obtained were determined and expressed as R2 and Q2 values, 
respectively. 
6.3.12 | Data and software availability 
The microbial DNA sequences have been deposited in the European Nucleotide Database 
(ENA) database under ID code PRJEB20054. 
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6.4 | Results 
6.4.1 | Study overview  
Following local advertisement, healthy Irish male and female Caucasian volunteers (n=90) 
aged 18 to 40 years and with a body mass index (BMI) of between 22 and 35kg/m2 
(predominantly overweight or obese) were recruited between January and August 2014 
(Figure 6.1). The study was conducted in accordance with the Declaration of Helsinki, and, 
prior to commencement, ethical approval was granted by the Cork Clinical Research Ethics 
Committee (CREC). All volunteers provided written informed consent. To prospectively 
measure the effect of de novo exercise training on gut microbiota, subjects were required to 
be physically inactive for at least 3 months prior to study entry (i.e. not engaged in regular 
structured or unstructured exercise beyond light physical activities of daily life). All 
participants were screened for specific exclusion criteria, including regular medication use 
and history of cardiovascular disease (CVD), diabetes mellitus, or autoimmune disorders 
(see Table 6.1 in the supplementary material). Volunteers who had received oral antibiotics 
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Figure 6.1 | Study design. The figure presents details of study recruitment and allocation of 
participants to intervention groups as follows: exercise-only group (E), exercise and protein 
supplementation group (EP), and whey protein supplementation-only group (P). Reasons 
for volunteer dropout and completion numbers are also outlined. See also supplementary 
table 6.1.  
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 Eligible volunteers were randomised into 2 intervention groups: an exercise-only 
group (E group) and an exercise plus daily whey protein supplementation group (EP 
group) (Figure 6.1). A separate parallel group consuming whey protein supplementation 
but not participating in exercise programs (P group) was included in the study as a control. 
To encourage recruitment to this control group, volunteers were offered an exercise 
program at a later date, but their participation in the program after the conclusion of the 
study was not followed extensively. All participants were observed and measured for 8 
weeks (n = 30 for each group). The exercise-only group (E) participated in an 8-week mixed 
aerobic and resistance exercise training program. The exercise plus whey protein 
supplementation group (EP) followed the same exercise program, in addition to consuming 
the once-daily whey protein supplement. All volunteers were asked to maintain usual ad 
libitum dietary intake during the intervention period and to refrain from taking additional 
vitamin, dietary, or herbal supplements. 
 Participants in the E and EP groups were required to train 3 times per week for 8 
weeks. The exercise program consisted of combined aerobic and resistance training. Aerobic 
exercise was standardized, progressive, and similar in energy expenditure to a “couch-to-
5km-running” program. The intensity of aerobic exercise was moderate, being graded 
between 5 and 7 of 10 on the modified Borg rating of perceived exertion (RPE) scale [29]. 
Resistance training consisted of 7 machine-based resistance exercises. Starting weights were 
calculated at induction at 70% of the individual’s one-repetition maximum value (1RM). 
Subjects were required to perform a minimum 3 sets of 8 repetitions. Resistance training 
was progressive with aims of increasing resistance weight by 15% to 20% over the 8-week 
period. 
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 To ensure a uniform and consistent increase in daily protein consumption, subjects 
in the P and EP arms of the study were required to take a daily 30-g protein supplement 
containing 24 g of whey protein (donated as an unrestricted grant by Carbery Group, 
Ballineen, Co. Cork, Ireland). The supplement comprised a blend of whey protein 
concentrate, isolate, and hydrolysed whey protein concentrate (see supplementary table 6.2 
for full nutritional details). Subjects’ compliance to daily whey protein supplementation was 
encouraged using daily text message reminders. Volunteers were required to return empty 
whey protein sachets to the study site fortnightly before the issuing of further supplement. 
Subjects with a compliance rate of less than 90% were excluded from the study. Baseline 
measurements were not significantly different between the three study groups (Table 6.1).  





Table 6.1 | Baseline demographic and anthropometric characteristics of the study 
participants with comparisons between the 3 intervention groups. 
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6.4.2 | 8 weeks of aerobic and resistance training improves body composition and 
cardio-respiratory fitness profiles in sedentary subjects 
A total of 74 of the 90 participants enrolled in the study completed the 8-week study period 
(reasons for dropping out are detailed in Figure 6.1). At entry, the intervention groups 
shared similar clinical and anthropometric characteristics. Following the intervention 
period, both E and EP group participants demonstrated significant and similar improve-
ments in predicted maximal aerobic capacity (VO2max) (Figure 6.2A). Furthermore, resting 
heart rate was significantly reduced following the intervention period in both of the 
exercising groups (E and EP) compared with the protein-only group (P = 0.005) (supplemen-
tary table 6.3). Compliance with the prescribed exercise program was high, with a median 
of 21 sessions (87.5%) performed in both the E and EP groups. The types and levels of 
exercise training undertaken in both groups were similar, with no statistically significant 
differences in the aerobic- and resistance-training workloads recorded (supplementary table 
6.4).  
Participants were predominantly overweight, with body fat percentages above 30%. 
There were no significant differences in the participants’ baseline levels of physical activity 
when assessed using the International Physical Activity Questionnaire [30]. All baseline 
values are expressed as medians and interquartile ranges (IQR). In contrast to the protein-
only group, the exercise-only group and the exercise plus protein supplementation group 
experienced significant decreases in percentage body fat, total fat mass, and trunk fat mass 
during the intervention period (Figure 6.2B and C), in addition to an increase in total lean 
tissue mass (Figure 6.2D) (all P < 0.001; see also supplementary table 6.3). 
  




Figure 6.2 | Alterations in cardiorespiratory fitness and body composition following 
exercise interventions, protein interventions, and combined interventions. (A) Peak 
aerobic capacity (VO2max) per kilogram of body weight as predicted using the Rockport 1-
mile walk test was higher in both the E and EP groups following the intervention period, 
indicating improved levels of cardiorespiratory fitness. Within-group comparisons were 
tested using the Wilcoxon signed-rank test (P < 0.001). (B) Changes in percentages of body 
fat following the intervention period as measured using DEXA. Percent body fat reduction 
was significantly greater in the exercise-only group and in the exercise plus protein 
supplementation group compared to the protein-only group. (C) Absolute changes in body 
fat mass (in kilograms) following the intervention period demonstrated a significantly 
greater reduction in both the exercise and exercise plus protein supplementation groups. 
(D) Absolute change in lean tissue mass (kg), measured using a three-compartment model, 
indicating significantly greater lean mass accretion in the E and EP groups than in the P 
group. Error bars represent 95% confidence intervals. See also supplementary tables 6.3 to 
6.5  
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Compliance with daily whey protein supplementation in the EP and P groups was high 
with only one participant excluded due to poor adherence to whey protein supplementa-
tion. Whey protein supplementation aside, dietary frequency patterns did not deviate from 
the volunteers’ usual intake at study entry (supplementary figure 6.1). Addition of the 30 g 
daily whey protein supplement did not favour the EP over E group with respect to body 
composition improvement; however, the study was not designed to test this hypothesis. No 
clinically relevant differences in resting-state serum proinflammatory markers were evident 
following any of the interventions (supplementary figure 6.2; see also supplementary table 
6.5). 
6.4.3 | Metagenomic assessment of microbiota after exercise and/or dietary 
adjustment 
Postintervention alterations (percent Δ) in gut microbial α-diversity did not identify 
significant modulation in taxonomic composition or metabolic pathways for any of the 
intervention groups compared to baseline (Figure 6.3A to D). A trend of median increase in 
bacterial diversity was observed for the E and EP groups (Figure 6.3B). These findings of 
moderate alterations of α-diversity were consistent across pairwise comparisons of the 
groups, with a few notable exceptions. Increased α-diversity of Archaea species in the P 
group following intervention was observed, as was a moderate enhancement of archaeal 
diversity in the P group compared to the EP group (P < 0.05 and P < 0.01, respectively; 
Figure 6.3E). After the intervention period, bacterial diversity was greater in the EP group 
than in the P group (P < 0.05; Figure 6.3F), while the diversity of virus species was lower in 
EP group than in the E group (P < 0.05; Figure 6.3G). 
Principal-coordinate analysis (PCoA) was used to present separation of measures 
from the taxonomic composition and metabolic pathway models (Figure 6.3H to O). Prior to 
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intervention, all 3 groups demonstrated similarity in measures of microbial metabolic 
pathways and taxonomic β-diversity (Figure 6.3H to K). A significant separation between 
the intervention groups was detected in the Bray-Curtis-derived dissimilarity matrices 
generated from participants postintervention for metabolic pathways (P = 0.054; Figure 
6.3L), the entirety of detected species (P < 0.001; Figure 6.3M), and species of bacteria (P < 
0.05) and viruses (P < 0.001) (Figure 6.3N and O, respectively). Archaea species did not 
differentiate with intervention (data not presented).  
Pairwise analysis of taxonomy compared according to high-level phylogeny (Ar-
chaea, Bacteria, and viruses) demonstrated significant alterations of detected virus species 
in both the EP and P groups following the intervention period that were absent from the 
exercise-only group (P < 0.001; Figure 6.4). There were no further significant separations for 
Archaea or Bacteria species or for metabolic pathways (supplementary figure 6.3A to I). An 
unsupervised partial-least-squares–discriminant analysis (PLS-DA) approach was used to 
identify underlying features of the metabolic pathways before and after the intervention 
period (supplementary figure 6.3J and K). Pathways associated with Prevotella copri were 
shown to cluster with the E group prior to intervention. Following intervention, this cluster 
was still present but, in addition, separate clusters of P. copri- and Bacteroides vulgatus-
associated pathways were apparent within the EP and P groups, respectively. Forty-eight 
species were detected as being differentially abundant within the three groups (false-
discovery rate [FDR] = 0.05). The majority of identified taxa were virus species, predomi-
nantly Lactococcus phage, within the P and EP groups. No Archaea were found to have 
significantly varied in abundance with treatment in any of the groups (supplementary table 
6.6).  
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Figure 6.3 | Intervention effects on taxonomic and functional pathway diversity of the 
intestinal microbiome.  
Chapter 6 217 
 
 
Figure 6.3 Continued 
(A to D) Percent change (Δ) of Shannon α-diversity H-index values following intervention. 
No significant variations were presented for taxonomic measurements (A to C) or metabolic 
pathways (D). (E to G) Pairwise statistical assessment of taxonomy α-diversity demon-
strates equal data with respect to the presence of taxonomy between groups at baseline. 
EP1, combined exercise and protein supplementation group, week 0; EP2, combined 
exercise and protein supplementation group, week 8; E1, exercise-only group, week 0; E2, 
exercise-only group, week 8; P1, protein-only group, week 0; P2, protein-only group, week 
8. (E) The diversity of Archaea was significantly altered after intervention within the P 
group (P < 0.05) and, similarly, was greater in the P group (P2) than in the EP group (EP2) 
(P < 0.01). (F) Postintervention bacterial diversity was greater in the EP group (EP2) in 
testing against the P group (P2) (P < 0.05). (G) Similar levels of virus diversity were 
presented in the protein supplementation groups (EP and P) following the intervention, 
with significantly lower diversity in the EP group than in the E group (P < 0.05). (H to O) 
Principal-coordinate analysis (PCoA) of relative abundance profiles for taxonomic and 
metabolic pathway constructions of the three groups demonstrates the influence of the 
interventions on the diversity of microbial populations. (H to K) Prior to intervention, 
group profiles of taxonomic and metabolic pathway diversity were not significantly 
differentiated. (L to O) Following intervention, a significant separation was identified 
between the groups for measures of (L) metabolic pathways (P = 0.054), (M) all detected 
species unsegregated by phylogeny (P < 0.001), (N) bacteria (P < 0.05), and (O) virus species 
(P < 0.001). Specific separations in diversity per intervention group are outlined further in 
Figure 6.4 for virus species and supplementary figure 6.3 for all other comparisons. 
Statistical assessment of PCoA dissimilarity matrices was performed with the Adonis2 
permutational multivariate analysis of variance (PERMANOVA) test. (H to O) Density plots 
were derived from kernel density estimates and scaled to a maximum estimated value of 1 
and display concentrations of plotted data along the corresponding plot axis. P values were 
calculated for α-diversity comparisons using the Wilcoxon signed-rank test.  
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Figure 6.4 | Pairwise analysis of detected virus taxonomy prior to and following 
intervention. 
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Figure 6.4 Continued 
(A to C) PCoA of virus species for each group, comparing virus profiles before and after the 
intervention period (time point 1 [TP1] [week 0] and time point 2 [TP2] [week 8], 
respectively). (A) The exercise-only group had virus diversity that was not significantly 
altered by intervention. (B and C) Diversity of viruses was significantly affected during the 
intervention period for both groups receiving protein supplementation (P < 0.001). The 
exercise plus protein supplementation group (B) and the protein-only group (C) demon-
strated reduced variability of diversity following intervention. Results of pairwise analysis 
of additional taxonomic and metabolic pathway profiles are presented in supplementary 
figure 6.3. Statistical assessment of PCoA dissimilarity matrices was performed with the 
Adonis2 PERMANOVA test. (A to C) Density plots were derived from kernel density 
estimates and scaled to a maximum estimated value of 1 and display concentrations of 
plotted data along the corresponding plot axis.  
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Of the total 23,019 general (e.g., coenzyme A biosynthesis) and taxonomically specif-
ic (e.g., coenzyme A biosynthesis in Akkermansia muciniphila) metabolic pathways included 
in the metagenomic construction of the models, 619 were identified as having significantly 
differed among the three intervention groups at either the pre-treatment or posttreatment 
time point (P < 0.05). Significantly altered pathways were organized according to a 
metabolic pathway hierarchy defined by the MetaCyc database and were structured as a 
heat map of low-level categories of classification (e.g., nucleotide biosynthesis) (supplemen-
tary figure 6.4). Scaled group means of pathway relative abundances demonstrated modest 
alterations of microbial metabolic potential. A complete list of the categorized pathways can 
be found in the supplemental material (supplementary table 6.6). Further assessment of 
pathways differing among all groups was performed both within each group (before and 
after treatment) and between the separate groups. No significant variation within groups 
was evident following P value correction for multiple testing. 
Untargeted metabolomic analysis of participant faecal-water and urinary samples 
revealed no significant separations either within each group pre- and postintervention or 
between groups at each time point with analysis of the full spectrum of metabolites. 
Subsequent targeted metabolomic quantification, guided by previous findings [31-33], 
revealed significant changes following intervention in the amount of glutamate (faecal 
water) and trans-aconitate (urine) in the protein-only group (P < 0.01 and P < 0.05, 
respectively; supplementary table 6.6, section 6.7 and Appendix B for metabolite 
quantifications). Comparisons of differences (percent Δ) in metabolite quantifications 
between all groups demonstrated significant variation in the levels of phenylacetylglycine 
(PAG) and trimethylamine N-oxide (TMAO) (P < 0.01 and P < 0.05, respectively) in urine, as 
well as of glutamate (P < 0.05) in faecal water, within all groups (supplementary table 6.6). 
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Such differences were also present in the paired comparisons. Levels of both PAG and 
TMAO were significantly reduced (Δ = −0.196 and −0.518, respectively) in the E group 
following the intervention period in comparison to the P group (P < 0.05, supplementary 
table 6.6). 
6.4.4 | Characterization of whey protein supplement microbial content 
Metagenomic sequencing of the whey protein supplement and of a non-dairy-based dietary 
supplement control revealed a taxonomic profile in the former that was characterized by 
high proportions of bacteriophage associated with lactic acid bacteria. Notably, these phage 
were also enriched in participants in receipt of the whey supplement (supplementary table 
6.6). The taxonomic composition of the whey protein and control demonstrated highly 
divergent microbial contents of the supplements, including taxa detected in participants. 
6.5 | Discussion 
To accurately and consistently increase daily protein intake, we selected a whey protein 
supplement. Whey protein, a widely used commercial supplement in elite sport and 
amateur fitness milieu, is known for its muscle accretion effects [34], in addition to its 
positive influence on energy metabolism [35-37] and, more recently, on appetite control [38]. 
In addition, its use facilitated analysis of the effect of a widely available exercise adjunct on 
the diversity, composition, and activity of microbial populations in the gut. Somewhat 
unexpectedly, individuals in the whey protein supplementation-only group (P) experienced 
a significant alteration in the β-diversity of the gut virome (Figure 6.4C). Furthermore, this 
change was mirrored in the combined exercise and protein supplementation (EP) group 
(Figure 6.4B), suggesting a robust effect of whey protein on the taxonomic richness of the 
gut virome. To explore this dynamic, a sample of the whey supplement and a sample of a 
non-dairy-based dietary supplement were sequenced for microbial content. Intriguingly, all 
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bacteriophage and two of the four bacterial species that were significantly altered in the 
groups receiving whey protein were present in high relative abundance within the whey 
protein supplement but not the control supplement. Further in-depth experimentation is 
required to determine whether virus particles from whey protein conclusively transmit to 
the human gut from consumption and, if so, whether they remain biologically active. 
However, the overlap in the taxonomic compositions of the whey supplement and 
participants’ gut microbiome provides a convincing explanation for the source of virome 
changes observed. 
 While this examination did not identify a significant impact of short-term combined 
aerobic and resistance exercise on the diversity of bacterial or archaeal constituents of the 
gut microbiome, subtle compositional and functional changes were detected in this analysis 
(Figure 6.3 and 6.4; see also supplementary figures 6.3 and 6.4). Although the results were 
not statistically significant, the groups engaged in exercise demonstrated less change in 
archaeal diversity than the protein-only group after the intervention period. In the case of 
the exercise-only group, a reduction in Archaea diversity was observed, suggesting that 
exercise acts against intestinal Archaea. More-extensive investigation is necessary to resolve 
this issue, but in view of a putative role for Archaea in intestinal disorders and as 
modulators of TMAO concentrations, such an inquiry is justified [39]. Changes in Bacteria 
diversity were similarly below the threshold of statistical significance; however, the median 
differences between groups indicated that those undertaking exercise had increases in 
bacterial diversity that were absent from the intervention group excluded from exercise. 
Curiously, the diversity of bacterial species was elevated in the EP group after intervention 
but the diversity of virus species was uniformly lower. The inverse relationship of these 
measures is counterintuitive, given the predominance of bacteriophage in the detected 
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viruses. However, the influx of such bacteriophage may explain the overall reduction of 
virus diversity within the group. Furthermore, this increase in the levels of bacteriophage 
may have been insufficient to profoundly influence the overall diversity of the Bacteria due 
to their selective targeting of only a few bacterial species. 
The absence of substantial modulation of the diversity of microbial populations in 
the gut following the 8-week exercise intervention mirrors recent findings in mice [40]. To 
date, most of the work in humans has focused on elite or professional athletes [10-12] and as 
a result has explored the relationship between established physical ‘fitness’ and the gut 
microbiota. Few prospective studies have examined the effect of exercise on the gut 
microbiota of physically inactive human volunteers [41]. The current study is the largest to 
have done so. It should be acknowledged that the unperturbed adult intestinal microbiome 
is resilient [42] and may not be subject to significant alteration following an 8-week 
intervention period. It is likely that the diverse, metabolically favourable intestinal 
microbiome evident in the elite athlete is the cumulative manifestation of many years of 
optimized nutrition and of high degrees of physical condition throughout youth and 
adolescence and during adult participation in professional sports [43]. Initial examination of 
the acute effects of extreme and prolonged endurance exercise, such as in trained military 
regiments, suggests that prolonged physical stress negatively impacts intestinal permeabil-
ity and gut microbiota composition [44]. However, the results of the present study indicate 
that exercise at moderate intensity does not exert a deleterious effect on gut microbial 
composition or function in the untrained subject. Furthermore, the results of this study 
signify that exercise-induced improvements in cardiorespiratory fitness and body 
composition are not dependent on substantial alteration of the diversity of microbial 
populations in the gut. Whether the limited changes in microbiome composition and 
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function detected in this study contributed to the witnessed improvements in body 
composition and fitness profiles remains unknown. 
 An intriguing exception to the otherwise minimal differences in metabolomic 
modification is represented by the controversial metabolite TMAO. Associations between 
TMAO and cardiovascular disease (CVD) have framed the metabolite as a disease factor; 
however, high levels have also been observed in populations with low CVD risk [45-48]. 
Elevated levels of TMAO have previously been found in elite athletes [11], and while the 
presence of TMAO may or may not have deleterious health implications, we demonstrate a 
potential modulatory effect of exercise on urinary TMAO levels. Participants in the exercise-
only group showed levels of urinary TMAO that were reduced below baseline with 
intervention, while the groups receiving whey protein had increased levels of the 
metabolite, with the combined-treatment group demonstrating lower levels than the 
protein-only group. The TMAO precursor phosphatidylcholine comprised less than 0.1% of 
the constituents of the whey protein supplement used in this study, suggesting a possible 
direct effect of whey protein and/or exercise on TMAO production. While the data represent 
a promising paradigm, further work will be necessary to determine the specific mechanisms 
involved and to rule out unintended dietary influence or influences of host biology (e.g., 
altered absorption of TMAO with exercise). Additionally, known microbial producers of 
TMAO [49] were absent from the taxonomic profiling. PAG concentrations were similarly 
reduced in the exercise-only group, although the metabolite has previously been associated 
with lean body composition and has been found to be present in increased concentrations in 
athletes. It has also recently been shown to decrease in urine in thoroughbred racehorses 
following exercise [50]. 
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Likewise, the data reflecting increased abundance of  P. copri-associated pathways 
detected in the EP group postintervention supports the work of others which suggested an 
active role for Prevotella species in host metabolic [51, 52] and immune health [53]. Studies 
have linked Prevotella with inflammatory and metabolic disorders, including rheumatoid 
arthritis [54, 55], ankylosing spondylitis [56], and type 2 diabetes mellitus [57]. Conversely, 
and consistent with our findings, increased physical activity has been associated with 
increases in Prevotella-related metabolic pathways in the gut microbiome [10]. 
 It is pertinent to acknowledge the difficulty in controlling all potential confounders 
of gut microbial composition and activity in this investigation (e.g., diet, wide BMI range). 
This study attempted to control for the potential impact of dietary variation by instruction 
of volunteers to maintain their usual ad libitum dietary intake. Food frequency questionnaire 
(FFQ) dietary analysis indicated stability in the volunteers’ dietary patterns; however, FFQ 
assessment is subject to its limitations, including recall bias [58]. 
 In conclusion, this prospective examination demonstrated that short-to-medium-
term combined exercise in healthy, physically inactive adults does not induce drastic 
alterations in the diversity of microbial populations in the gut. We highlight an interaction 
between whey protein intake and the β-diversity of the adult gut virome which requires 
further exploration. Furthermore, the functional activity of the gut microbiota does not 
appear to be extensively manipulated by short-term, moderate-intensity exercise and/or 
whey protein supplementation, although some changes, including alteration of levels of 
urinary TMAO and PAG excretion, were evident. The alterations in the diversity, 
composition, and metabolomic profiles of microbial gut populations that we and others 
have observed in habitual exercisers and professional athletes may represent late responses 
to exercise or fitness.  
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6.7 | Supplementary Content 
 
Supplementary Figure 6.1. Correspondence analysis of dietary intake of participants.  
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Supplementary Figure 6.1 continued. Self-reported dietary information from food 
frequency questionnaires (FFQ) for all participants was used to perform correspondence 
analysis of diet at the start and end of the intervention period. The exercise plus protein 
supplementation group (A and B), the exercise-only group (C and D), and the protein-only 
group (E and F) maintained diets that remained relatively unchanged during the 
intervention period. Participants were therefore undifferentiated before and after treatment 
in relation to diet. 
 
Supplementary Figure 6.2. Pre- and postintervention levels of the resting proinflammatory 
cytokines. Pre- and postintervention distribution of inflammatory cytokines (A) gamma 
interferon (IFN-γ), (B) IL-6, and (C) TNF-α. Dark central lines represent median values. Bars 
represent 95% confidence intervals. Outliers are denoted by hollow circles and extreme 
outliers by asterisks.  




Supplementary Figure 6.3.  
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Supplementary Figure 6.3 continued. Pairwise analysis of microbial taxonomy and 
metabolic pathways and unsupervised feature detection of pathways. PCoA of metabolic 
pathways and species-level taxonomy measurement subset according to phylogenetic 
domain (Archaea and Bacteria), comparing measurements before and after intervention 
(time point 1 [TP1] and time point 2 [TP2], respectively). (A to C) Metabolic pathways for 
the (A) exercise-only group, (B) exercise plus protein supplementation group, and (C) 
protein-only group. (D to F) Archaea species for the (D) exercise-only group, (E) exercise 
plus protein supplementation group, and (F) protein-only group. (G to I) Bacteria species 
for the (G) exercise-only group, (H) exercise plus protein supplementation group, and (I) 
protein-only group. (J and K) Cross-validated partial least-squares-discriminant analysis 
(PLS-DA) of metabolic pathways from all three groups before (J) and after (K) the 
intervention period identified clusters of pathways related to specific taxa. (J) Prior to 
treatment, metabolic pathways associated with Prevotella copri were identified in the 
exercise group (E). (K) After intervention, each group contained a tightly associated cluster 
of pathways corresponding to either Prevotella copri or Bacteroides vulgatus. The two groups 
undergoing exercise (E and EP) had separate Prevotella copri-related clusters, while the 
protein-only-group cluster was composed of Bacteroides vulgatus pathways. Each 
experimental group was statistically assessed for alterations in diversity resulting from the 
intervention, with no significant separations detected. Statistical assessment of PCoA 
dissimilarity matrices was performed with the Adonis2 permutational multivariate analysis 
of variance (PERMANOVA) test. (A to I) Density plots were derived from kernel density 
estimates and scaled to a maximum estimated value of 1 and display concentrations of 
plotted data along the corresponding plot axis.  
  




Supplementary Figure 6.4.  
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Supplementary Figure 6.4 continued. Categorical heat map of statistically significant 
metabolic pathways organized into low-level MetaCyc metabolic classifications. (A and B) 
Metabolic pathways of significantly (P < 0.05) varied relative abundances between groups 
before (A) and after (B) treatment were binned according to the MetaCyc database pathway 
classification. Scaled group means of pathway relative abundance values demonstrate shifts 
in the functional potential of the groups following the separate interventions. The Kruskal-
Wallis test was used to calculate the P values used in the identification of pathways 
included in metabolic classification. 
Inclusion Criteria 
 Low physical activity level as per the International Physical Activity Ques-
tionnaire (Short form)  
 Not currently or recently (last 3 months) involved in regular or organized 
amateur sport or exercise 
 Non-smoker 
 Not on regular medications 
 Aged 18 to 40 
 Body Mass Index between 22 to 35 (inclusive)  
Exclusion Criteria 
 Personal history of coronary artery disease, congenital heart disease or any 
cardiovascular disease 
 Family history of known coronary artery disease before 45 years of age 
 Uncontrolled hypertension (>140/90 mmHg)  
 Known renal or hepatic impairment 
 Type 1 or type 2 diabetes mellitus 
 Pulmonary disease – not including well-controlled, mild asthma 
 Primary or secondary immunodeficiency or autoimmune disorder 
 Current smoker or ex-smoker of less than 3 months duration 
 Psychiatric disorders including previous history of depression 
 A history of substance abuse 
 Current or recent involvement in another clinical research study 
 Known or suspected hypersensitivity to the dietary supplementation 
 Gastro-intestinal disease e.g. coeliac disease, inflammatory bowel disease, 
Irritable Bowel Syndrome 
 Previous significant gastro-intestinal surgery e.g. Total colectomy 
 Suspected or confirmed pregnancy 
Supplementary Table 6.1. Inclusion and exclusion criteria for study entry.  





Typical per 30g serving Typical per 100g serving 
Energy 125 kcal/521kJ 416 kcal/1743kJ 
Protein 24 g 80 g 
Carbohydrate 











Dietary fibre 0.08 g 0.26 g 
Salt 0.12 g 0.42 g 
Supplementary Table 6.2. Nutritional content of the daily whey protein supplement 
(30grams) administered to participants in the EP and P study groups. g, grams; kCal, 
kilocalories; kJ, kilojoules. 
 Intervention Groups  
 Exercise (E) 
(n=25) 





Weight (kg) -0.9 (-2.6, 0.9) -0.8 (-1.6, 0.1) -0.5 (-1.3, 0.6) 0.549 
BMI (kg/m2) -0.3 (-0.9, 0.2) -0.2 (-0.6, 0) -1.1 (-0.4, 0.2) 0.419 
Resting heart rate (BPM) -5 (-16, 6) ∞ -5 (-9, 3) Ψ 4 (-3, 10) 0.005* 
Systolic BP (mmHg) -8 (-12, 1) -8 (-16, 0) -4 (-11, 0) 0.545 
Diastolic BP (mmHg) -5 (-12, 1) -6 (-9, -2) -5 (-8, 0) 0.785 
Waist:Hip ratio -0.01 (-0.03, 0.01) -0.02 (-0.04, 0.01) 0 (-0.01, 0.04) 0.07 
Body fat (%)  -1.3 (-2.4, -0.5) ∞ -0.8 (-1.7, -0.5) Ψ 0.5 (-0.2, 1) <0.001* 
Fat mass (kg) -0.9 (-1.5, -2.7) ∞ -0.8 (-1.2, -0.4) Ψ 0.4 (-0.5, 0.9)  <0.001* 
Fat mass (trunk) (kg) -0.5 (-1, 02) ∞ -0.6 (-0.8, -1) Ψ 0.1 (-0.4, 0.6) 0.001* 
Lean tissue mass (kg) 0.7 (0.3, 1.8) ∞ 0.5 (-0.4, 1.1) Ψ -0.2 (-0.9, 0.3) 0.001* 
Weekly PA (METS) 
1,159  
(712, 1,964) ∞ 
1,265  




Weekly PA (kCals) 
1,442  
(818, 2,628) ∞ 
1,789  




Sitting time (hours/ week) -5 (-17, 2) -12 (-30, 1) -5 (-18, 1) 0.407 
Motorized transport 
(hours/week) 
0 (-3.3, 2.8) 0 (-1, 1.3) 0.1 (-0.4, 5) 0.519 
Supplementary Table 6.3  
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Supplementary Table 6.3 continued | Comparison of the postintervention changes (Δ) in 
clinical and anthropometric variables between groups. Between-group differences in 
postintervention changes were compared using Kruskal-Wallis tests (P values shown; *, P < 
0.05). When significantly different a Mann-Whitney U test was applied to determine 
between which groups the difference existed. "∞" indicates a difference between the E and P 
groups; "Ψ" indicates a difference between the EP and P groups (for all data, P < 0.05). BMI, 
body mass index; BP, blood pressure; bpm, beats per minute; weekly PA, self-reported 
weekly physical activity expenditure assessed using the International Physical Activity 
Questionnaire; kCals, kilocalories; METS, metabolic equivalents. 
Workload parameter Exercise Group (E) (n=25) Exercise + Protein Group 
(EP) (n=22) 
p-value  
Number of exercise 
sessions attended 
21 (16, 23) 21 (20, 23) 0.317 
Duration of aerobic training 
(mins) 
671 (436, 728) 625 (539, 685) 0.983 
Aerobic exercise energy 
expenditure (Cals) 
6,043 (3754, 7411) 5,869 (5291, 7324) 0.654 
Calories expended per body 
weight (Cals/kg) 
69 (47, 90) 74 (62, 83) 0.685 
Total number of repetitions  4,861 (4273, 6008) 4,874 (4281, 6136) 0.685 
Total weight lifted (Tonnes) 171.6 (136.8, 205) 169.7 (111, 238.4) 0.701 
Total weight lifted (kg) per 
kg of body weight 
1,962 (1753, 2282) 2,288 (1464, 2746) 0.43 
Supplementary Table 6.4. Measurement of aerobic and resistance training completed in the 
exercise and exercise plus protein intervention groups (8 weeks), with comparisons of 
workloads between the two groups. Median values and interquartile ranges (IQRs) are 
stated in the legend. Comparisons between groups were performed using Mann-
Whitney U tests. Mins, minutes; Cals, calories expended.  
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 Exercise (E) Group 
(n=25) 
Exercise + Protein (EP) 
Group (n=22) 






-0.05 (-0.21, 0.08) 0 (-0.23, 0.19) 0.02 (-0.11, 0.19) 0.385 
Interleukin 6 
(pg/ml) 
-0.01 (-0.2, 0.2) -0.04 (-0.28, 0.29) 0 (-0.17, 0.23) 0.893 
Interleukin 8 
(pg/ml) 
-5.53 (-29.79, 1.37) -20.14  
(-124.47, 0.61) Ψ 
-1.63 (-3.56, 1.38) 0.047* 
TNF-α 
(pg/ml) 
-0.1 (-0.66, 0.44) -0.02 (-1.19, 0.77) 0.11 (-0.24, 0.34) 0.293 
IFN-γ (pg/ml) 0.21 (-1.87, 3.39) 0.07 (-1.72, 2.83) -0.41 (-1.57, 1.3) 0.962 
CRP (mg/L) 0 (-0.5, 0) 0 (0, 0) 0 (0, 0) 0.71 
Supplementary Table 6.5 | Comparison of postintervention changes (Δ) in inflammatory 
markers between groups. Legend: between-group differences in postintervention changes 
were compared using the Kruskal-Wallis test (P values shown; *, P < 0.05). Median changes 
and interquartile ranges are stated. Where data were significantly different, a Mann-
Whitney U test was applied to determine between which groups the difference existed. "Ψ" 
denotes a significant difference between EP and P groups. TNF-α, tumour necrosis factor 
alpha; IFN-γ, interferon gamma; CRP, C-reactive protein.  
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ANCOM Detected Features 


























s__Lactococcus_phage_Tuc2009 5.00E-04 2.10E-03 2.07E-03 0.00E+00 
s__Lactococcus_phage_TP901.1 1.67E-04 1.54E-03 9.81E-04 0.00E+00 
s__Lactococcus_phage_340 8.54E-03 2.44E-01 3.36E-03 5.97E-04 
s__Lactococcus_phage_jm2 8.41E-03 3.75E-02 1.87E-03 0.00E+00 
s__Lactococcus_phage_jm3 6.22E-03 3.58E-02 1.14E-03 0.00E+00 
s__Lactococcus_phage_P680 1.57E-02 1.40E-01 1.85E-03 0.00E+00 
s__Lactococcus_phage_phi7 8.34E-03 3.69E-02 1.16E-03 5.97E-04 
s__Streptococcus_phage_Alq132 1.81E-03 9.05E-03 8.40E-02 5.97E-03 
s__Streptococcus_phage_Sfi19 2.49E-03 4.53E-03 5.45E-02 2.39E-03 
s__Streptococcus_phage_DT1 8.56E-03 1.98E-02 2.07E-01 1.01E-02 
s__Streptococcus_phage_7201 3.59E-03 9.28E-03 1.58E-01 7.16E-03 
s__Streptococcus_phage_Abc2 3.86E-03 1.53E-02 1.23E-01 8.35E-03 
s__Lactococcus_phage_SK1 8.92E-04 8.26E-03 3.50E-04 0.00E+00 
s__Lactococcus_phage_bIL170 5.03E-03 4.16E-02 1.05E-03 5.97E-04 
s__Lactococcus_phage_P008 2.54E-03 4.05E-02 1.12E-03 0.00E+00 
s__Lactococcus_phage_712 1.87E-03 1.88E-02 1.81E-03 0.00E+00 
s__Lactococcus_phage_jj50 1.06E-03 1.35E-02 4.03E-04 0.00E+00 






s__Vibrio_anguillarum 6.44E-06 1.33E-05 2.00E-06 5.00E-06 
s__Fervidobacterium_pennivorans 6.73E-06 1.08E-05 0.00E+00 1.25E-06 
s__Streptococcus_thermophilus 7.43E-04 1.28E-03 3.09E-01 5.64E-04 























s__Borrelia_hermsii 4.51E-06 2.32E-06 0.00E+00 0.00E+00 
s__Mycoplasma_pneumoniae 9.44E-07 6.61E-07 0.00E+00 0.00E+00 














ANCOM Detected Features 

























s__Streptococcus_phage_20617 7.11E-03 3.20E-03 9.97E-03 5.97E-04 
s__Lactococcus_phage_c2 1.05E-02 1.93E-02 4.62E-02 2.39E-03 
s__Lactococcus_phage_bIL67 2.29E-02 1.23E-02 1.83E-02 1.19E-03 
s__Lactococcus_phage_Tuc2009 2.45E-04 3.01E-03 2.07E-03 0.00E+00 
s__Lactococcus_phage_TP901.1 2.41E-04 1.89E-03 9.81E-04 0.00E+00 
s__Lactococcus_phage_r1t 6.31E-03 2.65E-03 3.14E-03 0.00E+00 
s__Lactococcus_phage_340 3.00E-02 2.33E-01 3.36E-03 5.97E-04 
s__Lactococcus_phage_jm2 1.61E-02 4.39E-02 1.87E-03 0.00E+00 
s__Lactococcus_phage_jm3 1.59E-02 4.12E-02 1.14E-03 0.00E+00 
s__Lactococcus_phage_P680 2.36E-02 1.45E-01 1.85E-03 0.00E+00 
s__Lactococcus_phage_phi7 1.48E-02 3.92E-02 1.16E-03 5.97E-04 
s__Streptococcus_phage_TP.778L 2.24E-04 9.90E-03 1.65E-02 1.19E-03 
s__Streptococcus_phage_Alq132 1.42E-03 1.09E-02 8.40E-02 5.97E-03 
s__Streptococcus_phage_Sfi19 1.43E-03 5.05E-03 5.45E-02 2.39E-03 
s__Streptococcus_phage_DT1 5.31E-03 1.83E-02 2.07E-01 1.01E-02 
s__Streptococcus_phage_7201 1.90E-03 1.09E-02 1.58E-01 7.16E-03 
s__Streptococcus_phage_Abc2 2.22E-03 1.66E-02 1.23E-01 8.35E-03 
s__Lactococcus_phage_SK1 5.05E-03 1.05E-02 3.50E-04 0.00E+00 
s__Lactococcus_phage_bIL170 1.42E-02 4.61E-02 1.05E-03 5.97E-04 
s__Lactococcus_phage_P008 1.24E-02 4.55E-02 1.12E-03 0.00E+00 
s__Lactococcus_phage_712 9.28E-03 2.24E-02 1.81E-03 0.00E+00 
s__Lactococcus_phage_jj50 8.44E-03 1.39E-02 4.03E-04 0.00E+00 












No significant OTUs detected NA NA NA NA 
Table component A 
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p < 0.05 
    
 
pFDR < 0.05 
    Urine Metabolites 
Metabolite 







Allantoin 0.824 0.917 0.545 0.601 0.197 0.331 
Carnitine 0.068 0.103 0.176 0.408 0.855 0.927 
Citrate 0.105 0.299 1.000 0.862 0.747 0.862 
Glycine 0.019 0.258 0.210 0.601 0.345 0.493 
Hippurate 0.924 0.954 0.750 0.736 0.527 0.660 
Leucine 0.030 0.248 0.679 0.917 0.623 0.959 
PAG 0.059 0.164 0.775 0.954 0.023 0.093 
Proline Betaine 0.633 0.617 0.702 0.507 0.584 0.533 
Succinate 0.566 0.478 0.321 0.667 0.252 0.455 
Trans Aconitate 0.874 0.991 0.371 0.125 0.004 0.046 
TMAO 0.042 0.062 0.305 0.125 0.107 0.172 
Valine 0.129 0.650 0.198 0.435 0.264 0.783 
       Faecal Metabolites 
Metabolite 








(DMA) 0.046 0.356 1.000 0.880 0.846 0.913 
Glutamate 0.919 0.881 0.424 0.507 0.023 0.007 
Methylamine 
(MA) 0.812 0.567 0.545 0.771 0.754 0.648 
Phenylacetate 0.338 0.517 0.483 0.522 0.754 0.648 
Serine 0.973 0.921 0.129 0.333 0.160 0.285 
Trimethylamine 
(TMA) 0.865 0.746 0.424 0.569 0.777 0.862 
Tyrosine 0.973 1.000 0.337 0.736 0.445 0.711 
 
  




p < 0.05  
pFDR < 0.05  
Urine Metabolite Group Comparison 
Metabolite 
Kruskal 
Wallis Mann Whitney U 
E vs EP vs 
P 
E vs P - p 
value 
E vs P 
pFDR 
E vs EP 
- p 
value 
E vs EP 
pFDR 
EP vs 





Allantoin 0.385 0.291 0.484 0.807 0.937 0.208 0.544 
Carnitine 0.325 0.173 0.484 0.862 0.940 0.242 0.559 
Citrate 0.392 0.272 0.484 0.211 0.544 0.957 0.957 
Glycine 0.062 0.050 0.201 0.037 0.255 0.703 0.937 
Hippurate 0.761 0.429 0.562 0.754 0.937 0.785 0.937 
Leucine 0.579 0.468 0.562 0.299 0.559 0.887 0.940 
PAG 0.006 0.001 0.014 0.311 0.559 0.057 0.255 
Proline Betaine 0.959 0.878 0.878 0.771 0.937 0.922 0.948 
Succinate 0.327 0.244 0.484 0.585 0.842 0.200 0.544 
Trans Aconitate 0.087 0.322 0.484 0.522 0.784 0.014 0.169 
TMAO 0.012 0.006 0.036 0.195 0.544 0.046 0.255 
Valine 0.118 0.775 0.845 0.055 0.255 0.106 0.426 
        Faecal Metabolite Group Comparison 
Metabolite 
Kruskal 
Wallis Mann Whitney U 
E vs EP vs 
P 
E vs P - p 
value 
E vs P 
pFDR 
E vs EP 
- p 
value 
E vs EP 
pFDR 
EP vs 






(DMA) 0.508 0.316 0.890 0.329 0.890 0.991 0.991 
Glutamate 0.028 0.100 0.890 0.656 0.891 0.005 0.105 
Methylamine 
(MA) 0.696 0.485 0.890 0.764 0.891 0.492 0.964 
Phenylacetate 0.623 0.363 0.890 0.691 0.891 0.551 0.964 
Serine 0.607 0.428 0.890 0.366 0.890 0.902 0.991 
Trimethylamine 
(TMA) 0.803 0.852 0.942 0.493 0.890 0.727 0.991 
Tyrosine 0.445 0.609 0.891 0.524 0.890 0.202 0.706 
Table component E 
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 Allantoin  Carnitine  Citrate  Glycine 
Percent 
Change 
E 0.040 -0.304 0.113 0.160 
EP 0.017 -0.323 -0.022 -0.186 








































































E -0.007 0.048 -0.196 -0.185 
EP -0.111 -0.011 -0.010 -0.127 






(271038) 2795 (8881) 
-43452 
(99096) -73172 (406198) 
EP 
-87427 
(361172) -727 (11098) 
-2168 
(129790) -36254 (281728) 






(330942) 3821 (6034) 
-55796 
(109741) -46720 (182241) 
EP 
9770 (311037) 1544 (9325) 
-10789 
(152512) -1626 (260571) 
P 
-106522 
(502221) 488 (11009) 
28683 
(132259) -8146 (139201) 
 
  





















Aconitate  TMAO  Valine 
Percent 
Change 
E -0.082 0.050 -0.518 0.025 
EP -0.032 0.008 0.005 -0.070 






(113554) 1394 (14816) 
-4324845 
(10001137) 1181 (7793) 
EP 
-9841 
(109029) 219 (13674) 
15418 
(4520714) -3787 (10604) 
P 
35728 
(138615) -3965 (8235) 
224051 






(107283) -476 (15042) 
-1581160 
(10243900) 1253 (5662) 
EP 
-48579 
(71425) 2013 (8208) 
-449763 
(1333768) -906 (10053) 
P 
27134 
(206848) -2690 (6076) 
746835 



















mine (DMA)  Glutamate 
 Methyla-
mine (MA)  Phenylacetate 
Percent 
Change 
E -0.051 -0.013 -0.003 0.139 
EP -0.008 0.076 -0.140 0.049 
























(123078) -3237 (34478) -159 (21834) 




(85236) -2431 (30736) -895 (26770) 
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15010 (45823) -3214 (45008) 
-9094 (56306) 
  
Table component F 
Supplementary Table 6.6. The following combined data: (A) ANCOM results for 
statistically varied taxa of subjects and for corresponding taxa in whey and control 
supplements with relative abundance values and a list of significantly varied metabolic 
pathways and the (B) associated MetaCyc metabolic categories as well as (C & D) targeted 
faecal and urinary metabolites with (E & F) corresponding paired statistical results. 
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Chapter 9  
―― 
SUMMARY AND CONCLUSION 
9.1 | Summary of original research 
The content presented in this thesis demonstrates substantial advancements made towards 
its primary aim to examine the capacity for influence of physical exercise on the human 
intestinal microbiome. Previous chapters have described observations stemming from a 
range of investigative frameworks that cross section host-microbe interactions within the 
context of exercise. Fortuitous access to unique populations ranging from professional 
athletes to IBD patients have enabled the opportunity to gain insights on numerous 
different aspects of physical activity’s impact on the human gut microbiome. The remainder 
of this current chapter outlines final considerations of the distinct sections of this thesis, 
before describing implications for the field of microbiome research, and finally offering 
suggestions of pursuits to carry the diet and exercise-microbiome paradigm into the future. 
9.1.1 | The athlete microbiome 
Detailed in chapter 3, the gut microbiome of elite athletes has been described as presenting 
a unique functional capacity. Building upon previous analysis of the same cohort, it was 
shown that not only do the athletes have a more diverse gut microbiome, but the metabolic 
capacity is primed for enhanced energy usage (section 3.5.1, figure 3.3) [1-3]. Additionally 
an enrichment of faecal concentrations of SCFAs, compounds with widely purported health 
benefits, within this group suggests that there may be positive influence on health (section 
3.5.2, figure 3.4) [4-6]. As stated previously, while elite athletes may be fit, their condition is 
not necessarily more healthy than non-athletic peers [7]. In addition to an increase of 
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beneficial metabolites, some, such as TMAO, are considered to be detrimental (section 3.5.2, 
supplementary figure 3.2) [8-12]. Furthermore, sensible speculation would be difficult to 
make on what the health impact would be of maintaining a gut microbiome with such 
irregular dynamics of energy expenditure and production without the nutritional resources 
provided by the dietary habits of high-performance athletes. 
9.1.2 | Computational interrogations of the athlete microbiome 
Two computational modelling approaches, presented separately in chapters 4 and 5, were 
used to further describe aspects of the athlete gut microbiome. In chapter 4 the original data 
from athletes and associated low and high BMI controls was applied to a novel mathemati-
cal modelling strategy that reclassified the participants based upon metabolomic profiles 
and ultimately predicted healthiness of diet (section 4.4.1, figure 4.1). Within these new 
participant classifications, no robust differences were detected in terms of the gut 
microbiome (section 4.4.4, and figure 4.3).  
Additionally in chapter 5, a Flux Balance Analysis (FBA) based approach was used 
to elaborate on the metabolic function of gut microbiota while simultaneously validating the 
method for novel result discovery. With this approach it was shown that of the microbial 
models present within the original taxonomic profiles, retention of diversity dynamics is 
achieved (i.e. the modelling accurately represents the results of metagenomic sequencing, 
see section 5.5.1 and figure 5.1). Furthermore, metabolic reactions resulting from the 
approach show statistically significant variation between athletes and controls. Intriguingly, 
potential insight on the original result of elevated TMAO in the athletes was gained from 
the approach and may justify more elaborate experimentation (section 5.5.3, and 




9.1.3 | Influence of short-term exercise and whey protein supplementation on the gut 
microbiome 
An initial finding of the investigation into the athlete microbiome was that dietary protein 
consumption and creatine kinase, a biological product of muscle damage and subsequent 
proxy for fitness, correlated with microbial diversity. To assess if these factors do indeed 
influence the gut microbiome we took adults that were healthy but physically inactive and 
had them undergo a short-term exercise regime, increased protein consumption in the form 
of whey protein, or a combination of both [13].  
Overall the identified effects of exercise on the gut microbiome were subtle. Howev-
er, we observed that participants consuming the whey protein supplement experienced a 
significant alteration in the β-diversity of the gut virome (refer to section 6.4.3, figures 6.3 
and 6.4, and supplementary table 6.6). We went on to profile the supplement itself with 
metagenomic sequencing, and determined that it was likely that a direct transmission of 
viral particles from the whey powder to the participants had occurred. To our knowledge, 
this marked the first presentation of such a finding. While this is an intriguing finding, it is 
important to note that examination of the virus component of the microbiome was not an 
explicit aim of the study. Accordingly, the investigative procedures used to analyse the 
virome were suboptimal, and therefor before strong conclusions are to be drawn on the 
matter a more tailored approach must be used to assess the virome within the study’s 
parameters. For example, of the 523 million reads that were taxonomically assigned at 
species level, only 0.035% matched viruses. With such a low proportion of reads available 
for taxonomic assessment, it is well within reason that the virome of the participants in 
question was only partially characterised. To address this limitation, methods for the 
targeted extraction and bioinformatic analysis of virus genetic material should be used [14, 
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15]. Despite bearing this limitation, the conclusions drawn from the study were that the 
potential effects of physical exercise on the microbiome likely require a longer duration to 
become pronounced, and whey protein powder may directly alter dynamics of the gut 
microbiome. 
9.1.4 | The vulnerable IBD gut microbiome and exercise 
As demonstrated in our assessment of exercise and whey protein as a novel stimulus to the 
gut microbiome, short-term physical activity has minimal influence on the function and 
composition of intestinal microbiota [13]. With these findings it was apparent that the 
limited effect of short-term exercise on the microbiome may be desirable in populations 
with reduced GI health. IBD patients were subsequently recruited as a cohort to assess if an 
exercise intervention could be utilized without detrimental perturbations to the gut 
microbiome while still transferring the broad systemic benefits of exercise. As anticipated, 
subtle changes were presented in the gut microbiome after IBD patients underwent the 
structured exercise intervention (sections 7.5.3 - 7.5.4 and figures 7.2 – 7.3). Curiously, one of 
the few statistically significant changes identified in the microbiome profiling was an 
increase in bacterial diversity patients after a control period without exercise. This 
highlights the unexpected challenges resulting from utilising humans as an experimental 
model, and potentially resulted from subconscious behavioural changes in anticipation of 
starting exercise. Despite this, the enrolled patients undergoing exercise treatment 
succeeded in improving their body composition and cardiorespiratory fitness (section 7.5.2 
and table 7.3). This suggests that in specific scenarios an adjunct therapy of short-term 





9.1.5 | Influence of prolonged exercise on the intestinal microbiome 
In order to address the possibility that previous efforts to affect the gut microbiome with 
exercise were unyielding of dramatic alterations due to the limited duration of the exercise 
period, 2 individuals were examined over the course of 6 months while undergoing self-
directed exercise. This observational study provided an opportunity to focus resources on 2 
participants, subsequently granting a robust picture of microbiome fluctuations in response 
to training events and health challenges. While the conclusions to be drawn are limited due 
to the small n number that prohibits comprehensive statistical analysis, trends in gut 
microbiome dynamics, suggest that alterations of the microbiome were influenced by the 
participants’ physical training (section 8.5.4 and figure 8.4).  
The study was also designed to accommodate health disruptions for the participants 
(i.e. to proceed with sample and data collection), and accordingly captured dramatic loss of 
microbiome diversity when one individual fell ill. Curiously, at another point, following a 
minor training injury and the use of anti-inflammatory drugs, a substantial increase in 
diversity was observed. These examples highlight the usefulness of employing similar 
study designs, as the inevitable variability of human life can be better tracked and the 
influences of unexpected events on the research focus can be better understood.  
9.2 | Implications for related research 
Study of the human gut microbiome has led to recognition of its profound influence on 
human health. With broad health implications spanning from diabetes and inflammatory 
bowel disease to psychiatric disorder and some forms of cancer, the gut microbiome has 
garnered increasing interest as a modifiable factor for health and disease [16-24]. 
Accordingly, there is a mounting call for means to exert controlled alteration of the 
microbiome, both in terms of taxonomic composition and ultimately function. Considerable 
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evidence has been put forth for pharmaceuticals, antibiotics as well as compounds not 
intended to target microbes, diet, and probiotics as effective modulators of the gut 
microbiome [25]. The body of information presented in this thesis offers further support for 
the inclusion of physical exercise as a factor of influence on the microbiome. Based upon the 
various studies detailed here, there are grounds to continue exploring the microbiomes of 
different high-performance athletes, as well as continuing to pursue exercise as an 
intervention in disease populations. Moving forward in this regard, it is worth noting the 
post hoc power analysis performed on the studies presented in this thesis (see section 2.8.1). 
Sample size estimation and power analysis of genetic sequencing focused microbiome 
studies is challenging due to the multivariate nature of taxonomic or pathway measure-
ments, and the consideration of sequencing factors (e.g. sequencing depth) [26, 27]. Despite 
the complexity of appropriate power analysis methods for the microbiome, and challenges 
to the conventions that guide such analysis, it is important to utilise this statistical approach 
to rationalise and guide microbiome research [28]. With the power analysis performed on 
measures of alpha diversity from the various studies described in this thesis, it was shown 
that largely the studies were adequately powered for the observation of changes in 
diversity. The notable exceptions, are the N of 1 observational study described in chapter 8, 
which by its nature is completely underpowered, and the exercise intervention study in IBD 
patients presented in chapter 7. For this intervention study, the observed effect size of 0.05 
at a significance level of 0.05, had a power of 29% with a sample size of 13. In this particular 
case there were challenges with participant recruitment and retention, which were only 
presented after the study had commenced. As a result of how underpowered the study was 
in regards to the detection of changes in diversity of the gut microbiome, results related to 




similar research forward if it is treated as a pilot study, with more aggressive recruitment 
used in the future to achieve sufficient sample sizes. 
9.3 | Relevant future efforts 
Eluted to previously, an enormous range of aspects related to the interaction of exercise and 
the gut microbiome remain to be pursued. Our research group is actively engaged in 
advancing the breadth of microbiomes from diverse athletic populations characterised, with 
aim to identify microbial variations associated to differences in sports type. A potential 
desired outcome of this continued endeavour being the isolation of specific microbes that 
confer advantages to certain aspects of athleticism. Finally, the well-established monumen-
tal influence of diet on the microbiome has been a persistent challenge in isolating the 
effects of physical activity upon the microbiota of the intestine [4, 29-34]. The construction of 
an intervention study examining a cohort with a set and prescribed diet, while engaging in 
exercise will be essential in advancing the exercise and diet-microbiome paradigm—
influences of physical activity and dietary nutrition on the human gut microbiome.  
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PWY.6270.isoprene.biosynthesis.I 0.001 0.001 0.036 0.062 
PWY.7316.dTDP.N.acetylviosamine.biosynthesis 0.001 0.002 0.002 0.659 
PWY.6859.all.trans.farnesol.biosynthesis 0.002 0.005 0.005 0.289 
PWY.7315.dTDP.N.acetylthomosamine.biosynthesis 0.002 0.003 0.003 0.848 
PWY.7663.gondoate.biosynthesis.anaerobic. 0.002 0.455 0.012 0.006 
PWY.5850.superpathway.of.menaquinol.6.biosynthesis.I 0.003 0.075 0.005 0.075 
PWY.5860.superpathway.of.demethylmenaquinol.6.biosynthesis. 0.003 0.071 0.005 0.071 
PWY.7392.taxadiene.biosynthesis.engineered. 0.003 0.005 0.013 0.201 
REDCITCYC.TCA.cycle.VIII.helicobacter. 0.003 0.792 0.009 0.011 
PWY.6060.malonate.degradation.II.biotin.dependent. 0.004 0.947 0.022 0.007 
PWY.6322.phosphinothricin.tripeptide.biosynthesis 0.004 0.002 0.021 0.402 
POLYISOPRENSYN.PWY.polyisoprenoid.biosynthesis.E.coli. 0.005 0.01 0.023 0.167 
PWY.5101.L.isoleucine.biosynthesis.II 0.005 0.115 0.007 0.115 
PWY0.1261.anhydromuropeptides.recycling 0.005 0.173 0.007 0.081 
PWY.7221.guanosine.ribonucleotides.de.novo.biosynthesis 0.006 0.826 0.018 0.018 
PWY.7560.methylerythritol.phosphate.pathway.II 0.006 0.015 0.978 0.008 
PWY.6906.chitin.derivatives.degradation 0.007 0.021 0.013 0.289 
PWY66.398.TCA.cycle.III.animals. 0.007 0.03 0.009 0.48 
PWY.5757.fosfomycin.biosynthesis 0.009 0.005 0.045 0.339 
PWY.7282.4.amino.2.methyl.5.phosphomethylpyrimidine.biosynthesis.yeast. 0.009 0.218 0.218 0.005 
THISYNARA.PWY. 
superpathway.of.thiamin.diphosphate.biosynthesis.III.eukaryotes. 0.009 0.072 0.013 0.149 
PWY0.1586.peptidoglycan.maturation.meso.diaminopimelate.containing. 0.01 0.028 0.012 0.86 
GALACTARDEG.PWY.D.galactarate.degradation.I 0.012 0.301 0.017 0.084 
GLUCARGALACTSU-
PER.superpathway.of.D.glucarate.and.D.galactarate.degradation 0.012 0.301 0.017 0.084 
PWY.5189.tetrapyrrole.biosynthesis.II.from.glycine. 0.013 0.482 0.017 0.084 
PWY.5283.L.lysine.degradation.V 0.013 0.572 0.028 0.028 
PWY.6737.starch.degradation.V 0.013 0.442 0.011 0.136 
DENOVOPURINE2.PWY. 
superpathway.of.purine.nucleotides.de.novo.biosynthesis.II 0.014 0.173 0.021 0.136 
NONOXIPENT.PWY. 
pentose.phosphate.pathway.non.oxidative.branch. 0.015 0.118 0.667 0.007 















PWY.5104.L.isoleucine.biosynthesis.IV 0.015 0.166 0.026 0.109 
PWY.6572.chondroitin.sulfate.degradation.I.bacterial. 0.015 0.019 0.019 0.883 
PWY.7277.sphingolipid.biosynthesis.mammals. 0.016 0.097 0.016 0.224 
ALLANTOINDEG.PWY. 
superpathway.of.allantoin.degradation.in.yeast 0.017 0.272 0.107 0.024 
HSERMETANA.PWY.L.methionine.biosynthesis.III 0.017 0.107 0.018 0.296 
LYSINE.DEG1.PWY.L.lysine.degradation.XI.mammalian. 0.017 0.068 0.031 0.176 
OANTIGEN.PWY.O.antigen.building.blocks.biosynthesis.E.coli. 0.017 0.244 0.015 0.224 
PWY.3001.superpathway.of.L.isoleucine.biosynthesis.I 0.017 0.023 0.023 0.499 
PWY.6629.superpathway.of.L.tryptophan.biosynthesis 0.017 0.391 0.033 0.066 
PWY66.389.phytol.degradation 0.017 0.014 0.533 0.043 
METHGLYUT.PWY.superpathway.of.methylglyoxal.degradation 0.018 0.049 0.021 0.627 
P23.PWY.reductive.TCA.cycle.I 0.018 0.344 0.153 0.017 
COA.PWY.coenzyme.A.biosynthesis.I 0.019 0.033 0.868 0.024 
UDPNAGSYN.PWY.UDP.N.acetyl.D.glucosamine.biosynthesis.I 0.019 0.253 0.019 0.206 
PWY.5188.tetrapyrrole.biosynthesis.I.from.glutamate. 0.02 0.524 0.024 0.102 
PWY.5918.superpathay.of.heme.biosynthesis.from.glutamate 0.02 0.162 0.024 0.162 
X.PWY.6307.L.tryptophan.degradation.X.mammalian.via.tryptamine. 0.02 0.022 0.608 0.022 
X.PWY.6358.superpathway.of.D.myo.inositol.1.4.5.trisphosphate.metabolism. 0.02 0.583 0.013 0.04 
PWY.4242.pantothenate.and.coenzyme.A.biosynthesis.III 0.021 0.136 0.292 0.019 
PWY.5862.superpathway.of.demethylmenaquinol.9.biosynthesis 0.021 0.21 0.035 0.124 
PWY.6901.superpathway.of.glucose.and.xylose.degradation 0.021 0.072 0.868 0.016 
PWY.4981.L.proline.biosynthesis.II.from.arginine. 0.022 0.025 0.497 0.025 
PWY.5667.CDP.diacylglycerol.biosynthesis.I 0.022 0.149 0.023 0.27 
PWY.5845.superpathway.of.menaquinol.9.biosynthesis 0.022 0.218 0.035 0.128 
PWY.5971.palmitate.biosynthesis.II.bacteria.and.plants. 0.022 0.047 0.027 0.941 
PWY0.1319.CDP.diacylglycerol.biosynthesis.II 0.022 0.149 0.023 0.27 
PWY.5896.superpathway.of.menaquinol.10.biosynthesis 0.023 0.061 0.035 0.362 
PWY.6313.serotonin.degradation 0.023 0.027 0.524 0.039 
PWY.6435.4.hydroxybenzoate.biosynthesis.V 0.023 0.061 0.026 0.648 
PWY.7094.fatty.acid.salvage 0.023 0.052 0.029 0.68 
THISYN.PWY.superpathway.of.thiamin.diphosphate.biosynthesis.I 0.023 0.025 0.025 0.638 
PWY.5136.fatty.acid.beta.oxidation.II.peroxisome. 0.025 0.107 0.022 0.517 
PWY.5676.acetyl.CoA.fermentation.to.butanoate.II 0.025 0.136 0.022 0.41 
PWY.7200.superpathway.of.pyrimidine.deoxyribonucleoside.salvage 0.025 0.809 0.043 0.043 
PWY0.1241.ADP.L.glycero.beta.D.manno.heptose.biosynthesis 0.025 0.826 0.054 0.054 
PWY.7644.heparin.degradation 0.026 0.644 0.083 0.083 
PWY3DJ.35471.L.ascorbate.biosynthesis.IV 0.026 0.033 0.033 0.871 
PWY.6491.D.galacturonate.degradation.III 0.027 0.048 0.033 0.935 
PWY66.422.D.galactose.degradation.V.Leloir.pathway. 0.027 0.229 0.025 0.257 
PWY.1501.mandelate.degradation.I 0.028 0.03 0.03 0.941 















X.PRPP.PWY.superpathway.of.histidine.purine.and.pyrimidine.biosynthesis. 0.029 0.17 0.03 0.31 
PWY.6124.inosine.5.phosphate.biosynthesis.II 0.029 0.312 0.312 0.016 
PWY.6163.chorismate.biosynthesis.from.3.dehydroquinate 0.029 0.235 0.235 0.024 
PWY.5392.reductive.TCA.cycle.II 0.03 0.843 0.062 0.058 
TRPSYN.PWY.L.tryptophan.biosynthesis 0.03 0.416 0.059 0.081 
PANTOSYN.PWY.pantothenate.and.coenzyme.A.biosynthesis.I 0.031 0.124 0.57 0.024 
RIBOSYN2.PWY.flavin.biosynthesis.I.bacteria.and.plants. 0.031 0.04 0.04 0.617 
PWY.6168.flavin.biosynthesis.III.fungi. 0.032 0.044 0.044 0.627 
KETOGLUCONMET.PWY.ketogluconate.metabolism 0.035 0.055 0.047 0.93 
PENTOSE.P.PWY.pentose.phosphate.pathway 0.035 0.281 0.618 0.015 
PWY.6123.inosine.5.phosphate.biosynthesis.I 0.038 0.422 0.429 0.016 
PWY.6165.chorismate.biosynthesis.II.archaea. 0.038 0.629 0.14 0.044 
PWY.6892.thiazole.biosynthesis.I.E.coli. 0.038 0.044 0.824 0.044 
FAO.PWY.fatty.acid.beta.oxidation.I 0.04 0.163 0.033 0.556 
BRANCHED.CHAIN.AA.SYN.PWY.superpathway.of.branched.amino.acid.bios
ynthesis 0.041 0.187 0.077 0.158 
XP4.PWY.superpathway.of.L.lysine.L.threonine.and.L.methionine.biosynthesis 0.041 0.17 0.057 0.233 
X.P461.PWY.hexitol.fermentation.to.lactate.formate.ethanol.and.acetate. 0.042 0.042 0.708 0.042 
X.PWY.7237.myo.chiro.and.scillo.inositol.degradation. 0.042 0.366 0.551 0.018 
PWY.7389.superpathway.of.anaerobic.energy.metabolism.invertebrates. 0.042 0.194 0.041 0.377 
PWY0.781.aspartate.superpathway 0.042 0.211 0.047 0.276 
P122.PWY.heterolactic.fermentation 0.044 0.056 0.153 0.153 
PWY66.375.leukotriene.biosynthesis 0.045 0.043 0.098 0.435 
X.GLCMANNANAUT.PWY.superpathway.of.N.acetylglucosamine.N.acetylman
nosamine.and.N.acetylneuraminate.degradation. 0.047 0.064 0.064 0.317 
THREOCAT.PWY.superpathway.of.L.threonine.metabolism 0.048 0.259 0.046 0.332 
FERMENTATION.PWY.mixed.acid.fermentation 0.049 0.281 0.281 0.051 
P241.PWY.coenzyme.B.biosynthesis 0.049 0.186 0.051 0.393 
PWY.5103.L.isoleucine.biosynthesis.III 0.049 0.262 0.102 0.128 
PWY.5705.allantoin.degradation.to.glyoxylate.III 0.049 0.509 0.191 0.054 
PWY.6121.5.aminoimidazole.ribonucleotide.biosynthesis.I 0.049 0.17 0.074 0.233 
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Supplementary Table 3.2 
Colour of group mean and standard deviation corresponding to pathways: High, low, and 
mid values 
MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
BRANCHED-CHAIN-AA-SYN-PWY: superpathway 
of branched amino acid biosynthesis 
6.49E+03 6.37E+03 6.13E+03 7.15E+02 6.03E+02 7.37E+02 
COA-PWY: coenzyme A biosynthesis I 4.36E+03 3.99E+03 4.46E+03 6.67E+02 9.71E+02 8.56E+02 
DENOVOPURINE2-PWY: superpathway of purine 
nucleotides de novo biosynthesis II 
2.92E+03 3.09E+03 3.38E+03 5.55E+02 6.63E+02 4.43E+02 
HSERMETANA-PWY: L-methionine biosynthesis 
III 
6.99E+03 6.56E+03 6.33E+03 1.03E+03 1.15E+03 1.15E+03 
LYSINE-AMINOAD-PWY: L-lysine biosynthesis IV 5.42E+01 6.26E+01 7.51E+01 2.44E+01 2.28E+01 2.58E+01 
OANTIGEN-PWY: O-antigen building blocks 
biosynthesis (E. coli) 
2.13E+03 2.39E+03 2.68E+03 6.07E+02 6.59E+02 5.73E+02 
P241-PWY: coenzyme B biosynthesis 1.42E+02 1.74E+02 1.92E+02 5.13E+01 6.26E+01 6.73E+01 
P4-PWY: superpathway of L-lysine, L-threonine 
and L-methionine biosynthesis I 
2.34E+03 2.58E+03 2.73E+03 5.72E+02 5.68E+02 5.72E+02 
PANTOSYN-PWY: pantothenate and coenzyme A 
biosynthesis I 
4.47E+03 4.24E+03 4.59E+03 4.89E+02 6.56E+02 6.62E+02 
POLYISOPRENSYN-PWY: polyisoprenoid 
biosynthesis (E. coli) 
3.08E+03 2.42E+03 2.75E+03 8.13E+02 8.60E+02 7.32E+02 
PWY0-1241: ADP-L-glycero-&beta;-D-manno-
heptose biosynthesis 
1.80E+02 1.66E+02 2.84E+02 8.71E+01 8.56E+01 1.00E+02 
PWY0-1319: CDP-diacylglycerol biosynthesis II 4.35E+03 4.10E+03 4.03E+03 3.83E+02 3.98E+02 5.11E+02 
PWY0-1586: peptidoglycan maturation (meso-
diaminopimelate containing) 
6.69E+03 5.91E+03 6.05E+03 9.10E+02 9.47E+02 1.02E+03 
PWY-3001: superpathway of L-isoleucine 
biosynthesis I 
6.04E+03 5.85E+03 5.79E+03 4.62E+02 4.48E+02 4.51E+02 
PWY3DJ-35471: L-ascorbate biosynthesis IV 2.43E+01 3.22E+01 3.71E+01 2.85E+01 2.88E+01 4.94E+01 
PWY-4242: pantothenate and coenzyme A 
biosynthesis III 
4.12E+03 3.92E+03 4.33E+03 4.34E+02 6.69E+02 6.65E+02 
PWY-4981: L-proline biosynthesis II (from 
arginine) 
1.47E+03 2.07E+03 1.63E+03 8.09E+02 8.24E+02 7.62E+02 
PWY-5101: L-isoleucine biosynthesis II 4.87E+03 4.51E+03 4.28E+03 7.27E+02 7.35E+02 7.32E+02 
PWY-5103: L-isoleucine biosynthesis III 6.14E+03 6.01E+03 5.79E+03 7.14E+02 5.98E+02 7.06E+02 
PWY-5104: L-isoleucine biosynthesis IV 7.01E+03 6.81E+03 6.58E+03 7.62E+02 6.28E+02 6.86E+02 
PWY-5188: tetrapyrrole biosynthesis I (from 
glutamate) 
1.01E+03 1.07E+03 1.33E+03 3.54E+02 3.71E+02 3.70E+02 
PWY-5189: tetrapyrrole biosynthesis II (from 
glycine) 
7.03E+02 7.56E+02 9.62E+02 2.56E+02 2.74E+02 2.83E+02 
PWY-5667: CDP-diacylglycerol biosynthesis I 4.35E+03 4.10E+03 4.03E+03 3.83E+02 3.98E+02 5.11E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
PWY-5757: fosfomycin biosynthesis 1.12E+00 3.23E+00 3.32E+00 9.79E-01 1.89E+00 1.32E+00 
PWY-5845: superpathway of menaquinol-9 
biosynthesis 
1.87E+02 2.07E+02 2.83E+02 1.85E+02 1.70E+02 2.88E+02 
PWY-5850: superpathway of menaquinol-6 
biosynthesis I 
1.47E+02 1.67E+02 2.53E+02 1.88E+02 1.76E+02 2.81E+02 
PWY-5860: superpathway of demethylmena-
quinol-6 biosynthesis I 
1.01E+02 1.15E+02 1.77E+02 1.33E+02 1.25E+02 2.09E+02 
PWY-5862: superpathway of demethylmena-
quinol-9 biosynthesis 
1.28E+02 1.42E+02 1.97E+02 1.31E+02 1.21E+02 2.14E+02 
PWY-5896: superpathway of menaquinol-10 
biosynthesis 
1.48E+02 1.71E+02 2.34E+02 1.89E+02 1.75E+02 2.81E+02 
PWY-5918: superpathay of heme biosynthesis 
from glutamate 
4.46E+02 5.02E+02 6.23E+02 1.66E+02 2.02E+02 2.38E+02 
PWY-5971: palmitate biosynthesis II (bacteria and 
plants) 
7.15E+03 6.31E+03 6.43E+03 1.04E+03 1.08E+03 1.17E+03 
PWY-6121: 5-aminoimidazole ribonucleotide 
biosynthesis I 
6.47E+03 5.97E+03 5.84E+03 1.20E+03 1.15E+03 1.11E+03 
PWY-6123: inosine-5'-phosphate biosynthesis I 5.83E+03 5.43E+03 5.83E+03 1.12E+03 1.11E+03 1.07E+03 
PWY-6124: inosine-5'-phosphate biosynthesis II 6.31E+03 5.82E+03 6.34E+03 1.43E+03 1.27E+03 1.37E+03 
PWY-6125: superpathway of guanosine 
nucleotides de novo biosynthesis II 
3.80E+03 4.19E+03 4.30E+03 9.29E+02 1.04E+03 9.20E+02 
PWY-6163: chorismate biosynthesis from 3-
dehydroquinate 
5.40E+03 5.23E+03 5.52E+03 5.17E+02 5.82E+02 5.92E+02 
PWY-6165: chorismate biosynthesis II (archaea) 2.56E+01 2.27E+01 4.21E+01 1.85E+01 2.88E+01 2.95E+01 
PWY-6168: flavin biosynthesis III (fungi) 5.04E+03 4.72E+03 4.65E+03 6.87E+02 7.35E+02 7.21E+02 
PWY-6270: isoprene biosynthesis I 5.44E+03 4.57E+03 4.92E+03 8.10E+02 1.04E+03 8.11E+02 
PWY-6322: phosphinothricin tripeptide 
biosynthesis 
1.42E+00 3.97E+00 4.38E+00 1.33E+00 1.79E+00 1.82E+00 
PWY-6358: superpathway of D-myo-inositol 
(1,4,5)-trisphosphate metabolism 
6.46E-02 6.08E-02 2.52E-03 1.29E-01 1.82E-01 8.37E-02 
PWY-6435: 4-hydroxybenzoate biosynthesis V 1.49E+03 1.77E+03 1.80E+03 4.35E+02 4.84E+02 4.95E+02 
PWY-6629: superpathway of L-tryptophan 
biosynthesis 
4.05E+02 4.44E+02 5.82E+02 2.01E+02 2.11E+02 2.69E+02 
PWY66-375: leukotriene biosynthesis 4.16E-01 6.84E-01 7.22E-01 6.45E-01 6.36E-01 3.54E-01 
PWY-6892: thiazole biosynthesis I (E. coli) 4.76E+03 4.39E+03 4.71E+03 7.61E+02 8.15E+02 9.12E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
PWY-7094: fatty acid salvage 1.11E+03 1.37E+03 1.37E+03 3.38E+02 3.75E+02 3.96E+02 
PWY-7200: superpathway of pyrimidine 
deoxyribonucleoside salvage 
3.76E+02 3.61E+02 4.98E+02 4.51E+02 3.72E+02 4.28E+02 
PWY-7221: guanosine ribonucleotides de novo 
biosynthesis 
7.11E+03 6.86E+03 7.41E+03 1.67E+03 1.68E+03 1.64E+03 
PWY-7277: sphingolipid biosynthesis (mammals) 0.00E+00 2.01E-01 7.95E-01 0.00E+00 4.90E-01 5.34E-01 
PWY-7282: 4-amino-2-methyl-5-
phosphomethylpyrimidine biosynthesis (yeast) 
3.03E+03 3.26E+03 2.78E+03 6.46E+02 6.11E+02 5.81E+02 
PWY-7315: dTDP-N-acetylthomosamine 
biosynthesis 
1.98E+02 3.58E+02 4.20E+02 1.15E+02 1.31E+02 2.48E+02 
PWY-7316: dTDP-N-acetylviosamine biosynthesis 4.01E+02 7.12E+02 7.25E+02 2.94E+02 2.87E+02 2.97E+02 
PWY-7392: taxadiene biosynthesis (engineered) 4.21E+03 3.43E+03 3.72E+03 7.55E+02 9.15E+02 7.39E+02 
PWY-7560: methylerythritol phosphate pathway II 5.41E+03 4.75E+03 5.36E+03 8.77E+02 9.93E+02 9.09E+02 
PWY-7663: gondoate biosynthesis (anaerobic) 9.30E+03 9.55E+03 8.60E+03 8.96E+02 1.05E+03 1.23E+03 
RIBOSYN2-PWY: flavin biosynthesis I (bacteria 
and plants) 
5.00E+03 4.65E+03 4.62E+03 6.97E+02 7.53E+02 6.80E+02 
THISYNARA-PWY: superpathway of thiamin 
diphosphate biosynthesis III (eukaryotes) 
5.27E+03 4.82E+03 4.67E+03 1.00E+03 9.97E+02 9.02E+02 
THISYN-PWY: superpathway of thiamin 
diphosphate biosynthesis I 
5.15E+03 4.58E+03 4.58E+03 9.44E+02 8.68E+02 8.47E+02 
TRPSYN-PWY: L-tryptophan biosynthesis 2.18E+02 2.35E+02 2.95E+02 1.50E+02 1.31E+02 1.88E+02 
UDPNAGSYN-PWY: UDP-N-acetyl-D-
glucosamine biosynthesis I 
1.40E+03 1.62E+03 1.93E+03 5.50E+02 5.92E+02 5.39E+02 
Polyamine Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
UDPNAGSYN-PWY: UDP-N-acetyl-D-
glucosamine biosynthesis I 
1.40E+03 1.62E+03 1.93E+03 5.50E+02 5.92E+02 5.39E+02 
Amino Acid Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
BRANCHED-CHAIN-AA-SYN-PWY: superpathway 
of branched amino acid biosynthesis 
6.49E+03 6.37E+03 6.13E+03 7.15E+02 6.03E+02 7.37E+02 
HSERMETANA-PWY: L-methionine biosynthesis 
III 
6.99E+03 6.56E+03 6.33E+03 1.03E+03 1.15E+03 1.15E+03 
LYSINE-AMINOAD-PWY: L-lysine biosynthesis IV 5.42E+01 6.26E+01 7.51E+01 2.44E+01 2.28E+01 2.58E+01 
P4-PWY: superpathway of L-lysine, L-threonine 
and L-methionine biosynthesis I 
2.34E+03 2.58E+03 2.73E+03 5.72E+02 5.68E+02 5.72E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
PWY-3001: superpathway of L-isoleucine 
biosynthesis I 
6.04E+03 5.85E+03 5.79E+03 4.62E+02 4.48E+02 4.51E+02 
PWY-4981: L-proline biosynthesis II (from 
arginine) 
1.47E+03 2.07E+03 1.63E+03 8.09E+02 8.24E+02 7.62E+02 
PWY-5101: L-isoleucine biosynthesis II 4.87E+03 4.51E+03 4.28E+03 7.27E+02 7.35E+02 7.32E+02 
PWY-5103: L-isoleucine biosynthesis III 6.14E+03 6.01E+03 5.79E+03 7.14E+02 5.98E+02 7.06E+02 
PWY-5104: L-isoleucine biosynthesis IV 7.01E+03 6.81E+03 6.58E+03 7.62E+02 6.28E+02 6.86E+02 
PWY-6629: superpathway of L-tryptophan 
biosynthesis 
4.05E+02 4.44E+02 5.82E+02 2.01E+02 2.11E+02 2.69E+02 
TRPSYN-PWY: L-tryptophan biosynthesis 2.18E+02 2.35E+02 2.95E+02 1.50E+02 1.31E+02 1.88E+02 
Aromatic Compound Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY-6163: chorismate biosynthesis from 3-
dehydroquinate 
5.40E+03 5.23E+03 5.52E+03 5.17E+02 5.82E+02 5.92E+02 
PWY-6165: chorismate biosynthesis II (archaea) 2.56E+01 2.27E+01 4.21E+01 1.85E+01 2.88E+01 2.95E+01 
PWY-6435: 4-hydroxybenzoate biosynthesis V 1.49E+03 1.77E+03 1.80E+03 4.35E+02 4.84E+02 4.95E+02 
Carbohydrates Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY0-1241: ADP-L-glycero-&beta;-D-manno-
heptose biosynthesis 
1.80E+02 1.66E+02 2.84E+02 8.71E+01 8.56E+01 1.00E+02 
PWY-7315: dTDP-N-acetylthomosamine 
biosynthesis 
1.98E+02 3.58E+02 4.20E+02 1.15E+02 1.31E+02 2.48E+02 
PWY-7316: dTDP-N-acetylviosamine biosynthesis 4.01E+02 7.12E+02 7.25E+02 2.94E+02 2.87E+02 2.97E+02 
Cell-Structure Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
OANTIGEN-PWY: O-antigen building blocks 
biosynthesis (E. coli) 
2.13E+03 2.39E+03 2.68E+03 6.07E+02 6.59E+02 5.73E+02 
PWY0-1586: peptidoglycan maturation (meso-
diaminopimelate containing) 
6.69E+03 5.91E+03 6.05E+03 9.10E+02 9.47E+02 1.02E+03 
PWY-7315: dTDP-N-acetylthomosamine 
biosynthesis 
1.98E+02 3.58E+02 4.20E+02 1.15E+02 1.31E+02 2.48E+02 
PWY-7316: dTDP-N-acetylviosamine biosynthesis 4.01E+02 7.12E+02 7.25E+02 2.94E+02 2.87E+02 2.97E+02 
UDPNAGSYN-PWY: UDP-N-acetyl-D-
glucosamine biosynthesis I 
1.40E+03 1.62E+03 1.93E+03 5.50E+02 5.92E+02 5.39E+02 
Cofactor-Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
COA-PWY: coenzyme A biosynthesis I 4.36E+03 3.99E+03 4.46E+03 6.67E+02 9.71E+02 8.56E+02 
P241-PWY: coenzyme B biosynthesis 1.42E+02 1.74E+02 1.92E+02 5.13E+01 6.26E+01 6.73E+01 
PANTOSYN-PWY: pantothenate and coenzyme A 
biosynthesis I 
4.47E+03 4.24E+03 4.59E+03 4.89E+02 6.56E+02 6.62E+02 
POLYISOPRENSYN-PWY: polyisoprenoid 
biosynthesis (E. coli) 
3.08E+03 2.42E+03 2.75E+03 8.13E+02 8.60E+02 7.32E+02 
PWY3DJ-35471: L-ascorbate biosynthesis IV 2.43E+01 3.22E+01 3.71E+01 2.85E+01 2.88E+01 4.94E+01 
PWY-4242: pantothenate and coenzyme A 
biosynthesis III 
4.12E+03 3.92E+03 4.33E+03 4.34E+02 6.69E+02 6.65E+02 
PWY-5188: tetrapyrrole biosynthesis I (from 
glutamate) 
1.01E+03 1.07E+03 1.33E+03 3.54E+02 3.71E+02 3.70E+02 
PWY-5189: tetrapyrrole biosynthesis II (from 
glycine) 
7.03E+02 7.56E+02 9.62E+02 2.56E+02 2.74E+02 2.83E+02 
PWY-5845: superpathway of menaquinol-9 
biosynthesis 
1.87E+02 2.07E+02 2.83E+02 1.85E+02 1.70E+02 2.88E+02 
PWY-5850: superpathway of menaquinol-6 
biosynthesis I 
1.47E+02 1.67E+02 2.53E+02 1.88E+02 1.76E+02 2.81E+02 
PWY-5860: superpathway of demethylmena-
quinol-6 biosynthesis I 
1.01E+02 1.15E+02 1.77E+02 1.33E+02 1.25E+02 2.09E+02 
PWY-5862: superpathway of demethylmena-
quinol-9 biosynthesis 
1.28E+02 1.42E+02 1.97E+02 1.31E+02 1.21E+02 2.14E+02 
PWY-5896: superpathway of menaquinol-10 
biosynthesis 
1.48E+02 1.71E+02 2.34E+02 1.89E+02 1.75E+02 2.81E+02 
PWY-5918: superpathay of heme biosynthesis 
from glutamate 
4.46E+02 5.02E+02 6.23E+02 1.66E+02 2.02E+02 2.38E+02 
PWY-6168: flavin biosynthesis III (fungi) 5.04E+03 4.72E+03 4.65E+03 6.87E+02 7.35E+02 7.21E+02 
PWY-6892: thiazole biosynthesis I (E. coli) 4.76E+03 4.39E+03 4.71E+03 7.61E+02 8.15E+02 9.12E+02 
PWY-7282: 4-amino-2-methyl-5-
phosphomethylpyrimidine biosynthesis (yeast) 
3.03E+03 3.26E+03 2.78E+03 6.46E+02 6.11E+02 5.81E+02 
RIBOSYN2-PWY: flavin biosynthesis I (bacteria 
and plants) 
5.00E+03 4.65E+03 4.62E+03 6.97E+02 7.53E+02 6.80E+02 
THISYNARA-PWY: superpathway of thiamin 
diphosphate biosynthesis III (eukaryotes) 
5.27E+03 4.82E+03 4.67E+03 1.00E+03 9.97E+02 9.02E+02 
THISYN-PWY: superpathway of thiamin 
diphosphate biosynthesis I 
5.15E+03 4.58E+03 4.58E+03 9.44E+02 8.68E+02 8.47E+02 
Lipid Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY0-1319: CDP-diacylglycerol biosynthesis II 4.35E+03 4.10E+03 4.03E+03 3.83E+02 3.98E+02 5.11E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
PWY-5667: CDP-diacylglycerol biosynthesis I 4.35E+03 4.10E+03 4.03E+03 3.83E+02 3.98E+02 5.11E+02 
PWY-5971: palmitate biosynthesis II (bacteria and 
plants) 
7.15E+03 6.31E+03 6.43E+03 1.04E+03 1.08E+03 1.17E+03 
PWY-7094: fatty acid salvage 1.11E+03 1.37E+03 1.37E+03 3.38E+02 3.75E+02 3.96E+02 
PWY-7277: sphingolipid biosynthesis (mammals) 0.00E+00 2.01E-01 7.95E-01 0.00E+00 4.90E-01 5.34E-01 
PWY-7663: gondoate biosynthesis (anaerobic) 9.30E+03 9.55E+03 8.60E+03 8.96E+02 1.05E+03 1.23E+03 
Hormone Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY66-375: leukotriene biosynthesis 4.16E-01 6.84E-01 7.22E-01 6.45E-01 6.36E-01 3.54E-01 
Nucleotide Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
DENOVOPURINE2-PWY: superpathway of purine 
nucleotides de novo biosynthesis II 
2.92E+03 3.09E+03 3.38E+03 5.55E+02 6.63E+02 4.43E+02 
PWY-6121: 5-aminoimidazole ribonucleotide 
biosynthesis I 
6.47E+03 5.97E+03 5.84E+03 1.20E+03 1.15E+03 1.11E+03 
PWY-6123: inosine-5'-phosphate biosynthesis I 5.83E+03 5.43E+03 5.83E+03 1.12E+03 1.11E+03 1.07E+03 
PWY-6124: inosine-5'-phosphate biosynthesis II 6.31E+03 5.82E+03 6.34E+03 1.43E+03 1.27E+03 1.37E+03 
PWY-6125: superpathway of guanosine 
nucleotides de novo biosynthesis II 
3.80E+03 4.19E+03 4.30E+03 9.29E+02 1.04E+03 9.20E+02 
PWY-7200: superpathway of pyrimidine 
deoxyribonucleoside salvage 
3.76E+02 3.61E+02 4.98E+02 4.51E+02 3.72E+02 4.28E+02 
PWY-7221: guanosine ribonucleotides de novo 
biosynthesis 
7.11E+03 6.86E+03 7.41E+03 1.67E+03 1.68E+03 1.64E+03 
Secondary Metabolite Biosynthesis High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY-5757: fosfomycin biosynthesis 1.12E+00 3.23E+00 3.32E+00 9.79E-01 1.89E+00 1.32E+00 
PWY-6270: isoprene biosynthesis I 5.44E+03 4.57E+03 4.92E+03 8.10E+02 1.04E+03 8.11E+02 
PWY-6322: phosphinothricin tripeptide 
biosynthesis 
1.42E+00 3.97E+00 4.38E+00 1.33E+00 1.79E+00 1.82E+00 
PWY-6358: superpathway of D-myo-inositol 
(1,4,5)-trisphosphate metabolism 
6.46E-02 6.08E-02 2.52E-03 1.29E-01 1.82E-01 8.37E-02 
PWY-7392: taxadiene biosynthesis (engineered) 4.21E+03 3.43E+03 3.72E+03 7.55E+02 9.15E+02 7.39E+02 
PWY-7560: methylerythritol phosphate pathway II 5.41E+03 4.75E+03 5.36E+03 8.77E+02 9.93E+02 9.09E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
ALLANTOINDEG-PWY: superpathway of allantoin 
degradation in yeast 
1.71E+02 1.47E+02 2.32E+02 1.43E+02 1.63E+02 1.87E+02 
FAO-PWY: fatty acid &beta;-oxidation I 1.52E+03 1.82E+03 1.89E+03 4.73E+02 5.23E+02 5.53E+02 
GALACTARDEG-PWY: D-galactarate degradation 
I 
2.70E+02 3.06E+02 3.97E+02 1.30E+02 1.38E+02 2.00E+02 
GLCMANNANAUT-PWY: superpathway of N-
acetylglucosamine, N-acetylmannosamine and N-
acetylneuraminate degradation 
9.84E+02 1.33E+03 1.17E+03 4.63E+02 4.78E+02 3.73E+02 
KETOGLUCONMET-PWY: ketogluconate 
metabolism 
2.51E+02 2.79E+02 3.08E+02 1.87E+02 1.84E+02 2.53E+02 
LACTOSECAT-PWY: lactose and galactose 
degradation I 
8.84E+02 9.39E+02 1.15E+03 4.59E+02 5.02E+02 5.00E+02 
LYSINE-DEG1-PWY: L-lysine degradation XI 
(mammalian) 
1.37E+00 2.63E+00 3.63E+00 2.06E+00 1.96E+00 1.90E+00 
P23-PWY: reductive TCA cycle I 3.15E+02 2.53E+02 4.21E+02 2.11E+02 1.92E+02 2.58E+02 
P461-PWY: hexitol fermentation to lactate, 
formate, ethanol and acetate 
4.53E+02 6.32E+02 4.97E+02 4.25E+02 4.45E+02 5.60E+02 
PWY0-1261: anhydromuropeptides recycling 1.18E+03 1.33E+03 1.71E+03 6.01E+02 6.12E+02 6.35E+02 
PWY-1501: mandelate degradation I 2.98E+00 5.44E+00 5.69E+00 2.48E+00 2.04E+00 2.25E+00 
PWY-5136: fatty acid &beta;-oxidation II 
(peroxisome) 
1.55E+03 1.86E+03 1.94E+03 4.73E+02 5.23E+02 5.52E+02 
PWY-5283: L-lysine degradation V 4.04E-01 6.21E-01 3.05E-01 5.66E-01 4.48E-01 5.76E-01 
PWY-5705: allantoin degradation to glyoxylate III 4.99E+01 3.52E+01 6.96E+01 5.12E+01 4.82E+01 1.15E+02 
PWY-6307: L-tryptophan degradation X 
(mammalian, via tryptamine) 
1.74E+03 2.22E+03 1.86E+03 6.16E+02 6.38E+02 6.32E+02 
PWY-6313: serotonin degradation 1.53E+03 1.97E+03 1.65E+03 5.30E+02 5.67E+02 5.75E+02 
PWY-6491: D-galacturonate degradation III 3.75E-01 7.57E-01 6.44E-01 1.06E+00 1.09E+00 9.72E-01 
PWY-6572: chondroitin sulfate degradation I 
(bacterial) 
1.39E+02 1.94E+02 1.92E+02 7.25E+01 6.75E+01 7.09E+01 
PWY66-389: phytol degradation 2.13E+03 2.90E+03 2.38E+03 8.36E+02 9.29E+02 9.98E+02 
PWY66-422: D-galactose degradation V (Leloir 
pathway) 
6.06E+03 5.69E+03 5.44E+03 1.15E+03 1.22E+03 1.27E+03 
PWY-6737: starch degradation V 6.69E+03 6.50E+03 6.07E+03 8.53E+02 9.71E+02 9.92E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
PWY-6901: superpathway of glucose and xylose 
degradation 
3.13E+03 3.88E+03 3.22E+03 1.28E+03 1.29E+03 1.24E+03 
PWY-6906: chitin derivatives degradation 1.97E+01 3.57E+01 6.50E+01 2.98E+01 4.93E+01 5.00E+01 
PWY-7237: myo-, chiro- and scillo-inositol 
degradation 
3.52E+03 4.09E+03 3.02E+03 1.91E+03 1.79E+03 1.88E+03 
PWY-7644: heparin degradation 7.16E-01 1.46E+00 1.42E+01 2.38E+00 1.34E+01 1.21E+01 
THREOCAT-PWY: superpathway of L-threonine 
metabolism 
8.66E+00 3.11E+01 2.54E+01 1.40E+01 1.28E+01 4.87E+01 
Alcohol Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY66-389: phytol degradation 2.13E+03 2.90E+03 2.38E+03 8.36E+02 9.29E+02 9.98E+02 
Amine Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
ALLANTOINDEG-PWY: superpathway of allantoin 
degradation in yeast 
1.71E+02 1.47E+02 2.32E+02 1.43E+02 1.63E+02 1.87E+02 
GLCMANNANAUT-PWY: superpathway of N-
acetylglucosamine, N-acetylmannosamine and N-
acetylneuraminate degradation 
9.84E+02 1.33E+03 1.17E+03 4.63E+02 4.78E+02 3.73E+02 
PWY-5705: allantoin degradation to glyoxylate III 4.99E+01 3.52E+01 6.96E+01 5.12E+01 4.82E+01 1.15E+02 
Amino Acid Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
LYSINE-DEG1-PWY: L-lysine degradation XI 
(mammalian) 
1.37E+00 2.63E+00 3.63E+00 2.06E+00 1.96E+00 1.90E+00 
PWY-5283: L-lysine degradation V 4.04E-01 6.21E-01 3.05E-01 5.66E-01 4.48E-01 5.76E-01 
PWY-6307: L-tryptophan degradation X 
(mammalian, via tryptamine) 
1.74E+03 2.22E+03 1.86E+03 6.16E+02 6.38E+02 6.32E+02 
THREOCAT-PWY: superpathway of L-threonine 
metabolism 
8.66E+00 3.11E+01 2.54E+01 1.40E+01 1.28E+01 4.87E+01 
Aromatic Compound Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY-1501: mandelate degradation I 2.98E+00 5.44E+00 5.69E+00 2.48E+00 2.04E+00 2.25E+00 
C1 Compounds High BMI Low BMI Athlete High BMI Low BMI Athlete 
P23-PWY: reductive TCA cycle I 3.15E+02 2.53E+02 4.21E+02 2.11E+02 1.92E+02 2.58E+02 
Carbohydrates Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
LACTOSECAT-PWY: lactose and galactose 
degradation I 
8.84E+02 9.39E+02 1.15E+03 4.59E+02 5.02E+02 5.00E+02 
PWY-6572: chondroitin sulfate degradation I 
(bacterial) 
1.39E+02 1.94E+02 1.92E+02 7.25E+01 6.75E+01 7.09E+01 
PWY66-422: D-galactose degradation V (Leloir 
pathway) 
6.06E+03 5.69E+03 5.44E+03 1.15E+03 1.22E+03 1.27E+03 
PWY-6737: starch degradation V 6.69E+03 6.50E+03 6.07E+03 8.53E+02 9.71E+02 9.92E+02 
PWY-6901: superpathway of glucose and xylose 
degradation 
3.13E+03 3.88E+03 3.22E+03 1.28E+03 1.29E+03 1.24E+03 
PWY-6906: chitin derivatives degradation 1.97E+01 3.57E+01 6.50E+01 2.98E+01 4.93E+01 5.00E+01 
PWY-7644: heparin degradation 7.16E-01 1.46E+00 1.42E+01 2.38E+00 1.34E+01 1.21E+01 
Carboxylates Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
GALACTARDEG-PWY: D-galactarate degradation 
I 
2.70E+02 3.06E+02 3.97E+02 1.30E+02 1.38E+02 2.00E+02 
KETOGLUCONMET-PWY: ketogluconate 
metabolism 
2.51E+02 2.79E+02 3.08E+02 1.87E+02 1.84E+02 2.53E+02 
PWY-6491: D-galacturonate degradation III 3.75E-01 7.57E-01 6.44E-01 1.06E+00 1.09E+00 9.72E-01 
Fatty Acid and Lipid Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
FAO-PWY: fatty acid &beta;-oxidation I 1.52E+03 1.82E+03 1.89E+03 4.73E+02 5.23E+02 5.53E+02 
PWY-5136: fatty acid &beta;-oxidation II 
(peroxisome) 
1.55E+03 1.86E+03 1.94E+03 4.73E+02 5.23E+02 5.52E+02 
Hormone Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY-6313: serotonin degradation 1.53E+03 1.97E+03 1.65E+03 5.30E+02 5.67E+02 5.75E+02 
Polymer Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY-6572: chondroitin sulfate degradation I 
(bacterial) 
1.39E+02 1.94E+02 1.92E+02 7.25E+01 6.75E+01 7.09E+01 
PWY-6737: starch degradation V 6.69E+03 6.50E+03 6.07E+03 8.53E+02 9.71E+02 9.92E+02 
PWY-6906: chitin derivatives degradation 1.97E+01 3.57E+01 6.50E+01 2.98E+01 4.93E+01 5.00E+01 
PWY-7644: heparin degradation 7.16E-01 1.46E+00 1.42E+01 2.38E+00 1.34E+01 1.21E+01 
Secondary Metabolite Degradation High BMI Low BMI Athlete High BMI Low BMI Athlete 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
GALACTARDEG-PWY: D-galactarate degradation 
I 
2.70E+02 3.06E+02 3.97E+02 1.30E+02 1.38E+02 2.00E+02 
KETOGLUCONMET-PWY: ketogluconate 
metabolism 
2.51E+02 2.79E+02 3.08E+02 1.87E+02 1.84E+02 2.53E+02 
P461-PWY: hexitol fermentation to lactate, 
formate, ethanol and acetate 
4.53E+02 6.32E+02 4.97E+02 4.25E+02 4.45E+02 5.60E+02 
PWY0-1261: anhydromuropeptides recycling 1.18E+03 1.33E+03 1.71E+03 6.01E+02 6.12E+02 6.35E+02 
PWY-6491: D-galacturonate degradation III 3.75E-01 7.57E-01 6.44E-01 1.06E+00 1.09E+00 9.72E-01 
PWY-7237: myo-, chiro- and scillo-inositol 
degradation 
3.52E+03 4.09E+03 3.02E+03 1.91E+03 1.79E+03 1.88E+03 
Energy Metabolism High BMI Low BMI Athlete High BMI Low BMI Athlete 
FERMENTATION-PWY: mixed acid fermentation 5.86E+02 4.70E+02 7.72E+02 3.80E+02 4.17E+02 4.38E+02 
NONOXIPENT-PWY: pentose phosphate pathway 
(non-oxidative branch) 
6.31E+03 6.75E+03 6.23E+03 9.61E+02 8.75E+02 8.81E+02 
P122-PWY: heterolactic fermentation 8.80E+02 1.21E+03 1.02E+03 4.15E+02 4.62E+02 4.17E+02 
P461-PWY: hexitol fermentation to lactate, 
formate, ethanol and acetate 
4.53E+02 6.32E+02 4.97E+02 4.25E+02 4.45E+02 5.60E+02 
PENTOSE-P-PWY: pentose phosphate pathway 2.87E+03 3.58E+03 2.82E+03 1.42E+03 1.40E+03 1.37E+03 
PWY-5676: acetyl-CoA fermentation to butanoate 
II 
1.16E+03 1.40E+03 1.49E+03 3.58E+02 3.83E+02 4.32E+02 
PWY-5913: TCA cycle VI (obligate autotrophs) 3.38E+02 2.58E+02 4.72E+02 2.69E+02 2.89E+02 3.04E+02 
PWY66-398: TCA cycle III (animals) 3.47E+02 4.53E+02 4.71E+02 1.31E+02 1.63E+02 1.52E+02 
PWY-6859: all-trans-farnesol biosynthesis 2.73E+03 2.06E+03 2.26E+03 5.95E+02 7.58E+02 6.16E+02 
PWY-7389: superpathway of anaerobic energy 
metabolism (invertebrates) 
3.64E+02 4.72E+02 5.50E+02 2.40E+02 2.50E+02 2.30E+02 
REDCITCYC: TCA cycle VIII (helicobacter) 2.89E+02 2.74E+02 4.68E+02 1.74E+02 1.61E+02 2.17E+02 
Fermentation High BMI Low BMI Athlete High BMI Low BMI Athlete 
FERMENTATION-PWY: mixed acid fermentation 5.86E+02 4.70E+02 7.72E+02 3.80E+02 4.17E+02 4.38E+02 
P122-PWY: heterolactic fermentation 8.80E+02 1.21E+03 1.02E+03 4.15E+02 4.62E+02 4.17E+02 
P461-PWY: hexitol fermentation to lactate, 
formate, ethanol and acetate 
4.53E+02 6.32E+02 4.97E+02 4.25E+02 4.45E+02 5.60E+02 
PWY-5676: acetyl-CoA fermentation to butanoate 
II 
1.16E+03 1.40E+03 1.49E+03 3.58E+02 3.83E+02 4.32E+02 
PWY-7389: superpathway of anaerobic energy 
metabolism (invertebrates) 
3.64E+02 4.72E+02 5.50E+02 2.40E+02 2.50E+02 2.30E+02 
Pentose-Phosphate-Cycle High BMI Low BMI Athlete High BMI Low BMI Athlete 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
NONOXIPENT-PWY: pentose phosphate pathway 
(non-oxidative branch) 
6.31E+03 6.75E+03 6.23E+03 9.61E+02 8.75E+02 8.81E+02 
PENTOSE-P-PWY: pentose phosphate pathway 2.87E+03 3.58E+03 2.82E+03 1.42E+03 1.40E+03 1.37E+03 
TCA Variants High BMI Low BMI Athlete High BMI Low BMI Athlete 
PWY-5913: TCA cycle VI (obligate autotrophs) 3.38E+02 2.58E+02 4.72E+02 2.69E+02 2.89E+02 3.04E+02 
PWY66-398: TCA cycle III (animals) 3.47E+02 4.53E+02 4.71E+02 1.31E+02 1.63E+02 1.52E+02 
REDCITCYC: TCA cycle VIII (helicobacter) 2.89E+02 2.74E+02 4.68E+02 1.74E+02 1.61E+02 2.17E+02 
Metabolic-Clusters High BMI Low BMI Athlete High BMI Low BMI Athlete 
OANTIGEN-PWY: O-antigen building blocks 
biosynthesis (E. coli) 
2.13E+03 2.39E+03 2.68E+03 6.07E+02 6.59E+02 5.73E+02 
Super-Pathways High BMI Low BMI Athlete High BMI Low BMI Athlete 
ALLANTOINDEG-PWY: superpathway of allantoin 
degradation in yeast 
1.71E+02 1.47E+02 2.32E+02 1.43E+02 1.63E+02 1.87E+02 
BRANCHED-CHAIN-AA-SYN-PWY: superpathway 
of branched amino acid biosynthesis 
6.49E+03 6.37E+03 6.13E+03 7.15E+02 6.03E+02 7.37E+02 
DENOVOPURINE2-PWY: superpathway of purine 
nucleotides de novo biosynthesis II 
2.92E+03 3.09E+03 3.38E+03 5.55E+02 6.63E+02 4.43E+02 
GLCMANNANAUT-PWY: superpathway of N-
acetylglucosamine, N-acetylmannosamine and N-
acetylneuraminate degradation 
9.84E+02 1.33E+03 1.17E+03 4.63E+02 4.78E+02 3.73E+02 
HSERMETANA-PWY: L-methionine biosynthesis 
III 
6.99E+03 6.56E+03 6.33E+03 1.03E+03 1.15E+03 1.15E+03 
KETOGLUCONMET-PWY: ketogluconate 
metabolism 
2.51E+02 2.79E+02 3.08E+02 1.87E+02 1.84E+02 2.53E+02 
OANTIGEN-PWY: O-antigen building blocks 
biosynthesis (E. coli) 
2.13E+03 2.39E+03 2.68E+03 6.07E+02 6.59E+02 5.73E+02 
P461-PWY: hexitol fermentation to lactate, 
formate, ethanol and acetate 
4.53E+02 6.32E+02 4.97E+02 4.25E+02 4.45E+02 5.60E+02 
P4-PWY: superpathway of L-lysine, L-threonine 
and L-methionine biosynthesis I 
2.34E+03 2.58E+03 2.73E+03 5.72E+02 5.68E+02 5.72E+02 
PANTOSYN-PWY: pantothenate and coenzyme A 
biosynthesis I 
4.47E+03 4.24E+03 4.59E+03 4.89E+02 6.56E+02 6.62E+02 
PENTOSE-P-PWY: pentose phosphate pathway 2.87E+03 3.58E+03 2.82E+03 1.42E+03 1.40E+03 1.37E+03 
POLYISOPRENSYN-PWY: polyisoprenoid 
biosynthesis (E. coli) 
3.08E+03 2.42E+03 2.75E+03 8.13E+02 8.60E+02 7.32E+02 
PWY-3001: superpathway of L-isoleucine 
biosynthesis I 
6.04E+03 5.85E+03 5.79E+03 4.62E+02 4.48E+02 4.51E+02 
PWY-4242: pantothenate and coenzyme A 
biosynthesis III 
4.12E+03 3.92E+03 4.33E+03 4.34E+02 6.69E+02 6.65E+02 
PWY-5676: acetyl-CoA fermentation to butanoate 
II 
1.16E+03 1.40E+03 1.49E+03 3.58E+02 3.83E+02 4.32E+02 
PWY-5705: allantoin degradation to glyoxylate III 4.99E+01 3.52E+01 6.96E+01 5.12E+01 4.82E+01 1.15E+02 
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MetaCyc Metabolic Category 
Group Mean of Relative Abundance for 
Statistically Significant Pathways (P 
value <.05) 
Standard Deviation 
PWY-5845: superpathway of menaquinol-9 
biosynthesis 
1.87E+02 2.07E+02 2.83E+02 1.85E+02 1.70E+02 2.88E+02 
PWY-5850: superpathway of menaquinol-6 
biosynthesis I 
1.47E+02 1.67E+02 2.53E+02 1.88E+02 1.76E+02 2.81E+02 
PWY-5860: superpathway of demethylmena-
quinol-6 biosynthesis I 
1.01E+02 1.15E+02 1.77E+02 1.33E+02 1.25E+02 2.09E+02 
PWY-5862: superpathway of demethylmena-
quinol-9 biosynthesis 
1.28E+02 1.42E+02 1.97E+02 1.31E+02 1.21E+02 2.14E+02 
PWY-5896: superpathway of menaquinol-10 
biosynthesis 
1.48E+02 1.71E+02 2.34E+02 1.89E+02 1.75E+02 2.81E+02 
PWY-5918: superpathay of heme biosynthesis 
from glutamate 
4.46E+02 5.02E+02 6.23E+02 1.66E+02 2.02E+02 2.38E+02 
PWY-6125: superpathway of guanosine 
nucleotides de novo biosynthesis II 
3.80E+03 4.19E+03 4.30E+03 9.29E+02 1.04E+03 9.20E+02 
PWY-6165: chorismate biosynthesis II (archaea) 2.56E+01 2.27E+01 4.21E+01 1.85E+01 2.88E+01 2.95E+01 
PWY-6270: isoprene biosynthesis I 5.44E+03 4.57E+03 4.92E+03 8.10E+02 1.04E+03 8.11E+02 
PWY-6358: superpathway of D-myo-inositol 
(1,4,5)-trisphosphate metabolism 
6.46E-02 6.08E-02 2.52E-03 1.29E-01 1.82E-01 8.37E-02 
PWY-6629: superpathway of L-tryptophan 
biosynthesis 
4.05E+02 4.44E+02 5.82E+02 2.01E+02 2.11E+02 2.69E+02 
PWY-6901: superpathway of glucose and xylose 
degradation 
3.13E+03 3.88E+03 3.22E+03 1.28E+03 1.29E+03 1.24E+03 
PWY-7200: superpathway of pyrimidine 
deoxyribonucleoside salvage 
3.76E+02 3.61E+02 4.98E+02 4.51E+02 3.72E+02 4.28E+02 
PWY-7237: myo-, chiro- and scillo-inositol 
degradation 
3.52E+03 4.09E+03 3.02E+03 1.91E+03 1.79E+03 1.88E+03 
PWY-7277: sphingolipid biosynthesis (mammals) 0.00E+00 2.01E-01 7.95E-01 0.00E+00 4.90E-01 5.34E-01 
PWY-7389: superpathway of anaerobic energy 
metabolism (invertebrates) 
3.64E+02 4.72E+02 5.50E+02 2.40E+02 2.50E+02 2.30E+02 
PWY-7392: taxadiene biosynthesis (engineered) 4.21E+03 3.43E+03 3.72E+03 7.55E+02 9.15E+02 7.39E+02 
THISYNARA-PWY: superpathway of thiamin 
diphosphate biosynthesis III (eukaryotes) 
5.27E+03 4.82E+03 4.67E+03 1.00E+03 9.97E+02 9.02E+02 
THISYN-PWY: superpathway of thiamin 
diphosphate biosynthesis I 
5.15E+03 4.58E+03 4.58E+03 9.44E+02 8.68E+02 8.47E+02 
THREOCAT-PWY: superpathway of L-threonine 
metabolism 
8.66E+00 3.11E+01 2.54E+01 1.40E+01 1.28E+01 4.87E+01 
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Supplementary Table 3.8 
Athlete 




ceae_bacterium_1_1_57FAA 5.72E-03 6.53E-04 1.71E-02 1.36E-01 6.53E-01 
Isovaleric 
PWY-5154: 
NO_NAME|g_Flavonifractor.s_Flavonifractor_plautii 3.87E-04 8.50E-04 1.16E-03 2.67E-01 7.25E-01 
Valeric PWY-7220: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 7.33E-03 1.48E-03 1.47E-02 1.22E-01 6.45E-01 
Valeric PWY-7222: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 7.33E-03 1.48E-03 1.47E-02 1.22E-01 6.45E-01 
Isobutyric 
PWY-3841: 
NO_NAME|g_Coprococcus.s_Coprococcus_catus 7.01E-03 1.51E-03 2.28E-02 1.25E-01 6.47E-01 
Valeric PWY-6386: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.13E-03 2.01E-03 1.23E-02 1.32E-01 6.51E-01 
Valeric PWY-7221: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.43E-03 3.63E-03 1.29E-02 1.29E-01 6.50E-01 
Isovaleric 
PWY-7400: 








ocatenulatum 1.60E-04 4.50E-03 4.80E-04 3.04E-01 7.43E-01 
Valeric PWY-5100: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.57E-03 4.70E-03 1.31E-02 1.28E-01 6.49E-01 
Valeric PWY-6163: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.86E-03 5.38E-03 1.17E-02 1.34E-01 6.53E-01 
Valeric 
PYRIDNUCSYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.35E-03 5.50E-03 1.27E-02 1.30E-01 6.50E-01 
Valeric 
RHAMCAT-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 7.04E-03 5.50E-03 1.41E-02 1.24E-01 6.47E-01 
Isobutyric 
PWY-6313: 
NO_NAME|g_Coprococcus.s_Coprococcus_catus 4.38E-03 5.67E-03 1.31E-02 1.50E-01 6.62E-01 
Valeric PWY-6385: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 4.93E-03 5.77E-03 9.87E-03 1.44E-01 6.58E-01 
Valeric PWY-2942: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.35E-03 5.77E-03 1.07E-02 1.39E-01 6.55E-01 
Valeric 
PEPTIDOGLYCANSYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.77E-03 5.77E-03 1.15E-02 1.35E-01 6.53E-01 
Valeric 
PANTO-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.83E-03 5.77E-03 1.17E-02 1.35E-01 6.53E-01 




SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric 
DTDPRHAMSYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 9.72E-03 5.77E-03 1.94E-02 1.06E-01 6.36E-01 
Valeric 
GLUCONEO-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.10E-03 6.04E-03 1.02E-02 1.42E-01 6.57E-01 
Valeric 
PWY66-400: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.32E-03 6.04E-03 1.06E-02 1.40E-01 6.56E-01 
Valeric PWY-7229: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 7.62E-03 6.04E-03 1.52E-02 1.20E-01 6.44E-01 
Valeric PWY-6126: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 8.04E-03 6.04E-03 1.61E-02 1.17E-01 6.42E-01 
Valeric 
DAPLYSINESYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.24E-03 6.31E-03 1.05E-02 1.41E-01 6.56E-01 
Valeric PWY-6122: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 4.67E-03 6.85E-03 9.35E-03 1.47E-01 6.60E-01 
Valeric PWY-6277: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 4.67E-03 6.85E-03 9.35E-03 1.47E-01 6.60E-01 
Valeric PWY-6121: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.20E-03 6.85E-03 1.04E-02 1.41E-01 6.56E-01 
Valeric 
ANAGLYCOLYSIS-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.89E-03 7.12E-03 1.18E-02 1.34E-01 6.52E-01 
Valeric PWY-1042: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.60E-03 7.38E-03 1.12E-02 1.37E-01 6.54E-01 
Valeric 
PWY66-422: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.65E-03 7.38E-03 1.13E-02 1.37E-01 6.54E-01 
Valeric PWY-5505: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.67E-03 7.38E-03 1.13E-02 1.36E-01 6.54E-01 
Valeric PWY-7219: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.80E-03 7.38E-03 1.16E-02 1.35E-01 6.53E-01 
Valeric PWY-5686: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.16E-03 7.38E-03 1.23E-02 1.32E-01 6.51E-01 
Valeric PWY-7663: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.27E-03 7.38E-03 1.25E-02 1.31E-01 6.50E-01 
Valeric PWY-7664: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.40E-03 7.65E-03 1.28E-02 1.30E-01 6.50E-01 
Valeric PWY-6282: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.53E-03 7.65E-03 1.31E-02 1.28E-01 6.49E-01 
Butyric PWY-7039: NO_NAME 7.73E-04 7.90E-03 4.64E-03 2.36E-01 7.09E-01 
Isobutyric 
PWY-724: 
NO_NAME|g_Flavonifractor.s_Flavonifractor_plautii 1.00E-02 8.46E-03 3.01E-02 1.04E-01 6.34E-01 




SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric PWY-5659: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.05E-03 8.73E-03 1.01E-02 1.43E-01 6.57E-01 
Valeric 
PWYG-321: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.02E-03 9.26E-03 1.20E-02 1.33E-01 6.52E-01 
Valeric PWY-6387: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.38E-03 9.26E-03 1.28E-02 1.30E-01 6.50E-01 
Valeric 
FASYN-ELONG-PWY: 
































ocatenulatum 7.58E-07 9.69E-03 4.55E-06 4.85E-01 8.26E-01 
Valeric 
SER-GLYSYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.09E-03 9.80E-03 1.22E-02 1.32E-01 6.51E-01 
Valeric 
BIOTIN-BIOSYNTHESIS-PWY: 




uinis 2.96E-03 1.03E-02 1.78E-02 1.71E-01 6.73E-01 
Valeric 
GLUTORN-PWY: 




uinis 7.96E-03 1.09E-02 4.78E-02 1.17E-01 6.42E-01 
Valeric PWY-6519: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.53E-03 1.09E-02 1.11E-02 1.38E-01 6.54E-01 




ocatenulatum 4.40E-03 1.10E-02 1.32E-02 1.50E-01 6.62E-01 




















ocatenulatum 1.02E-02 1.10E-02 3.06E-02 1.03E-01 6.34E-01 
Valeric PWY-4984: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.02E-03 1.11E-02 1.00E-02 1.43E-01 6.58E-01 
Valeric 
CITRULBIO-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.12E-03 1.11E-02 1.02E-02 1.42E-01 6.57E-01 
Valeric 
ARGSYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.32E-03 1.17E-02 1.06E-02 1.40E-01 6.56E-01 
Valeric PWY-7400: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.34E-03 1.17E-02 1.07E-02 1.40E-01 6.56E-01 
Valeric PWY-5097: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.01E-03 1.17E-02 1.20E-02 1.33E-01 6.52E-01 
Valeric PWY-7388: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.12E-03 1.17E-02 1.22E-02 1.32E-01 6.51E-01 




































ceae_bacterium_1_1_57FAA 2.19E-03 1.32E-02 6.56E-03 1.86E-01 6.82E-01 












ceae_bacterium_1_1_57FAA 7.76E-03 1.32E-02 2.33E-02 1.19E-01 6.43E-01 
Valeric PWY-5989: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.51E-03 1.33E-02 1.30E-02 1.29E-01 6.49E-01 
Valeric 
P108-PWY: 
































































ocatenulatum 3.96E-03 1.46E-02 1.19E-02 1.56E-01 6.65E-01 












ocatenulatum 8.86E-03 1.46E-02 2.66E-02 1.11E-01 6.39E-01 
Valeric PWY-7237: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.98E-03 1.46E-02 1.20E-02 1.33E-01 6.52E-01 
Valeric ARO-PWY: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.75E-03 1.47E-02 1.15E-02 1.36E-01 6.53E-01 
Valeric 
COMPLETE-ARO-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.80E-03 1.47E-02 1.16E-02 1.35E-01 6.53E-01 
Valeric 
PANTOSYN-PWY: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.83E-03 1.53E-02 1.17E-02 1.35E-01 6.53E-01 
Valeric 
COA-PWY-1: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 4.48E-03 1.54E-02 8.95E-03 1.49E-01 6.61E-01 
Valeric PWY-7111: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.72E-03 1.57E-02 1.14E-02 1.36E-01 6.53E-01 
Valeric PWY-5667: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.75E-03 1.57E-02 1.15E-02 1.35E-01 6.53E-01 
Valeric 
PWY0-1319: 
NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 5.75E-03 1.57E-02 1.15E-02 1.35E-01 6.53E-01 
Valeric PWY-5973: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 6.01E-03 1.79E-02 1.20E-02 1.33E-01 6.52E-01 
Valeric PWY-4242: NO_NAME|g_Alistipes.s_Alistipes_sp_AP11 4.07E-03 1.87E-02 8.15E-03 1.54E-01 6.64E-01 




























ocatenulatum 2.79E-04 1.94E-02 8.36E-04 2.81E-01 7.32E-01 












































ceae_bacterium_3_1_46FAA 3.02E-02 2.15E-02 4.53E-02 3.54E-02 5.91E-01 
Isobutyric 
PWY66-422: 
NO_NAME|g_Coprococcus.s_Coprococcus_catus 4.98E-03 2.25E-02 2.99E-02 1.43E-01 6.58E-01 
Isovaleric 
PWY-724: 
































ceae_bacterium_1_1_57FAA 8.42E-04 2.58E-02 5.05E-03 2.32E-01 7.07E-01 




















































































ocatenulatum 5.12E-04 3.39E-02 2.87E-03 2.55E-01 7.19E-01 




































ocatenulatum 6.17E-03 3.39E-02 2.66E-02 1.32E-01 6.51E-01 
Isobutyric 
PWY-5188: 




uinis 3.02E-03 3.46E-02 1.81E-02 1.70E-01 6.73E-01 
Isovaleric 
ARGSYN-PWY: 
































ceae_bacterium_7_1_58FAA 3.81E-03 4.16E-02 2.08E-02 1.58E-01 6.66E-01 
Isobutyric 
PWY-7199: 
NO_NAME|g_Flavonifractor.s_Flavonifractor_plautii 4.71E-03 4.89E-02 1.41E-02 1.46E-01 6.59E-01 




Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Butyric PWY0-881: NO_NAME 7.53E-05 4.52E-04 6.55E-01 4.80E-01 8.95E-01 
Valeric 
PWY-3841: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 1.19E-04 7.15E-04 -6.80E-01 -8.89E-01 -4.56E-01 
Isovaleric SALVADEHYPOX-PWY: NO_NAME|unclassified 1.46E-04 8.74E-04 6.44E-01 4.45E-01 8.86E-01 
Butyric PWY0-881: NO_NAME|unclassified 1.51E-04 9.06E-04 4.22E-01 4.43E-01 8.85E-01 
Isobutyric SALVADEHYPOX-PWY: NO_NAME|unclassified 3.94E-04 1.18E-03 6.36E-01 3.87E-01 8.70E-01 
Valeric 
PWY-6124: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 2.47E-04 1.48E-03 -6.84E-01 -8.78E-01 -4.15E-01 
Isovaleric PWY-5088: NO_NAME 2.79E-04 1.67E-03 6.47E-01 4.08E-01 8.76E-01 
Butyric 
POLYAMSYN-PWY: 




phila 4.67E-04 2.80E-03 6.07E-01 3.77E-01 8.67E-01 
Butyric 
PWY-6305: 




phila 5.53E-04 3.32E-03 6.30E-01 3.66E-01 8.64E-01 
Isobutyric PWY-7209: NO_NAME|unclassified 1.15E-03 3.46E-03 6.13E-01 3.18E-01 8.49E-01 
Valeric PWY-7209: NO_NAME|unclassified 8.09E-04 3.46E-03 6.70E-01 3.42E-01 8.56E-01 
Isobutyric PWY66-398: NO_NAME|unclassified 1.24E-03 3.71E-03 5.27E-01 3.13E-01 8.48E-01 




phila 6.59E-04 3.95E-03 5.22E-01 3.55E-01 8.60E-01 
Isovaleric PWY-7209: NO_NAME|unclassified 2.05E-03 4.10E-03 6.16E-01 2.78E-01 8.36E-01 
Isovaleric GLUDEG-II-PWY: NO_NAME 6.91E-04 4.15E-03 6.51E-01 3.52E-01 8.60E-01 
Isobutyric URSIN-PWY: NO_NAME|unclassified 6.92E-04 4.15E-03 5.64E-01 3.52E-01 8.60E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isobutyric PWY-5464: NO_NAME|unclassified 1.47E-03 4.40E-03 6.03E-01 3.01E-01 8.44E-01 




phila 7.65E-04 4.59E-03 6.10E-01 3.45E-01 8.58E-01 
Isobutyric PWY-5088: NO_NAME 1.55E-03 4.65E-03 6.26E-01 2.98E-01 8.43E-01 
Isobutyric PWY-6595: NO_NAME|unclassified 1.73E-03 5.19E-03 6.17E-01 2.90E-01 8.40E-01 
































phila 1.00E-03 6.02E-03 5.25E-01 3.27E-01 8.52E-01 
Isobutyric PWY-6606: NO_NAME|unclassified 2.02E-03 6.05E-03 5.69E-01 2.79E-01 8.37E-01 












phila 1.03E-03 6.21E-03 5.93E-01 3.25E-01 8.51E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isobutyric ILEUDEG-PWY: NO_NAME 1.31E-03 6.42E-03 5.49E-01 3.09E-01 8.46E-01 
















phila 2.21E-03 6.64E-03 6.00E-01 2.72E-01 8.35E-01 
Valeric 
FASYN-INITIAL-PWY: 








phila 1.21E-03 7.29E-03 5.22E-01 3.14E-01 8.48E-01 
Butyric 
FUCCAT-PWY: 




phila 1.25E-03 7.48E-03 6.04E-01 3.13E-01 8.48E-01 
Isobutyric P261-PWY: NO_NAME 1.82E-03 7.51E-03 6.25E-01 2.86E-01 8.39E-01 




phila 1.26E-03 7.55E-03 5.22E-01 3.12E-01 8.47E-01 
Acetic PWY-6993: NO_NAME 1.26E-03 7.56E-03 5.26E-01 3.12E-01 8.47E-01 












phila 1.28E-03 7.66E-03 5.22E-01 3.11E-01 8.47E-01 
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Low BMI Control 












vens 2.69E-03 8.08E-03 6.14E-01 2.58E-01 8.30E-01 
Isobutyric PWY-5464: NO_NAME 3.01E-03 8.30E-03 5.95E-01 2.50E-01 8.27E-01 
Isovaleric PWY-5464: NO_NAME 2.55E-03 8.30E-03 5.58E-01 2.62E-01 8.31E-01 




phila 1.38E-03 8.30E-03 5.15E-01 3.06E-01 8.45E-01 
Isovaleric PWY-181: NO_NAME 1.39E-03 8.33E-03 5.01E-01 3.05E-01 8.45E-01 
Acetic PWY-6823: NO_NAME 2.78E-03 8.34E-03 6.01E-01 2.55E-01 8.29E-01 




phila 1.40E-03 8.40E-03 5.27E-01 3.05E-01 8.45E-01 
Isobutyric ILEUDEG-PWY: NO_NAME|unclassified 1.74E-03 8.42E-03 5.00E-01 2.89E-01 8.40E-01 








arius 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
Butyric PWY-7251: NO_NAME 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
Butyric PWY-7251: NO_NAME|unclassified 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
Butyric PWY66-388: NO_NAME 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
Butyric PWY66-388: NO_NAME|unclassified 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Butyric PWY-6109: NO_NAME 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
Butyric PWY-6109: NO_NAME|unclassified 1.43E-03 8.56E-03 3.69E-01 3.03E-01 8.45E-01 
















mii 1.48E-03 8.89E-03 5.01E-01 3.01E-01 8.44E-01 
Valeric ILEUDEG-PWY: NO_NAME|unclassified 4.49E-03 8.99E-03 6.31E-01 2.19E-01 8.17E-01 
Isobutyric PWY-6309: NO_NAME|unclassified 3.05E-03 9.16E-03 5.25E-01 2.48E-01 8.27E-01 
Isovaleric PWY-6309: NO_NAME|unclassified 2.17E-03 9.16E-03 4.96E-01 2.74E-01 8.35E-01 




phila 3.14E-03 9.41E-03 5.08E-01 2.46E-01 8.26E-01 
Butyric 
PWY-7219: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 1.60E-03 9.60E-03 2.99E-01 2.95E-01 8.42E-01 
Butyric 
HOMOSER-METSYN-PWY: 




phila 3.25E-03 9.75E-03 6.03E-01 2.44E-01 8.25E-01 
Butyric 
PWY-5189: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 1.64E-03 9.87E-03 2.99E-01 2.93E-01 8.41E-01 








phila 1.71E-03 1.03E-02 5.09E-01 2.91E-01 8.41E-01 
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Low BMI Control 








phila 1.71E-03 1.03E-02 5.93E-01 2.90E-01 8.41E-01 
Proprionic PWY-6344: NO_NAME 1.72E-03 1.03E-02 6.02E-01 2.90E-01 8.40E-01 




phila 1.76E-03 1.06E-02 5.12E-01 2.88E-01 8.40E-01 




















phila 3.61E-03 1.08E-02 5.05E-01 2.36E-01 8.22E-01 
Butyric 
PWY-5973: 




phila 1.83E-03 1.10E-02 5.86E-01 2.86E-01 8.39E-01 
Acetic PWY-5677: NO_NAME 2.57E-03 1.11E-02 4.81E-01 2.61E-01 8.31E-01 
Valeric PWY-5677: NO_NAME 3.70E-03 1.11E-02 5.92E-01 2.34E-01 8.22E-01 
Butyric 
GLUTORN-PWY: 








phila 3.77E-03 1.13E-02 5.08E-01 2.32E-01 8.21E-01 
Isobutyric PWY-7242: NO_NAME|unclassified 3.77E-03 1.13E-02 4.62E-01 2.32E-01 8.21E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric PWY-7242: NO_NAME|unclassified 2.24E-03 1.13E-02 4.22E-01 2.71E-01 8.34E-01 
Butyric 
MET-SAM-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 1.89E-03 1.14E-02 2.47E-01 2.83E-01 8.38E-01 




phila 1.93E-03 1.16E-02 5.77E-01 2.82E-01 8.38E-01 
Isobutyric PWY-5081: NO_NAME|unclassified 5.04E-03 1.17E-02 4.52E-01 2.10E-01 8.13E-01 
Isovaleric PWY-5081: NO_NAME|unclassified 2.85E-03 1.17E-02 4.39E-01 2.53E-01 8.28E-01 




phila 3.90E-03 1.17E-02 5.83E-01 2.30E-01 8.20E-01 
Isovaleric PWY-5179: NO_NAME|unclassified 1.96E-03 1.17E-02 3.59E-01 2.81E-01 8.37E-01 
















phila 3.95E-03 1.19E-02 5.83E-01 2.29E-01 8.20E-01 
Isobutyric PWY-6470: NO_NAME|unclassified 3.99E-03 1.20E-02 4.73E-01 2.28E-01 8.20E-01 




phila 2.00E-03 1.20E-02 5.04E-01 2.80E-01 8.37E-01 
Butyric PWY-6823: NO_NAME|unclassified 2.00E-03 1.20E-02 5.35E-01 2.80E-01 8.37E-01 
Isovaleric PWY-5994: NO_NAME|unclassified 2.00E-03 1.20E-02 5.08E-01 2.79E-01 8.37E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Butyric 
PWY-5188: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 2.00E-03 1.20E-02 1.58E-01 2.79E-01 8.37E-01 
Valeric 
PWY-6163: 
















phila 4.11E-03 1.23E-02 5.83E-01 2.26E-01 8.19E-01 




mii 2.08E-03 1.25E-02 5.01E-01 2.77E-01 8.36E-01 
Isovaleric PWY-6470: NO_NAME|unclassified 6.26E-03 1.25E-02 4.40E-01 1.92E-01 8.07E-01 
Butyric 
PWY-7221: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 2.09E-03 1.25E-02 3.09E-01 2.76E-01 8.36E-01 
Isobutyric PWY-5179: NO_NAME|unclassified 4.22E-03 1.27E-02 3.55E-01 2.24E-01 8.18E-01 




phila 4.27E-03 1.28E-02 5.02E-01 2.23E-01 8.18E-01 
Valeric 
PANTOSYN-PWY: 








phila 4.42E-03 1.33E-02 5.68E-01 2.20E-01 8.17E-01 
Butyric 
PWY-6892: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 2.22E-03 1.33E-02 7.97E-02 2.72E-01 8.35E-01 
Isobutyric PWY-4981: NO_NAME|unclassified 4.45E-03 1.33E-02 5.45E-01 2.20E-01 8.17E-01 
Isovaleric PWY-4981: NO_NAME|unclassified 2.76E-03 1.33E-02 5.49E-01 2.56E-01 8.29E-01 
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Low BMI Control 




phila 4.45E-03 1.34E-02 5.20E-01 2.19E-01 8.17E-01 
Valeric 
LACTOSECAT-PWY: 








phila 4.53E-03 1.36E-02 5.74E-01 2.18E-01 8.16E-01 




phila 4.63E-03 1.39E-02 5.18E-01 2.16E-01 8.16E-01 
Butyric 
PWY-7388: 
NO_NAME|g_Veillonella.s_Veillonella_parvula 2.32E-03 1.39E-02 5.38E-01 2.69E-01 8.33E-01 
Isobutyric GLUDEG-II-PWY: NO_NAME 4.66E-03 1.40E-02 6.31E-01 2.16E-01 8.16E-01 
Isobutyric PWY-7003: NO_NAME|unclassified 4.74E-03 1.42E-02 5.19E-01 2.15E-01 8.15E-01 
Isobutyric PWY-6644: NO_NAME|unclassified 4.75E-03 1.42E-02 4.63E-01 2.15E-01 8.15E-01 
Butyric 
PWY-6891: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 2.40E-03 1.44E-02 7.30E-02 2.66E-01 8.33E-01 
Isovaleric URSIN-PWY: NO_NAME|unclassified 4.80E-03 1.44E-02 5.42E-01 2.14E-01 8.15E-01 




phila 4.81E-03 1.44E-02 5.08E-01 2.13E-01 8.15E-01 
Valeric PWY-6608: NO_NAME|unclassified 2.42E-03 1.45E-02 7.06E-01 2.66E-01 8.32E-01 
Butyric 
METSYN-PWY: 








phila 2.43E-03 1.46E-02 4.99E-01 2.65E-01 8.32E-01 
Isobutyric PWY-7654: NO_NAME|unclassified 3.49E-03 1.46E-02 5.53E-01 2.38E-01 8.23E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric PWY-7654: NO_NAME|unclassified 4.87E-03 1.46E-02 5.32E-01 2.12E-01 8.14E-01 
















us 2.48E-03 1.49E-02 1.44E-01 2.64E-01 8.32E-01 
Isovaleric PWY-6644: NO_NAME 2.48E-03 1.49E-02 5.16E-01 2.64E-01 8.32E-01 
Isobutyric PWY-5081: NO_NAME 6.12E-03 1.49E-02 4.91E-01 1.94E-01 8.08E-01 
Isovaleric PWY-5081: NO_NAME 3.65E-03 1.49E-02 4.74E-01 2.35E-01 8.22E-01 
Valeric PWY-5081: NO_NAME 7.47E-03 1.49E-02 5.27E-01 1.78E-01 8.02E-01 
Valeric PWY-5464: NO_NAME|unclassified 7.48E-03 1.50E-02 6.22E-01 1.78E-01 8.02E-01 
Isobutyric P163-PWY: NO_NAME|unclassified 5.03E-03 1.51E-02 5.19E-01 2.10E-01 8.13E-01 
























mii 2.58E-03 1.55E-02 5.38E-01 2.61E-01 8.31E-01 
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Low BMI Control 




phila 2.58E-03 1.55E-02 5.18E-01 2.61E-01 8.31E-01 
Butyric 
PWY-7013: 












phila 2.70E-03 1.56E-02 5.20E-01 2.58E-01 8.30E-01 
Butyric 
PWY-6387: 




vens 7.85E-03 1.57E-02 5.98E-01 1.74E-01 8.00E-01 
Butyric 
PEPTIDOGLYCANSYN-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 2.64E-03 1.59E-02 2.36E-01 2.59E-01 8.30E-01 
Valeric SALVADEHYPOX-PWY: NO_NAME|unclassified 8.02E-03 1.60E-02 6.23E-01 1.72E-01 8.00E-01 
Valeric PWY-7654: NO_NAME|unclassified 8.03E-03 1.61E-02 5.56E-01 1.72E-01 8.00E-01 
Isobutyric P164-PWY: NO_NAME|unclassified 5.40E-03 1.62E-02 6.58E-01 2.04E-01 8.11E-01 








phila 5.42E-03 1.63E-02 5.04E-01 2.04E-01 8.11E-01 
Butyric 
PWY-5347: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 2.71E-03 1.63E-02 2.47E-01 2.57E-01 8.30E-01 
Butyric 
PWY-6168: 








phila 5.45E-03 1.63E-02 4.92E-01 2.04E-01 8.11E-01 
Isobutyric PWY-7654: NO_NAME 3.79E-03 1.64E-02 5.55E-01 2.32E-01 8.21E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 




phila 2.73E-03 1.64E-02 5.08E-01 2.57E-01 8.29E-01 
Valeric FAO-PWY: NO_NAME|unclassified 2.74E-03 1.64E-02 6.75E-01 2.57E-01 8.29E-01 
Valeric PWY-7654: NO_NAME 8.25E-03 1.65E-02 5.68E-01 1.70E-01 7.99E-01 
Valeric PWY-5306: NO_NAME|unclassified 2.76E-03 1.65E-02 3.67E-01 2.56E-01 8.29E-01 
Butyric 
PWY-7663: 








phila 3.37E-03 1.68E-02 5.77E-01 2.41E-01 8.24E-01 
Butyric 
COA-PWY: 




phila 5.63E-03 1.69E-02 5.73E-01 2.01E-01 8.10E-01 
Valeric 
PWY-6123: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 2.82E-03 1.69E-02 -5.89E-01 -8.29E-01 -2.54E-01 
Valeric 
PWY-7229: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 2.83E-03 1.70E-02 -6.07E-01 -8.29E-01 -2.54E-01 
Isobutyric ARGORNPROST-PWY: NO_NAME|unclassified 5.67E-03 1.70E-02 4.79E-01 2.00E-01 8.10E-01 
Isovaleric METH-ACETATE-PWY: NO_NAME|unclassified 2.84E-03 1.71E-02 5.36E-01 2.54E-01 8.29E-01 
Isovaleric PWY-1622: NO_NAME 2.85E-03 1.71E-02 5.16E-01 2.53E-01 8.28E-01 
Butyric 
PWY-5104: 
NO_NAME|g_Veillonella.s_Veillonella_atypica 2.87E-03 1.72E-02 4.60E-01 2.53E-01 8.28E-01 
Isovaleric PWY-5088: NO_NAME|unclassified 2.88E-03 1.73E-02 6.16E-01 2.53E-01 8.28E-01 
Isobutyric PWY-6309: NO_NAME 5.79E-03 1.74E-02 4.87E-01 1.99E-01 8.09E-01 
Isovaleric PWY-6309: NO_NAME 4.62E-03 1.74E-02 4.57E-01 2.17E-01 8.16E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 




phila 5.80E-03 1.74E-02 4.88E-01 1.98E-01 8.09E-01 
Valeric 
PWY-6126: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 2.91E-03 1.74E-02 -6.07E-01 -8.28E-01 -2.52E-01 
Valeric PROPFERM-PWY: NO_NAME|unclassified 2.98E-03 1.79E-02 5.61E-01 2.50E-01 8.27E-01 
Isobutyric PWY-6644: NO_NAME 5.96E-03 1.79E-02 5.03E-01 1.96E-01 8.09E-01 
Butyric 
PWYG-321: 
NO_NAME|g_Veillonella.s_Veillonella_parvula 3.01E-03 1.80E-02 5.42E-01 2.50E-01 8.27E-01 
Valeric PWY-7420: NO_NAME|unclassified 3.01E-03 1.81E-02 5.45E-01 2.49E-01 8.27E-01 
Butyric 
PWY-7208: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.01E-03 1.81E-02 2.53E-01 2.49E-01 8.27E-01 
Isobutyric PWY-5173: NO_NAME|unclassified 7.67E-03 1.82E-02 4.61E-01 1.76E-01 8.01E-01 
Isovaleric PWY-5173: NO_NAME|unclassified 7.76E-03 1.82E-02 4.27E-01 1.75E-01 8.01E-01 
Valeric PWY-5173: NO_NAME|unclassified 9.08E-03 1.82E-02 5.18E-01 1.62E-01 7.96E-01 
Acetic PWY-5109: NO_NAME 6.06E-03 1.82E-02 4.62E-01 1.95E-01 8.08E-01 
Butyric 
PWY-5101: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.05E-03 1.83E-02 3.69E-01 2.49E-01 8.27E-01 
Isobutyric PWY-181: NO_NAME 6.12E-03 1.84E-02 4.91E-01 1.94E-01 8.08E-01 
Isobutyric 
3-HYDROXYPHENYLACETATE-DEGRADATION-
PWY: NO_NAME|unclassified 5.37E-03 1.85E-02 4.78E-01 2.05E-01 8.12E-01 
Isovaleric 
3-HYDROXYPHENYLACETATE-DEGRADATION-
PWY: NO_NAME|unclassified 6.16E-03 1.85E-02 4.95E-01 1.94E-01 8.08E-01 
Butyric 
ARGININE-SYN4-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.08E-03 1.85E-02 1.52E-01 2.48E-01 8.26E-01 
Butyric 
FASYN-ELONG-PWY: 
NO_NAME|g_Veillonella.s_Veillonella_parvula 3.10E-03 1.86E-02 5.42E-01 2.47E-01 8.26E-01 
Isobutyric PWY66-399: NO_NAME 6.21E-03 1.86E-02 5.43E-01 1.93E-01 8.07E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric PWY66-399: NO_NAME 4.39E-03 1.86E-02 5.08E-01 2.21E-01 8.17E-01 
Butyric 
PWY-6282: 




phila 6.28E-03 1.88E-02 5.68E-01 1.92E-01 8.07E-01 
Valeric 
SALVADEHYPOX-PWY: 




mii 3.15E-03 1.89E-02 5.42E-01 2.46E-01 8.26E-01 
Valeric PWY-7420: NO_NAME 3.16E-03 1.90E-02 5.45E-01 2.46E-01 8.26E-01 
Butyric 
PWY-6313: 




















us 3.23E-03 1.94E-02 1.29E-01 2.44E-01 8.25E-01 
Isobutyric PWY-5306: NO_NAME|unclassified 6.49E-03 1.95E-02 4.07E-01 1.89E-01 8.06E-01 
Butyric PWY-5744: NO_NAME|unclassified 3.25E-03 1.95E-02 2.31E-01 2.44E-01 8.25E-01 
Isobutyric PWY-7383: NO_NAME 6.49E-03 1.95E-02 5.44E-01 1.89E-01 8.06E-01 








phila 3.43E-03 1.96E-02 5.76E-01 2.40E-01 8.24E-01 
Butyric 
PWY-7664: 
NO_NAME|g_Veillonella.s_Veillonella_parvula 3.28E-03 1.97E-02 5.42E-01 2.43E-01 8.25E-01 
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Low BMI Control 




us 3.29E-03 1.97E-02 1.44E-01 2.43E-01 8.25E-01 
Butyric PWY-6993: NO_NAME 6.58E-03 1.97E-02 5.21E-01 1.88E-01 8.06E-01 




luenzae 3.29E-03 1.97E-02 2.90E-01 2.43E-01 8.25E-01 












phila 3.34E-03 2.01E-02 5.09E-01 2.42E-01 8.24E-01 
Butyric 
PWY-3001: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.39E-03 2.03E-02 2.44E-01 2.40E-01 8.24E-01 
Butyric 
PWY-2942: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.40E-03 2.04E-02 2.94E-01 2.40E-01 8.24E-01 




phila 3.47E-03 2.08E-02 5.71E-01 2.39E-01 8.23E-01 
Valeric 
PANTOSYN-PWY: 




luenzae 3.48E-03 2.09E-02 2.90E-01 2.39E-01 8.23E-01 
Isobutyric PWY-7383: NO_NAME|unclassified 6.97E-03 2.09E-02 5.10E-01 1.84E-01 8.04E-01 
Isovaleric PWY-7383: NO_NAME|unclassified 4.88E-03 2.09E-02 4.74E-01 2.12E-01 8.14E-01 
Valeric 
PWY-5686: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 3.50E-03 2.10E-02 -6.07E-01 -8.23E-01 -2.38E-01 
Isobutyric PWY-5676: NO_NAME|unclassified 7.01E-03 2.10E-02 5.81E-01 1.83E-01 8.04E-01 
Isovaleric PWY-5676: NO_NAME|unclassified 6.26E-03 2.10E-02 5.70E-01 1.92E-01 8.07E-01 
Appendix A 347 
 
 
Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Butyric 
PWY0-862: 




aciens 3.54E-03 2.12E-02 -4.92E-01 -8.23E-01 -2.37E-01 








phila 7.10E-03 2.13E-02 4.99E-01 1.82E-01 8.03E-01 
Butyric 
FASYN-INITIAL-PWY: 








phila 3.57E-03 2.14E-02 5.44E-01 2.36E-01 8.23E-01 
Acetic 
PWY-6126: 
NO_NAME|g_Dialister.s_Dialister_invisus 3.58E-03 2.15E-02 3.25E-01 2.36E-01 8.23E-01 








phila 3.62E-03 2.16E-02 5.61E-01 2.36E-01 8.22E-01 
Butyric 
VALSYN-PWY: 




phila 7.22E-03 2.17E-02 5.44E-01 1.81E-01 8.03E-01 








phila 4.06E-03 2.17E-02 5.74E-01 2.27E-01 8.19E-01 
Valeric 
ARO-PWY: 
NO_NAME|g_Eubacterium.s_Eubacterium_hallii 3.63E-03 2.18E-02 -4.19E-01 -8.22E-01 -2.35E-01 
Butyric PWY-7024: NO_NAME 3.64E-03 2.19E-02 2.31E-01 2.35E-01 8.22E-01 
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Low BMI Control 




us 3.65E-03 2.19E-02 1.44E-01 2.35E-01 8.22E-01 
Butyric 
BRANCHED-CHAIN-AA-SYN-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.67E-03 2.20E-02 2.98E-01 2.35E-01 8.22E-01 
Isobutyric PWY-7094: NO_NAME|unclassified 7.35E-03 2.21E-02 4.29E-01 1.79E-01 8.02E-01 
Valeric PWY-7094: NO_NAME|unclassified 3.91E-03 2.21E-02 6.81E-01 2.30E-01 8.20E-01 
Acetic 
PWY-841: 
NO_NAME|g_Dialister.s_Dialister_invisus 3.68E-03 2.21E-02 3.25E-01 2.34E-01 8.22E-01 
Isobutyric 
1CMET2-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 7.40E-03 2.22E-02 -5.64E-01 -8.02E-01 -1.79E-01 
Valeric 
1CMET2-PWY: 




us 3.71E-03 2.22E-02 1.44E-01 2.34E-01 8.22E-01 
Valeric 
COMPLETE-ARO-PWY: 




arius 3.74E-03 2.24E-02 5.07E-01 2.33E-01 8.21E-01 
Butyric 
PWY-5097: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.74E-03 2.24E-02 3.24E-01 2.33E-01 8.21E-01 
Acetic PWY-5989: NO_NAME|unclassified 7.50E-03 2.25E-02 4.14E-01 1.78E-01 8.02E-01 












phila 4.38E-03 2.26E-02 5.23E-01 2.21E-01 8.17E-01 








spiraceae_bacterium_3_1_46FAA 4.85E-03 2.31E-02 3.47E-01 2.13E-01 8.14E-01 
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Low BMI Control 




spiraceae_bacterium_3_1_46FAA 7.69E-03 2.31E-02 5.30E-01 1.76E-01 8.01E-01 
Acetic 
DENOVOPURINE2-PWY: 
NO_NAME|g_Dialister.s_Dialister_invisus 3.84E-03 2.31E-02 3.25E-01 2.31E-01 8.21E-01 
Butyric 
PWY-6385: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.85E-03 2.31E-02 2.07E-01 2.31E-01 8.21E-01 
Valeric 
PWY-7388: 
NO_NAME|g_Eubacterium.s_Eubacterium_hallii 3.88E-03 2.33E-02 -4.10E-01 -8.20E-01 -2.30E-01 
Acetic 
PWY-6125: 
NO_NAME|g_Dialister.s_Dialister_invisus 3.91E-03 2.34E-02 3.25E-01 2.30E-01 8.20E-01 
Butyric 
PWY-6386: 




luenzae 3.92E-03 2.35E-02 3.31E-01 2.29E-01 8.20E-01 
Valeric 
PWY-6737: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 3.92E-03 2.35E-02 -6.07E-01 -8.20E-01 -2.29E-01 
Butyric 
PWY-5103: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 3.93E-03 2.36E-02 2.95E-01 2.29E-01 8.20E-01 
Acetic 
PWY0-166: 




us 3.94E-03 2.36E-02 1.29E-01 2.29E-01 8.20E-01 




luenzae 3.96E-03 2.38E-02 3.31E-01 2.29E-01 8.20E-01 
Isobutyric PWY-5088: NO_NAME|unclassified 7.94E-03 2.38E-02 5.95E-01 1.73E-01 8.00E-01 








spiraceae_bacterium_5_1_63FAA 4.01E-03 2.41E-02 5.04E-01 2.28E-01 8.20E-01 
Acetic 
PWY-7210: 
NO_NAME|g_Dialister.s_Dialister_invisus 4.03E-03 2.42E-02 3.25E-01 2.27E-01 8.20E-01 
Acetic 
PWY-7184: 
NO_NAME|g_Dialister.s_Dialister_invisus 4.03E-03 2.42E-02 3.25E-01 2.27E-01 8.20E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric 
FUCCAT-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 4.03E-03 2.42E-02 -5.42E-01 -8.19E-01 -2.27E-01 
Acetic 
PWY-7198: 
NO_NAME|g_Dialister.s_Dialister_invisus 4.03E-03 2.42E-02 3.25E-01 2.27E-01 8.19E-01 
Acetic 
PWY-7220: 
NO_NAME|g_Dialister.s_Dialister_invisus 4.07E-03 2.44E-02 3.25E-01 2.27E-01 8.19E-01 
Acetic 
PWY-7222: 
NO_NAME|g_Dialister.s_Dialister_invisus 4.07E-03 2.44E-02 3.25E-01 2.27E-01 8.19E-01 
Acetic 
PWY-6545: 
NO_NAME|g_Dialister.s_Dialister_invisus 4.08E-03 2.45E-02 3.25E-01 2.26E-01 8.19E-01 
Valeric PWY-6606: NO_NAME|unclassified 1.22E-02 2.45E-02 6.66E-01 1.36E-01 7.86E-01 
Acetic 
PWY-5022: 
NO_NAME|g_Dorea.s_Dorea_longicatena 6.41E-03 2.45E-02 4.05E-01 1.90E-01 8.06E-01 
Butyric 
PWY-5022: 
NO_NAME|g_Dorea.s_Dorea_longicatena 8.17E-03 2.45E-02 2.44E-01 1.70E-01 7.99E-01 
Butyric PWY-5744: NO_NAME 4.10E-03 2.46E-02 2.31E-01 2.26E-01 8.19E-01 








phila 8.27E-03 2.48E-02 5.60E-01 1.69E-01 7.99E-01 
Isobutyric PWY-5177: NO_NAME|unclassified 8.30E-03 2.49E-02 4.84E-01 1.69E-01 7.99E-01 




us 4.15E-03 2.49E-02 1.29E-01 2.25E-01 8.19E-01 
Butyric 
GOLPDLCAT-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 4.17E-03 2.50E-02 3.44E-02 2.25E-01 8.19E-01 
Isobutyric PWY-6435: NO_NAME|unclassified 8.35E-03 2.50E-02 4.60E-01 1.69E-01 7.98E-01 
Isobutyric PWY-5265: NO_NAME|unclassified 1.05E-02 2.51E-02 5.11E-01 1.50E-01 7.91E-01 
Isovaleric PWY-5265: NO_NAME|unclassified 1.25E-02 2.51E-02 4.68E-01 1.34E-01 7.85E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 




phila 4.20E-03 2.52E-02 4.88E-01 2.24E-01 8.18E-01 
Isovaleric ARGORNPROST-PWY: NO_NAME|unclassified 1.28E-02 2.55E-02 4.34E-01 1.32E-01 7.84E-01 




us 4.32E-03 2.59E-02 1.29E-01 2.22E-01 8.18E-01 
Isobutyric 
PWY-7197: 
NO_NAME|g_Bilophila.s_Bilophila_wadsworthia 4.61E-03 2.59E-02 5.29E-01 2.17E-01 8.16E-01 
Isovaleric 
PWY-7197: 




















phila 5.13E-03 2.64E-02 5.77E-01 2.08E-01 8.13E-01 
Butyric 
PWY-724: 












arius 4.41E-03 2.65E-02 4.68E-01 2.20E-01 8.17E-01 
Butyric 
THRESYN-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 4.42E-03 2.65E-02 2.60E-01 2.20E-01 8.17E-01 
Butyric 
PWY-6630: 




us 4.45E-03 2.67E-02 1.29E-01 2.20E-01 8.17E-01 
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Low BMI Control 








us 4.48E-03 2.69E-02 1.44E-01 2.19E-01 8.17E-01 








us 4.51E-03 2.71E-02 1.29E-01 2.18E-01 8.16E-01 
Isovaleric P185-PWY: NO_NAME|unclassified 4.52E-03 2.71E-02 4.16E-01 2.18E-01 8.16E-01 
Isobutyric PWY-6609: NO_NAME|unclassified 1.36E-02 2.72E-02 4.53E-01 1.27E-01 7.82E-01 
Isovaleric PWY-6609: NO_NAME|unclassified 1.11E-02 2.72E-02 4.30E-01 1.44E-01 7.89E-01 
Valeric PWY-6609: NO_NAME|unclassified 7.66E-03 2.72E-02 7.08E-01 1.76E-01 8.01E-01 
Butyric 
PWY-7315: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 4.54E-03 2.72E-02 5.47E-02 2.18E-01 8.16E-01 
Butyric 
PWY-7316: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 4.54E-03 2.72E-02 5.47E-02 2.18E-01 8.16E-01 




spiraceae_bacterium_5_1_63FAA 4.57E-03 2.74E-02 2.80E-01 2.18E-01 8.16E-01 




us 4.59E-03 2.76E-02 1.44E-01 2.17E-01 8.16E-01 












us 4.65E-03 2.79E-02 1.44E-01 2.16E-01 8.16E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric 
1CMET2-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.40E-02 2.79E-02 -5.08E-01 -7.81E-01 -1.24E-01 
Butyric 
PWY-5367: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 4.66E-03 2.80E-02 3.97E-02 2.16E-01 8.16E-01 
Isobutyric 
PWY-7357: 
NO_NAME|g_Dorea.s_Dorea_longicatena 5.08E-03 2.80E-02 -5.75E-01 -8.13E-01 -2.09E-01 
Isovaleric 
PWY-7357: 
NO_NAME|g_Dorea.s_Dorea_longicatena 9.34E-03 2.80E-02 -5.24E-01 -7.95E-01 -1.59E-01 
Valeric 
PWY-7237: 
NO_NAME|g_Dorea.s_Dorea_longicatena 4.71E-03 2.82E-02 -3.27E-01 -8.15E-01 -2.15E-01 
Isobutyric PWY-6353: NO_NAME|unclassified 9.43E-03 2.83E-02 4.49E-01 1.58E-01 7.95E-01 




us 4.73E-03 2.84E-02 1.44E-01 2.15E-01 8.15E-01 
Valeric 
PWY-6628: 




us 4.74E-03 2.85E-02 1.44E-01 2.15E-01 8.15E-01 
Isobutyric PWY-7197: NO_NAME|unclassified 9.23E-03 2.86E-02 4.87E-01 1.60E-01 7.95E-01 
Isovaleric PWY-7197: NO_NAME|unclassified 9.52E-03 2.86E-02 4.84E-01 1.58E-01 7.94E-01 
Butyric 
PWY-7388: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 4.78E-03 2.87E-02 3.16E-01 2.14E-01 8.15E-01 
Isobutyric PWY66-391: NO_NAME|unclassified 1.44E-02 2.87E-02 4.44E-01 1.22E-01 7.80E-01 
Isovaleric PWY66-391: NO_NAME|unclassified 9.79E-03 2.87E-02 4.09E-01 1.55E-01 7.93E-01 
Valeric PWY66-391: NO_NAME|unclassified 1.25E-02 2.87E-02 6.73E-01 1.34E-01 7.85E-01 
Isobutyric VALDEG-PWY: NO_NAME|unclassified 9.58E-03 2.88E-02 5.48E-01 1.57E-01 7.94E-01 
Isovaleric VALDEG-PWY: NO_NAME|unclassified 5.50E-03 2.88E-02 5.65E-01 2.03E-01 8.11E-01 
Isobutyric PWY66-399: NO_NAME|unclassified 9.60E-03 2.88E-02 5.43E-01 1.57E-01 7.94E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric PWY66-399: NO_NAME|unclassified 8.39E-03 2.88E-02 5.13E-01 1.68E-01 7.98E-01 




aciens 4.81E-03 2.88E-02 -4.00E-01 -8.15E-01 -2.13E-01 
Valeric PWY-6628: NO_NAME|unclassified 4.84E-03 2.90E-02 6.81E-01 2.13E-01 8.15E-01 




us 4.84E-03 2.90E-02 1.44E-01 2.13E-01 8.14E-01 
Isobutyric P185-PWY: NO_NAME|unclassified 9.68E-03 2.90E-02 4.03E-01 1.56E-01 7.94E-01 
Isobutyric PWY3O-355: NO_NAME 7.13E-03 2.91E-02 5.30E-01 1.82E-01 8.03E-01 




us 4.86E-03 2.92E-02 1.44E-01 2.13E-01 8.14E-01 
Butyric 
ILEUSYN-PWY: 




mii 4.89E-03 2.94E-02 4.84E-01 2.12E-01 8.14E-01 
Valeric PYRIDNUCSAL-PWY: NO_NAME|unclassified 4.90E-03 2.94E-02 6.64E-01 2.12E-01 8.14E-01 
Isovaleric 
7ALPHADEHYDROX-PWY: 
NO_NAME|unclassified 5.01E-03 3.01E-02 4.77E-01 2.10E-01 8.14E-01 
Valeric PWY-7224: NO_NAME|unclassified 5.01E-03 3.01E-02 6.14E-01 2.10E-01 8.13E-01 
Isobutyric 
PWY-6122: 
NO_NAME|g_Dorea.s_Dorea_longicatena 9.69E-03 3.02E-02 -5.49E-01 -7.94E-01 -1.56E-01 
Isobutyric 
PWY-6277: 
NO_NAME|g_Dorea.s_Dorea_longicatena 9.69E-03 3.02E-02 -5.49E-01 -7.94E-01 -1.56E-01 
Isovaleric 
PWY-6122: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.47E-02 3.02E-02 -5.20E-01 -7.79E-01 -1.19E-01 
Isovaleric 
PWY-6277: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.47E-02 3.02E-02 -5.20E-01 -7.79E-01 -1.19E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric 
PWY-6122: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.51E-02 3.02E-02 -3.75E-01 -7.79E-01 -1.17E-01 
Valeric 
PWY-6277: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.51E-02 3.02E-02 -3.75E-01 -7.79E-01 -1.17E-01 
Butyric 
PWY-7539: 




us 5.06E-03 3.04E-02 1.44E-01 2.09E-01 8.13E-01 












us 5.11E-03 3.07E-02 1.44E-01 2.09E-01 8.13E-01 
Valeric PWY-6630: NO_NAME|unclassified 5.14E-03 3.08E-02 6.06E-01 2.08E-01 8.13E-01 
Butyric 
PWY-7111: 








us 5.18E-03 3.11E-02 1.44E-01 2.08E-01 8.13E-01 
Proprionic PWY-6609: NO_NAME 5.20E-03 3.12E-02 -4.88E-01 -8.12E-01 -2.07E-01 
Valeric 
LACTOSECAT-PWY: 








us 5.28E-03 3.17E-02 1.44E-01 2.06E-01 8.12E-01 
Valeric PWYG-321: NO_NAME|unclassified 1.06E-02 3.18E-02 5.64E-01 1.48E-01 7.91E-01 




spiraceae_bacterium_5_1_63FAA 5.38E-03 3.23E-02 -5.26E-01 -8.12E-01 -2.05E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric 
PWY-5973: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 5.39E-03 3.23E-02 -6.07E-01 -8.11E-01 -2.04E-01 












mii 5.44E-03 3.26E-02 4.80E-01 2.04E-01 8.11E-01 
Valeric 
NONMEVIPP-PWY: 
NO_NAME|g_Eubacterium.s_Eubacterium_hallii 5.45E-03 3.27E-02 -3.45E-01 -8.11E-01 -2.04E-01 
Valeric 
PWY-7560: 
NO_NAME|g_Eubacterium.s_Eubacterium_hallii 5.45E-03 3.27E-02 -3.45E-01 -8.11E-01 -2.04E-01 
Isobutyric PWY-7397: NO_NAME 9.87E-03 3.28E-02 2.46E-01 1.54E-01 7.93E-01 
Isovaleric PWY-7397: NO_NAME 1.20E-02 3.28E-02 2.62E-01 1.37E-01 7.87E-01 








us 5.49E-03 3.29E-02 1.44E-01 2.03E-01 8.11E-01 
Butyric 
SER-GLYSYN-PWY: 




us 5.50E-03 3.30E-02 1.44E-01 2.03E-01 8.11E-01 
Valeric 
3-HYDROXYPHENYLACETATE-DEGRADATION-
PWY: NO_NAME|unclassified 1.66E-02 3.31E-02 4.61E-01 1.09E-01 7.75E-01 
Isobutyric PWY-6588: NO_NAME|unclassified 1.11E-02 3.32E-02 5.79E-01 1.45E-01 7.89E-01 








phila 1.12E-02 3.35E-02 5.67E-01 1.44E-01 7.89E-01 
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Low BMI Control 








arius 5.60E-03 3.36E-02 3.54E-01 2.01E-01 8.10E-01 
Butyric 
PWY-5103: 




us 5.67E-03 3.40E-02 1.29E-01 2.00E-01 8.10E-01 
Butyric 
HSERMETANA-PWY: 




us 5.70E-03 3.42E-02 1.44E-01 2.00E-01 8.10E-01 








phila 7.98E-03 3.44E-02 5.71E-01 1.72E-01 8.00E-01 
Butyric PWY-7664: NO_NAME|unclassified 1.38E-02 3.44E-02 2.51E-01 1.25E-01 7.82E-01 




arius 5.76E-03 3.46E-02 5.07E-01 1.99E-01 8.10E-01 
Acetic PWY-5109: NO_NAME|unclassified 1.15E-02 3.46E-02 4.90E-01 1.41E-01 7.88E-01 








phila 1.16E-02 3.48E-02 4.74E-01 1.41E-01 7.88E-01 
Proprionic PWY-6284: NO_NAME|unclassified 5.79E-03 3.48E-02 -5.74E-01 -8.09E-01 -1.99E-01 
Isobutyric P162-PWY: NO_NAME|unclassified 1.16E-02 3.49E-02 2.74E-01 1.40E-01 7.88E-01 
Valeric P162-PWY: NO_NAME|unclassified 7.46E-03 3.49E-02 6.17E-01 1.78E-01 8.02E-01 
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Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric PWY-6471: NO_NAME|unclassified 5.84E-03 3.51E-02 6.64E-01 1.98E-01 8.09E-01 
Valeric PWY-5136: NO_NAME|unclassified 5.84E-03 3.51E-02 6.91E-01 1.98E-01 8.09E-01 
Butyric 
PWY-6609: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 5.85E-03 3.51E-02 9.64E-02 1.98E-01 8.09E-01 
Proprionic PWY-6285: NO_NAME|unclassified 5.86E-03 3.51E-02 -5.69E-01 -8.09E-01 -1.98E-01 












us 5.91E-03 3.55E-02 1.29E-01 1.97E-01 8.09E-01 
Isovaleric PWY-6435: NO_NAME|unclassified 1.78E-02 3.55E-02 4.19E-01 1.03E-01 7.73E-01 




aciens 5.96E-03 3.58E-02 -4.02E-01 -8.09E-01 -1.96E-01 








us 5.97E-03 3.58E-02 1.44E-01 1.96E-01 8.09E-01 
Valeric PWY-7242: NO_NAME|unclassified 1.79E-02 3.58E-02 6.26E-01 1.02E-01 7.72E-01 
Proprionic PWY-6113: NO_NAME|unclassified 5.97E-03 3.58E-02 -5.69E-01 -8.08E-01 -1.96E-01 
Butyric P562-PWY: NO_NAME|unclassified 5.99E-03 3.59E-02 3.36E-01 1.96E-01 8.08E-01 
Butyric PWY-5971: NO_NAME|unclassified 1.82E-02 3.64E-02 2.84E-01 1.00E-01 7.72E-01 
Valeric PWY-5971: NO_NAME|unclassified 1.23E-02 3.64E-02 5.62E-01 1.36E-01 7.86E-01 
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Low BMI Control 








us 6.07E-03 3.64E-02 1.44E-01 1.95E-01 8.08E-01 
Isobutyric HISTSYN-PWY: NO_NAME 1.22E-02 3.65E-02 -3.95E-01 -7.86E-01 -1.36E-01 








us 6.12E-03 3.67E-02 1.44E-01 1.94E-01 8.08E-01 
Butyric 
COMPLETE-ARO-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 6.13E-03 3.68E-02 1.58E-01 1.94E-01 8.08E-01 
Acetic ARGORNPROST-PWY: NO_NAME 1.23E-02 3.70E-02 4.65E-01 1.35E-01 7.86E-01 
Butyric ARGORNPROST-PWY: NO_NAME 1.13E-02 3.70E-02 3.77E-01 1.43E-01 7.89E-01 
Valeric URSIN-PWY: NO_NAME|unclassified 1.86E-02 3.72E-02 4.82E-01 9.83E-02 7.71E-01 
Isobutyric PWY-7288: NO_NAME|unclassified 1.48E-02 3.73E-02 4.44E-01 1.19E-01 7.79E-01 
Isovaleric PWY-7288: NO_NAME|unclassified 9.05E-03 3.73E-02 4.09E-01 1.62E-01 7.96E-01 
Valeric PWY-7288: NO_NAME|unclassified 1.86E-02 3.73E-02 6.73E-01 9.81E-02 7.71E-01 
Butyric PWY-5973: NO_NAME|unclassified 1.25E-02 3.74E-02 2.64E-01 1.34E-01 7.85E-01 
Isobutyric CENTFERM-PWY: NO_NAME|unclassified 1.13E-02 3.74E-02 4.70E-01 1.43E-01 7.89E-01 
Valeric CENTFERM-PWY: NO_NAME|unclassified 1.25E-02 3.74E-02 5.12E-01 1.34E-01 7.85E-01 
Valeric PWY-7224: NO_NAME 6.25E-03 3.75E-02 5.97E-01 1.93E-01 8.07E-01 
Isobutyric PWY-6590: NO_NAME|unclassified 1.09E-02 3.75E-02 4.90E-01 1.46E-01 7.90E-01 
Valeric PWY-6590: NO_NAME|unclassified 1.25E-02 3.75E-02 5.16E-01 1.34E-01 7.85E-01 
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SCFA Pathway p value P correct BH PPMC LCI UCI 
Isobutyric PWY-6662: NO_NAME|unclassified 1.25E-02 3.76E-02 4.17E-01 1.34E-01 7.85E-01 








us 6.28E-03 3.77E-02 1.44E-01 1.92E-01 8.07E-01 
Valeric PWY-5676: NO_NAME|unclassified 1.89E-02 3.77E-02 7.14E-01 9.70E-02 7.70E-01 
Butyric 
BRANCHED-CHAIN-AA-SYN-PWY: 
NO_NAME|g_Veillonella.s_Veillonella_parvula 6.31E-03 3.78E-02 3.74E-01 1.92E-01 8.07E-01 
Isobutyric 
HOMOSER-METSYN-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.13E-02 3.79E-02 -5.07E-01 -7.89E-01 -1.43E-01 
Isovaleric 
HOMOSER-METSYN-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.89E-02 3.79E-02 -4.59E-01 -7.70E-01 -9.67E-02 
Valeric 
HOMOSER-METSYN-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.31E-02 3.79E-02 -3.54E-01 -7.84E-01 -1.30E-01 
Valeric P163-PWY: NO_NAME|unclassified 1.89E-02 3.79E-02 5.40E-01 9.66E-02 7.70E-01 
Isobutyric PWY0-1296: NO_NAME|unclassified 1.27E-02 3.81E-02 4.52E-01 1.33E-01 7.85E-01 








spiraceae_bacterium_7_1_58FAA 8.36E-03 3.82E-02 5.84E-01 1.69E-01 7.98E-01 
Butyric PWY0-862: NO_NAME|unclassified 1.28E-02 3.84E-02 2.64E-01 1.32E-01 7.84E-01 
Acetic PWY3O-355: NO_NAME|unclassified 6.39E-03 3.84E-02 4.58E-01 1.91E-01 8.06E-01 
Butyric 
PWY-6628: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 6.40E-03 3.84E-02 6.87E-02 1.91E-01 8.06E-01 
Butyric PWY-6282: NO_NAME|unclassified 1.35E-02 3.84E-02 2.60E-01 1.27E-01 7.83E-01 
Valeric PWY-6282: NO_NAME|unclassified 1.92E-02 3.84E-02 5.21E-01 9.54E-02 7.70E-01 
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Low BMI Control 




eriales_bacterium_1_1_47 6.43E-03 3.86E-02 -4.38E-01 -8.06E-01 -1.90E-01 








mii 6.47E-03 3.88E-02 4.83E-01 1.90E-01 8.06E-01 
Butyric 
PWY-5973: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 6.48E-03 3.89E-02 2.21E-01 1.90E-01 8.06E-01 
Butyric 
ARGSYN-PWY: 




us 6.51E-03 3.90E-02 1.44E-01 1.89E-01 8.06E-01 
Butyric 
PWY-7400: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 6.51E-03 3.90E-02 3.48E-01 1.89E-01 8.06E-01 
































mii 6.60E-03 3.96E-02 4.73E-01 1.88E-01 8.06E-01 
Butyric PWY-7385: NO_NAME|unclassified 6.65E-03 3.99E-02 5.36E-01 1.87E-01 8.05E-01 
Valeric PWY-5973: NO_NAME|unclassified 2.00E-02 4.00E-02 5.25E-01 9.17E-02 7.68E-01 
362 Chapter 3 additional material  
 
 
Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric PWY-5306: NO_NAME|unclassified 2.00E-02 4.00E-02 3.99E-01 9.17E-02 7.68E-01 
Valeric PWY0-862: NO_NAME|unclassified 2.01E-02 4.02E-02 5.25E-01 9.12E-02 7.68E-01 
Butyric 
PWY-5667: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 6.75E-03 4.05E-02 1.54E-01 1.86E-01 8.05E-01 
Butyric 
PWY0-1319: 








us 6.77E-03 4.06E-02 1.44E-01 1.86E-01 8.05E-01 
Isobutyric PWY-5173: NO_NAME 1.95E-02 4.07E-02 5.31E-01 9.40E-02 7.69E-01 
Isovaleric PWY-5173: NO_NAME 2.04E-02 4.07E-02 4.91E-01 8.99E-02 7.67E-01 












us 6.83E-03 4.10E-02 1.44E-01 1.85E-01 8.05E-01 
Butyric 
PWY-5104: 




aciens 6.87E-03 4.12E-02 -4.10E-01 -8.04E-01 -1.85E-01 
Butyric 
DTDPRHAMSYN-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 6.89E-03 4.14E-02 9.93E-02 1.85E-01 8.04E-01 
Valeric METHGLYUT-PWY: NO_NAME 6.89E-03 4.14E-02 6.13E-01 1.84E-01 8.04E-01 
Isobutyric PWY-5989: NO_NAME|unclassified 2.08E-02 4.16E-02 3.97E-01 8.79E-02 7.67E-01 




spiraceae_bacterium_5_1_63FAA 6.99E-03 4.19E-02 -4.05E-01 -8.04E-01 -1.83E-01 
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SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric PWY-6595: NO_NAME|unclassified 2.10E-02 4.20E-02 5.45E-01 8.70E-02 7.66E-01 
Valeric 
PWY-7221: 
NO_NAME|g_Eubacterium.s_Eubacterium_hallii 7.02E-03 4.21E-02 -4.27E-01 -8.04E-01 -1.83E-01 
Isobutyric RIBOSYN2-PWY: NO_NAME 1.40E-02 4.21E-02 -5.05E-01 -7.81E-01 -1.24E-01 
Isovaleric RIBOSYN2-PWY: NO_NAME 1.09E-02 4.21E-02 -4.90E-01 -7.90E-01 -1.46E-01 
Valeric PWY-5789: NO_NAME 7.02E-03 4.21E-02 5.09E-01 1.83E-01 8.04E-01 
Butyric 
PWY-7219: 
















us 7.07E-03 4.24E-02 1.44E-01 1.82E-01 8.03E-01 
Valeric PWY-6122: NO_NAME|unclassified 7.10E-03 4.26E-02 6.09E-01 1.82E-01 8.03E-01 








spiraceae_bacterium_3_1_46FAA 2.13E-02 4.26E-02 5.42E-01 8.57E-02 7.66E-01 




mii 7.16E-03 4.30E-02 4.96E-01 1.81E-01 8.03E-01 
Isobutyric METH-ACETATE-PWY: NO_NAME|unclassified 1.44E-02 4.31E-02 5.09E-01 1.22E-01 7.80E-01 
Isobutyric FAO-PWY: NO_NAME|unclassified 1.45E-02 4.34E-02 4.04E-01 1.21E-01 7.80E-01 
Valeric PWY-6309: NO_NAME 2.18E-02 4.36E-02 5.29E-01 8.36E-02 7.65E-01 
364 Chapter 3 additional material  
 
 
Low BMI Control 
SCFA Pathway p value P correct BH PPMC LCI UCI 
Isobutyric 
PWY-6737: 
NO_NAME|g_Dorea.s_Dorea_longicatena 8.96E-03 4.36E-02 -5.37E-01 -7.96E-01 -1.63E-01 
Isovaleric 
PWY-6737: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.79E-02 4.36E-02 -4.88E-01 -7.72E-01 -1.02E-01 
Valeric 
PWY-6737: 
NO_NAME|g_Dorea.s_Dorea_longicatena 2.18E-02 4.36E-02 -4.14E-01 -7.65E-01 -8.35E-02 




spiraceae_bacterium_5_1_63FAA 7.28E-03 4.37E-02 -3.37E-01 -8.03E-01 -1.80E-01 
Valeric PWY-6518: NO_NAME|unclassified 7.31E-03 4.39E-02 3.61E-01 1.80E-01 8.02E-01 




us 7.35E-03 4.41E-02 1.44E-01 1.79E-01 8.02E-01 
Isobutyric 
7ALPHADEHYDROX-PWY: 
















us 7.43E-03 4.46E-02 1.29E-01 1.78E-01 8.02E-01 
Isobutyric HEME-BIOSYNTHESIS-II: NO_NAME 2.09E-02 4.47E-02 4.30E-01 8.75E-02 7.66E-01 
Isovaleric HEME-BIOSYNTHESIS-II: NO_NAME 2.24E-02 4.47E-02 4.17E-01 8.12E-02 7.64E-01 
Valeric HEME-BIOSYNTHESIS-II: NO_NAME 1.89E-02 4.47E-02 4.23E-01 9.69E-02 7.70E-01 
Butyric 
PWY-6121: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 7.46E-03 4.48E-02 1.94E-02 1.78E-01 8.02E-01 
Isobutyric 
ARO-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.32E-02 4.48E-02 -5.65E-01 -7.83E-01 -1.29E-01 
Isovaleric 
ARO-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 2.24E-02 4.48E-02 -5.18E-01 -7.64E-01 -8.11E-02 
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SCFA Pathway p value P correct BH PPMC LCI UCI 
Valeric 
ARO-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 2.05E-02 4.48E-02 -3.67E-01 -7.67E-01 -8.92E-02 
Acetic 
CITRULBIO-PWY: 
NO_NAME|g_Bacteroides.s_Bacteroides_eggerthii 1.95E-02 4.50E-02 5.52E-01 9.40E-02 7.69E-01 
Butyric 
CITRULBIO-PWY: 
NO_NAME|g_Bacteroides.s_Bacteroides_eggerthii 1.28E-02 4.50E-02 4.17E-01 1.32E-01 7.84E-01 
Proprionic 
CITRULBIO-PWY: 
NO_NAME|g_Bacteroides.s_Bacteroides_eggerthii 2.25E-02 4.50E-02 5.93E-01 8.07E-02 7.64E-01 
Isovaleric CENTFERM-PWY: NO_NAME|unclassified 2.26E-02 4.52E-02 4.23E-01 8.02E-02 7.63E-01 
Butyric 
PWY-6123: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 7.54E-03 4.52E-02 3.44E-02 1.77E-01 8.02E-01 
Butyric 
PWY-5100: 
NO_NAME|g_Veillonella.s_Veillonella_parvula 7.54E-03 4.52E-02 4.58E-01 1.77E-01 8.02E-01 
Isobutyric 
COMPLETE-ARO-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 1.32E-02 4.53E-02 -5.65E-01 -7.83E-01 -1.29E-01 
Isovaleric 
COMPLETE-ARO-PWY: 
NO_NAME|g_Dorea.s_Dorea_longicatena 2.27E-02 4.53E-02 -5.18E-01 -7.63E-01 -7.99E-02 
Valeric 
COMPLETE-ARO-PWY: 








us 7.59E-03 4.56E-02 1.44E-01 1.77E-01 8.01E-01 
Valeric PWY0-1586: NO_NAME|unclassified 7.61E-03 4.56E-02 6.99E-01 1.76E-01 8.01E-01 
Isobutyric GLUDEG-II-PWY: NO_NAME|unclassified 1.53E-02 4.59E-02 6.32E-01 1.16E-01 7.78E-01 
Valeric 
COA-PWY: 












arius 7.76E-03 4.66E-02 3.49E-01 1.75E-01 8.01E-01 
Valeric PWY0-1261: NO_NAME|unclassified 7.76E-03 4.66E-02 6.31E-01 1.75E-01 8.01E-01 
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aciens 7.79E-03 4.67E-02 -4.00E-01 -8.01E-01 -1.74E-01 
Isobutyric THISYNARA-PWY: NO_NAME 1.57E-02 4.70E-02 -5.49E-01 -7.77E-01 -1.14E-01 
Isovaleric THISYNARA-PWY: NO_NAME 1.51E-02 4.70E-02 -5.62E-01 -7.78E-01 -1.17E-01 
Valeric PWY-7197: NO_NAME|unclassified 2.36E-02 4.72E-02 5.73E-01 7.60E-02 7.62E-01 
Valeric 
VALSYN-PWY: 




mii 7.90E-03 4.74E-02 4.89E-01 1.73E-01 8.00E-01 
Isobutyric PROPFERM-PWY: NO_NAME|unclassified 2.37E-02 4.74E-02 2.97E-01 7.57E-02 7.61E-01 




us 7.92E-03 4.75E-02 1.29E-01 1.73E-01 8.00E-01 




arius 1.59E-02 4.76E-02 4.59E-01 1.13E-01 7.77E-01 
Isobutyric PWY-6641: NO_NAME 8.56E-03 4.77E-02 5.58E-01 1.66E-01 7.98E-01 
Isovaleric PWY-6641: NO_NAME 1.59E-02 4.77E-02 5.48E-01 1.13E-01 7.77E-01 
Valeric PWY-6123: NO_NAME|unclassified 7.96E-03 4.78E-02 5.99E-01 1.73E-01 8.00E-01 








aciens 8.04E-03 4.82E-02 -4.80E-01 -8.00E-01 -1.72E-01 
Valeric 
CALVIN-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_gnavus 8.04E-03 4.83E-02 -6.07E-01 -8.00E-01 -1.72E-01 
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SCFA Pathway p value P correct BH PPMC LCI UCI 
Isovaleric FAO-PWY: NO_NAME|unclassified 2.42E-02 4.83E-02 3.70E-01 7.39E-02 7.61E-01 
Isobutyric PWY-7187: NO_NAME|unclassified 2.03E-02 4.87E-02 4.39E-01 9.04E-02 7.68E-01 
Isovaleric PWY-7187: NO_NAME|unclassified 2.43E-02 4.87E-02 4.21E-01 7.32E-02 7.60E-01 
















mii 8.12E-03 4.87E-02 4.87E-01 1.71E-01 7.99E-01 
Isobutyric GALACTUROCAT-PWY: NO_NAME|unclassified 1.68E-02 4.88E-02 4.17E-01 1.08E-01 7.75E-01 
Isovaleric GALACTUROCAT-PWY: NO_NAME|unclassified 2.44E-02 4.88E-02 3.81E-01 7.29E-02 7.60E-01 




mii 8.15E-03 4.89E-02 4.84E-01 1.71E-01 7.99E-01 
Butyric 
ARO-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 8.17E-03 4.90E-02 8.93E-02 1.70E-01 7.99E-01 
Valeric 
PWY-6168: 




mii 8.21E-03 4.93E-02 4.84E-01 1.70E-01 7.99E-01 
Isobutyric FUCCAT-PWY: NO_NAME|unclassified 1.64E-02 4.93E-02 4.69E-01 1.10E-01 7.75E-01 
Butyric 
GLYCOGENSYNTH-PWY: 
NO_NAME|g_Blautia.s_Ruminococcus_obeum 8.24E-03 4.94E-02 4.81E-02 1.70E-01 7.99E-01 
Butyric 
ILEUSYN-PWY: 




aciens 8.29E-03 4.97E-02 -3.38E-01 -7.99E-01 -1.69E-01 
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CHAPTER 6 ADDITIONAL MATERIAL 
Supplementary Table 6.6 – Component C  
Values presented as log fold change of measured faecal metabolites before and after 
treatment (LOG2 (Timepoint2)- LOG2 (Timepoint1)). 
 






10 0.36 -0.82 0.21 0.18 0.69 -0.03 
34 -0.35 1.44 -0.66 0.45 -0.39 0.14 
45 -1.08 -0.77 -0.08 0.52 0.30 -0.16 
47 0.22 0.24 0.56 0.68 -0.20 0.09 
49 -0.83 -1.36 1.01 0.38 1.07 0.19 
50 -0.38 0.18 -0.05 0.16 -0.95 0.26 
54 0.37 1.00 0.18 0.51 -0.47 0.13 
57 0.71 2.03 -0.37 0.92 0.10 0.20 
58 0.69 -0.63 0.56 0.28 -0.34 0.08 
62 0.06 -1.15 0.17 0.39 -1.30 0.38 
64 -0.94 -0.24 -0.69 0.17 0.45 0.06 
67 -0.14 -0.65 0.40 -0.95 0.97 -0.02 
74 0.04 -0.86 0.64 0.06 0.83 0.16 
79 0.00 -0.63 0.52 0.31 -0.16 0.08 
81 -0.36 0.44 -0.04 -0.18 0.82 0.11 
84 0.72 -0.07 0.20 0.22 -0.29 0.11 
85 -0.37 -2.18 0.54 -0.12 -0.32 -0.62 
86 0.87 -0.76 -0.14 0.17 0.32 -0.01 
87 -0.26 -2.89 0.07 -0.08 -0.15 0.06 
89 0.85 -2.89 0.43 0.01 0.22 0.09 
91 0.63 0.48 0.89 1.24 0.43 0.39 
94 -0.53 -2.49 -0.26 -0.62 -0.44 -0.39 
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8 0.49 -0.07 -0.40 -1.17 -1.58 -0.09 
16 -0.53 -0.97 0.15 -0.66 -0.12 -0.52 
21 0.31 1.30 1.20 0.88 0.21 0.19 
22 0.00 -0.59 1.13 0.43 0.67 0.10 
25 -1.12 -0.98 -0.89 -0.50 0.03 0.10 
26 -0.04 -3.06 0.13 0.20 -1.30 0.30 
29 0.00 -1.01 -0.17 -0.96 0.06 -0.11 
32 0.24 -1.01 -0.79 -0.13 -0.41 0.30 
35 0.75 -0.83 0.01 -0.21 -0.22 0.12 
37 0.33 -0.68 -0.08 0.56 0.56 -0.03 
39 0.66 -0.31 0.35 -0.16 0.22 0.04 
42 0.24 3.36 0.14 -1.30 0.47 -0.58 
43 -1.52 0.86 -0.80 -0.47 0.46 0.12 
46 0.60 1.56 0.14 0.37 0.50 0.26 
56 0.26 0.39 -0.11 0.00 -0.50 -0.03 
68 0.01 -0.34 0.23 -0.43 0.24 -0.09 
70 1.02 -1.67 0.53 0.40 -1.90 0.03 
73 1.06 -1.92 -0.18 -0.53 0.55 -0.36 
78 -0.29 0.15 0.33 -0.44 -0.05 0.14 
82 -0.14 -0.51 -0.04 -0.07 -0.33 -0.19 
90 -0.22 0.76 0.52 0.59 0.06 0.04 
98 -0.60 -0.42 -0.49 0.26 -0.10 0.10 
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1 -0.13 -0.19 -0.02 -0.16 -1.09 -0.19 
4 0.52 -0.64 -1.16 -0.25 -1.03 -0.30 
5 0.07 0.75 0.01 0.40 -0.55 0.32 
9 -0.58 -0.58 0.38 0.40 0.05 0.45 
12 -1.09 -0.12 0.02 -0.33 1.43 0.00 
14 -0.13 1.66 -0.07 -0.88 -0.43 -0.19 
15 -0.17 0.20 0.43 -0.35 2.45 -0.04 
18 0.88 2.05 0.47 0.66 -1.11 0.22 
19 -0.21 1.92 0.18 -0.72 -0.33 0.13 
23 -0.16 0.45 0.54 -1.25 -0.61 -0.08 
36 -0.30 -2.48 1.01 0.09 2.33 0.03 
96 -0.25 -1.82 -0.97 -0.57 0.54 0.15 
99 -0.12 -0.06 -0.89 -0.90 0.94 -0.22 
102 1.12 -1.32 0.11 -0.56 -0.85 -0.75 
104 0.42 -0.52 0.08 0.49 -0.73 -0.05 
105 -1.02 -0.23 -1.00 0.16 -0.21 -0.05 
106 0.29 -2.11 0.20 0.14 0.50 0.20 
108 -0.81 1.76 -0.37 0.31 -0.87 0.34 
109 -1.26 1.43 0.42 0.51 0.16 0.15 
110 -1.45 0.39 -0.36 -0.09 0.22 0.12 
111 0.77 0.15 -0.39 0.21 1.25 0.13 
112 1.67 -0.97 -0.15 0.03 -0.60 -0.09 
115 -0.75 2.59 0.97 0.70 -0.72 0.23 
117 -1.76 0.67 0.14 -0.53 -0.29 -0.13 
  














10 -0.12 -1.26 0.18 -0.45 -0.11 0.01 
34 -0.98 1.67 -1.22 -0.87 -3.12 0.12 
45 -0.64 -0.38 0.50 0.30 -1.56 0.00 
47 -0.61 0.98 0.06 -0.28 0.84 -0.01 
49 -0.81 0.92 0.24 -0.06 1.55 0.38 
50 -0.55 0.33 0.63 0.99 -0.97 0.23 
54 -1.29 1.03 -0.16 -0.40 -0.44 0.34 
57 -0.90 0.63 -0.87 -0.05 0.31 0.23 
58 0.65 0.62 -0.36 0.30 0.28 -0.12 
62 0.96 -2.39 -1.16 0.01 -2.04 -0.02 
64 0.95 -0.37 -0.76 -0.80 0.22 0.10 
67 0.89 -0.50 -0.30 -0.40 -0.89 -0.12 
74 -0.22 0.40 0.82 -0.02 0.04 0.14 
79 -0.40 -0.60 -0.12 0.29 -0.62 0.11 
81 -1.69 -0.54 0.29 1.13 -2.81 0.03 
84 -0.71 -0.87 -0.35 -0.69 -0.04 0.00 
85 0.02 -0.31 0.14 0.06 -4.64 -0.68 
86 -0.55 -0.13 0.14 0.71 -1.47 0.01 
87 -0.56 0.69 0.14 -0.28 0.27 0.06 
89 -0.44 -2.91 0.03 -0.67 -3.78 0.24 
91 0.06 -1.32 -0.58 0.45 2.72 0.11 
94 0.17 -1.35 -0.69 1.62 -1.78 -0.60 
  




















8 2.48 -1.73 -0.34 0.12 2.35 0.01 
16 -1.08 0.51 0.81 -0.40 -0.13 -0.25 
21 -1.03 -0.53 -0.61 -0.13 1.53 -0.02 
22 -1.43 0.72 0.40 0.48 0.14 0.17 
25 -0.08 0.40 -0.50 -0.45 -0.54 0.24 
26 0.80 -0.91 -0.34 0.36 -0.35 0.17 
29 0.25 -2.49 1.02 -0.01 -2.78 -0.18 
32 -0.38 0.99 -0.40 0.82 -0.82 0.10 
35 -1.20 -1.57 -0.84 0.80 -0.30 0.14 
37 -0.02 -0.06 0.15 -0.14 -0.22 -0.31 
39 0.74 -0.24 -0.35 0.31 -0.13 -0.17 
42 -0.32 0.29 -0.39 0.08 -0.95 -0.75 
43 0.56 0.03 -0.27 -0.45 0.35 -0.15 
46 -1.00 0.71 -0.06 0.08 -1.20 0.06 
56 -0.99 1.78 -0.17 -1.51 -0.09 -0.06 
68 -0.40 -2.04 -0.27 0.31 -1.42 -0.14 
70 -0.06 -1.73 -0.18 0.41 -1.97 -0.20 
73 0.50 -1.12 -0.35 0.15 0.65 -0.62 
78 0.90 0.24 0.95 0.33 0.84 0.07 
82 0.36 1.92 -0.21 -0.53 0.29 0.13 
90 -0.08 0.90 -0.41 0.13 -0.49 -0.03 
98 1.56 -0.35 0.42 1.31 0.24 -0.01 
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1 0.91 -0.04 1.08 -0.46 0.82 -0.12 
4 0.52 -1.21 -0.63 -0.06 0.09 -0.23 
5 -0.01 0.81 -0.15 -0.15 0.67 0.29 
9 0.63 -1.68 -0.50 -0.04 0.87 0.38 
12 0.72 -2.62 0.53 0.39 -0.40 -0.07 
14 0.76 3.28 0.74 -1.30 0.58 0.38 
15 -0.23 -0.19 1.21 -0.41 1.24 -0.13 
18 0.07 0.72 -0.38 -0.12 0.02 -0.12 
19 0.79 -0.25 0.20 0.10 0.34 -0.10 
23 0.71 0.95 0.59 -0.20 1.11 -0.20 
36 0.56 0.39 -0.41 0.01 -1.17 0.08 
96 0.63 0.19 -1.01 -0.18 1.16 -0.14 
99 -0.15 0.61 0.43 0.07 -0.36 -0.05 
102 -0.02 -1.53 0.08 -0.15 0.99 -0.47 
104 -0.13 -0.05 -0.24 -0.19 -2.72 0.17 
105 0.90 -0.22 -0.44 -0.23 2.24 0.32 
106 -0.02 -1.24 -1.22 -0.22 0.53 0.32 
108 -0.38 0.45 -0.44 -0.82 -0.25 0.27 
109 0.07 0.62 0.65 -0.66 0.87 0.24 
110 1.46 -0.35 0.95 -0.59 -0.22 0.18 
111 -0.57 -1.30 -0.72 0.35 -2.70 -0.02 
112 -0.09 -0.20 0.35 -0.04 1.61 0.07 
115 1.56 1.45 0.73 0.03 0.51 0.30 
117 -0.03 -0.09 1.04 -0.58 2.19 -0.09 
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Supplementary Table 6.6 – Component D 
Values presented as log fold change of measured urinary metabolites before and after 




















10 0.33 0.17 -0.43 -0.02 0.16 -0.41 0.56 
34 -0.10 -0.74 -0.08 0.25 -0.20 0.52 -0.34 
47 -0.23 0.10 0.82 0.68 0.16 0.19 0.34 
49 -0.24 -1.21 0.95 -0.60 -0.79 0.52 -1.64 
50 0.09 0.53 -1.27 -0.23 0.12 -0.45 0.23 
54 -0.02 1.19 -0.64 0.23 0.87 -0.49 1.73 
57 -0.49 0.10 0.45 -0.16 0.44 0.53 0.66 
58 0.03 -0.28 -0.18 1.43 -0.26 1.28 -0.35 
62 -0.03 -0.10 0.11 -0.10 -0.19 0.57 -0.16 
64 -0.36 -0.77 0.29 0.32 -0.17 0.57 -0.80 
67 -0.20 -0.14 -0.06 0.00 -0.17 -0.20 -0.02 
74 -0.03 0.80 0.85 0.99 0.16 -0.05 0.79 
79 0.16 0.74 0.30 0.68 0.07 0.43 0.05 
81 0.06 0.56 0.11 -0.48 0.44 -0.23 0.42 
84 -0.06 -0.11 -0.23 0.87 -0.03 0.27 -0.25 
85 -0.04 0.05 -0.17 0.18 0.05 -0.80 0.23 
86 -0.15 0.58 -0.10 -0.10 0.61 -0.10 0.84 
87 0.00 -0.44 -0.66 -0.16 -0.04 0.07 -0.45 
89 -0.05 -0.73 0.26 0.20 -0.48 0.59 -0.73 
91 -0.20 -0.07 -0.73 -0.15 -0.04 -3.03 -0.08 
94 -0.05 -0.38 -0.44 -0.91 -0.22 -2.04 -0.46 
  
























8 0.15 0.79 -0.84 1.00 0.69 0.65 1.04 
16 -0.07 -0.20 -1.39 0.16 -0.15 -0.50 -0.16 
21 -0.28 -0.29 0.21 -0.22 -0.29 0.57 -0.36 
22 -0.31 -0.16 1.07 -0.44 0.39 0.09 0.31 
25 0.30 -0.29 -0.76 0.89 0.25 0.63 -0.04 
26 -0.59 0.31 0.24 -0.48 0.24 0.02 0.48 
29 0.48 0.96 -0.95 0.24 0.29 -0.61 0.81 
32 -0.04 0.33 0.10 -0.13 0.03 0.35 -0.01 
35 0.00 -0.27 0.00 -0.44 0.09 0.68 -0.12 
37 -0.18 -0.12 0.54 0.15 -0.18 0.14 -0.48 
39 0.43 0.26 -0.30 -0.12 0.03 -1.63 -0.01 
42 -0.41 0.39 0.69 -0.04 0.43 0.28 0.67 
43 -0.12 0.04 -0.37 0.27 0.25 0.34 0.40 
46 0.05 0.17 -0.01 -0.09 0.06 -0.92 0.03 
56 0.04 0.00 0.71 0.05 -0.08 1.78 0.02 
68 -0.07 -0.24 0.17 0.19 -0.20 0.59 -0.51 
70 0.03 -0.13 0.23 -0.06 -0.14 0.03 -0.22 
73 0.50 0.12 0.08 1.09 -0.14 0.27 -0.25 
78 -0.36 -0.56 -0.70 -0.34 0.41 -1.19 0.63 
82 0.07 0.60 0.34 0.55 0.25 0.38 0.55 
90 0.01 -0.36 -0.28 0.01 -0.04 0.61 -0.34 
98 0.39 0.69 -1.76 0.31 0.07 -1.12 0.21 
  


















1 0.19 -0.02 -0.05 0.08 0.01 -0.02 0.22 
5 -0.39 -0.84 0.58 -0.58 0.11 -0.19 -0.30 
9 0.08 0.00 -0.05 -0.48 0.55 -1.02 0.35 
12 0.03 -0.34 -0.97 0.62 0.18 -0.58 0.07 
14 0.89 -0.39 -0.64 0.23 0.03 1.73 -0.07 
15 -0.62 -0.61 1.26 -0.90 1.29 2.19 0.77 
18 -0.43 -1.66 0.94 -0.74 -0.04 1.78 -0.72 
19 -0.06 -0.28 0.04 -0.45 0.02 -0.07 -0.13 
23 0.25 -0.44 -0.25 -0.27 -0.36 0.83 -0.87 
36 0.43 0.50 0.47 1.12 -0.09 -0.10 0.53 
96 -0.46 -0.21 -0.12 -0.03 0.26 -0.33 0.18 
99 -0.34 0.19 0.07 0.58 0.38 0.28 0.03 
102 0.00 -0.51 0.31 -0.02 -0.28 0.96 -0.92 
104 -0.15 0.28 -0.25 0.37 0.62 -0.30 0.64 
105 0.11 -0.44 -0.22 0.24 0.13 -0.47 -0.13 
106 0.01 -1.00 -0.40 -0.47 -0.45 -0.16 -0.73 
108 0.03 -0.29 0.18 0.28 0.22 0.51 -0.28 
109 0.20 -0.40 -0.11 0.33 0.14 0.26 -0.24 
110 0.33 -1.14 2.58 0.88 -0.29 -0.07 -0.80 
111 0.33 0.74 -0.23 -0.43 0.35 -0.94 0.54 
112 -0.56 0.36 0.02 -0.23 0.40 -0.87 0.81 
115 0.06 -0.18 -0.14 0.04 -0.33 -0.26 -0.20 
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GALACTUROCAT-PWY: D-galacturonate degradation  4.99E-08 2.01E-05 2.29E-03 9.18E-03 6.89E-03 
GLCMANNANAUT-PWY: superpathway of N-acetylglucosamine, N-
acetylmannosamine and N-acetylneuraminate degradation 
4.99E-08 2.01E-05 3.43E-03 7.46E-03 4.02E-03 
PWY-5030: L-histidine degradation III 4.99E-08 2.01E-05 5.96E-03 1.31E-03 4.65E-03 
PWY-5177: glutaryl-CoA degradation 4.99E-08 2.01E-05 1.58E-03 8.18E-03 6.59E-03 
PWY-6305: putrescine biosynthesis IV 4.99E-08 2.01E-05 1.79E-03 7.80E-03 6.00E-03 
PWY-6507: 4-deoxy-L-threo-hex-4-enopyranuronate degradation 4.99E-08 2.01E-05 1.39E-03 6.61E-03 5.22E-03 
SER-GLYSYN-PWY: superpathway of L-serine and glycine 
biosynthesis I 
4.99E-08 2.01E-05 2.26E-03 8.69E-03 6.43E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
9.97E-08 2.44E-05 1.85E-03 1.43E-04 1.71E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_stercoris 
9.97E-08 2.44E-05 1.50E-03 9.40E-05 1.41E-03 
PWY-7357: thiamin formation from pyrithiamine and oxythiamine 
(yeast)| 
g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
9.97E-08 2.44E-05 3.04E-04 2.01E-03 1.70E-03 
BRANCHED-CHAIN-AA-SYN-PWY: superpathway of branched amino 
acid biosynthesis| 
g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 4.70E-04 2.07E-03 1.60E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 5.03E-04 2.70E-03 2.19E-03 
ILEUSYN-PWY: L-isoleucine biosynthesis I (from threo-
nine)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 5.30E-04 2.33E-03 1.80E-03 
PWY-5103: L-isoleucine biosynthesis 
III|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 4.67E-04 2.03E-03 1.57E-03 
PWY-5177: glutaryl-CoA degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 5.97E-04 2.50E-03 1.91E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 5.53E-04 2.41E-03 1.86E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 4.40E-04 2.70E-03 2.26E-03 
PWY-724: superpathway of L-lysine, L-threonine and L-methionine 
biosynthesis II|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 3.50E-04 1.89E-03 1.54E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_stercoris 1.99E-07 2.44E-05 1.56E-03 1.48E-04 1.42E-03 












UNINTEGRATED|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 1.99E-07 2.44E-05 5.26E-04 2.48E-03 1.96E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.99E-07 2.44E-05 5.30E-04 2.33E-03 1.80E-03 
ASPASN-PWY: superpathway of L-aspartate and L-asparagine 
biosynthesis|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 4.14E-04 2.14E-03 1.73E-03 
GALACTUROCAT-PWY: D-galacturonate degradation 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 6.16E-04 2.77E-03 2.16E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_vulgatus 
3.49E-07 2.44E-05 1.72E-03 2.74E-04 1.44E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate contain-
ing)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 3.23E-04 2.09E-03 1.76E-03 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 6.25E-04 2.65E-03 2.03E-03 
PWY-3001: superpathway of L-isoleucine biosynthesis 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 4.57E-04 2.41E-03 1.95E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_vulgatus 
3.49E-07 2.44E-05 1.75E-03 2.08E-04 1.54E-03 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 2.92E-04 2.17E-03 1.88E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 2.72E-04 2.00E-03 1.73E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 3.54E-04 2.30E-03 1.95E-03 
PWY-6507: 4-deoxy-L-threo-hex-4-enopyranuronate degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 5.14E-04 2.24E-03 1.72E-03 
PWY-6737: starch degradation 
V|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 4.84E-04 2.77E-03 2.28E-03 
SER-GLYSYN-PWY: superpathway of L-serine and glycine 
biosynthesis I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 2.85E-04 1.93E-03 1.65E-03 
THISYNARA-PWY: superpathway of thiamin diphosphate 
biosynthesis III (eukary-
otes)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 3.37E-04 1.93E-03 1.59E-03 
THRESYN-PWY: superpathway of L-threonine biosynthe-
sis|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.49E-07 2.44E-05 4.53E-04 2.54E-03 2.08E-03 
ARO-PWY: chorismate biosynthesis I 3.49E-07 2.44E-05 4.59E-03 8.72E-03 4.13E-03 
PWY-7242: D-fructuronate degradation 3.49E-07 2.44E-05 2.46E-03 6.70E-03 4.25E-03 
GLCMANNANAUT-PWY: superpathway of N-acetylglucosamine, N-
acetylmannosamine and N-acetylneuraminate degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 4.00E-04 2.17E-03 1.77E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 3.13E-04 1.95E-03 1.64E-03 














5.98E-07 2.44E-05 5.76E-04 2.51E-03 1.93E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 5.85E-04 2.82E-03 2.23E-03 
PWY-6123: inosine-5'-phosphate biosynthesis 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 5.48E-04 2.86E-03 2.32E-03 
PWY-6317: galactose degradation I (Leloir path-
way)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 3.53E-04 1.85E-03 1.50E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Bacteroides.s_Bacteroides_vulgatus 
5.98E-07 2.44E-05 1.84E-03 2.60E-04 1.58E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 3.13E-04 1.95E-03 1.64E-03 
PWY66-422: D-galactose degradation V (Leloir path-
way)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.98E-07 2.44E-05 3.53E-04 1.85E-03 1.50E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Bacteroides.s_Bacteroides_vulgatus 
5.98E-07 2.44E-05 1.84E-03 2.60E-04 1.58E-03 
COMPLETE-ARO-PWY: superpathway of aromatic amino acid 
biosynthesis 
5.98E-07 2.44E-05 4.96E-03 9.29E-03 4.34E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
9.47E-07 2.44E-05 4.04E-04 2.01E-03 1.60E-03 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
9.47E-07 2.44E-05 5.92E-04 2.71E-03 2.12E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
9.47E-07 2.44E-05 4.35E-04 2.82E-03 2.38E-03 
PWY-6737: starch degradation V 9.47E-07 2.44E-05 3.44E-03 7.34E-03 3.90E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.60E-03 2.60E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.60E-03 0.00E+00 1.60E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.94E-03 0.00E+00 1.94E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
1.49E-06 2.44E-05 0.00E+00 2.00E-03 2.00E-03 
ASPASN-PWY: superpathway of L-aspartate and L-asparagine 
biosynthesis|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.78E-03 0.00E+00 1.78E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.84E-03 0.00E+00 1.84E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.40E-03 0.00E+00 1.40E-03 
COA-PWY: coenzyme A biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.49E-06 2.44E-05 0.00E+00 2.51E-03 2.51E-03 
HISDEG-PWY: L-histidine degradation 
I|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.93E-03 0.00E+00 1.93E-03 
HISTSYN-PWY: L-histidine biosynthe-
sis|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.82E-03 0.00E+00 1.82E-03 
NONOXIPENT-PWY: pentose phosphate pathway (non-oxidative 
branch)|g_Phascolarctobacterium.s_Phascolarctobacterium_succinat
utens 
1.49E-06 2.44E-05 0.00E+00 2.05E-03 2.05E-03 












PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.84E-03 0.00E+00 1.84E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 3.44E-03 3.44E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 2.05E-03 0.00E+00 2.05E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_fragilis 
1.49E-06 2.44E-05 7.87E-04 0.00E+00 7.87E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_massiliensis 
1.49E-06 2.44E-05 0.00E+00 2.53E-03 2.53E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.49E-06 2.44E-05 0.00E+00 1.99E-03 1.99E-03 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.80E-03 2.80E-03 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.84E-03 0.00E+00 1.84E-03 
PWY-1269: CMP-3-deoxy-D-manno-octulosonate biosynthesis 
I|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.83E-03 0.00E+00 1.83E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.94E-03 2.94E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.96E-03 0.00E+00 1.96E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_massiliensis 
1.49E-06 2.44E-05 0.00E+00 2.18E-03 2.18E-03 
PWY-2942: L-lysine biosynthesis III|g_Dialister.s_Dialister_invisus 1.49E-06 2.44E-05 1.71E-03 0.00E+00 1.71E-03 
PWY-2942: L-lysine biosynthesis III|g_Prevotella.s_Prevotella_copri 1.49E-06 2.44E-05 0.00E+00 3.86E-03 3.86E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.92E-03 2.92E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.75E-03 0.00E+00 1.75E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.88E-03 2.88E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.92E-03 0.00E+00 1.92E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_massiliensis 
1.49E-06 2.44E-05 0.00E+00 2.22E-03 2.22E-03 
PWY-5097: L-lysine biosynthesis VI|g_Dialister.s_Dialister_invisus 1.49E-06 2.44E-05 1.70E-03 0.00E+00 1.70E-03 
PWY-5097: L-lysine biosynthesis VI|g_Prevotella.s_Prevotella_copri 1.49E-06 2.44E-05 0.00E+00 3.84E-03 3.84E-03 
PWY-5188: tetrapyrrole biosynthesis I (from gluta-
mate)|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.38E-03 0.00E+00 1.38E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.56E-03 0.00E+00 1.56E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.47E-03 0.00E+00 1.47E-03 
PWY-5686: UMP biosynthe-
sis|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.98E-03 0.00E+00 1.98E-03 












PWY-5686: UMP biosynthesis|g_Alistipes.s_Alistipes_putredinis 1.49E-06 2.44E-05 0.00E+00 2.94E-03 2.94E-03 
PWY-5686: UMP biosynthe-
sis|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 3.17E-03 3.17E-03 
PWY-5686: UMP biosynthesis|g_Bacteroides.s_Bacteroides_faecis 1.49E-06 2.44E-05 1.94E-03 0.00E+00 1.94E-03 
PWY-5686: UMP biosynthesis|g_Dialister.s_Dialister_invisus 1.49E-06 2.44E-05 1.47E-03 0.00E+00 1.47E-03 
PWY-5686: UMP biosynthesis|g_Prevotella.s_Prevotella_copri 1.49E-06 2.44E-05 0.00E+00 3.78E-03 3.78E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.77E-03 2.77E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.81E-03 0.00E+00 1.81E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 2.00E-03 0.00E+00 2.00E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.54E-03 0.00E+00 1.54E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.89E-03 0.00E+00 1.89E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.48E-03 0.00E+00 1.48E-03 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.77E-03 0.00E+00 1.77E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Prevotella.s_Prevotella_copri 
1.49E-06 2.44E-05 0.00E+00 3.50E-03 3.50E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.89E-03 0.00E+00 1.89E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.48E-03 0.00E+00 1.48E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-
containing)|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 2.05E-03 0.00E+00 2.05E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 2.10E-03 0.00E+00 2.10E-03 
PWY-6609: adenine and adenosine salvage 
III|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.52E-03 0.00E+00 1.52E-03 
PWY-6700: queuosine biosynthe-
sis|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.83E-03 0.00E+00 1.83E-03 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 2.58E-03 2.58E-03 
PWY-6700: queuosine biosynthesis|g_Prevotella.s_Prevotella_copri 1.49E-06 2.44E-05 0.00E+00 3.92E-03 3.92E-03 
PWY-6703: preQ0 biosynthesis|g_Bacteroides.s_Bacteroides_faecis 1.49E-06 2.44E-05 1.32E-03 0.00E+00 1.32E-03 
PWY-6703: preQ0 biosynthesis|g_Dialister.s_Dialister_invisus 1.49E-06 2.44E-05 1.41E-03 0.00E+00 1.41E-03 












PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.96E-03 0.00E+00 1.96E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Parabacteroides.s_Parabacteroides_merdae 
1.49E-06 2.44E-05 0.00E+00 1.51E-03 1.51E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Phascolarctobacterium.s_Phascolarctobacterium_succinat
utens 
1.49E-06 2.44E-05 0.00E+00 1.95E-03 1.95E-03 
PWY-7197: pyrimidine deoxyribonucleotide phosphoryla-
tion|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.18E-03 0.00E+00 1.18E-03 
PWY-7208: superpathway of pyrimidine nucleobases 
salvage|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.24E-03 0.00E+00 1.24E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.81E-03 0.00E+00 1.81E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_putredinis 
1.49E-06 2.44E-05 0.00E+00 3.39E-03 3.39E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_coprocola 
1.49E-06 2.44E-05 0.00E+00 3.10E-03 3.10E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.62E-03 0.00E+00 1.62E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
1.49E-06 2.44E-05 0.00E+00 2.12E-03 2.12E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bifidobacterium.s_Bifidobacterium_bifidum 
1.49E-06 2.44E-05 7.34E-04 0.00E+00 7.34E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.60E-03 0.00E+00 1.60E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Eubacterium.s_Eubacterium_ventriosum 
1.49E-06 2.44E-05 1.35E-03 0.00E+00 1.35E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_merdae 
1.49E-06 2.44E-05 0.00E+00 2.40E-03 2.40E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.49E-06 2.44E-05 0.00E+00 1.70E-03 1.70E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Prevotella.s_Prevotella_copri 
1.49E-06 2.44E-05 0.00E+00 3.71E-03 3.71E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.23E-03 0.00E+00 1.23E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
1.49E-06 2.44E-05 0.00E+00 2.68E-03 2.68E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bifidobacterium.s_Bifidobacterium_bifidum 
1.49E-06 2.44E-05 6.98E-04 0.00E+00 6.98E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.42E-03 0.00E+00 1.42E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Prevotella.s_Prevotella_copri 
1.49E-06 2.44E-05 0.00E+00 3.72E-03 3.72E-03 
PWY-7228: superpathway of guanosine nucleotides de novo 
biosynthesis I|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.24E-03 0.00E+00 1.24E-03 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.96E-03 0.00E+00 1.96E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.56E-03 0.00E+00 1.56E-03 












PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Dialister.s_Dialister_invisus 
1.49E-06 2.44E-05 1.47E-03 0.00E+00 1.47E-03 
PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.54E-03 0.00E+00 1.54E-03 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.52E-03 0.00E+00 1.52E-03 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Bacteroides.s_Bacteroides_faecis 
1.49E-06 2.44E-05 1.66E-03 0.00E+00 1.66E-03 
UNINTEGRAT-
ED|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.99E-03 0.00E+00 1.99E-03 
UNINTEGRATED|g_Alistipes.s_Alistipes_putredinis 1.49E-06 2.44E-05 0.00E+00 2.81E-03 2.81E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_coprocola 1.49E-06 2.44E-05 0.00E+00 2.93E-03 2.93E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_faecis 1.49E-06 2.44E-05 1.95E-03 0.00E+00 1.95E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_fragilis 1.49E-06 2.44E-05 1.57E-03 0.00E+00 1.57E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_massiliensis 1.49E-06 2.44E-05 0.00E+00 3.01E-03 3.01E-03 
UNINTEGRATED|g_Bifidobacterium.s_Bifidobacterium_bifidum 1.49E-06 2.44E-05 6.64E-04 0.00E+00 6.64E-04 
UNINTEGRATED|g_Blautia.s_Ruminococcus_gnavus 1.49E-06 2.44E-05 1.70E-03 0.00E+00 1.70E-03 
UNINTEGRATED|g_Dialister.s_Dialister_invisus 1.49E-06 2.44E-05 1.51E-03 0.00E+00 1.51E-03 
UNINTEGRATED|g_Eubacterium.s_Eubacterium_ventriosum 1.49E-06 2.44E-05 1.39E-03 0.00E+00 1.39E-03 
UNINTEGRATED|g_Parabacteroides.s_Parabacteroides_distasonis 1.49E-06 2.44E-05 0.00E+00 2.46E-03 2.46E-03 
UNINTEGRATED|g_Parabacteroides.s_Parabacteroides_merdae 1.49E-06 2.44E-05 0.00E+00 2.30E-03 2.30E-03 
UNINTEGRATED|g_Paraprevotella.s_Paraprevotella_clara 1.49E-06 2.44E-05 0.00E+00 2.73E-03 2.73E-03 
UNINTEGRAT-
ED|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.49E-06 2.44E-05 0.00E+00 1.97E-03 1.97E-03 
UNINTEGRATED|g_Prevotella.s_Prevotella_copri 1.49E-06 2.44E-05 0.00E+00 3.77E-03 3.77E-03 
UNINTEGRATED|g_Ruminococcus.s_Ruminococcus_callidus 1.49E-06 2.44E-05 0.00E+00 2.52E-03 2.52E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Acidaminococcus.s_Acidaminococcus_sp_BV3L6 
1.49E-06 2.44E-05 1.96E-03 0.00E+00 1.96E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_merdae 
1.49E-06 2.44E-05 0.00E+00 1.51E-03 1.51E-03 
PWY-5005: biotin biosynthesis II 1.49E-06 2.44E-05 4.69E-03 0.00E+00 4.69E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Bacteroides.s_Bacteroides_vulgatus 
1.50E-06 2.44E-05 1.78E-03 2.63E-04 1.51E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_vulgatus 
1.50E-06 2.44E-05 1.70E-03 2.91E-04 1.41E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.50E-06 2.44E-05 6.79E-04 2.76E-03 2.08E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Bacteroides.s_Bacteroides_vulgatus 
1.50E-06 2.44E-05 1.78E-03 2.50E-04 1.53E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.50E-06 2.44E-05 6.79E-04 2.76E-03 2.08E-03 
PWY-7220: adenosine deoxyribonucleotides de novo biosynthesis 
II|g_Bacteroides.s_Bacteroides_vulgatus 
1.50E-06 2.44E-05 1.74E-03 2.66E-04 1.47E-03 












PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.50E-06 2.44E-05 5.30E-04 2.87E-03 2.34E-03 
PWY-7222: guanosine deoxyribonucleotides de novo biosynthesis 
II|g_Bacteroides.s_Bacteroides_vulgatus 
1.50E-06 2.44E-05 1.74E-03 2.66E-04 1.47E-03 
PWY-7228: superpathway of guanosine nucleotides de novo 
biosynthesis I|g_Bacteroides.s_Bacteroides_vulgatus 
1.50E-06 2.44E-05 1.74E-03 2.78E-04 1.46E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis II 1.50E-06 2.44E-05 4.47E-03 7.25E-03 2.78E-03 
PWY-6163: chorismate biosynthesis from 3-dehydroquinate 1.50E-06 2.44E-05 4.70E-03 8.89E-03 4.18E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis 
1.50E-06 2.44E-05 4.47E-03 7.25E-03 2.78E-03 
PWY0-162: superpathway of pyrimidine ribonucleotides de novo 
biosynthesis 
1.50E-06 2.44E-05 4.38E-03 8.67E-03 4.30E-03 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis I 1.50E-06 2.44E-05 5.59E-03 1.67E-03 3.92E-03 
PWY-4242: pantothenate and coenzyme A biosynthesis 
III|g_Bacteroides.s_Bacteroides_xylanisolvens 
2.08E-06 3.37E-05 1.61E-03 2.70E-05 1.58E-03 
GALACT-GLUCUROCAT-PWY: superpathway of hexuronide and 
hexuronate degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
2.24E-06 3.48E-05 5.99E-04 2.44E-03 1.84E-03 
NONOXIPENT-PWY: pentose phosphate pathway (non-oxidative 
branch)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
2.24E-06 3.48E-05 3.13E-04 2.10E-03 1.79E-03 
PWY-5659: GDP-mannose biosynthe-
sis|g_Bacteroides.s_Bacteroides_ovatus 
2.24E-06 3.48E-05 2.02E-03 3.09E-04 1.71E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_vulgatus 
2.24E-06 3.48E-05 1.78E-03 2.65E-04 1.51E-03 
PWY-6126: superpathway of adenosine nucleotides de novo 
biosynthesis II|g_Bacteroides.s_Bacteroides_vulgatus 
2.24E-06 3.48E-05 1.77E-03 2.64E-04 1.51E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bacteroides.s_Bacteroides_vulgatus 
2.24E-06 3.48E-05 1.78E-03 2.68E-04 1.51E-03 
PWY-7229: superpathway of adenosine nucleotides de novo 
biosynthesis I|g_Bacteroides.s_Bacteroides_vulgatus 
2.24E-06 3.48E-05 1.78E-03 2.72E-04 1.50E-03 
NONOXIPENT-PWY: pentose phosphate pathway (non-oxidative 
branch) 
2.24E-06 3.48E-05 5.12E-03 8.68E-03 3.56E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_vulgatus 
3.34E-06 5.04E-05 1.78E-03 2.82E-04 1.50E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Bacteroides.s_Bacteroides_uniformis 
3.34E-06 5.04E-05 1.47E-03 2.89E-04 1.18E-03 
PWY-6609: adenine and adenosine salvage 
III|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.34E-06 5.04E-05 4.92E-04 2.35E-03 1.86E-03 
PWY-7242: D-fructuronate degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.34E-06 5.04E-05 5.99E-04 2.43E-03 1.84E-03 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.34E-06 5.04E-05 5.40E-04 2.30E-03 1.76E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_stercoris 
3.40E-06 5.11E-05 1.52E-03 1.69E-05 1.51E-03 












PWY66-422: D-galactose degradation V (Leloir path-
way)|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_
1_63FAA 
3.45E-06 5.14E-05 1.15E-03 5.04E-05 1.10E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_ovatus 
4.28E-06 6.32E-05 1.70E-03 6.58E-05 1.64E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_xylanisolvens 
4.28E-06 6.32E-05 1.35E-03 4.34E-05 1.31E-03 
GLUCUROCAT-PWY: superpathway of &beta;-D-glucuronide and D-
glucuronate degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
4.84E-06 6.41E-05 5.85E-04 2.33E-03 1.74E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_ovatus 
4.84E-06 6.41E-05 1.79E-03 3.08E-04 1.48E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_vulgatus 
4.84E-06 6.41E-05 1.77E-03 3.48E-04 1.42E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_vulgatus 
4.84E-06 6.41E-05 1.68E-03 2.91E-04 1.39E-03 
PWY-6317: galactose degradation I (Leloir path-
way)|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_
1_63FAA 
5.45E-06 6.41E-05 1.05E-03 5.46E-05 9.92E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_coprocola 
5.52E-06 6.41E-05 0.00E+00 2.51E-03 2.51E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_faecis 
5.52E-06 6.41E-05 1.67E-03 0.00E+00 1.67E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.52E-06 6.41E-05 0.00E+00 2.27E-03 2.27E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Bacteroides.s_Bacteroides_fragilis 
5.52E-06 6.41E-05 1.09E-03 0.00E+00 1.09E-03 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Alistipes.s_Alistipes_finegoldii 
5.52E-06 6.41E-05 6.41E-04 0.00E+00 6.41E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Parabacteroides.s_Parabacteroides_merdae 
5.52E-06 6.41E-05 0.00E+00 1.62E-03 1.62E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_fragilis 
5.52E-06 6.41E-05 8.38E-04 0.00E+00 8.38E-04 
PWY-2942: L-lysine biosynthesis 
III|g_Parabacteroides.s_Parabacteroides_merdae 
5.52E-06 6.41E-05 0.00E+00 1.97E-03 1.97E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_massiliensis 
5.52E-06 6.41E-05 0.00E+00 2.52E-03 2.52E-03 
PWY-3841: folate transformations 
II|g_Parabacteroides.s_Parabacteroides_merdae 
5.52E-06 6.41E-05 0.00E+00 1.87E-03 1.87E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Parabacteroides.s_Parabacteroides_merdae 
5.52E-06 6.41E-05 0.00E+00 2.23E-03 2.23E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_coprocola 
5.52E-06 6.41E-05 0.00E+00 2.45E-03 2.45E-03 
PWY-5686: UMP biosynthesis|g_Bacteroides.s_Bacteroides_fragilis 5.52E-06 6.41E-05 7.44E-04 0.00E+00 7.44E-04 
PWY-5686: UMP biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_merdae 
5.52E-06 6.41E-05 0.00E+00 1.77E-03 1.77E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Alistipes.s_Alistipes_putredinis 
5.52E-06 6.41E-05 0.00E+00 2.65E-03 2.65E-03 












PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Alistipes.s_Alistipes_putredinis 
5.52E-06 6.41E-05 0.00E+00 2.63E-03 2.63E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Eubacterium.s_Eubacterium_ventriosum 
5.52E-06 6.41E-05 1.10E-03 0.00E+00 1.10E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.52E-06 6.41E-05 0.00E+00 1.87E-03 1.87E-03 
PWY-6123: inosine-5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_faecis 
5.52E-06 6.41E-05 1.61E-03 0.00E+00 1.61E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Bacteroides.s_Bacteroides_massiliensis 
5.52E-06 6.41E-05 0.00E+00 3.27E-03 3.27E-03 
PWY-6168: flavin biosynthesis III (fun-
gi)|g_Bacteroides.s_Bacteroides_faecis 
5.52E-06 6.41E-05 1.64E-03 0.00E+00 1.64E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Alistipes.s_Alistipes_putredinis 
5.52E-06 6.41E-05 0.00E+00 2.63E-03 2.63E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Eubacterium.s_Eubacterium_ventriosum 
5.52E-06 6.41E-05 1.10E-03 0.00E+00 1.10E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.52E-06 6.41E-05 0.00E+00 1.87E-03 1.87E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Bifidobacterium.s_Bifidobacterium_bifidum 
5.52E-06 6.41E-05 6.30E-04 0.00E+00 6.30E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bifidobacterium.s_Bifidobacterium_bifidum 
5.52E-06 6.41E-05 6.09E-04 0.00E+00 6.09E-04 




5.52E-06 6.41E-05 0.00E+00 1.80E-03 1.80E-03 
PWY-6527: stachyose degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.52E-06 6.41E-05 0.00E+00 1.64E-03 1.64E-03 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_faecis 
5.52E-06 6.41E-05 1.41E-03 0.00E+00 1.41E-03 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
5.52E-06 6.41E-05 0.00E+00 2.14E-03 2.14E-03 
PWY-6700: queuosine biosynthesis|g_Dialister.s_Dialister_invisus 5.52E-06 6.41E-05 1.39E-03 0.00E+00 1.39E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
5.52E-06 6.41E-05 0.00E+00 1.93E-03 1.93E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Bacteroides.s_Bacteroides_massiliensis 
5.52E-06 6.41E-05 0.00E+00 1.79E-03 1.79E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
5.52E-06 6.41E-05 0.00E+00 2.37E-03 2.37E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_fragilis 
5.52E-06 6.41E-05 6.76E-04 0.00E+00 6.76E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Paraprevotella.s_Paraprevotella_clara 
5.52E-06 6.41E-05 0.00E+00 3.16E-03 3.16E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_callidus 
5.52E-06 6.41E-05 0.00E+00 2.51E-03 2.51E-03 












PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
5.52E-06 6.41E-05 0.00E+00 2.59E-03 2.59E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_coprocola 
5.52E-06 6.41E-05 0.00E+00 2.45E-03 2.45E-03 
SER-GLYSYN-PWY: superpathway of L-serine and glycine 
biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.52E-06 6.41E-05 0.00E+00 1.98E-03 1.98E-03 
UNINTEGRATED|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 5.52E-06 6.41E-05 0.00E+00 1.75E-03 1.75E-03 
UNINTEGRATED|g_Alistipes.s_Alistipes_shahii 5.52E-06 6.41E-05 0.00E+00 1.85E-03 1.85E-03 
UNINTEGRATED|g_Coprococcus.s_Coprococcus_comes 5.52E-06 6.41E-05 0.00E+00 1.23E-03 1.23E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
5.52E-06 6.41E-05 0.00E+00 1.79E-03 1.79E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.52E-06 6.41E-05 0.00E+00 1.71E-03 1.71E-03 
GLUCONEO-PWY: gluconeogenesis I 5.52E-06 6.41E-05 0.00E+00 5.53E-03 5.53E-03 
PWY-821: superpathway of sulfur amino acid biosynthesis 
(Saccharomyces cerevisiae) 
5.52E-06 6.41E-05 3.48E-03 0.00E+00 3.48E-03 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_stercoris 
5.68E-06 6.57E-05 1.47E-03 4.86E-05 1.43E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_stercoris 
6.05E-06 6.86E-05 1.54E-03 4.04E-05 1.50E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_stercoris 
6.05E-06 6.86E-05 1.46E-03 3.94E-05 1.42E-03 
PWY-5686: UMP biosynthesis|g_Bacteroides.s_Bacteroides_stercoris 6.05E-06 6.86E-05 1.48E-03 4.63E-05 1.44E-03 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Bacteroides.s_Bacteroides_ovatus 
6.05E-06 6.86E-05 2.01E-03 4.56E-05 1.96E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_stercoris 
6.05E-06 6.86E-05 1.46E-03 3.94E-05 1.42E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_stercoris 
6.32E-06 7.00E-05 1.53E-03 4.45E-05 1.48E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_stercoris 
6.32E-06 7.00E-05 1.50E-03 4.22E-05 1.46E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Bacteroides.s_Bacteroides_stercoris 
6.32E-06 7.00E-05 1.39E-03 4.22E-05 1.35E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Bacteroides.s_Bacteroides_xylanisolvens 
6.32E-06 7.00E-05 1.33E-03 3.33E-05 1.30E-03 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Bacteroides.s_Bacteroides_stercoris 
6.32E-06 7.00E-05 1.42E-03 4.51E-05 1.38E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Bacteroides.s_Bacteroides_xylanisolvens 
6.32E-06 7.00E-05 1.33E-03 3.33E-05 1.30E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Bacteroides.s_Bacteroides_ovatus 
6.51E-06 7.09E-05 1.56E-03 9.90E-05 1.46E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_ovatus 
6.51E-06 7.09E-05 1.87E-03 1.21E-04 1.75E-03 
PWY-5686: UMP biosynthesis|g_Bacteroides.s_Bacteroides_ovatus 6.51E-06 7.09E-05 1.86E-03 1.31E-04 1.73E-03 












PWY66-400: glycolysis VI (metazo-
an)|g_Bacteroides.s_Bacteroides_ovatus 
6.51E-06 7.09E-05 1.82E-03 1.33E-04 1.68E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_stercoris 
6.63E-06 7.18E-05 1.50E-03 6.31E-05 1.43E-03 
HISDEG-PWY: L-histidine degradation I 6.68E-06 7.18E-05 6.13E-03 7.56E-04 5.37E-03 
PWY-6531: mannitol cycle 6.68E-06 7.18E-05 3.84E-03 7.79E-04 3.06E-03 
PWY-7456: mannan degrada-
tion|g_Bacteroides.s_Bacteroides_ovatus 
6.69E-06 7.18E-05 1.40E-03 5.33E-05 1.35E-03 
GALACT-GLUCUROCAT-PWY: superpathway of hexuronide and 
hexuronate degradation 
6.93E-06 7.32E-05 3.51E-03 8.34E-03 4.83E-03 
PWY-1269: CMP-3-deoxy-D-manno-octulosonate biosynthesis I 6.93E-06 7.32E-05 5.19E-03 1.64E-03 3.55E-03 
PWY-5101: L-isoleucine biosynthesis II 6.93E-06 7.32E-05 5.44E-03 1.93E-03 3.51E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthesis 6.93E-06 7.32E-05 5.18E-03 1.05E-02 5.32E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_uniformis 
7.07E-06 7.42E-05 1.37E-03 1.17E-04 1.26E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Bacteroides.s_Bacteroides_stercoris 
7.07E-06 7.42E-05 1.58E-03 5.33E-05 1.53E-03 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_uniformis 
7.28E-06 7.61E-05 1.78E-03 1.45E-04 1.64E-03 
PANTOSYN-PWY: pantothenate and coenzyme A biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
7.85E-06 8.14E-05 1.92E-03 1.24E-04 1.79E-03 
PWY-1269: CMP-3-deoxy-D-manno-octulosonate biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
7.85E-06 8.14E-05 1.78E-03 1.03E-04 1.68E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_ovatus 
8.08E-06 8.14E-05 1.82E-03 1.07E-04 1.71E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_stercoris 
8.08E-06 8.14E-05 1.48E-03 7.63E-05 1.40E-03 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Bacteroides.s_Bacteroides_ovatus 
8.08E-06 8.14E-05 1.94E-03 1.39E-04 1.80E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Bacteroides.s_Bacteroides_ovatus 
8.08E-06 8.14E-05 1.54E-03 1.07E-04 1.43E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bacteroides.s_Bacteroides_ovatus 
8.08E-06 8.14E-05 1.52E-03 9.56E-05 1.43E-03 
PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage|g_Bacteroides.s_Bacteroides_ovatus 
8.08E-06 8.14E-05 2.17E-03 1.59E-04 2.01E-03 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
8.08E-06 8.14E-05 2.01E-03 1.67E-04 1.84E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_ovatus 
8.22E-06 8.14E-05 1.79E-03 1.63E-04 1.63E-03 
COA-PWY: coenzyme A biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
8.22E-06 8.14E-05 2.09E-03 1.90E-04 1.90E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_stercoris 
8.22E-06 8.14E-05 1.53E-03 7.76E-05 1.45E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Bacteroides.s_Bacteroides_stercoris 
8.22E-06 8.14E-05 1.51E-03 7.65E-05 1.43E-03 
THISYNARA-PWY: superpathway of thiamin diphosphate 
biosynthesis III (eukaryotes)|g_Bacteroides.s_Bacteroides_ovatus 
8.22E-06 8.14E-05 2.10E-03 1.63E-04 1.94E-03 














8.22E-06 8.14E-05 1.51E-03 7.65E-05 1.43E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_vulgatus 
8.29E-06 8.15E-05 1.88E-03 1.96E-04 1.68E-03 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
8.29E-06 8.15E-05 2.18E-04 2.31E-03 2.09E-03 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Bacteroides.s_Bacteroides_ovatus 
8.78E-06 8.54E-05 1.73E-03 1.10E-04 1.62E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Bacteroides.s_Bacteroides_uniformis 
8.78E-06 8.54E-05 1.40E-03 1.48E-04 1.25E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bacteroides.s_Bacteroides_uniformis 
8.78E-06 8.54E-05 1.46E-03 1.45E-04 1.31E-03 
PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage|g_Bacteroides.s_Bacteroides_uniformis 
9.06E-06 8.78E-05 1.69E-03 1.44E-04 1.55E-03 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_ovatus 
9.33E-06 8.98E-05 1.93E-03 1.24E-04 1.80E-03 
PWY-4984: urea cycle 9.33E-06 8.98E-05 5.50E-04 7.66E-03 7.11E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_vulgatus 9.72E-06 9.24E-05 1.78E-03 3.83E-04 1.40E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthesis 9.72E-06 9.24E-05 5.42E-03 1.75E-03 3.67E-03 
PWY-5686: UMP biosynthesis 9.72E-06 9.24E-05 4.90E-03 1.06E-02 5.68E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_uniformis 
9.73E-06 9.24E-05 1.45E-03 1.49E-04 1.30E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Bifidobacterium.s_Bifidobacterium_longum 
9.87E-06 9.31E-05 1.02E-03 8.69E-05 9.30E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Bifidobacterium.s_Bifidobacterium_longum 
9.87E-06 9.31E-05 1.02E-03 8.69E-05 9.30E-04 
ANAGLYCOLYSIS-PWY: glycolysis III (from glu-
cose)|g_Bacteroides.s_Bacteroides_ovatus 
1.02E-05 9.44E-05 1.94E-03 2.05E-04 1.74E-03 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Bacteroides.s_Bacteroides_ovatus 
1.02E-05 9.44E-05 1.75E-03 1.66E-04 1.59E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_ovatus 
1.02E-05 9.44E-05 1.99E-03 1.74E-04 1.82E-03 
PWY-7282: 4-amino-2-methyl-5-phosphomethylpyrimidine 
biosynthesis (yeast)|g_Bacteroides.s_Bacteroides_ovatus 
1.02E-05 9.44E-05 2.04E-03 1.60E-04 1.88E-03 
PWY-7323: superpathway of GDP-mannose-derived O-antigen 
building blocks biosynthesis|g_Bacteroides.s_Bacteroides_ovatus 
1.02E-05 9.44E-05 1.89E-03 1.48E-04 1.74E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Bacteroides.s_Bacteroides_vulgatus 
1.03E-05 9.49E-05 1.72E-03 1.83E-04 1.53E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Bifidobacterium.s_Bifidobacterium_longum 
1.04E-05 9.62E-05 9.49E-04 7.10E-05 8.78E-04 




1.07E-05 9.81E-05 1.06E-03 7.87E-05 9.84E-04 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Bacteroides.s_Bacteroides_uniformis 
1.09E-05 9.93E-05 1.38E-03 1.40E-04 1.24E-03 
PWY-6609: adenine and adenosine salvage 
III|g_Bacteroides.s_Bacteroides_caccae 
1.09E-05 9.93E-05 8.80E-04 8.03E-05 8.00E-04 












COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_caccae 
1.15E-05 1.04E-04 8.26E-04 7.41E-05 7.51E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_uniformis 
1.15E-05 1.04E-04 1.47E-03 1.39E-04 1.33E-03 
PWY-5686: UMP biosynthe-
sis|g_Bacteroides.s_Bacteroides_uniformis 
1.15E-05 1.04E-04 1.59E-03 1.76E-04 1.41E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_uniformis 
1.15E-05 1.04E-04 1.47E-03 1.39E-04 1.33E-03 
PWY-6123: inosine-5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
1.24E-05 1.10E-04 1.71E-03 2.00E-04 1.51E-03 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_stercoris 
1.24E-05 1.10E-04 1.69E-03 1.20E-04 1.57E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_caccae 
1.24E-05 1.10E-04 8.24E-04 7.10E-05 7.53E-04 
PWY-4242: pantothenate and coenzyme A biosynthesis 
III|g_Bacteroides.s_Bacteroides_ovatus 
1.24E-05 1.10E-04 1.47E-03 1.22E-04 1.35E-03 
PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage|g_Bacteroides.s_Bacteroides_caccae 
1.24E-05 1.10E-04 8.02E-04 6.79E-05 7.34E-04 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_caccae 
1.24E-05 1.10E-04 8.26E-04 7.65E-05 7.49E-04 
ASPASN-PWY: superpathway of L-aspartate and L-asparagine 
biosynthesis|g_Bacteroides.s_Bacteroides_ovatus 
1.26E-05 1.10E-04 1.76E-03 1.77E-04 1.58E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_ovatus 
1.26E-05 1.10E-04 1.92E-03 1.74E-04 1.74E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bifidobacterium.s_Bifidobacterium_longum 
1.30E-05 1.14E-04 8.99E-04 6.47E-05 8.35E-04 
PWY-621: sucrose degradation III (sucrose invert-
ase)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.36E-05 1.18E-04 7.02E-04 2.07E-03 1.36E-03 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_caccae 1.36E-05 1.18E-04 1.04E-03 2.91E-04 7.45E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Alistipes.s_Alistipes_finegoldii 
1.39E-05 1.19E-04 5.44E-04 7.18E-06 5.36E-04 
HOMOSER-METSYN-PWY: L-methionine biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
1.39E-05 1.19E-04 8.31E-04 2.11E-05 8.10E-04 
PWY-5659: GDP-mannose biosynthe-
sis|g_Alistipes.s_Alistipes_finegoldii 
1.39E-05 1.19E-04 5.79E-04 4.51E-06 5.74E-04 
PWY-7199: pyrimidine deoxyribonucleosides sal-
vage|g_Alistipes.s_Alistipes_finegoldii 
1.39E-05 1.19E-04 5.35E-04 1.06E-05 5.24E-04 
PWY-7371: 1,4-dihydroxy-6-naphthoate biosynthesis 
II|g_Alistipes.s_Alistipes_finegoldii 
1.39E-05 1.19E-04 6.24E-04 8.69E-06 6.15E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_uniformis 
1.53E-05 1.29E-04 1.36E-03 1.81E-04 1.18E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
1.53E-05 1.29E-04 1.89E-03 2.12E-04 1.68E-03 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Bacteroides.s_Bacteroides_caccae 
1.53E-05 1.29E-04 8.26E-04 9.52E-05 7.31E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_ovatus 
1.53E-05 1.29E-04 1.89E-03 2.12E-04 1.68E-03 
PWY-6703: preQ0 biosynthesis|g_Bacteroides.s_Bacteroides_caccae 1.54E-05 1.30E-04 8.86E-04 1.13E-04 7.73E-04 












PWY-6609: adenine and adenosine salvage 
III|g_Bacteroides.s_Bacteroides_ovatus 
1.55E-05 1.30E-04 1.99E-03 2.44E-04 1.75E-03 
PWY-7323: superpathway of GDP-mannose-derived O-antigen 
building blocks biosynthesis 
1.55E-05 1.30E-04 4.71E-03 8.90E-04 3.82E-03 
PWY-6125: superpathway of guanosine nucleotides de novo 
biosynthesis II|g_Bacteroides.s_Bacteroides_vulgatus 
1.56E-05 1.31E-04 1.72E-03 2.03E-04 1.52E-03 
ARGSYNBSUB-PWY: L-arginine biosynthesis II (acetyl 
cycle)|g_Bifidobacterium.s_Bifidobacterium_longum 
1.61E-05 1.32E-04 9.46E-04 1.00E-04 8.46E-04 
UDPNAGSYN-PWY: UDP-N-acetyl-D-glucosamine biosynthesis 
I|g_Bifidobacterium.s_Bifidobacterium_longum 
1.61E-05 1.32E-04 7.57E-04 6.46E-05 6.92E-04 
PWY-6737: starch degradation V|g_Alistipes.s_Alistipes_finegoldii 1.64E-05 1.32E-04 5.95E-04 8.14E-06 5.86E-04 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
1.65E-05 1.32E-04 9.01E-04 6.97E-05 8.31E-04 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_uniformis 
1.66E-05 1.32E-04 1.31E-03 1.24E-04 1.19E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_caccae 
1.66E-05 1.32E-04 8.32E-04 9.02E-05 7.41E-04 
COA-PWY: coenzyme A biosynthesis 
I|g_Bacteroides.s_Bacteroides_xylanisolvens 
1.72E-05 1.32E-04 1.64E-03 2.05E-04 1.44E-03 
PWY-5686: UMP biosynthesis|g_Alistipes.s_Alistipes_finegoldii 1.73E-05 1.32E-04 6.67E-04 8.75E-06 6.59E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
1.73E-05 1.32E-04 8.52E-04 4.17E-05 8.10E-04 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_uniformis 
1.76E-05 1.32E-04 1.27E-03 1.40E-04 1.13E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_caccae 
1.83E-05 1.32E-04 8.57E-04 1.13E-04 7.44E-04 
PWY0-1586: peptidoglycan maturation (meso-diaminopimelate 
containing)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
1.86E-05 1.32E-04 1.95E-04 2.08E-03 1.89E-03 
CITRULBIO-PWY: L-citrulline biosynthesis 1.88E-05 1.32E-04 1.20E-03 7.67E-03 6.47E-03 
PHOSLIPSYN-PWY: superpathway of phospholipid biosynthesis I 
(bacteria) 
1.88E-05 1.32E-04 6.38E-03 1.16E-03 5.22E-03 
PWY4FS-7: phosphatidylglycerol biosynthesis I (plastidic) 1.88E-05 1.32E-04 6.33E-03 1.18E-03 5.15E-03 
PWY4FS-8: phosphatidylglycerol biosynthesis II (non-plastidic) 1.88E-05 1.32E-04 6.33E-03 1.18E-03 5.15E-03 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_fragilis 
1.88E-05 1.32E-04 7.11E-04 0.00E+00 7.11E-04 
HISDEG-PWY: L-histidine degradation I|g_Alistipes.s_Alistipes_shahii 1.88E-05 1.32E-04 0.00E+00 1.47E-03 1.47E-03 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Alistipes.s_Alistipes_putredinis 
1.88E-05 1.32E-04 0.00E+00 2.90E-03 2.90E-03 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.70E-03 1.70E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Alistipes.s_Alistipes_putredinis 
1.88E-05 1.32E-04 0.00E+00 2.05E-03 2.05E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Eubacterium.s_Eubacterium_ventriosum 
1.88E-05 1.32E-04 1.12E-03 0.00E+00 1.12E-03 












PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Paraprevotella.s_Paraprevotella_clara 
1.88E-05 1.32E-04 0.00E+00 2.22E-03 2.22E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Alistipes.s_Alistipes_putredinis 
1.88E-05 1.32E-04 0.00E+00 2.38E-03 2.38E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate contain-
ing)|g_Parabacteroides.s_Parabacteroides_merdae 
1.88E-05 1.32E-04 0.00E+00 1.87E-03 1.87E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Parabacteroides.s_Parabacteroides_distasonis 
1.88E-05 1.32E-04 0.00E+00 1.86E-03 1.86E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.75E-03 1.75E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Parabacteroides.s_Parabacteroides_merdae 
1.88E-05 1.32E-04 0.00E+00 1.88E-03 1.88E-03 
PWY-5686: UMP biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
1.88E-05 1.32E-04 0.00E+00 1.68E-03 1.68E-03 
PWY-5686: UMP biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.98E-03 1.98E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.88E-03 1.88E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Alistipes.s_Alistipes_putredinis 
1.88E-05 1.32E-04 0.00E+00 2.44E-03 2.44E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Parabacteroides.s_Parabacteroides_merdae 
1.88E-05 1.32E-04 0.00E+00 2.10E-03 2.10E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate containing)|g_Alistipes.s_Alistipes_putredinis 
1.88E-05 1.32E-04 0.00E+00 2.45E-03 2.45E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Parabacteroides.s_Parabacteroides_merdae 
1.88E-05 1.32E-04 0.00E+00 2.13E-03 2.13E-03 
PWY-6700: queuosine biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
1.88E-05 1.32E-04 0.00E+00 2.39E-03 2.39E-03 
PWY-6700: queuosine biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.60E-03 1.60E-03 
PWY-6737: starch degradation 
V|g_Catenibacterium.s_Catenibacterium_mitsuokai 
1.88E-05 1.32E-04 0.00E+00 5.76E-04 5.76E-04 
PWY-6737: starch degradation 
V|g_Coprococcus.s_Coprococcus_comes 
1.88E-05 1.32E-04 0.00E+00 1.46E-03 1.46E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Catenibacterium.s_Catenibacterium_mitsuokai 
1.88E-05 1.32E-04 0.00E+00 5.13E-04 5.13E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Parabacteroides.s_Parabacteroides_distasonis 
1.88E-05 1.32E-04 0.00E+00 1.68E-03 1.68E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Paraprevotella.s_Paraprevotella_clara 
1.88E-05 1.32E-04 0.00E+00 1.55E-03 1.55E-03 




1.88E-05 1.32E-04 0.00E+00 2.03E-03 2.03E-03 












PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.88E-05 1.32E-04 0.00E+00 7.73E-04 7.73E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_putredinis 
1.88E-05 1.32E-04 0.00E+00 1.80E-03 1.80E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 2.11E-03 2.11E-03 
PWY-7228: superpathway of guanosine nucleotides de novo 
biosynthesis I|g_Bacteroides.s_Bacteroides_massiliensis 
1.88E-05 1.32E-04 0.00E+00 1.87E-03 1.87E-03 
PWY-7237: myo-, chiro- and scillo-inositol degrada-
tion|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1
_63FAA 
1.88E-05 1.32E-04 1.00E-03 0.00E+00 1.00E-03 
PWY-724: superpathway of L-lysine, L-threonine and L-methionine 
biosynthesis 
II|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.79E-03 1.79E-03 
PWY-7357: thiamin formation from pyrithiamine and oxythiamine 
(yeast)|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatut
ens 
1.88E-05 1.32E-04 0.00E+00 1.70E-03 1.70E-03 
PWY-7560: methylerythritol phosphate pathway 
II|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.63E-03 1.63E-03 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Bacteroides.s_Bacteroides_fragilis 
1.88E-05 1.32E-04 7.24E-04 0.00E+00 7.24E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Parabacteroides.s_Parabacteroides_merdae 
1.88E-05 1.32E-04 0.00E+00 1.88E-03 1.88E-03 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Eubacterium.s_Eubacterium_ventriosum 
1.88E-05 1.32E-04 1.30E-03 0.00E+00 1.30E-03 




1.88E-05 1.32E-04 0.00E+00 1.73E-03 1.73E-03 
THRESYN-PWY: superpathway of L-threonine biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.73E-03 1.73E-03 
TRPSYN-PWY: L-tryptophan biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.88E-05 1.32E-04 0.00E+00 1.53E-03 1.53E-03 
UNINTEGRATED|g_Catenibacterium.s_Catenibacterium_mitsuokai 1.88E-05 1.32E-04 0.00E+00 6.25E-04 6.25E-04 
UNINTEGRAT-
ED|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.88E-05 1.32E-04 0.00E+00 7.88E-04 7.88E-04 
UNINTEGRATED|g_Ruminococcus.s_Ruminococcus_lactaris 1.88E-05 1.32E-04 0.00E+00 1.11E-03 1.11E-03 
UNINTEGRATED|g_Veillonella.s_Veillonella_parvula 1.88E-05 1.32E-04 5.98E-04 0.00E+00 5.98E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Catenibacterium.s_Catenibacterium_mitsuokai 
1.88E-05 1.32E-04 0.00E+00 5.13E-04 5.13E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
1.88E-05 1.32E-04 0.00E+00 1.68E-03 1.68E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Paraprevotella.s_Paraprevotella_clara 
1.88E-05 1.32E-04 0.00E+00 1.55E-03 1.55E-03 












FUC-RHAMCAT-PWY: superpathway of fucose and rhamnose 
degradation 
1.88E-05 1.32E-04 3.23E-03 0.00E+00 3.23E-03 
P162-PWY: L-glutamate degradation V (via hydroxyglutarate) 1.88E-05 1.32E-04 2.54E-03 0.00E+00 2.54E-03 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Bacteroides.s_Bacteroides_ovatus 
1.92E-05 1.34E-04 1.70E-03 2.52E-04 1.45E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Alistipes.s_Alistipes_finegoldii 
2.03E-05 1.41E-04 6.67E-04 1.10E-05 6.56E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Alistipes.s_Alistipes_finegoldii 
2.03E-05 1.41E-04 5.44E-04 9.80E-06 5.34E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Alistipes.s_Alistipes_finegoldii 
2.03E-05 1.41E-04 5.54E-04 9.62E-06 5.44E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Alistipes.s_Alistipes_finegoldii 
2.03E-05 1.41E-04 5.54E-04 9.62E-06 5.44E-04 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_caccae 
2.12E-05 1.46E-04 8.06E-04 7.69E-05 7.29E-04 
UNINTEGRATED|g_Bifidobacterium.s_Bifidobacterium_longum 2.12E-05 1.46E-04 1.11E-03 1.47E-04 9.63E-04 
PWY-5686: UMP biosynthesis|g_Bacteroides.s_Bacteroides_caccae 2.25E-05 1.54E-04 8.13E-04 1.08E-04 7.05E-04 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_ovatus 
2.31E-05 1.58E-04 1.85E-03 2.17E-04 1.63E-03 
ILEUSYN-PWY: L-isoleucine biosynthesis I (from threo-
nine)|g_Bifidobacterium.s_Bifidobacterium_longum 
2.32E-05 1.58E-04 1.08E-03 1.16E-04 9.65E-04 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_caccae 
2.34E-05 1.59E-04 9.41E-04 1.17E-04 8.24E-04 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Bacteroides.s_Bacteroides_vulgatus 
2.34E-05 1.59E-04 1.80E-03 2.31E-04 1.57E-03 
COBALSYN-PWY: adenosylcobalamin salvage from cobinamide 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
2.36E-05 1.60E-04 3.66E-04 2.18E-03 1.82E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_ovatus 
2.36E-05 1.60E-04 2.11E-03 2.29E-04 1.88E-03 
ARGSYN-PWY: L-arginine biosynthesis I (via L-
ornithine)|g_Bifidobacterium.s_Bifidobacterium_longum 
2.46E-05 1.66E-04 9.62E-04 1.03E-04 8.60E-04 
PWY-7400: L-arginine biosynthesis IV (archaebacte-
ria)|g_Bifidobacterium.s_Bifidobacterium_longum 
2.46E-05 1.66E-04 9.64E-04 1.02E-04 8.62E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Alistipes.s_Alistipes_finegoldii 
2.52E-05 1.69E-04 6.19E-04 1.13E-05 6.07E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_finegoldii 
2.52E-05 1.69E-04 5.39E-04 1.29E-05 5.26E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Alistipes.s_Alistipes_finegoldii 
2.52E-05 1.69E-04 6.19E-04 1.13E-05 6.07E-04 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Bacteroides.s_Bacteroides_ovatus 
2.53E-05 1.69E-04 1.93E-03 3.92E-04 1.54E-03 
HSERMETANA-PWY: L-methionine biosynthesis III 2.53E-05 1.69E-04 2.22E-03 7.66E-03 5.45E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_caccae 
2.65E-05 1.75E-04 8.69E-04 1.26E-04 7.42E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_caccae 
2.65E-05 1.75E-04 8.84E-04 1.05E-04 7.79E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_caccae 
2.65E-05 1.75E-04 8.84E-04 1.05E-04 7.79E-04 












PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Bifidobacterium.s_Bifidobacterium_longum 
2.85E-05 1.88E-04 1.07E-03 1.28E-04 9.43E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
2.89E-05 1.90E-04 3.89E-04 2.18E-03 1.79E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_finegoldii 
3.12E-05 2.05E-04 5.84E-04 1.61E-05 5.68E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_
63FAA 
3.13E-05 2.05E-04 1.00E-03 8.95E-05 9.15E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Bifidobacterium.s_Bifidobacterium_longum 
3.21E-05 2.09E-04 1.08E-03 1.41E-04 9.40E-04 
P161-PWY: acetylene degradation 3.33E-05 2.17E-04 2.20E-03 1.24E-04 2.07E-03 
PWY-5484: glycolysis II (from fructose 6-phosphate) 3.40E-05 2.20E-04 5.77E-03 2.08E-03 3.68E-03 
UNMAPPED 3.40E-05 2.20E-04 5.48E-03 1.69E-02 1.14E-02 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_caccae 
3.46E-05 2.24E-04 8.55E-04 1.42E-04 7.13E-04 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Bacteroides.s_Bacteroides_caccae 
4.12E-05 2.66E-04 8.67E-04 1.18E-04 7.49E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_dorei 
4.22E-05 2.71E-04 8.42E-05 1.97E-03 1.88E-03 
PWY-6936: seleno-amino acid biosynthe-
sis|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_
63FAA 
4.23E-05 2.71E-04 8.57E-04 1.62E-05 8.41E-04 
PYRIDNUCSYN-PWY: NAD biosynthesis I (from aspar-
tate)|g_Alistipes.s_Alistipes_finegoldii 
4.23E-05 2.71E-04 6.16E-04 8.53E-06 6.07E-04 
COA-PWY: coenzyme A biosynthesis 
I|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
4.28E-05 2.74E-04 3.40E-04 2.19E-03 1.85E-03 
UNINTEGRATED|g_Dorea.s_Dorea_longicatena 4.53E-05 2.88E-04 5.78E-04 1.46E-03 8.79E-04 
PWY-5097: L-lysine biosynthesis VI 4.53E-05 2.88E-04 5.17E-03 1.07E-02 5.50E-03 
PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage 
4.53E-05 2.88E-04 5.78E-03 2.49E-03 3.29E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bifidobacterium.s_Bifidobacterium_longum 
4.58E-05 2.90E-04 1.04E-03 1.18E-04 9.20E-04 




4.74E-05 3.00E-04 9.95E-04 1.41E-04 8.54E-04 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_ovatus 
5.02E-05 3.16E-04 1.64E-03 2.13E-04 1.43E-03 
PWY-6703: preQ0 biosynthesis|g_Bacteroides.s_Bacteroides_ovatus 5.02E-05 3.16E-04 1.39E-03 2.26E-04 1.17E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_caccae 
5.22E-05 3.25E-04 8.60E-04 1.74E-04 6.86E-04 
ARO-PWY: chorismate biosynthesis 
I|g_Alistipes.s_Alistipes_finegoldii 
5.24E-05 3.25E-04 5.75E-04 6.34E-06 5.69E-04 
PWY-6163: chorismate biosynthesis from 3-
dehydroquinate|g_Alistipes.s_Alistipes_finegoldii 
5.24E-05 3.25E-04 5.57E-04 5.60E-06 5.51E-04 
UNINTEGRATED|g_Alistipes.s_Alistipes_finegoldii 5.25E-05 3.25E-04 6.58E-04 3.03E-05 6.28E-04 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_vulgatus 
5.26E-05 3.25E-04 1.73E-03 2.44E-04 1.49E-03 












PWY-4242: pantothenate and coenzyme A biosynthesis 
III|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
5.61E-05 3.25E-04 8.22E-05 2.05E-03 1.97E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
5.82E-05 3.25E-04 7.41E-04 9.12E-05 6.50E-04 
PWY-7371: 1,4-dihydroxy-6-naphthoate biosynthesis II 5.84E-05 3.25E-04 1.63E-03 1.14E-04 1.52E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_massiliensis 
5.96E-05 3.25E-04 0.00E+00 1.77E-03 1.77E-03 
ARO-PWY: chorismate biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.96E-05 3.25E-04 0.00E+00 1.76E-03 1.76E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Alistipes.s_Alistipes_putredinis 
5.96E-05 3.25E-04 0.00E+00 1.90E-03 1.90E-03 
COA-PWY: coenzyme A biosynthesis 
I|g_Eubacterium.s_Eubacterium_ventriosum 
5.96E-05 3.25E-04 9.11E-04 0.00E+00 9.11E-04 
COBALSYN-PWY: adenosylcobalamin salvage from cobinamide 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.96E-05 3.25E-04 0.00E+00 1.97E-03 1.97E-03 
COMPLETE-ARO-PWY: superpathway of aromatic amino acid 
biosynthe-
sis|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.96E-05 3.25E-04 0.00E+00 1.77E-03 1.77E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Alistipes.s_Alistipes_shahii 
5.96E-05 3.25E-04 0.00E+00 1.95E-03 1.95E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_dorei 
5.96E-05 3.25E-04 0.00E+00 1.92E-03 1.92E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Parabacteroides.s_Parabacteroides_distasonis 
5.96E-05 3.25E-04 0.00E+00 1.31E-03 1.31E-03 
PANTOSYN-PWY: pantothenate and coenzyme A biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.96E-05 3.25E-04 0.00E+00 2.01E-03 2.01E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 8.75E-04 0.00E+00 8.75E-04 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate contain-
ing)|g_Eubacterium.s_Eubacterium_ventriosum 
5.96E-05 3.25E-04 1.13E-03 0.00E+00 1.13E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 1.85E-03 1.85E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 8.36E-04 0.00E+00 8.36E-04 
PWY-3841: folate transformations 
II|g_Parabacteroides.s_Parabacteroides_distasonis 
5.96E-05 3.25E-04 0.00E+00 1.54E-03 1.54E-03 
PWY-4041: &gamma;-glutamyl cy-
cle|g_Escherichia.s_Escherichia_coli 
5.96E-05 3.25E-04 5.92E-04 0.00E+00 5.92E-04 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 7.49E-04 0.00E+00 7.49E-04 
PWY-5097: L-lysine biosynthesis 
VI|g_Parabacteroides.s_Parabacteroides_distasonis 
5.96E-05 3.25E-04 0.00E+00 1.39E-03 1.39E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 1.87E-03 1.87E-03 
PWY-5188: tetrapyrrole biosynthesis I (from gluta-
mate)|g_Ruminococcus.s_Ruminococcus_callidus 
5.96E-05 3.25E-04 0.00E+00 1.99E-03 1.99E-03 












PWY-5659: GDP-mannose biosynthesis|g_Alistipes.s_Alistipes_shahii 5.96E-05 3.25E-04 0.00E+00 1.59E-03 1.59E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 1.94E-03 1.94E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 4.52E-04 0.00E+00 4.52E-04 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Parabacteroides.s_Parabacteroides_distasonis 
5.96E-05 3.25E-04 0.00E+00 1.02E-03 1.02E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
5.96E-05 3.25E-04 0.00E+00 1.79E-03 1.79E-03 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 9.45E-04 0.00E+00 9.45E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
5.96E-05 3.25E-04 0.00E+00 7.09E-04 7.09E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Eubacterium.s_Eubacterium_ventriosum 
5.96E-05 3.25E-04 1.05E-03 0.00E+00 1.05E-03 




5.96E-05 3.25E-04 0.00E+00 1.77E-03 1.77E-03 
PWY-6270: isoprene biosynthesis 
I|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
5.96E-05 3.25E-04 0.00E+00 1.61E-03 1.61E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
5.96E-05 3.25E-04 0.00E+00 1.79E-03 1.79E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 1.61E-03 1.61E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 9.60E-04 0.00E+00 9.60E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Eubacterium.s_Eubacterium_ventriosum 
5.96E-05 3.25E-04 1.19E-03 0.00E+00 1.19E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 1.57E-03 1.57E-03 
PWY-6609: adenine and adenosine salvage 
III|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 6.49E-04 0.00E+00 6.49E-04 
PWY-6703: preQ0 biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
5.96E-05 3.25E-04 0.00E+00 2.22E-03 2.22E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_merdae 
5.96E-05 3.25E-04 0.00E+00 1.09E-03 1.09E-03 
PWY-6737: starch degradation V|g_Blautia.s_Ruminococcus_gnavus 5.96E-05 3.25E-04 1.02E-03 0.00E+00 1.02E-03 
PWY-6737: starch degradation 
V|g_Eubacterium.s_Eubacterium_ventriosum 
5.96E-05 3.25E-04 9.22E-04 0.00E+00 9.22E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Coprococcus.s_Coprococcus_comes 
5.96E-05 3.25E-04 0.00E+00 9.71E-04 9.71E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Eubacterium.s_Eubacterium_ventriosum 
5.96E-05 3.25E-04 9.15E-04 0.00E+00 9.15E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Blautia.s_Ruminococcus_gnavus 
5.96E-05 3.25E-04 7.62E-04 0.00E+00 7.62E-04 












PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Catenibacterium.s_Catenibacterium_mitsuokai 
5.96E-05 3.25E-04 0.00E+00 6.03E-04 6.03E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Coprococcus.s_Coprococcus_comes 
5.96E-05 3.25E-04 0.00E+00 9.57E-04 9.57E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Fusobacterium.s_Fusobacterium_varium 
5.96E-05 3.25E-04 5.08E-04 0.00E+00 5.08E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
5.96E-05 3.25E-04 0.00E+00 1.25E-03 1.25E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_fragilis 
5.96E-05 3.25E-04 7.17E-04 0.00E+00 7.17E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 2.33E-03 2.33E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_callidus 
5.96E-05 3.25E-04 0.00E+00 1.58E-03 1.58E-03 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Blautia.s_Ruminococcus_gnavus 
5.96E-05 3.25E-04 8.09E-04 0.00E+00 8.09E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Paraprevotella.s_Paraprevotella_clara 
5.96E-05 3.25E-04 0.00E+00 1.94E-03 1.94E-03 
UNINTEGRATED|g_Barnesiella.s_Barnesiella_intestinihominis 5.96E-05 3.25E-04 0.00E+00 1.42E-03 1.42E-03 
UNINTEGRATED|g_Fusobacterium.s_Fusobacterium_varium 5.96E-05 3.25E-04 4.69E-04 0.00E+00 4.69E-04 
GLYCOLYSIS-TCA-GLYOX-BYPASS: superpathway of glycolysis, 
pyruvate dehydrogenase, TCA, and glyoxylate bypass 
5.96E-05 3.25E-04 1.67E-03 0.00E+00 1.67E-03 
PWY-4041: &gamma;-glutamyl cycle 5.96E-05 3.25E-04 1.74E-03 0.00E+00 1.74E-03 
TCA-GLYOX-BYPASS: superpathway of glyoxylate bypass and TCA 5.96E-05 3.25E-04 1.60E-03 0.00E+00 1.60E-03 
PWY-6527: stachyose degradation|g_Dorea.s_Dorea_longicatena 5.97E-05 3.25E-04 3.65E-04 1.14E-03 7.78E-04 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_ovatus 5.97E-05 3.25E-04 2.07E-03 6.48E-04 1.42E-03 
ANAEROFRUCAT-PWY: homolactic fermentation 5.97E-05 3.25E-04 6.62E-03 3.48E-03 3.14E-03 
GLYCOLYSIS: glycolysis I (from glucose 6-phosphate) 5.97E-05 3.25E-04 5.79E-03 2.17E-03 3.61E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis I 5.97E-05 3.25E-04 5.48E-03 7.98E-03 2.50E-03 
PWY-6317: galactose degradation I (Leloir pathway) 5.97E-05 3.25E-04 3.73E-03 6.42E-03 2.68E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Bacteroides.s_Bacteroides_uniformis 
6.40E-05 3.47E-04 1.50E-03 2.04E-04 1.30E-03 
NONOXIPENT-PWY: pentose phosphate pathway (non-oxidative 
branch)|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_
5_1_63FAA 
7.12E-05 3.85E-04 9.81E-04 1.36E-04 8.44E-04 
PWY-6737: starch degradation 
V|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
7.12E-05 3.85E-04 1.16E-03 1.42E-04 1.02E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Bacteroides.s_Bacteroides_caccae 
7.42E-05 4.00E-04 9.60E-04 1.69E-04 7.92E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Bacteroides.s_Bacteroides_caccae 
7.75E-05 4.16E-04 8.69E-04 1.91E-04 6.78E-04 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Bacteroides.s_Bacteroides_caccae 
7.75E-05 4.16E-04 8.17E-04 1.75E-04 6.42E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Bacteroides.s_Bacteroides_caccae 
7.75E-05 4.16E-04 8.69E-04 1.91E-04 6.78E-04 














7.82E-05 4.18E-04 8.06E-04 1.15E-04 6.92E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_caccae 
7.82E-05 4.18E-04 9.63E-04 3.00E-04 6.63E-04 
DENOVOPURINE2-PWY: superpathway of purine nucleotides de 
novo biosynthesis II 
7.90E-05 4.21E-04 7.24E-04 6.41E-03 5.69E-03 
PWY-7539: 6-hydroxymethyl-dihydropterin diphosphate biosynthesis 
III (Chlamydia)|g_Bacteroides.s_Bacteroides_xylanisolvens 
8.29E-05 4.41E-04 1.05E-03 1.32E-04 9.21E-04 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_thetaiotaomicron 8.36E-05 4.44E-04 2.91E-04 2.52E-03 2.23E-03 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1
_63FAA 
8.77E-05 4.65E-04 1.22E-03 1.48E-04 1.08E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_caccae 
9.32E-05 4.93E-04 8.28E-04 1.62E-04 6.67E-04 
COBALSYN-PWY: adenosylcobalamin salvage from cobinamide I 1.01E-04 5.35E-04 3.52E-03 6.54E-03 3.01E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthesis 1.01E-04 5.35E-04 5.10E-03 1.05E-02 5.35E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Alistipes.s_Alistipes_finegoldii 
1.05E-04 5.48E-04 5.70E-04 1.17E-05 5.59E-04 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Alistipes.s_Alistipes_finegoldii 
1.05E-04 5.48E-04 5.77E-04 1.18E-05 5.65E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate containing)|g_Alistipes.s_Alistipes_finegoldii 
1.05E-04 5.48E-04 5.61E-04 1.09E-05 5.50E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Roseburia.s_Roseburia_inulinivorans 
1.05E-04 5.48E-04 5.10E-04 1.50E-05 4.95E-04 
PWY-621: sucrose degradation III (sucrose invert-
ase)|g_Eubacterium.s_Eubacterium_rectale 




1.06E-04 5.52E-04 1.13E-03 1.92E-04 9.36E-04 
PWY-7187: pyrimidine deoxyribonucleotides de novo biosynthesis II 1.16E-04 6.02E-04 8.19E-04 5.97E-03 5.15E-03 
PWY0-1586: peptidoglycan maturation (meso-diaminopimelate 
containing)|g_Escherichia.s_Escherichia_coli 
1.20E-04 6.23E-04 5.39E-04 2.67E-06 5.37E-04 
UNINTEGRATED|g_Escherichia.s_Escherichia_coli 1.20E-04 6.23E-04 4.55E-04 1.77E-06 4.53E-04 
GLYOXYLATE-BYPASS: glyoxylate cycle 1.20E-04 6.23E-04 1.79E-03 3.73E-05 1.75E-03 
P461-PWY: hexitol fermentation to lactate, formate, ethanol and 
acetate 
1.23E-04 6.38E-04 3.80E-03 7.51E-04 3.05E-03 
P441-PWY: superpathway of N-acetylneuraminate degradation 1.27E-04 6.55E-04 3.53E-03 7.65E-04 2.77E-03 
METSYN-PWY: L-homoserine and L-methionine biosynthesis 1.31E-04 6.72E-04 2.11E-03 4.63E-03 2.51E-03 
PWY66-422: D-galactose degradation V (Leloir pathway) 1.31E-04 6.72E-04 3.75E-03 6.45E-03 2.70E-03 
PWY-1269: CMP-3-deoxy-D-manno-octulosonate biosynthesis 
I|g_Bacteroides.s_Bacteroides_caccae 
1.47E-04 7.51E-04 7.42E-04 1.66E-04 5.76E-04 
PWY4LZ-257: superpathway of fermentation (Chlamydomonas 
reinhardtii) 
1.48E-04 7.56E-04 2.96E-03 2.67E-04 2.69E-03 












BRANCHED-CHAIN-AA-SYN-PWY: superpathway of branched amino 
acid biosynthesis|g_Bifidobacterium.s_Bifidobacterium_longum 
1.50E-04 7.63E-04 8.90E-04 9.35E-05 7.96E-04 
PWY-5103: L-isoleucine biosynthesis 
III|g_Bifidobacterium.s_Bifidobacterium_longum 
1.50E-04 7.63E-04 8.80E-04 9.19E-05 7.88E-04 




1.56E-04 7.94E-04 7.97E-04 6.66E-05 7.30E-04 
PWY-5100: pyruvate fermentation to acetate and lactate 
II|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 




1.59E-04 8.05E-04 1.35E-03 2.04E-04 1.14E-03 
PWY-2942: L-lysine biosynthesis III 1.67E-04 8.11E-04 5.20E-03 1.06E-02 5.38E-03 
PWY-5347: superpathway of L-methionine biosynthesis 
(transsulfuration) 
1.67E-04 8.11E-04 2.41E-03 4.96E-03 2.55E-03 
ASPASN-PWY: superpathway of L-aspartate and L-asparagine 
biosynthesis|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 3.93E-04 0.00E+00 3.93E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bifidobacterium.s_Bifidobacterium_bifidum 
1.75E-04 8.11E-04 5.11E-04 0.00E+00 5.11E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Eubacterium.s_Eubacterium_ventriosum 
1.75E-04 8.11E-04 9.58E-04 0.00E+00 9.58E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Paraprevotella.s_Paraprevotella_clara 
1.75E-04 8.11E-04 0.00E+00 1.39E-03 1.39E-03 
GALACTUROCAT-PWY: D-galacturonate degradation 
I|g_Alistipes.s_Alistipes_shahii 
1.75E-04 8.11E-04 0.00E+00 9.30E-04 9.30E-04 
GLYCOGENSYNTH-PWY: glycogen biosynthesis I (from ADP-D-
Glucose)|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.75E-04 8.11E-04 0.00E+00 7.22E-04 7.22E-04 
GLYOXYLATE-BYPASS: glyoxylate cy-
cle|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 4.78E-04 0.00E+00 4.78E-04 
HISDEG-PWY: L-histidine degradation 
I|g_Fusobacterium.s_Fusobacterium_varium 
1.75E-04 8.11E-04 3.89E-04 0.00E+00 3.89E-04 




1.75E-04 8.11E-04 0.00E+00 1.46E-03 1.46E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
1.75E-04 8.11E-04 0.00E+00 1.94E-03 1.94E-03 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_dorei 
1.75E-04 8.11E-04 0.00E+00 1.34E-03 1.34E-03 
PWY-4242: pantothenate and coenzyme A biosynthesis 
III|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.75E-04 8.11E-04 0.00E+00 1.33E-03 1.33E-03 
PWY-5100: pyruvate fermentation to acetate and lactate 
II|g_Eubacterium.s_Eubacterium_ventriosum 
1.75E-04 8.11E-04 8.92E-04 0.00E+00 8.92E-04 
PWY-5173: superpathway of acetyl-CoA biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 6.19E-04 0.00E+00 6.19E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Coprococcus.s_Coprococcus_comes 
1.75E-04 8.11E-04 0.00E+00 1.13E-03 1.13E-03 












PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Eubacterium.s_Eubacterium_ventriosum 
1.75E-04 8.11E-04 1.24E-03 0.00E+00 1.24E-03 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Roseburia.s_Roseburia_inulinivorans 
1.75E-04 8.11E-04 5.51E-04 0.00E+00 5.51E-04 
PWY-5686: UMP biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
1.75E-04 8.11E-04 0.00E+00 1.43E-03 1.43E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 4.08E-04 0.00E+00 4.08E-04 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Roseburia.s_Roseburia_inulinivorans 
1.75E-04 8.11E-04 8.08E-04 0.00E+00 8.08E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Eubacterium.s_Eubacterium_ventriosum 
1.75E-04 8.11E-04 9.75E-04 0.00E+00 9.75E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.75E-04 8.11E-04 0.00E+00 7.65E-04 7.65E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Fusobacterium.s_Fusobacterium_varium 
1.75E-04 8.11E-04 3.89E-04 0.00E+00 3.89E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Ruminococcus.s_Ruminococcus_callidus 
1.75E-04 8.11E-04 0.00E+00 1.65E-03 1.65E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Paraprevotella.s_Paraprevotella_clara 
1.75E-04 8.11E-04 0.00E+00 1.34E-03 1.34E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Ruminococcus.s_Ruminococcus_callidus 
1.75E-04 8.11E-04 0.00E+00 1.34E-03 1.34E-03 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.75E-04 8.11E-04 0.00E+00 7.65E-04 7.65E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Fusobacterium.s_Fusobacterium_varium 
1.75E-04 8.11E-04 3.89E-04 0.00E+00 3.89E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Ruminococcus.s_Ruminococcus_callidus 
1.75E-04 8.11E-04 0.00E+00 1.65E-03 1.65E-03 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatutens 
1.75E-04 8.11E-04 0.00E+00 1.96E-03 1.96E-03 





1.75E-04 8.11E-04 0.00E+00 1.48E-03 1.48E-03 
PWY-6700: queuosine biosynthe-
sis|g_Bacteroides.s_Bacteroides_fragilis 
1.75E-04 8.11E-04 8.56E-04 0.00E+00 8.56E-04 
PWY-6700: queuosine biosynthe-
sis|g_Paraprevotella.s_Paraprevotella_clara 
1.75E-04 8.11E-04 0.00E+00 1.05E-03 1.05E-03 
PWY-6703: preQ0 biosynthesis|g_Bacteroides.s_Bacteroides_dorei 1.75E-04 8.11E-04 0.00E+00 2.71E-03 2.71E-03 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Blautia.s_Ruminococcus_gnavus 
1.75E-04 8.11E-04 8.82E-04 0.00E+00 8.82E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 4.98E-04 0.00E+00 4.98E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Ruminococcus.s_Ruminococcus_lactaris 
1.75E-04 8.11E-04 0.00E+00 6.80E-04 6.80E-04 
PWY-7197: pyrimidine deoxyribonucleotide phosphoryla-
tion|g_Phascolarctobacterium.s_Phascolarctobacterium_succinatuten
s 
1.75E-04 8.11E-04 0.00E+00 1.89E-03 1.89E-03 












PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Veillonella.s_Veillonella_parvula 
1.75E-04 8.11E-04 6.39E-04 0.00E+00 6.39E-04 
PWY0-1061: superpathway of L-alanine biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 5.28E-04 0.00E+00 5.28E-04 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Eubacterium.s_Eubacterium_ventriosum 
1.75E-04 8.11E-04 9.98E-04 0.00E+00 9.98E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Coprococcus.s_Coprococcus_comes 
1.75E-04 8.11E-04 0.00E+00 1.13E-03 1.13E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Eubacterium.s_Eubacterium_ventriosum 
1.75E-04 8.11E-04 1.24E-03 0.00E+00 1.24E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Roseburia.s_Roseburia_inulinivorans 
1.75E-04 8.11E-04 5.51E-04 0.00E+00 5.51E-04 
PWY66-422: D-galactose degradation V (Leloir path-
way)|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.75E-04 8.11E-04 0.00E+00 6.25E-04 6.25E-04 
PYRIDNUCSYN-PWY: NAD biosynthesis I (from aspar-
tate)|g_Alistipes.s_Alistipes_shahii 
1.75E-04 8.11E-04 0.00E+00 1.22E-03 1.22E-03 
THRESYN-PWY: superpathway of L-threonine biosynthe-
sis|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.75E-04 8.11E-04 0.00E+00 7.06E-04 7.06E-04 
UDPNAGSYN-PWY: UDP-N-acetyl-D-glucosamine biosynthesis 
I|g_Escherichia.s_Escherichia_coli 
1.75E-04 8.11E-04 5.54E-04 0.00E+00 5.54E-04 
UNINTEGRATED|g_Alistipes.s_Alistipes_indistinctus 1.75E-04 8.11E-04 0.00E+00 1.15E-03 1.15E-03 
UNINTEGRATED|g_Clostridium.s_Clostridium_bolteae 1.75E-04 8.11E-04 8.22E-04 0.00E+00 8.22E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Coprococcus.s_Coprococcus_comes 
1.75E-04 8.11E-04 0.00E+00 7.99E-04 7.99E-04 
PWY-6630: superpathway of L-tyrosine biosynthesis 1.75E-04 8.11E-04 1.72E-03 0.00E+00 1.72E-03 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_uniformis 
1.94E-04 8.94E-04 1.49E-03 3.48E-04 1.15E-03 
HEXITOLDEGSUPER-PWY: superpathway of hexitol degradation 
(bacteria) 
1.94E-04 8.94E-04 4.54E-03 1.53E-03 3.01E-03 
COLANSYN-PWY: colanic acid building blocks biosynthesis 1.96E-04 9.03E-04 6.77E-03 2.33E-03 4.44E-03 
PWY0-1298: superpathway of pyrimidine deoxyribonucleosides 
degradation 
2.28E-04 1.05E-03 4.02E-03 1.18E-03 2.84E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_uniformis 
2.37E-04 1.09E-03 1.47E-03 4.02E-04 1.07E-03 
HOMOSER-METSYN-PWY: L-methionine biosynthesis I 2.69E-04 1.23E-03 1.92E-03 4.29E-03 2.37E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
2.76E-04 1.26E-03 9.35E-04 1.83E-04 7.52E-04 
PENTOSE-P-PWY: pentose phosphate pathway 2.81E-04 1.28E-03 5.18E-03 2.09E-03 3.09E-03 
PWY-5690: TCA cycle II (plants and fungi) 2.90E-04 1.32E-03 9.51E-04 6.18E-03 5.23E-03 
PWY0-1297: superpathway of purine deoxyribonucleosides 
degradation 
3.21E-04 1.46E-03 3.61E-03 8.18E-04 2.80E-03 
UNINTEGRATED|g_Eubacterium.s_Eubacterium_eligens 3.22E-04 1.46E-03 3.34E-04 3.74E-03 3.40E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_dorei 
3.24E-04 1.47E-03 1.93E-05 1.08E-03 1.06E-03 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Bifidobacterium.s_Bifidobacterium_longum 
3.30E-04 1.49E-03 6.50E-04 5.22E-05 5.98E-04 












PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_uniformis 
3.36E-04 1.52E-03 1.48E-03 3.69E-04 1.11E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Faecalibacterium.s_Faecalibacterium_prausnitzii 
3.38E-04 1.52E-03 5.43E-04 2.12E-03 1.58E-03 
PWY-6151: S-adenosyl-L-methionine cycle I 3.38E-04 1.52E-03 5.16E-03 9.73E-03 4.57E-03 
PYRIDNUCSYN-PWY: NAD biosynthesis I (from aspartate) 3.38E-04 1.52E-03 3.88E-03 7.60E-03 3.71E-03 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_uniformis 




3.39E-04 1.52E-03 1.09E-03 1.70E-04 9.16E-04 
TCA: TCA cycle I (prokaryotic) 3.63E-04 1.62E-03 1.46E-03 6.46E-03 5.00E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_dorei 
3.92E-04 1.75E-03 8.14E-06 1.14E-03 1.13E-03 
FERMENTATION-PWY: mixed acid fermentation 3.92E-04 1.75E-03 1.72E-03 2.79E-05 1.69E-03 
PWY-6628: superpathway of L-phenylalanine biosynthesis 3.92E-04 1.75E-03 1.91E-03 2.53E-05 1.88E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_xylanisolvens 
4.01E-04 1.78E-03 9.53E-04 8.19E-05 8.71E-04 
PWY-6609: adenine and adenosine salvage 
III|g_Bacteroides.s_Bacteroides_xylanisolvens 
4.01E-04 1.78E-03 1.06E-03 9.83E-05 9.59E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
4.08E-04 1.81E-03 1.21E-03 2.31E-04 9.77E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
4.08E-04 1.81E-03 1.21E-03 2.31E-04 9.77E-04 
GLUCUROCAT-PWY: superpathway of &beta;-D-glucuronide and D-
glucuronate degradation 
4.21E-04 1.86E-03 4.28E-03 7.88E-03 3.60E-03 
PWY-6527: stachyose degradation 4.21E-04 1.86E-03 3.93E-03 6.27E-03 2.34E-03 
PWY66-400: glycolysis VI (metazoan) 4.21E-04 1.86E-03 3.77E-03 1.48E-03 2.28E-03 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Roseburia.s_Roseburia_inulinivorans 
4.74E-04 1.99E-03 9.49E-04 6.52E-05 8.84E-04 
RIBOSYN2-PWY: flavin biosynthesis I (bacteria and plants) 4.76E-04 1.99E-03 4.18E-03 1.66E-03 2.52E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.03E-03 1.03E-03 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Parabacteroides.s_Parabacteroides_merdae 
4.83E-04 1.99E-03 0.00E+00 7.96E-04 7.96E-04 
ARO-PWY: chorismate biosynthesis 
I|g_Roseburia.s_Roseburia_inulinivorans 
4.83E-04 1.99E-03 5.72E-04 0.00E+00 5.72E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Parabacteroides.s_Parabacteroides_merdae 
4.83E-04 1.99E-03 0.00E+00 1.27E-03 1.27E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
4.83E-04 1.99E-03 0.00E+00 5.16E-04 5.16E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Escherichia.s_Escherichia_coli 
4.83E-04 1.99E-03 5.43E-04 0.00E+00 5.43E-04 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate contain-
ing)|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.13E-03 1.13E-03 












PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Paraprevotella.s_Paraprevotella_clara 
4.83E-04 1.99E-03 0.00E+00 1.43E-03 1.43E-03 
PWY-1269: CMP-3-deoxy-D-manno-octulosonate biosynthesis 
I|g_Alistipes.s_Alistipes_shahii 
4.83E-04 1.99E-03 0.00E+00 1.23E-03 1.23E-03 
PWY-5100: pyruvate fermentation to acetate and lactate 
II|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
4.83E-04 1.99E-03 0.00E+00 6.47E-04 6.47E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.39E-03 1.39E-03 
PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Alistipes.s_Alistipes_shahii 
4.83E-04 1.99E-03 0.00E+00 8.34E-04 8.34E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Blautia.s_Ruminococcus_gnavus 
4.83E-04 1.99E-03 9.17E-04 0.00E+00 9.17E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Blautia.s_Ruminococcus_gnavus 
4.83E-04 1.99E-03 9.15E-04 0.00E+00 9.15E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Catenibacterium.s_Catenibacterium_mitsuokai 
4.83E-04 1.99E-03 0.00E+00 4.78E-04 4.78E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Coprococcus.s_Coprococcus_comes 
4.83E-04 1.99E-03 0.00E+00 8.22E-04 8.22E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Collinsella.s_Collinsella_aerofaciens 
4.83E-04 1.99E-03 0.00E+00 4.21E-04 4.21E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Blautia.s_Ruminococcus_gnavus 
4.83E-04 1.99E-03 9.15E-04 0.00E+00 9.15E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Catenibacterium.s_Catenibacterium_mitsuokai 
4.83E-04 1.99E-03 0.00E+00 4.78E-04 4.78E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Coprococcus.s_Coprococcus_comes 
4.83E-04 1.99E-03 0.00E+00 8.22E-04 8.22E-04 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.09E-03 1.09E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.11E-03 1.11E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bacteroides.s_Bacteroides_dorei 
4.83E-04 1.99E-03 0.00E+00 8.20E-04 8.20E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.22E-03 1.22E-03 
PWY-6608: guanosine nucleotides degradation 
III|g_Escherichia.s_Escherichia_coli 
4.83E-04 1.99E-03 3.74E-04 0.00E+00 3.74E-04 
PWY-6609: adenine and adenosine salvage 
III|g_Escherichia.s_Escherichia_coli 
4.83E-04 1.99E-03 5.28E-04 0.00E+00 5.28E-04 
PWY-6700: queuosine biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_callidus 
4.83E-04 1.99E-03 0.00E+00 1.72E-03 1.72E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_callidus 
4.83E-04 1.99E-03 0.00E+00 1.56E-03 1.56E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Barnesiella.s_Barnesiella_intestinihominis 
4.83E-04 1.99E-03 0.00E+00 1.83E-03 1.83E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
4.83E-04 1.99E-03 6.11E-04 0.00E+00 6.11E-04 












PWY-7220: adenosine deoxyribonucleotides de novo biosynthesis 
II|g_Bacteroides.s_Bacteroides_dorei 
4.83E-04 1.99E-03 0.00E+00 1.03E-03 1.03E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_shahii 
4.83E-04 1.99E-03 0.00E+00 1.02E-03 1.02E-03 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Eubacterium.s_Eubacterium_ventriosum 
4.83E-04 1.99E-03 1.10E-03 0.00E+00 1.10E-03 
PWY-7222: guanosine deoxyribonucleotides de novo biosynthesis 
II|g_Bacteroides.s_Bacteroides_dorei 
4.83E-04 1.99E-03 0.00E+00 1.03E-03 1.03E-03 
PWY-7228: superpathway of guanosine nucleotides de novo 
biosynthesis I|g_Bacteroides.s_Bacteroides_dorei 
4.83E-04 1.99E-03 0.00E+00 1.10E-03 1.10E-03 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Parabacteroides.s_Parabacteroides_distasonis 
4.83E-04 1.99E-03 0.00E+00 1.39E-03 1.39E-03 
SALVADEHYPOX-PWY: adenosine nucleotides degradation 
II|g_Escherichia.s_Escherichia_coli 
4.83E-04 1.99E-03 4.11E-04 0.00E+00 4.11E-04 
TRPSYN-PWY: L-tryptophan biosynthe-
sis|g_Bacteroides.s_Bacteroides_fragilis 
4.83E-04 1.99E-03 9.21E-04 0.00E+00 9.21E-04 
UNINTEGRATED|g_Coprococcus.s_Coprococcus_catus 4.83E-04 1.99E-03 0.00E+00 1.15E-03 1.15E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
4.83E-04 1.99E-03 6.39E-04 0.00E+00 6.39E-04 
KETOGLUCONMET-PWY: ketogluconate metabolism 4.83E-04 1.99E-03 1.50E-03 0.00E+00 1.50E-03 




4.89E-04 2.01E-03 8.71E-04 1.30E-04 7.41E-04 
PWY-7560: methylerythritol phosphate pathway II 5.23E-04 2.15E-03 6.65E-03 3.16E-03 3.49E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_xylanisolvens 
5.65E-04 2.32E-03 1.81E-03 5.86E-04 1.23E-03 
PWY-6123: inosine-5'-phosphate biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
5.70E-04 2.33E-03 7.58E-04 5.63E-05 7.02E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Roseburia.s_Roseburia_inulinivorans 
5.70E-04 2.33E-03 5.29E-04 2.89E-05 5.00E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Eubacterium.s_Eubacterium_ramulus 
5.80E-04 2.37E-03 5.28E-04 2.54E-05 5.03E-04 
NONMEVIPP-PWY: methylerythritol phosphate pathway I 6.46E-04 2.63E-03 5.68E-03 9.63E-03 3.94E-03 
PWY-6270: isoprene biosynthesis I 6.46E-04 2.63E-03 6.64E-03 3.26E-03 3.38E-03 
PWY66-409: superpathway of purine nucleotide salvage 6.48E-04 2.64E-03 2.82E-03 7.00E-04 2.12E-03 
PWY-5173: superpathway of acetyl-CoA biosynthesis 7.02E-04 2.85E-03 1.86E-03 1.00E-04 1.76E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
7.07E-04 2.87E-03 7.40E-04 7.65E-05 6.64E-04 
PWY-6147: 6-hydroxymethyl-dihydropterin diphosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_xylanisolvens 
7.24E-04 2.94E-03 9.85E-04 2.40E-04 7.45E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bifidobacterium.s_Bifidobacterium_longum 
7.41E-04 3.00E-03 7.02E-04 1.25E-04 5.77E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_thetaiotaomicron 
8.34E-04 3.37E-03 2.82E-04 2.09E-03 1.81E-03 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
8.40E-04 3.39E-03 8.12E-04 1.33E-04 6.79E-04 
















8.40E-04 3.39E-03 8.12E-04 1.33E-04 6.79E-04 
PWY-6123: inosine-5'-phosphate biosynthesis 
I|g_Bifidobacterium.s_Bifidobacterium_longum 
9.17E-04 3.69E-03 8.23E-04 8.15E-05 7.42E-04 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_dorei 9.71E-04 3.90E-03 6.77E-04 1.89E-03 1.21E-03 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Roseburia.s_Roseburia_intestinalis 
9.82E-04 3.94E-03 1.01E-03 1.39E-04 8.74E-04 




1.00E-03 4.01E-03 6.77E-04 1.08E-04 5.70E-04 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Anaerostipes.s_Anaerostipes_hadrus 
1.02E-03 4.05E-03 9.56E-04 9.02E-05 8.66E-04 
PWY-5791: 1,4-dihydroxy-2-naphthoate biosynthesis II (plants) 1.02E-03 4.05E-03 2.32E-03 2.51E-04 2.07E-03 
PWY-5837: 1,4-dihydroxy-2-naphthoate biosynthesis I 1.02E-03 4.05E-03 2.32E-03 2.51E-04 2.07E-03 
PWY-5897: superpathway of menaquinol-11 biosynthesis 1.02E-03 4.05E-03 2.33E-03 2.59E-04 2.07E-03 
PWY-5898: superpathway of menaquinol-12 biosynthesis 1.02E-03 4.05E-03 2.33E-03 2.59E-04 2.07E-03 
PWY-5899: superpathway of menaquinol-13 biosynthesis 1.02E-03 4.05E-03 2.33E-03 2.59E-04 2.07E-03 
PWY0-1415: superpathway of heme biosynthesis from 
uroporphyrinogen-III 
1.02E-03 4.05E-03 1.74E-03 9.11E-05 1.65E-03 




1.17E-03 4.49E-03 6.88E-04 9.12E-05 5.97E-04 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_xylanisolvens 1.18E-03 4.49E-03 1.52E-03 6.55E-04 8.66E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Eubacterium.s_Eubacterium_ramulus 
1.18E-03 4.49E-03 4.64E-04 9.16E-06 4.55E-04 
PWY-6892: thiazole biosynthesis I (E. coli) 1.18E-03 4.49E-03 1.65E-03 3.54E-05 1.61E-03 
THISYN-PWY: superpathway of thiamin diphosphate biosynthesis I 1.18E-03 4.49E-03 1.79E-03 4.48E-05 1.75E-03 
POLYAMINSYN3-PWY: superpathway of polyamine biosynthesis II 1.19E-03 4.49E-03 1.03E-03 7.56E-03 6.52E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_dorei 
1.25E-03 4.49E-03 0.00E+00 8.69E-04 8.69E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_fragilis 
1.25E-03 4.49E-03 4.96E-04 0.00E+00 4.96E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Parabacteroides.s_Parabacteroides_distasonis 
1.25E-03 4.49E-03 0.00E+00 8.52E-04 8.52E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Veillonella.s_Veillonella_parvula 
1.25E-03 4.49E-03 6.33E-04 0.00E+00 6.33E-04 
COA-PWY: coenzyme A biosynthesis 
I|g_Veillonella.s_Veillonella_parvula 
1.25E-03 4.49E-03 4.92E-04 0.00E+00 4.92E-04 
GLCMANNANAUT-PWY: superpathway of N-acetylglucosamine, N-
acetylmannosamine and N-acetylneuraminate degrada-
tion|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 4.66E-04 0.00E+00 4.66E-04 














1.25E-03 4.49E-03 3.92E-04 0.00E+00 3.92E-04 
NONMEVIPP-PWY: methylerythritol phosphate pathway 
I|g_Paraprevotella.s_Paraprevotella_clara 
1.25E-03 4.49E-03 0.00E+00 1.51E-03 1.51E-03 
NONOXIPENT-PWY: pentose phosphate pathway (non-oxidative 
branch)|g_Blautia.s_Ruminococcus_gnavus 
1.25E-03 4.49E-03 6.92E-04 0.00E+00 6.92E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
1.25E-03 4.49E-03 0.00E+00 8.16E-04 8.16E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Blautia.s_Ruminococcus_gnavus 
1.25E-03 4.49E-03 6.83E-04 0.00E+00 6.83E-04 
PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Ruminococcus.s_Ruminococcus_callidus 
1.25E-03 4.49E-03 0.00E+00 1.26E-03 1.26E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Coprococcus.s_Coprococcus_comes 
1.25E-03 4.49E-03 0.00E+00 8.07E-04 8.07E-04 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 4.33E-04 0.00E+00 4.33E-04 
PWY-2942: L-lysine biosynthesis 
III|g_Catenibacterium.s_Catenibacterium_mitsuokai 
1.25E-03 4.49E-03 0.00E+00 4.71E-04 4.71E-04 
PWY-4702: phytate degradation I|g_Escherichia.s_Escherichia_coli 1.25E-03 4.49E-03 5.17E-04 0.00E+00 5.17E-04 
PWY-5188: tetrapyrrole biosynthesis I (from gluta-
mate)|g_Fusobacterium.s_Fusobacterium_varium 
1.25E-03 4.49E-03 4.20E-04 0.00E+00 4.20E-04 
PWY-5384: sucrose degradation IV (sucrose phosphory-
lase)|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 5.81E-04 0.00E+00 5.81E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Barnesiella.s_Barnesiella_intestinihominis 
1.25E-03 4.49E-03 0.00E+00 9.02E-04 9.02E-04 
PWY-5686: UMP biosynthe-
sis|g_Eubacterium.s_Eubacterium_ventriosum 
1.25E-03 4.49E-03 7.34E-04 0.00E+00 7.34E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.25E-03 4.49E-03 0.00E+00 6.96E-04 6.96E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Ruminococcus.s_Ruminococcus_callidus 
1.25E-03 4.49E-03 0.00E+00 8.30E-04 8.30E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Flavonifractor.s_Flavonifractor_plautii 
1.25E-03 4.49E-03 4.89E-04 0.00E+00 4.89E-04 
PWY-6125: superpathway of guanosine nucleotides de novo 
biosynthesis II|g_Bacteroides.s_Bacteroides_dorei 
1.25E-03 4.49E-03 0.00E+00 1.10E-03 1.10E-03 
PWY-6126: superpathway of adenosine nucleotides de novo 
biosynthesis II|g_Bacteroides.s_Bacteroides_dorei 
1.25E-03 4.49E-03 0.00E+00 7.75E-04 7.75E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Roseburia.s_Roseburia_inulinivorans 
1.25E-03 4.49E-03 4.66E-04 0.00E+00 4.66E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Flavonifractor.s_Flavonifractor_plautii 
1.25E-03 4.49E-03 4.89E-04 0.00E+00 4.89E-04 
PWY-6305: putrescine biosynthesis 
IV|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 4.05E-04 0.00E+00 4.05E-04 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Bacteroides.s_Bacteroides_fragilis 
1.25E-03 4.49E-03 6.27E-04 0.00E+00 6.27E-04 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Bacteroides.s_Bacteroides_fragilis 
1.25E-03 4.49E-03 7.84E-04 0.00E+00 7.84E-04 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Blautia.s_Ruminococcus_gnavus 
1.25E-03 4.49E-03 8.20E-04 0.00E+00 8.20E-04 












PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Coprococcus.s_Coprococcus_comes 
1.25E-03 4.49E-03 0.00E+00 8.30E-04 8.30E-04 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Eubacterium.s_Eubacterium_ventriosum 
1.25E-03 4.49E-03 9.12E-04 0.00E+00 9.12E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Blautia.s_Ruminococcus_gnavus 
1.25E-03 4.49E-03 8.51E-04 0.00E+00 8.51E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Coprococcus.s_Coprococcus_comes 
1.25E-03 4.49E-03 0.00E+00 8.11E-04 8.11E-04 
PWY-6609: adenine and adenosine salvage 
III|g_Alistipes.s_Alistipes_shahii 
1.25E-03 4.49E-03 0.00E+00 8.51E-04 8.51E-04 
PWY-6609: adenine and adenosine salvage 
III|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.25E-03 4.49E-03 0.00E+00 5.10E-04 5.10E-04 
PWY-6609: adenine and adenosine salvage 
III|g_Eubacterium.s_Eubacterium_ventriosum 
1.25E-03 4.49E-03 8.69E-04 0.00E+00 8.69E-04 
PWY-6737: starch degradation 
V|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.25E-03 4.49E-03 0.00E+00 5.65E-04 5.65E-04 
PWY-6737: starch degradation 
V|g_Fusobacterium.s_Fusobacterium_varium 
1.25E-03 4.49E-03 4.05E-04 0.00E+00 4.05E-04 
PWY-6936: seleno-amino acid biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 5.43E-04 0.00E+00 5.43E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_shahii 
1.25E-03 4.49E-03 0.00E+00 1.07E-03 1.07E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Flavonifractor.s_Flavonifractor_plautii 
1.25E-03 4.49E-03 4.85E-04 0.00E+00 4.85E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Blautia.s_Ruminococcus_gnavus 
1.25E-03 4.49E-03 6.31E-04 0.00E+00 6.31E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Coprococcus.s_Coprococcus_comes 
1.25E-03 4.49E-03 0.00E+00 6.83E-04 6.83E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Fusobacterium.s_Fusobacterium_varium 
1.25E-03 4.49E-03 3.81E-04 0.00E+00 3.81E-04 
PWY-7228: superpathway of guanosine nucleotides de novo 
biosynthesis I|g_Parabacteroides.s_Parabacteroides_distasonis 
1.25E-03 4.49E-03 0.00E+00 1.81E-03 1.81E-03 
PWY-7229: superpathway of adenosine nucleotides de novo 
biosynthesis I|g_Bacteroides.s_Bacteroides_dorei 
1.25E-03 4.49E-03 0.00E+00 7.47E-04 7.47E-04 
PWY-7282: 4-amino-2-methyl-5-phosphomethylpyrimidine 
biosynthesis (yeast)|g_Bacteroides.s_Bacteroides_fragilis 
1.25E-03 4.49E-03 6.21E-04 0.00E+00 6.21E-04 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 4.92E-04 0.00E+00 4.92E-04 
PWY0-1241: ADP-L-glycero-&beta;-D-manno-heptose 
biosynthesis|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 4.09E-04 0.00E+00 4.09E-04 
PWY0-1261: anhydromuropeptides recy-
cling|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 5.28E-04 0.00E+00 5.28E-04 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
1.25E-03 4.49E-03 0.00E+00 6.08E-04 6.08E-04 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Fusobacterium.s_Fusobacterium_varium 
1.25E-03 4.49E-03 3.16E-04 0.00E+00 3.16E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Barnesiella.s_Barnesiella_intestinihominis 
1.25E-03 4.49E-03 0.00E+00 9.02E-04 9.02E-04 












PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage|g_Bacteroides.s_Bacteroides_fragilis 
1.25E-03 4.49E-03 6.38E-04 0.00E+00 6.38E-04 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_fragilis 
1.25E-03 4.49E-03 8.00E-04 0.00E+00 8.00E-04 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 5.40E-04 0.00E+00 5.40E-04 
SER-GLYSYN-PWY: superpathway of L-serine and glycine 
biosynthesis I|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 6.36E-04 0.00E+00 6.36E-04 
SO4ASSIM-PWY: sulfate reduction I (assimilato-
ry)|g_Escherichia.s_Escherichia_coli 
1.25E-03 4.49E-03 4.64E-04 0.00E+00 4.64E-04 
UNINTEGRATED|g_Alistipes.s_Alistipes_onderdonkii 1.25E-03 4.49E-03 0.00E+00 1.20E-03 1.20E-03 
UNINTEGRATED|g_Flavonifractor.s_Flavonifractor_plautii 1.25E-03 4.49E-03 8.37E-04 0.00E+00 8.37E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_lactaris 
1.25E-03 4.49E-03 0.00E+00 5.95E-04 5.95E-04 
ENTBACSYN-PWY: enterobactin biosynthesis 1.25E-03 4.49E-03 1.75E-03 0.00E+00 1.75E-03 
GLYCOL-GLYOXDEG-PWY: superpathway of glycol metabolism and 
degradation 
1.25E-03 4.49E-03 1.66E-03 0.00E+00 1.66E-03 
POLYISOPRENSYN-PWY: polyisoprenoid biosynthesis (E. coli) 1.25E-03 4.49E-03 1.85E-03 0.00E+00 1.85E-03 
PWY-6891: thiazole biosynthesis II (Bacillus) 1.25E-03 4.49E-03 1.35E-03 0.00E+00 1.35E-03 
PWY-6895: superpathway of thiamin diphosphate biosynthesis II 1.25E-03 4.49E-03 1.45E-03 0.00E+00 1.45E-03 
PWY-7254: TCA cycle VII (acetate-producers) 1.25E-03 4.49E-03 1.48E-03 0.00E+00 1.48E-03 
PWY-7198: pyrimidine deoxyribonucleotides de novo biosynthesis IV 1.28E-03 4.58E-03 3.36E-03 1.13E-03 2.22E-03 
P461-PWY: hexitol fermentation to lactate, formate, ethanol and 
acetate|g_Anaerostipes.s_Anaerostipes_hadrus 
1.33E-03 4.77E-03 6.54E-04 5.83E-05 5.95E-04 
ARO-PWY: chorismate biosynthesis 
I|g_Roseburia.s_Roseburia_intestinalis 
1.34E-03 4.79E-03 9.98E-04 1.31E-04 8.67E-04 
COMPLETE-ARO-PWY: superpathway of aromatic amino acid 
biosynthesis|g_Roseburia.s_Roseburia_intestinalis 
1.34E-03 4.79E-03 9.95E-04 1.34E-04 8.61E-04 
PPGPPMET-PWY: ppGpp biosynthesis 1.39E-03 4.96E-03 3.00E-03 8.38E-04 2.17E-03 
PWY-6703: preQ0 biosynthe-
sis|g_Anaerostipes.s_Anaerostipes_hadrus 
1.43E-03 5.07E-03 7.81E-04 3.22E-05 7.49E-04 
PWY-7204: pyridoxal 5'-phosphate salvage II (plants) 1.43E-03 5.07E-03 1.90E-03 4.51E-05 1.86E-03 
BRANCHED-CHAIN-AA-SYN-PWY: superpathway of branched amino 
acid biosynthesis 
1.43E-03 5.08E-03 3.85E-03 6.35E-03 2.50E-03 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Anaerostipes.s_Anaerostipes_hadrus 
1.47E-03 5.21E-03 9.28E-04 1.02E-04 8.27E-04 
PWY-6163: chorismate biosynthesis from 3-
dehydroquinate|g_Roseburia.s_Roseburia_intestinalis 
1.58E-03 5.61E-03 1.00E-03 1.41E-04 8.62E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Anaerostipes.s_Anaerostipes_hadrus 
1.59E-03 5.61E-03 7.21E-04 6.50E-05 6.56E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Anaerostipes.s_Anaerostipes_hadrus 
1.59E-03 5.61E-03 7.21E-04 6.50E-05 6.56E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Dorea.s_Dorea_longicatena 
1.64E-03 5.79E-03 4.68E-04 1.30E-03 8.29E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Dorea.s_Dorea_longicatena 
1.64E-03 5.79E-03 4.68E-04 1.30E-03 8.29E-04 












PWY-621: sucrose degradation III (sucrose invert-
ase)|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_
1_63FAA 
1.66E-03 5.83E-03 1.15E-03 1.95E-04 9.57E-04 
PWY-7383: anaerobic energy metabolism (invertebrates, cytosol) 1.69E-03 5.95E-03 1.13E-03 5.39E-03 4.26E-03 




1.71E-03 6.00E-03 7.37E-04 5.51E-05 6.82E-04 
METSYN-PWY: L-homoserine and L-methionine biosynthe-
sis|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_
63FAA 
1.71E-03 6.00E-03 7.29E-04 4.81E-05 6.81E-04 




1.71E-03 6.00E-03 6.83E-04 4.73E-05 6.35E-04 
PWY-6588: pyruvate fermentation to ace-
tone|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_
1_63FAA 
1.76E-03 6.14E-03 7.47E-04 1.10E-04 6.37E-04 
PWY-5384: sucrose degradation IV (sucrose phosphorylase) 1.76E-03 6.14E-03 1.47E-03 2.72E-04 1.20E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Anaerostipes.s_Anaerostipes_hadrus 
1.89E-03 6.60E-03 7.14E-04 7.64E-05 6.37E-04 
PWY-5686: UMP biosynthe-
sis|g_Anaerostipes.s_Anaerostipes_hadrus 
2.06E-03 7.15E-03 6.87E-04 5.01E-05 6.37E-04 
PWY-7328: superpathway of UDP-glucose-derived O-antigen building 
blocks biosynthesis 
2.06E-03 7.15E-03 2.69E-03 2.65E-04 2.43E-03 
ASPASN-PWY: superpathway of L-aspartate and L-asparagine 
biosynthesis|g_Roseburia.s_Roseburia_intestinalis 
2.06E-03 7.17E-03 9.45E-04 1.29E-04 8.16E-04 
POLYAMSYN-PWY: superpathway of polyamine biosynthesis I 2.08E-03 7.21E-03 3.59E-03 7.56E-03 3.97E-03 
CALVIN-PWY: Calvin-Benson-Bassham cy-
cle|g_Anaerostipes.s_Anaerostipes_hadrus 
2.10E-03 7.25E-03 9.47E-04 1.31E-04 8.16E-04 
THRESYN-PWY: superpathway of L-threonine biosynthe-
sis|g_Anaerostipes.s_Anaerostipes_hadrus 
2.10E-03 7.25E-03 7.45E-04 1.33E-04 6.12E-04 
PWY-5863: superpathway of phylloquinol biosynthesis 2.10E-03 7.25E-03 2.75E-03 4.98E-04 2.25E-03 
COBALSYN-PWY: adenosylcobalamin salvage from cobinamide 
I|g_Roseburia.s_Roseburia_intestinalis 
2.15E-03 7.41E-03 1.08E-03 1.62E-04 9.22E-04 
RHAMCAT-PWY: L-rhamnose degradation 
I|g_Bacteroides.s_Bacteroides_xylanisolvens 
2.22E-03 7.64E-03 1.32E-03 4.33E-04 8.87E-04 
GLCMANNANAUT-PWY: superpathway of N-acetylglucosamine, N-
acetylmannosamine and N-acetylneuraminate degrada-
tion|g_Dorea.s_Dorea_longicatena 
2.24E-03 7.71E-03 5.13E-04 1.73E-03 1.22E-03 
VALSYN-PWY: L-valine biosynthe-
sis|g_Anaerostipes.s_Anaerostipes_hadrus 
2.24E-03 7.71E-03 8.21E-04 1.00E-04 7.20E-04 




2.33E-03 8.00E-03 9.86E-04 2.54E-04 7.32E-04 
PWY-6163: chorismate biosynthesis from 3-
dehydroquinate|g_Roseburia.s_Roseburia_inulinivorans 
2.46E-03 8.41E-03 5.17E-04 2.79E-05 4.89E-04 
PWY-7357: thiamin formation from pyrithiamine and oxythiamine 
(yeast)|g_Roseburia.s_Roseburia_inulinivorans 
2.46E-03 8.41E-03 4.13E-04 2.23E-05 3.91E-04 












PWY-7357: thiamin formation from pyrithiamine and oxythiamine 
(yeast) 
2.49E-03 8.50E-03 6.12E-03 8.51E-03 2.38E-03 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Anaerostipes.s_Anaerostipes_hadrus 
2.66E-03 9.06E-03 7.68E-04 1.17E-04 6.51E-04 
PWY66-422: D-galactose degradation V (Leloir path-
way)|g_Anaerostipes.s_Anaerostipes_hadrus 
2.66E-03 9.06E-03 7.83E-04 1.12E-04 6.71E-04 




2.74E-03 9.28E-03 7.86E-04 1.79E-04 6.07E-04 
PWY-5676: acetyl-CoA fermentation to butanoate II 2.82E-03 9.28E-03 2.69E-03 5.45E-03 2.76E-03 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Roseburia.s_Roseburia_intestinalis 
2.83E-03 9.28E-03 9.20E-04 1.62E-04 7.58E-04 
MET-SAM-PWY: superpathway of S-adenosyl-L-methionine 
biosynthesis 
2.96E-03 9.28E-03 2.22E-03 4.25E-03 2.02E-03 
PWY-6897: thiamin salvage II 2.96E-03 9.28E-03 6.23E-03 8.85E-03 2.62E-03 
PWY-7199: pyrimidine deoxyribonucleosides salvage 2.96E-03 9.28E-03 4.03E-03 7.03E-03 3.00E-03 
PWY-6737: starch degradation 
V|g_Roseburia.s_Roseburia_inulinivorans 
3.00E-03 9.28E-03 5.91E-04 1.13E-04 4.78E-04 
1CMET2-PWY: N10-formyl-tetrahydrofolate biosynthe-
sis|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.12E-04 0.00E+00 6.12E-04 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.55E-04 0.00E+00 5.55E-04 
ARGININE-SYN4-PWY: L-ornithine de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_xylanisolvens 
3.08E-03 9.28E-03 0.00E+00 9.31E-04 9.31E-04 
AST-PWY: L-arginine degradation II (AST path-
way)|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.73E-04 0.00E+00 4.73E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
3.08E-03 9.28E-03 0.00E+00 1.25E-03 1.25E-03 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 4.55E-04 0.00E+00 4.55E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Odoribacter.s_Odoribacter_splanchnicus 
3.08E-03 9.28E-03 8.84E-04 0.00E+00 8.84E-04 
COA-PWY-1: coenzyme A biosynthesis II (mammali-
an)|g_Ruminococcus.s_Ruminococcus_callidus 
3.08E-03 9.28E-03 0.00E+00 7.23E-04 7.23E-04 
COA-PWY: coenzyme A biosynthesis 
I|g_Odoribacter.s_Odoribacter_splanchnicus 
3.08E-03 9.28E-03 8.09E-04 0.00E+00 8.09E-04 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.81E-04 0.00E+00 5.81E-04 
DTDPRHAMSYN-PWY: dTDP-L-rhamnose biosynthesis 
I|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.77E-04 0.00E+00 4.77E-04 
FUCCAT-PWY: fucose degradation|g_Escherichia.s_Escherichia_coli 3.08E-03 9.28E-03 5.79E-04 0.00E+00 5.79E-04 
GLUCOSE1PMETAB-PWY: glucose and glucose-1-phosphate 
degradation|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 3.72E-04 0.00E+00 3.72E-04 
GLYCOL-GLYOXDEG-PWY: superpathway of glycol metabolism and 
degradation|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 5.17E-04 0.00E+00 5.17E-04 
HEMESYN2-PWY: heme biosynthesis II (anaero-
bic)|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 5.25E-04 0.00E+00 5.25E-04 
P461-PWY: hexitol fermentation to lactate, formate, ethanol and 
acetate|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.94E-04 0.00E+00 4.94E-04 












PANTO-PWY: phosphopantothenate biosynthesis 
I|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.18E-04 0.00E+00 5.18E-04 
PANTOSYN-PWY: pantothenate and coenzyme A biosynthesis 
I|g_Eubacterium.s_Eubacterium_ventriosum 
3.08E-03 9.28E-03 8.37E-04 0.00E+00 8.37E-04 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate contain-
ing)|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
3.08E-03 9.28E-03 0.00E+00 1.02E-03 1.02E-03 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Bacteroides.s_Bacteroides_dorei 
3.08E-03 9.28E-03 0.00E+00 5.91E-04 5.91E-04 
PEPTIDOGLYCANSYN-PWY: peptidoglycan biosynthesis I (meso-
diaminopimelate containing)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.35E-04 0.00E+00 5.35E-04 
POLYISOPRENSYN-PWY: polyisoprenoid biosynthesis (E. 
coli)|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 5.90E-04 0.00E+00 5.90E-04 
PWY-1042: glycolysis IV (plant cyto-
sol)|g_Bacteroides.s_Bacteroides_xylanisolvens 
3.08E-03 9.28E-03 0.00E+00 1.56E-03 1.56E-03 
PWY-2941: L-lysine biosynthesis 
II|g_Catenibacterium.s_Catenibacterium_mitsuokai 
3.08E-03 9.28E-03 0.00E+00 4.69E-04 4.69E-04 
PWY-2942: L-lysine biosynthesis 
III|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.52E-04 0.00E+00 6.52E-04 
PWY-2942: L-lysine biosynthesis 
III|g_Veillonella.s_Veillonella_parvula 
3.08E-03 9.28E-03 5.75E-04 0.00E+00 5.75E-04 
PWY-3841: folate transformations 
II|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.16E-04 0.00E+00 6.16E-04 
PWY-4242: pantothenate and coenzyme A biosynthesis 
III|g_Eubacterium.s_Eubacterium_ventriosum 
3.08E-03 9.28E-03 8.73E-04 0.00E+00 8.73E-04 
PWY-4984: urea cycle|g_Flavonifractor.s_Flavonifractor_plautii 3.08E-03 9.28E-03 6.71E-04 0.00E+00 6.71E-04 
PWY-5083: NAD/NADH phosphorylation and dephosphoryla-
tion|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 5.97E-04 0.00E+00 5.97E-04 
PWY-5097: L-lysine biosynthesis 
VI|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.07E-04 0.00E+00 6.07E-04 
PWY-5097: L-lysine biosynthesis 
VI|g_Barnesiella.s_Barnesiella_intestinihominis 
3.08E-03 9.28E-03 0.00E+00 1.17E-03 1.17E-03 
PWY-5097: L-lysine biosynthesis 
VI|g_Catenibacterium.s_Catenibacterium_mitsuokai 
3.08E-03 9.28E-03 0.00E+00 4.61E-04 4.61E-04 
PWY-5189: tetrapyrrole biosynthesis II (from gly-
cine)|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 3.82E-04 0.00E+00 3.82E-04 
PWY-5659: GDP-mannose biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.36E-04 0.00E+00 4.36E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.91E-04 0.00E+00 5.91E-04 
PWY-5667: CDP-diacylglycerol biosynthesis 
I|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 3.70E-04 0.00E+00 3.70E-04 
PWY-5686: UMP biosynthe-
sis|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 4.93E-04 0.00E+00 4.93E-04 
PWY-5686: UMP biosynthe-
sis|g_Catenibacterium.s_Catenibacterium_mitsuokai 
3.08E-03 9.28E-03 0.00E+00 4.03E-04 4.03E-04 
PWY-5686: UMP biosynthe-
sis|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
3.08E-03 9.28E-03 0.00E+00 5.06E-04 5.06E-04 












PWY-5695: urate biosynthesis/inosine 5'-phosphate degrada-
tion|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 4.57E-04 0.00E+00 4.57E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Coprococcus.s_Coprococcus_comes 
3.08E-03 9.28E-03 0.00E+00 6.36E-04 6.36E-04 
PWY-6121: 5-aminoimidazole ribonucleotide biosynthesis 
I|g_Fusobacterium.s_Fusobacterium_varium 
3.08E-03 9.28E-03 3.74E-04 0.00E+00 3.74E-04 
PWY-6122: 5-aminoimidazole ribonucleotide biosynthesis 
II|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 3.68E-04 0.00E+00 3.68E-04 
PWY-6123: inosine-5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.27E-04 0.00E+00 5.27E-04 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.25E-04 0.00E+00 5.25E-04 
PWY-6124: inosine-5'-phosphate biosynthesis 
II|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 5.23E-04 0.00E+00 5.23E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Catenibacterium.s_Catenibacterium_mitsuokai 
3.08E-03 9.28E-03 0.00E+00 4.52E-04 4.52E-04 
PWY-6151: S-adenosyl-L-methionine cycle 
I|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.80E-04 0.00E+00 4.80E-04 
PWY-6277: superpathway of 5-aminoimidazole ribonucleotide 
biosynthesis|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 3.68E-04 0.00E+00 3.68E-04 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 4.80E-04 0.00E+00 4.80E-04 
PWY-6385: peptidoglycan biosynthesis III (mycobacte-
ria)|g_Eubacterium.s_Eubacterium_ventriosum 
3.08E-03 9.28E-03 7.97E-04 0.00E+00 7.97E-04 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
3.08E-03 9.28E-03 0.00E+00 1.05E-03 1.05E-03 
PWY-6386: UDP-N-acetylmuramoyl-pentapeptide biosynthesis II 
(lysine-containing)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 4.86E-04 0.00E+00 4.86E-04 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Adlercreutzia.s_Adlercreutzia_equolifaciens 
3.08E-03 9.28E-03 0.00E+00 1.09E-03 1.09E-03 
PWY-6387: UDP-N-acetylmuramoyl-pentapeptide biosynthesis I 
(meso-diaminopimelate contain-
ing)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.23E-04 0.00E+00 5.23E-04 
PWY-6608: guanosine nucleotides degradation 
III|g_Coprococcus.s_Coprococcus_catus 
3.08E-03 9.28E-03 0.00E+00 7.98E-04 7.98E-04 
PWY-6609: adenine and adenosine salvage 
III|g_Blautia.s_Ruminococcus_gnavus 
3.08E-03 9.28E-03 8.06E-04 0.00E+00 8.06E-04 
PWY-6703: preQ0 biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_lactaris 
3.08E-03 9.28E-03 0.00E+00 9.42E-04 9.42E-04 
PWY-6859: all-trans-farnesol biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 5.95E-04 0.00E+00 5.95E-04 
PWY-6936: seleno-amino acid biosynthe-
sis|g_Erysipelotrichaceae_noname.s_Eubacterium_biforme 
3.08E-03 9.28E-03 0.00E+00 5.76E-04 5.76E-04 
PWY-6936: seleno-amino acid biosynthe-
sis|g_Eubacterium.s_Eubacterium_ventriosum 
3.08E-03 9.28E-03 7.85E-04 0.00E+00 7.85E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Barnesiella.s_Barnesiella_intestinihominis 
3.08E-03 9.28E-03 0.00E+00 7.71E-04 7.71E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Coprococcus.s_Coprococcus_catus 
3.08E-03 9.28E-03 0.00E+00 7.74E-04 7.74E-04 












PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_
7_1_58FAA 
3.08E-03 9.28E-03 6.60E-04 0.00E+00 6.60E-04 
PWY-7111: pyruvate fermentation to isobutanol (engi-
neered)|g_Veillonella.s_Veillonella_parvula 
3.08E-03 9.28E-03 4.09E-04 0.00E+00 4.09E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Alistipes.s_Alistipes_indistinctus 
3.08E-03 9.28E-03 0.00E+00 6.40E-04 6.40E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.72E-04 0.00E+00 5.72E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Clostridium.s_Clostridium_bolteae 
3.08E-03 9.28E-03 5.77E-04 0.00E+00 5.77E-04 
PWY-7219: adenosine ribonucleotides de novo biosynthe-
sis|g_Ruminococcus.s_Ruminococcus_lactaris 
3.08E-03 9.28E-03 0.00E+00 6.60E-04 6.60E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.24E-04 0.00E+00 5.24E-04 
PWY-7221: guanosine ribonucleotides de novo biosynthe-
sis|g_Flavonifractor.s_Flavonifractor_plautii 
3.08E-03 9.28E-03 5.62E-04 0.00E+00 5.62E-04 
PWY-7242: D-fructuronate degrada-
tion|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.64E-04 0.00E+00 4.64E-04 
PWY-7282: 4-amino-2-methyl-5-phosphomethylpyrimidine 
biosynthesis (yeast)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.27E-04 0.00E+00 6.27E-04 
PWY-7663: gondoate biosynthesis (anaero-
bic)|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.40E-04 0.00E+00 6.40E-04 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Catenibacterium.s_Catenibacterium_mitsuokai 
3.08E-03 9.28E-03 0.00E+00 3.61E-04 3.61E-04 
PWY0-1296: purine ribonucleosides degrada-
tion|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.20E-04 0.00E+00 4.20E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 5.91E-04 0.00E+00 5.91E-04 
PWY0-1319: CDP-diacylglycerol biosynthesis 
II|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 3.70E-04 0.00E+00 3.70E-04 
PWY0-1586: peptidoglycan maturation (meso-diaminopimelate 
containing)|g_Veillonella.s_Veillonella_parvula 
3.08E-03 9.28E-03 6.19E-04 0.00E+00 6.19E-04 
PWY0-845: superpathway of pyridoxal 5'-phosphate biosynthesis and 
salvage|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.14E-04 0.00E+00 6.14E-04 
PWY66-400: glycolysis VI (metazo-
an)|g_Bacteroides.s_Bacteroides_xylanisolvens 
3.08E-03 9.28E-03 0.00E+00 1.30E-03 1.30E-03 
PYRIDOXSYN-PWY: pyridoxal 5'-phosphate biosynthesis 
I|g_Bacteroides.s_Bacteroides_sp_3_2_5 
3.08E-03 9.28E-03 6.07E-04 0.00E+00 6.07E-04 
THRESYN-PWY: superpathway of L-threonine biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
3.08E-03 9.28E-03 4.77E-04 0.00E+00 4.77E-04 
THRESYN-PWY: superpathway of L-threonine biosynthe-
sis|g_Veillonella.s_Veillonella_parvula 
3.08E-03 9.28E-03 5.37E-04 0.00E+00 5.37E-04 
UNINTEGRATED|g_Bacteroides.s_Bacteroides_finegoldii 3.08E-03 9.28E-03 0.00E+00 1.79E-03 1.79E-03 




3.08E-03 9.28E-03 7.74E-04 0.00E+00 7.74E-04 
UNINTEGRATED|g_Ruminococcus.s_Ruminococcus_bromii 3.08E-03 9.28E-03 0.00E+00 5.86E-04 5.86E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Barnesiella.s_Barnesiella_intestinihominis 
3.08E-03 9.28E-03 0.00E+00 7.71E-04 7.71E-04 















3.08E-03 9.28E-03 6.60E-04 0.00E+00 6.60E-04 
VALSYN-PWY: L-valine biosynthe-
sis|g_Veillonella.s_Veillonella_parvula 
3.08E-03 9.28E-03 4.09E-04 0.00E+00 4.09E-04 
AST-PWY: L-arginine degradation II (AST pathway) 3.08E-03 9.28E-03 1.20E-03 0.00E+00 1.20E-03 
P105-PWY: TCA cycle IV (2-oxoglutarate decarboxylase) 3.08E-03 9.28E-03 1.42E-03 0.00E+00 1.42E-03 
PWY-2723: trehalose degradation V 3.08E-03 9.28E-03 1.57E-03 0.00E+00 1.57E-03 
PWY-561: superpathway of glyoxylate cycle and fatty acid 
degradation 
3.08E-03 9.28E-03 1.27E-03 0.00E+00 1.27E-03 
PWY-5723: Rubisco shunt 3.08E-03 9.28E-03 1.42E-03 0.00E+00 1.42E-03 
PWY-6731: starch degradation III 3.08E-03 9.28E-03 1.95E-03 0.00E+00 1.95E-03 
PWY-6823: molybdenum cofactor biosynthesis 3.08E-03 9.28E-03 1.34E-03 0.00E+00 1.34E-03 
PWY-7269: NAD/NADP-NADH/NADPH mitochondrial interconversion 
(yeast) 
3.08E-03 9.28E-03 1.20E-03 0.00E+00 1.20E-03 
PWY-7315: dTDP-N-acetylthomosamine biosynthesis 3.08E-03 9.28E-03 1.51E-03 0.00E+00 1.51E-03 
PWY-6317: galactose degradation I (Leloir path-
way)|g_Anaerostipes.s_Anaerostipes_hadrus 
3.14E-03 9.46E-03 8.15E-04 1.20E-04 6.95E-04 
PWY-6969: TCA cycle V (2-oxoglutarate:ferredoxin oxidoreductase) 3.19E-03 9.61E-03 1.29E-03 5.63E-03 4.33E-03 
ARO-PWY: chorismate biosynthesis 
I|g_Lachnospiraceae_noname.s_Lachnospiraceae_bacterium_5_1_6
3FAA 
3.22E-03 9.67E-03 7.73E-04 1.81E-04 5.92E-04 
PWY-5686: UMP biosynthe-
sis|g_Bifidobacterium.s_Bifidobacterium_longum 
3.22E-03 9.67E-03 6.26E-04 7.82E-05 5.48E-04 
NAD-BIOSYNTHESIS-II: NAD salvage pathway 
II|g_Escherichia.s_Escherichia_coli 
3.33E-03 9.96E-03 5.96E-04 9.58E-06 5.86E-04 
PWY0-1533: methylphosphonate degradation 
I|g_Escherichia.s_Escherichia_coli 
3.33E-03 9.96E-03 4.30E-04 5.90E-06 4.24E-04 
TRPSYN-PWY: L-tryptophan biosynthe-
sis|g_Escherichia.s_Escherichia_coli 
3.33E-03 9.96E-03 5.20E-04 9.23E-06 5.11E-04 
 
Supplementary Table 8.2 | Metabolic pathways with significantly varied relative 
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fdatish (format data 'ish) 
#' Format data in a certain way 
#'  
#' @param input R object or file - required 
#' @param subject ID of individuals - one of: row/col position, NULL, or blank 
#' @param group Group variable - one of: row/col position, NULL, or blank 
#' @param VarOrient - are variables along rows or cols - one of: "row" or "col" 
#' @return list containing numeric data, identification variables as factors, and
 the two     #' combined 
#' @seealso N/A 
#' @export 
#' @examples 
#' fthis <- data_frame( 
#' ids = letters[1:10],  
#' grouping = rep(letters[1:2], 5),  
#' var_1 = sample(.1:10),  
#' var_2 = sample(.1:10),  




#' wd <- getwd() 
#' wd_file <- paste0(wd,"cool_data.txt") 
#' fdatish("wd_file") 
#'   
#ADD OPTION FOR BASE/DATA/NAME ONLY 
fdatish <- function(input, subject, group, VarOrient){ 
  if(missing(input)==TRUE){ 
    print("Huh, there isn't data supplied, we cannot proceed!  
(Hint: input = `your_data.txt`/your_data)") 
    stopifnot(missing(input)==FALSE) 
  } 
  if(is.matrix(input) == FALSE && is.data.frame(input) == FALSE){ 
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    #DETECT AND DEFINE FILE TYPE WITH INPUT TITLE EG pizza.txt 
    print("the data supplied is NOT an object") 
    sep.var <- readLines(input, n = 1) 
    if (grepl(",", sep.var)) {sep.var = ","} 
    if (grepl("\\;", sep.var)) {sep.var = ";"} 
    if (grepl("\\t", sep.var)) {sep.var = "\t"} 
    if(missing(VarOrient)==TRUE){ 
      print(sep.var) 
      fdat.tmp <- read.table(input, sep = sep.var) 
      rowvarP = 0;colvarP = 0 
      if(ncol(fdat.tmp) == nrow(fdat.tmp)) {rowvarP = 0;colvarP = 0} 
      if(ncol(fdat.tmp) < nrow(fdat.tmp)) {rowvarP = 1} else {colvarP = 1} 
      if(length(levels(fdat.tmp[,1])) == nrow(fdat.tmp)) {rowvarP = rowvarP + 1} 
      print(rowvarP);print(colvarP) 
      if(rowvarP == colvarP) {print("Orientation could not be determined. Specify
 'VarOrient'")} 
      if(rowvarP > colvarP) { 
        VarOrient = "row" 
        print("It was detected that your variable are along the rows. Congrats?") 
      } else if(rowvarP < colvarP){ 
          VarOrient = "col" 
        print("It was detected that your variable are along the cols. Congrats?")
}  
    } 
    if(VarOrient == "col"|VarOrient == "cols"){ 
      fdat.core <- as.matrix(read.table(input, 
                                        row.names = NULL,  
                                        quote=NULL,  
                                        comment="",  
                                        sep=sep.var,  
                                        stringsAsFactors=FALSE,  
                                        header=TRUE)) 
    } else if(VarOrient == "row"|VarOrient == "rows"){ 
      fdat.core <- t(as.matrix(read.table(input,  
                                          row.names = 1, 
                                          quote=NULL,  
                                          comment="",   
                                          sep=sep.var,  
                                          stringsAsFactors=FALSE,  
                                          header=FALSE))) 
    }   
448 Original Programming  
 
 
  } else { 
    fdat.core <- input 
  } 
  if(missing(subject) == TRUE) { 
    print("subject missing") 
  } else if(is.null(subject)) { 
    print("NULL SUBJECT") 
  } else if(missing(subject) == FALSE){ 
    pos.ID <- subject 
  }  
  if(missing(group) == TRUE){ 
    print("group missing") 
  } else if(is.null(group)) { 
    print("NULL GROUP") 
  } else if(missing(group) == FALSE){ 
    pos.GRP <- group 
  }  
  if(exists("pos.GRP")==TRUE|exists("pos.ID")==TRUE){ 
    print("G|I=T") 
    if(exists("pos.GRP")==TRUE&exists("pos.ID")==TRUE){ 
      print("G&I=T") 
      pos.GRP <- as.numeric(pos.GRP) 
      pos.ID <- as.numeric(pos.ID) 
      if(pos.GRP < pos.ID){ 
        fdat.names <- fdat.core[,c(pos.GRP,pos.ID)] 
      } else if(pos.GRP > pos.ID){ 
        fdat.names <- fdat.core[,c(pos.ID,pos.GRP)]} 
      dimnames(fdat.names)[[2]][pos.GRP] <- "GRP.var" 
      dimnames(fdat.names)[[2]][pos.ID] <- "ID.var" 
      fdat.names <- as.data.frame(fdat.names)} 
    if(exists("pos.GRP")==TRUE&exists("pos.ID")==FALSE){ 
      fdat.names <- fdat.core[,c(pos.GRP)] 
      dimnames(fdat.names)[[2]][pos.GRP] <- "GRP.var" 
      fdat.names <- as.data.frame(fdat.names)} 
    if(exists("pos.GRP")==FALSE&exists("pos.ID")==TRUE){ 
      fdat.names <- fdat.core[,c(pos.ID)] 
      dimnames(fdat.names)[[2]][pos.ID] <- "ID.var" 
      fdat.names <- as.data.frame(fdat.names)} 
    #ADD OPT FOR METADATA 
  } 
  if((pos.GRP < length(fdat.core)|pos.ID < length(fdat.core))&(pos.GRP == 1|pos.I
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D == 1)){ 
    fdat.data <- fdat.core[,-(1:length(fdat.names))];print("Base table arranged: 
name-data") 
  } else { 
    fdat.data <- fdat.core[,(1:(length(fdat.core)-length(fdat.names)))]; 
print("Base table arranged: data-name") 
  } 
  class(fdat.data) <- "numeric" 
  fdat.base <- cbind.data.frame(fdat.names, fdat.data) 
  fdat.out <- structure(list(base=fdat.base,data = fdat.data, names = fdat.names)
) 
  return(fdat.out) 
} 
 
fdis (format distance) 
#' Format data in preparation for ordination 
#'  
#' @param var.mat matrix of variables, preferably as fdatish object. e.g. taxa - 
required 
#' @param ID Classifier of subject subset e.g. group - one of: row/col position, 
NULL, or blank 
#' @param pair.ID Classifier of paired samples - factor list 
#' @param nom.hi First list of classifiers defining variable subset e.g. d_bacter
ia - one of: list 
#' @param nom.lo Final list of classifiers defining variable subset e.g. _species
 - one of: object 
#' @param nom.split Classifier of sample subsetting - factor list 
#' @param rm.var Remove empty variables i.e. variables with sum = 0 - one of: TRU
E or FALSE 
#' @param rm.unpar Remove sites/subjects unpaired according to 'pair.ID' - one of
: TRUE or FALSE 
#' @param opt.split Subset data according to grouping variable - one of: TRUE, FA
LSE or BOTH 
#' @param opt.norm Perform normalisation on supplied data - one of: TRUE or FALSE 
#' @param opt.comb Combine RA from separate subsets - one of: TRUE, FALSE or BOTH 
#' @param opt.Mnorm Perform normalisation on subsets of variables - one of: TRUE 
or FALSE 
#' @param opt.dist Generate distance matrix for data - one of: TRUE or FALSE 
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#' @param opt.comment Provide commentary on function processing - one of: TRUE or
 FALSE 
#' @param norm.meth Method of normalisation to be performed by vegan::decostand -
 one of: "total","max","freq","normalize","range","standardize","pa"  
#' @param dist.meth Ordination method - one of "PCOA" or "NMDS" 
#'  
#' @return list containing numeric data, identification variables as factors, and
 the two combined 
#' @seealso ampvis2 
#' @export 
#' @examples 
#' fthisDat <- data_frame( 
#' ids = letters[1:10],  
#' grouping = rep(letters[1:2], 5), 
#' TimePoint = rep(1:2,5)  
#' var_1 = sample(.1:10),  
#' var_2 = sample(.1:10), 
#' var_3 = sample(.1:10),  
#' var_4 = sample(.1:10),   
#' var_5 = sample(.1:10)) 
#'  
#' fdis_out <- fdis(var.mat = fthisDat[4:8], ID = fthisDat$ids, pair.ID = fthisDa
t$TimePoint,  
#'                 nom.hi = list("A","B","C"), nom.lo = "D", nom.split, 
#'                 rm.var = FALSE, rm.unpar = FALSE,  
#'                 opt.split = FALSE, opt.norm = TRUE, opt.Mnorm = FALSE, opt.com
b = FALSE, opt.dist = TRUE, opt.comment = FALSE,  
#'                 norm.meth = "total", dist.meth = "NMDS") 
#'  
# 
# NEED TO IMPLEMENT METHOD FOR PATHWAY (| and __S) 
fdis <- function(var.mat, ID, pair.ID,  
                 nom.hi, nom.lo, nom.split, 
                 rm.var = FALSE, rm.unpar = FALSE,  
                 opt.split = FALSE, opt.norm, opt.Mnorm, opt.comb, opt.dist, opt.
comment = FALSE, norm.meth, dist.meth){ 
#VARIABLE ASSESSMENT 
  if (opt.comment != TRUE && opt.comment != FALSE){ 
    opt.comment = FALSE 
  } 
  if (missing(var.mat)==TRUE){ 
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    if(opt.comment == TRUE){ 
    print("Huh, data aren't supplied, we cannot proceed! (Hint: var.mat = `your_d
ata.txt`/your_data)") 
    } 
    stopifnot(missing(var.mat)==FALSE) 
  } 
  if (is.matrix(var.mat) == FALSE && is.data.frame(var.mat) == FALSE | is.numeric
(var.mat) == FALSE){ 
    if (opt.comment == TRUE){ 
    print("'var.mat' is in unacceptable format, atempting to fix...") 
    } 
    if (is.numeric(var.mat) == FALSE){ 
      if (missing(ID) == TRUE | missing(pair.ID) == TRUE | missing(nom.split) == 
TRUE){ 
        ID.tmp <- var.mat[,sapply(var.mat, is.factor)] 
      } 
      var.mat <- as.matrix(var.mat[,sapply(var.mat, is.numeric)]) 
      if (is.numeric(var.mat) == FALSE){ 
        if (opt.comment == TRUE){ 
          stop ( "Could not convert 'var.mat' to an acceptable format") 
          print("Could not convert 'var.mat' to an acceptable format") 
        } 
      } else { 
        if (opt.comment == TRUE){ 
          print("'var.mat' successfully converted") 
        } 
      } 
    } 
  } 
  if (missing(ID) == TRUE){ 
    if (opt.comment == TRUE){ 
    print( "Huh, no identification variables are supplied, attempting to locate.w
e cannot proceed!  
(Hint: ID = your_data$GROUP)") 
    } 
    if (exists("ID.tmp") == TRUE){ 
      if (length(ID.tmp) == 1){ 
        ID <- ID.tmp 
        if (opt.comment == TRUE){ 
        print(paste("ID variable used:", colnames(ID.tmp)[1])) 
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        } 
      } 
      if (length(ID.tmp) > 1){ 
        if (length(grep("G",colnames(ID.tmp), value = FALSE, ignore.case = TRUE))
 > 0){ 
          if (length(grep("G",colnames(ID.tmp), value = FALSE, ignore.case = TRUE
)) > 1){ 
            if (length(grep("Group",colnames(ID.tmp), value = FALSE, ignore.case 
= TRUE)) == 1){ 
              if (opt.comment == TRUE){ 
                print(paste("ID variable used:", colnames(ID.tmp)[grep("Group",co
lnames(ID.tmp),  
value = FALSE, ignore.case = TRUE)])) 
              } 
              ID <- ID.tmp[grep("Group", colnames(ID.tmp), value = TRUE, ignore.c
ase = TRUE)] 
            } 
            if (length(grep("G.p",colnames(ID.tmp), value = FALSE, ignore.case = 
TRUE)) == 1){ 
              if (opt.comment == TRUE){ 
                print(paste("ID variable used:", colnames(ID.tmp)[grep("G.p",coln
ames(ID.tmp),  
value = FALSE, ignore.case = TRUE)])) 
              } 
              ID <- ID.tmp[grep("G.p", colnames(ID.tmp), value = TRUE, ignore.cas
e = TRUE)] 
            } 
          } else { 
            if (length(grep("G",colnames(ID.tmp), value = FALSE, ignore.case = TR
UE)) == 1){ 
              ID <- ID.tmp[grep("G", colnames(ID.tmp), value = TRUE, ignore.case 
= TRUE)] 
              if (opt.comment == TRUE){ 
                print(paste("ID variable used:", colnames(ID.tmp)[grep("G",colnam
es(ID.tmp),  
value = FALSE, ignore.case = TRUE)])) 
              } 
            } 
          } 
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        } 
        if (length(grep("G",colnames(ID.tmp), value = FALSE, ignore.case = TRUE))
 == 0){ 
          for (i in 1 : length(ID.tmp)){ 
            if (exists("ID") == FALSE){ 
              if (length(levels(ID.tmp[[i]])) > 1){ 
                ID <- ID.tmp[[i]] 
                if (opt.comment == TRUE){ 
                  print(paste("ID variable used:", colnames(ID.tmp)[[i]])) 
                } 
              } 
            } 
          } 
        } 
      } 
    } 
  } 
  if(is.factor(ID) == FALSE | is.character(ID) == TRUE){ 
    if(opt.comment == TRUE){ 
    print("'ID' is in an unacceptable format, atempting to fix...") 
    } 
    if(is.character(ID) == TRUE){ 
      ID <- as.factor(ID) 
    } 
    if(is.factor(ID) == FALSE){ 
      if(opt.comment == TRUE){ 
      print("Fix unsuccessful, try suppling as factor!") 
      } 
    } 
  } 
  if(missing(nom.hi)== TRUE | is.null(nom.hi) == TRUE && missing(nom.lo) == TRUE 
|  
is.null(nom.lo) == TRUE){ 
    if(opt.comment == TRUE){ 
    print("Variable subsetting not applied") 
    } 
    nom.hi = NULL 
    nom.lo = NULL 
  } else { 
    if(missing(nom.hi)==TRUE){ 
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      if(opt.comment == TRUE){ 
      print("High level variable subsetting not applied") 
      } 
      nom.hi = NULL 
    } 
    if(is.list(nom.hi) == FALSE && is.character(nom.hi) == FALSE){ 
      if(opt.comment == TRUE){ 
      print("'nom.hi' is in an unacceptable format, atempting to fix...") 
      } 
      if(is.character(nom.hi) == TRUE){ 
        nom.hi <- as.list(nom.hi) 
      } 
      if(is.list(nom.hi) == FALSE){ 
        if(opt.comment == TRUE){ 
        print("Fix unsuccessful, try suppling as list!") 
        } 
      } 
    }  
    if(missing(nom.lo)==TRUE){ 
      if(opt.comment == TRUE){ 
      print("Low level variable subsetting not applied") 
      } 
      nom.lo = NULL 
    } 
    if(is.character(nom.lo) == FALSE){ 
      if(opt.comment == TRUE){ 
      print("'nom.lo' is in an unacceptable format, atempting to fix...") 
      } 
      if(is.character(nom.lo) == FALSE){ 
        nom.lo <- as.character(nom.lo) 
      } 
      if(is.character(nom.lo) == FALSE){ 
        if(opt.comment == TRUE){ 
        print("Fix unsuccessful, try suppling as character!") 
        } 
      } 
    } 
  } 
  if(missing(opt.split) == TRUE | is.null(opt.split) | opt.split == FALSE){ 
    if(opt.comment == TRUE){ 
    print("Subjects will not be split") 
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    } 
    nom.split = NULL 
    opt.split = FALSE 
  } 
  if(opt.split == "Both" | opt.split == "both" | opt.split == "B" | opt.split == 
"b"){ 
    opt.split = "BOTH" 
  } 
  if(missing(nom.split)==TRUE | is.null(nom.split) == TRUE && opt.split == TRUE |
 opt.split == "BOTH"){ 
    if(opt.comment == TRUE){ 
    print("Identification variable for split (nom.split) not found, using 'ID' va
riable") 
    } 
    nom.split <- ID 
  } 
  if(missing(rm.var)==TRUE){ 
    if(opt.comment == TRUE){ 
    print("Empty variables will not be removed") 
    } 
    rm.var = FALSE 
  } 
  if(missing(rm.unpar)==TRUE){ 
    if(opt.comment == TRUE){ 
    print("Unpaired subjects will not be removed") 
    } 
    rm.unpar = FALSE 
    stopifnot(missing(rm.unpar)==FALSE) 
  } 
  if(rm.unpar == TRUE && missing(pair.ID) == TRUE){ 
    if(opt.comment == TRUE){ 
    print("ID to match samples is missing, unpaired subjects will not be removed"
) 
    } 
    rm.unpar = FALSE 
  } 
  if(rm.unpar == TRUE && missing(pair.ID) == FALSE){ 
    if(is.factor(pair.ID) == FALSE){ 
      if(is.character(pair.ID) == FALSE){ 
      if(opt.comment == TRUE){ 
      print("'pair.ID' is in an unacceptable format, atempting to fix...") 
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      } 
      if(is.character(pair.ID) == TRUE){ 
        pair.ID <- as.factor(pair.ID) 
      } 
      if(is.factor(pair.ID) == FALSE){ 
        if(opt.comment == TRUE){ 
        print("Fix unsuccessful, try suppling as factor!") 
        } 
        rm.unpar = FALSE 
        pair.ID = NULL 
      } 
    } 
    } 
  } 
  if(missing(opt.norm)==TRUE){ 
    if(opt.comment == TRUE){ 
    print("Data will not be normalised") 
    } 
    opt.norm = FALSE 
  } 
  if(missing(opt.Mnorm) == TRUE){ 
    if(opt.norm == TRUE){ 
      if(is.null(nom.hi) == FALSE){ 
        if(opt.comment == TRUE){ 
        print("Normalisation performed separately according to 'nom.hi") 
        } 
        opt.Mnorm = TRUE 
      } else {if(is.null(nom.hi) == TRUE){ 
        if(opt.comment == TRUE){ 
        print("Normalisation performed on full data set") 
        } 
        opt.Mnorm = FALSE 
      }} 
    } 
  } 
  if(missing(opt.comb)==TRUE){ 
    if(opt.comment == TRUE){ 
    print("Data will not be combined") 
    } 
    opt.comb = FALSE 
  } 
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  if(opt.comb == "Both" | opt.comb == "both" | opt.comb == "B" | opt.comb == "b")
{ 
    opt.comb = "BOTH" 
  } 
  if(missing(opt.dist) == TRUE){ 
    if(opt.comment == TRUE){ 
    print("Distance matrix will not be generated") 
    } 
    opt.dist = FALSE 
  } 
  if(missing(norm.meth)==TRUE && missing(opt.norm)==TRUE | opt.norm == FALSE){ 
    if(opt.comment == TRUE){ 
    print("Data will definitely not be normalised") 
    } 
  }  
  if(missing(norm.meth)==TRUE && opt.norm == TRUE){ 
    print("Default normalisation - total: divide by margin total") 
    norm.meth = "total" 
  } 
  if(missing(dist.meth)==TRUE && opt.dist == TRUE){ 
    if(opt.comment == TRUE){ 
    print("Default ordination - PCoA") 
    } 
    dist.meth = "PCOA" 
  } 
  if(missing(dist.meth)==FALSE && opt.dist == TRUE){ 
    if(dist.meth != "PCOA" && dist.meth != "NMDS"){ 
    if(opt.comment == TRUE){ 
      print("Ordination method not supplied as 'PCOA' or 'NMDS', attempting to fi
x") 
    } 
      if(dist.meth == "pcoa" | dist.meth == "Pcoa" | dist.meth == "PCoA"){ 
        if(opt.comment == TRUE){ 
          print("Option determined: 'PCOA'") 
        } 
        dist.meth = "PCOA" 
      } 
      if(dist.meth == "nmds" | dist.meth == "Nmds" | dist.meth == "nMDS"){ 
        if(opt.comment == TRUE){ 
          print("Option determined: 'NMDS'") 
        } 
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        dist.meth = "NMDS" 
      } 
    } 
    if(dist.meth != "PCOA" && dist.meth != "NMDS"){ 
    if(opt.comment == TRUE){ 
      print("Could NOT determine ordination method. Default used: 'PCOA'") 
    } 
      dist.meth = "PCOA"} 
  } 
  if(missing(dist.meth)==TRUE && missing(opt.dist)==TRUE | opt.dist == FALSE){ 
    if(opt.comment == TRUE){ 
    print("Ordination data not generated") 
    } 
  } 
  # Remove unpaired samples 
  if(rm.unpar == TRUE && is.null(pair.ID) == FALSE){ 
    var.mat <- var.mat[pair.ID %in% (pair.ID)[duplicated(pair.ID)==TRUE],] 
    ID <- ID[pair.ID %in% pair.ID[duplicated(pair.ID)==TRUE]] 
    nom.split <- nom.split[pair.ID %in% pair.ID[duplicated(pair.ID)==TRUE]] 
  } 
  # SUBSET BY VARIABLE NAMES i.e. low lvl extraction -- IMPLEMENT METHOD FOR 'PAT
HWAYS' 
  if(is.null(nom.hi) == FALSE | is.null(nom.lo) == FALSE){ 
    fdis.VAR.sub <- list() 
    if(is.null(nom.hi) == FALSE){ 
      for (j in 1: length(nom.hi)){ 
        fdis.VAR.sub[[length(fdis.VAR.sub)+1]] <- 
          var.mat[,c(grep(nom.hi[[j]], colnames(var.mat)))] 
        if(is.null(nom.lo) == FALSE){ 
          fdis.VAR.sub[[length(fdis.VAR.sub)]] <- 
            as.data.frame(fdis.VAR.sub[[length(fdis.VAR.sub)]][,c(grep(nom.lo, co
lnames(fdis.VAR.sub[[length(fdis.VAR.sub)]])))]) #AS>DATA>FRAME ADDED 
        }  
#        str(fdis.VAR.sub) 
        if (exists("rm.var") == FALSE) {rm.var = FALSE} 
        if (rm.var == TRUE){ 
#          if(fdis.VAR.sub[[length(fdis.VAR.sub)]]) 
          fdis.VAR.sub[[length(fdis.VAR.sub)]] <-  
            fdis.VAR.sub[[length(fdis.VAR.sub)]][,c(which(colSums(fdis.VAR.sub[[l
ength(fdis.VAR.sub)]])!=0)), drop = FALSE] #ADDITION OF DROP 
        } 
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      } 
    } 
    if(is.null(nom.hi) == TRUE && is.null(nom.lo) == FALSE){ 
      fdis.VAR.sub[[length(fdis.VAR.sub)+1]] <- 
        var.mat[,c(grep(nom.lo, colnames(var.mat)))] 
      if (exists("rm.var") == FALSE) {rm.var = FALSE} 
      if (rm.var == TRUE){ 
        fdis.VAR.sub[[length(fdis.VAR.sub)]] <-  
          fdis.VAR.sub[[length(fdis.VAR.sub)]][,c(which(colSums(fdis.VAR.sub[[len
gth(fdis.VAR.sub)]])!=0)), drop = FALSE]#ADDITION OF DROP 
      } 
    } 
  } 
  # Normalisation of multiple sets # POSSIBLE NEED FOR MARGIN.VAR 
  if(opt.norm == TRUE){ 
    fdis.norm <- list() 
    if(exists("fdis.VAR.sub")){ 
      if(opt.Mnorm == TRUE){ 
        for (i in 1 : length(fdis.VAR.sub)){ 
          fdis.norm[[length(fdis.norm) + 1]] <- decostand(fdis.VAR.sub[[i]], meth
od = norm.meth) 
        }  
      } else { 
        if(opt.Mnorm == FALSE){ 
          if(length(fdis.VAR.sub) > 1){ 
            for(i in 1 : length(fdis.VAR.sub)){ 
              if(i == 1){ 
                fdis.norm.tmp <- fdis.VAR.sub[[i]]   
              } 
              if(i > 1){ 
                fdis.norm.tmp <- cbind(fdis.norm.tmp, fdis.VAR.sub[[i]]) 
              } 
            } 
            fdis.norm <- decostand(fdis.norm.tmp, method = norm.meth) 
          } 
          if(length(fdis.VAR.sub) == 1){ 
            fdis.norm <- decostand(fdis.VAR.sub, method = norm.meth) 
          } 
        } 
      } 
    } 
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    # Combine sets 
    # MAY BE BROKEN - CHECK ID=TRUE colnames!!!!!!!! 
    # NOT ACCEPTING PATHWAY DATA WITH LOW LENGTH 
    if(opt.comb == TRUE | opt.comb == "BOTH"){ 
      for (i in 1 : length(fdis.norm)){ 
        if (i == 1) { 
          fdis.norm.tmp <- fdis.norm[[i]] 
        } else { 
          if (i < length(fdis.norm)){ 
            if (nrow(fdis.norm.tmp)==nrow(fdis.norm[[i]])){ 
              fdis.norm.tmp <- cbind(fdis.norm.tmp, fdis.norm[[i]]) 
            } 
            if (nrow(fdis.norm.tmp)!=nrow(fdis.norm[[i]]) && ncol(fdis.norm.tmp)=
=ncol(fdis.norm[[i]])){ 
              fdis.norm.tmp <- rbind(fdis.norm.tmp, fdis.norm[[i]]) 
            } 
          } 
        } 
        if (i == length(fdis.norm)){ 
          if (nrow(fdis.norm[[i]])==nrow(fdis.norm[[i-1]])){ 
            fdis.norm.tmp <- cbind(fdis.norm.tmp, fdis.norm[[i]]) 
          } 
          if (nrow(fdis.norm[[i]])!=nrow(fdis.norm[[i-1]]) && ncol(fdis.norm.tmp)
==ncol(fdis.norm[[i]])){ 
            fdis.norm.tmp <- cbind(fdis.norm.tmp, fdis.norm[[i]]) 
          } 
        } 
      } 
      fdis.Mnorm <- list() 
      fdis.Mnorm[[1]] <- fdis.norm.tmp 
      if(opt.comb == "BOTH"){ 
        fdis.norm[[length(fdis.norm)+1]] <- fdis.Mnorm 
        fdis.Mnorm <- fdis.norm 
      } 
    } 
  } 
  # SUBSETTING DATA #!!!!!ADD DETAIL ON SPLIT COMMENT DYSFUNCTIONAL WITH INPUTS O
F 1 COLUMN!!!! 
  if(opt.split == TRUE | opt.split == "BOTH"){ 
    fdis.split <- list() 
    for(i in 1 : length(fdis.norm)){ 
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      fdis.split.tmp <- (split(data.frame(fdis.norm[[i]]), nom.split)) 
      for(j in 1: length(levels(nom.split))){ 
        fdis.split[[length(fdis.split) + 1]] <- fdis.split.tmp[[j]]   
        if(rm.var == TRUE){ 
          if(opt.split == TRUE){ 
            if(opt.comment == TRUE){ 
              print(paste("Checking for empty variables following data subsetting
 in: ", 
levels(nom.split)[j])) 
            } 
            fdis.split[[length(fdis.split)]] <- fdis.split[[length(fdis.split)]][
,c(which(colSums(fdis.split[[length(fdis.split)]])!=0))] 
            #print(ncol(fdis.split[[length(fdis.split)]])) 
            #str(fdis.split) 
            if(is.null(ncol(fdis.split[[length(fdis.split)]])) == TRUE){ 
              str(fdis.split[[length(fdis.split)]]) 
              print(ncol(fdis.split[[length(fdis.split)]])) 
              if(opt.comment == TRUE){ 
                print(paste(nom.hi[[i]],"-",levels(nom.split)[j],"-","All variabl
es removed  
after subsetting")) 
              } 
            } 
            if(is.null(ncol(fdis.split[[length(fdis.split)]])) == FALSE){ 
              if(ncol(fdis.split[[length(fdis.split)]]) != ncol(fdis.split.tmp[[j
]])){ 
                if(opt.comment == TRUE){ 
                  print("Empty variables removed after subsetting") 
                } 
              } 
            } 
            if(is.null(ncol(fdis.split[[length(fdis.split)]])) == FALSE){ 
            if(ncol(fdis.split[[length(fdis.split)]]) == ncol(fdis.split.tmp[[j]]
)){ 
              if(opt.comment == TRUE){ 
                print("No empty variables detected after subsetting") 
              } 
            } 
            } 
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          } 
        } 
      } 
    } 
    if(opt.split == "BOTH"){ 
      for(i in 1 : length(fdis.norm)){ 
        fdis.split[[length(fdis.split) + 1]] <- fdis.norm[[i]] 
        if(rm.var == TRUE){ 
          if(opt.split == "BOTH"){ 
          if(opt.comment == TRUE){ 
            print(paste("Checking for empty variables following data subsetting i
n: ", 
levels(nom.split)[i])) 
          } 
          fdis.split[[length(fdis.split)]] <- fdis.split[[length(fdis.split)]][,c
(which(colSums(fdis.split[[length(fdis.split)]])!=0))] 
          if(ncol(fdis.split[[length(fdis.split)]]) != ncol(fdis.norm[[i]])){ 
            if(opt.comment == TRUE){ 
              print("Empty variables removed after subsetting") 
            } 
          } 
          if(ncol(fdis.split[[length(fdis.split)]]) == ncol(fdis.norm[[i]])){ 
            if(opt.comment == TRUE){ 
              print("No empty variables detected after subsetting") 
            } 
          } 
          } 
        } 
      } 
    } 
  } 
  # Distance matrix generation OPT for methods 
  # ADD OPT - POINT OR FULL WCMDSCALE OUT 
  if(opt.dist == TRUE){ 
    print("467") 
    fdis.dist <- list() 
    fdis.eig <- list() 
    if(exists("fdis.split") == TRUE){ 
      fdis.norm <- fdis.split 
    } 
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    if(dist.meth == "PCOA"){ 
      for(i in 1: length(fdis.norm)){ 
        fdis.dist[[length(fdis.dist) + 1]] <- vegdist(fdis.norm[[i]], method = "b
ray") 
        fdis.dist[[length(fdis.dist)]] <- wcmdscale(fdis.dist[[length(fdis.dist)]
], k=2, w=rep(1, nrow(fdis.norm[[i]])), eig = TRUE) 
        fdis.eig[[length(fdis.eig) + 1]] <- eigenvals(fdis.dist[[length(fdis.dist
)]]) 
        fdis.eig[[length(fdis.eig)]] <- (fdis.eig[[length(fdis.eig)]]/sum(fdis.ei
g[[length(fdis.eig)]])) 
        fdis.dist[[length(fdis.dist)]] <- data.frame(fdis.dist[[length(fdis.dist)
]]$points) 
      } 
    } 
    if(dist.meth == "NMDS"){ 
      for(i in 1: length(fdis.norm)){ 
        fdis.dist[[length(fdis.dist) + 1]] <- metaMDS(fdis.norm[[i]], k = 2) 
      } 
    } 
  } 
  # COMPLETE STRATEGY FOR APPLICATION OF SUBJECT DETAILS TO OUTPUT 
#  if(opt.ID.out == TRUE) 
  ID.out.tmp <- as.data.frame(cbind(as.character(ID), nom.split)) 
  colnames(ID.out.tmp) <- c("GRP.var", "nom.split") 
  ID.out.tmp <- split(ID.out.tmp, ID.out.tmp$nom.split) 
  ID.out <- list() 
  for(i in 1 : (length(levels(ID))/length(levels(nom.split)))){ 
    for(j in 1 : length(levels(nom.split))){ 
      ID.out[[length(ID.out) + 1]] <- ID.out.tmp[[j]] 
      ID.out[[length(ID.out)]]$Variable.ID <- nom.hi[[i]] 
    } 
  } 
#  print(str(fdis.norm)) 
  if(opt.dist == TRUE){ 
  for(i in 1 : length(fdis.dist)){ 
    fdis.dist[[i]] <- cbind(ID.out[[i]], fdis.dist[[i]]) 
  } 
  } 
  if(opt.norm == TRUE && opt.dist == TRUE){ 
    fdis.out <- structure(list(RA = fdis.norm, Distance = fdis.dist, eigan = fdis
.eig))     
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  } 
  if(opt.norm == TRUE && opt.dist == FALSE){ 
    fdis.out <- structure(list(RA = fdis.norm))     
  } 
  if(opt.norm == FALSE && opt.dist == TRUE){ 
    fdis.out <- structure(list(Data = fdis.norm, Distance = fdis.dist, eigan = fd
is.eig))     
  } 
  return(fdis.out) 
} 
geom.insec Generate intersection points of a given value (e.g. median) to close geoms in GGPlot2 
geom.insec <- function(gg.dat, group.var, x.var, y.var, cross.var){ 
  out.tmp <- NULL 
  for(i in 1 : length(unique(group.var))){ 
    input.tmp <- gg.dat[group.var == levels(group.var)[i],] 
    x.tmp <- as.numeric(x.var[group.var == levels(group.var)[i]]) 
    y.tmp <- y.var[group.var == levels(group.var)[i]] 
    cord.tmp <- as.data.frame(cbind(x.tmp, y.tmp)) 
    grp.tmp <- do.call("rbind", 
                       sapply(1:(length(group.var[which(group.var == group.var[i]
)]) - 1), function(j){ 
                         regres <- lm(x.tmp ~ y.tmp, cord.tmp[j:(j+1),]) 
                         if (regres$qr$rank < 2) return(NULL) 
                         mSec <- predict(regres, newdata = data.frame(y.tmp = uni
que(cross.var[group.var == levels(group.var)[i]]))) 
                         if (x.tmp[j] < mSec & mSec < x.tmp[j+1]) 
                           return(data.frame(x = mSec, y = unique(cross.var[group
.var ==  
levels(group.var)[i]]))) 
                         else return(NULL) 
                       } 
                       ) 
    ) 
    merge.tmp <- input.tmp[1:(nrow(grp.tmp)),] 
    for (k in 1 : (ncol(input.tmp))){ 
      if (identical(as.numeric(x.tmp), as.numeric(as.character(input.tmp[1:(nrow(
input.tmp)),k]))) == TRUE |  
          identical(as.numeric(y.tmp), as.numeric((input.tmp[,k]))) == TRUE) { 
        if (identical(as.numeric(x.tmp), as.numeric(as.character(input.tmp[1:(nro
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w(input.tmp)),k]))) == TRUE){ 
          merge.tmp[k] <- grp.tmp$x 
        } 
        if (identical(as.numeric(y.tmp), as.numeric((input.tmp[,k]))) == TRUE){ 
          merge.tmp[k] <- grp.tmp$y 
        } 
      } 
    } 
    out.tmp = rbind(out.tmp, merge.tmp) 
  } 
  return(out.tmp) 
} 
 
GG.data.mSec <- geom.insec(gg.dat = GG.data.in.form,  
                           group.var = GG.data.in.form$group.ID,  
                           x.var = GG.data.in.form$TP,  
                           y.var = GG.data.in.form$multi.sites.raw,  
                           cross.var = GG.data.in.form$multi.sites.mean) 
falph (Normalise and generate alpha diversity on data) 
falph <- function(site.mat, site.ID, group.ID,  
                  div.meth = "shannon", norm.meth = "total", margin.var = 1, 
                  opt.comment = FALSE, output.opt) { 
  falph.in <- site.mat 
  if (is.list(falph.in) == TRUE) {falph.tmp <- list()} 
  if (is.list(falph.in) == FALSE) {falph.tmp = NULL} 
  if (is.list(falph.in) == TRUE) { 
    for (i in 1:length(falph.in)) { 
      multi.sites = NULL 
      if (is.null(norm.meth) == FALSE) { 
        if (norm.meth == "wisconsin") { 
          names.tmp <- falph.in[[i]][1:(sum(sapply(falph.in[[i]], is.factor)))] 
          data.tmp <- falph.in[[i]][ 
(sum(sapply(falph.in[[i]], is.factor)) + 1) : ncol(falph.in[[i]])] 
          data.tmp <- wisconsin(data.tmp) 
          falph.in[[i]] <- cbind(names.tmp, data.tmp) 
        } 
        if (norm.meth != "wisconsin") { 
          names.tmp <- falph.in[[i]][1:(sum(sapply(falph.in[[i]], is.factor)))] 
          data.tmp <- falph.in[[i]][ 
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(sum(sapply(falph.in[[i]], is.factor)) + 1) : ncol(falph.in[[i]])] 
          data.tmp <- decostand(data.tmp, method = norm.meth, MARGIN = margin.var
) 
          falph.in[[i]] <- cbind(names.tmp, data.tmp) 
        } 
      } 
      for (j in 1:length(site.ID)) { 
        site.tmp <- diversity(falph.in[[i]][j,(sum(sapply(falph.in[[i]], is.facto
r))+1) : ncol(falph.in[[i]])], index = div.meth) 
        multi.sites <- rbind(multi.sites, site.tmp) 
      } 
#      ID.tmp <- cbind(as.character(site.ID), as.character(group.ID)) 
      ID.tmp <- as.data.frame(cbind(as.character(site.ID), as.character(group.ID)
)) 
      colnames(ID.tmp) <- c("site.ID", "group.ID") 
      if (exists("pwy.opt") == FALSE) {pwy.opt = FALSE} 
      if (pwy.opt == FALSE){ 
      ID.tmp$taxa = nom.hi[[i]] 
      } 
      ID.tmp$Diversity = div.meth 
      multi.sites <- cbind(ID.tmp, multi.sites) 
      falph.tmp[[length(falph.tmp) + 1]] <- multi.sites 
    } 
  } 
  if (output.opt == "short") {falph.out <- falph.tmp} 
  if (output.opt == "long") { 
    if (is.list(falph.tmp) == TRUE) { 
      melt.tmp = NULL 
      for (i in 1:length(falph.tmp)) { 
        melt.tmp = rbind(melt.tmp, falph.tmp[[i]]) 
        melt.tmp$taxa = as.factor(melt.tmp$taxa) 
      } 
      falph.out = melt.tmp 
    } 
  } 
  return(falph.out) 
} 
BD.PCoA.GG (Wrapper function to generate GGplot2 ordination plots) 
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BD.PCoA.gg <- function(gg.Kin){ 
  plot.out.PCoA <- 
  { 
    { 
      if (exists("col.fill") == FALSE | exists("grouping.var.main") == FALSE){ 
        if (exists("grouping.var.main")==FALSE){ 
          print("Bummer! 'grouping.var.main' was not set, attempting to guess wha
t you want...  
'GG.data.in$grp/GRP.var/Group' being used") 
          if ("grp"%in%names(GG.data.in) == FALSE & "GRP.var"%in%names(GG.data.in
) == FALSE &  
"Group"%in%names(GG.data.in) == FALSE){ 
            print("Oh shit, the grouping variable wasn't detected in the GG.data.
in object!! 
 GGplot cannot proceed.  
                  Check the status of the variables!") 
          } else { 
            if("grp"%in%names(GG.data.in) == TRUE){ 
              grouping.var.main = GG.data.in$grp; print("GG.data.in$grp used to d
efine groups")} 
            if("GRP.var"%in%names(GG.data.in) == TRUE){ 
              grouping.var.main = GG.data.in$GRP.var; print("GG.data.in$GRP.var u
sed to define  
groups")} 
            if("Group"%in%names(GG.data.in) == TRUE){ 
              grouping.var.main = GG.data.in$Group; print("GG.data.in$Group used 
to define groups")} 
          } 
          if (exists("col.fill") == FALSE) { 
            col.fill <- distinctColorPalette(k = length(levels(grouping.var.main)
)) 
            print(c("Palette Generated: ", col.fill)) 
          } 
      } 
        } 
      if (exists("axis.data.X") == FALSE) { 
        if ("V1"%in%names(GG.data.in) == TRUE) { 
          axis.data.X <- GG.data.in$V1 
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          print("Using GG.data.in$V1 as X variable")} 
        else if ("Dim1"%in%names(GG.data.in) == TRUE) { 
          axis.data.X <- GG.data.in$Dim1 
          print("Using GG.data.in$Dim1 as X variable")} 
        else if ("V1"%in%names(GG.data.in) == FALSE & "Dim1"%in%names(GG.data.in)
 == FALSE)  
{axis.data.X <- GG.data.in[1] 
        print("X axis variable not supplied, using GG.data.in[1]")} 
      } 
      if (exists("axis.data.Y") == FALSE) { 
        if ("V2"%in%names(GG.data.in) == TRUE) { 
          axis.data.Y <- GG.data.in$V2 
          print("Using GG.data.in$V2 as Y variable")} 
        else if ("Dim2"%in%names(GG.data.in) == TRUE) { 
          axis.data.Y <- GG.data.in$Dim2 
          print("Using GG.data.in$Dim2 as Y variable")} 
        else if ("V2"%in%names(GG.data.in) == FALSE & "Dim2"%in%names(GG.data.in)
 == FALSE)  
{axis.data.Y <- GG.data.in[2] 
        print("Y axis variable not supplied, using GG.data.in[2]")} 
      } 
      if (exists("alpha.col.var") == FALSE) {alpha.col.var <- 1.0} 
      if (exists("alpha.fil.var") == FALSE) {alpha.fil.var <- 1.0} 
      if (exists("lab.var") == FALSE) {lab.var <- levels(grouping.var.main)} 
      if (exists("siz.dot.opt") == FALSE) {siz.dot.opt <- 2} 
      if (exists("guide.var") == FALSE) {  
        guide.var <-  
          guides(alpha = FALSE,  
                 size = FALSE,  
                 color = guide_legend(override.aes = list(size = 5)),  
                 fill = guide_legend(keywidth = 3, keyheight = 2) 
          ) 
      } 
      if (exists("theme.var") == FALSE) { 
        theme.var <- 
          theme(plot.title = element_text(hjust = 0.5), 
                plot.margin = margin(10,10,10,10, "pt"), 
                axis.text.x = element_text(size = rel(1.0), face = "bold"), 
                axis.title.x = element_text(size = rel(1.0), face = "bold",  
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margin = margin(10,10,10,10, "pt")), 
                axis.text.y = element_text(size = rel(1.0), face = "bold"), 
                axis.title.y = element_text(size = rel(1.0), face = "bold",  
margin = margin(10,10,10,10, "pt")), 
                legend.text = element_text(size = rel(0.8), colour = "black",  
angle = 0, face = "bold"), 
                strip.text.x = element_text(size = rel(1.0), face = "bold",  
margin = margin(1.5,1.5,1.5,1.5, "pt")), 
                axis.ticks.length = unit(5, "pt"), 
                axis.ticks.y = element_line(size = rel(.8)), 
                axis.ticks.x = element_line(size = rel(.8)), 
                panel.grid.minor = element_blank(), 
                panel.grid.major = element_line(size = rel(.3)), 
                legend.background = element_rect(color = "black"), 
                legend.key.size = unit(2, "cm"), 
                legend.position = "right", 
                legend.margin = margin(-10.0,10.0,10.0,10.0))} 
      if (is.list(guide.var) == FALSE){ 
        if (guide.var == "blank") { 
          guide.var = NULL 
          theme.var + theme(legend.position = "none") 
        } 
      } 
      { 
        if (exists("themeBW.var") == FALSE) {themeBW.var <-  
          theme_bw(base_size = 18, 
                   if (Sys.info()['sysname']=="Windows"){loadfonts(device = "win"
);base_family = "sans"} 
                   else {base_family = "Helvetica"}) 
        } 
        if (exists("hex.mode.on")==FALSE) {hex.mode.on = FALSE} 
        if (hex.mode.on == TRUE) { 
          ggplot(NULL, aes(axis.data.X, axis.data.Y)) 
        } else { 
          ggplot() 
        } 
      } 
  } + 
      themeBW.var +       
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      theme.var + 
      { 
        if (exists("elip.opt") == FALSE) {elip.opt = FALSE} 
        if (hex.mode.on == FALSE & elip.opt == TRUE) { 
          if (exists("sub.scale.opt") == FALSE) {sub.scale.opt = FALSE} 
          elip.pout <- list() 
          elip.pout[[1]] <- stat_ellipse(aes(axis.data.X, axis.data.Y, fill = eli
p.fill.var), show.legend = FALSE,  
                                         type = "t", level = elip.fill.CI, geom =
 "polygon" 
          )   
          elip.pout[[2]] <- stat_ellipse(level = elip.fill.CI, 
                                         #if (identical(elip.fill.var,elip.colo.v
ar) ==TRUE){} 
                                         if (sub.scale.opt == TRUE){ 
                                           aes(axis.data.X, axis.data.Y, fill = e
lip.colo.var) 
                                         } else { 
                                           aes(axis.data.X, axis.data.Y, color = 
elip.colo.var)  
                                         } )  
          elip.pout 
        }   
      } + 
      geom_vline(xintercept = 0) +  
      geom_hline(yintercept = 0) + 
      { 
        if (exists("hex.mode.dot") == FALSE) {hex.mode.dot = TRUE} 
        if (exists("dot.outline.opt") == FALSE) {dot.outline.opt = FALSE} 
        if (hex.mode.dot == TRUE){ 
          if (dot.outline.opt == TRUE) { 
            geom_point(data = GG.data.in, 
                       aes(axis.data.X, axis.data.Y, 
                           color = "black"), 
                       size = siz.dot.opt+1) 
          } 
        } 
      } + { 
        if (hex.mode.dot == TRUE){ 
        geom_point(data = GG.data.in, 
                   aes(axis.data.X, axis.data.Y, 
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                       color = grouping.var.main), 
                   size = siz.dot.opt) 
        } 
      } + 
      { 
        if (exists("hex.mode.on") == FALSE) {hex.mode.on = FALSE} # NEEDDS WORK!!
!!!!! 
        if (hex.mode.on == TRUE){ 
          hex.mode.pout <- list() 
          for (h in 1 : 3){#length(hex.mode.dat)){ 
            hex.mode.pout[[h]] <- stat_binhex(data = hex.mode.dat[[h]], 
                                              bins = hex.mode.bin, position = "id
entity",  
                                              aes( 
                                                x = hex.mode.dat[[h]]$Dim1, 
                                                y = hex.mode.dat[[h]]$Dim2, 
                                                alpha = ..count..), fill = hex.mo
de.col[h]) 
          } 
          hex.mode.pout 
        } 
      } + { 
        if(exists("sub.ID.opt") == FALSE) {sub.ID.opt = FALSE} 
        if(sub.ID.opt == TRUE) { 
          if (sub.ID.all == TRUE) { 
            data.tmp = GG.data.in}  
          else if (sub.ID.all == FALSE) { 
            data.tmp = sub.ID.repel} 
          geom_label_repel( 
            data = data.tmp, 
            size = rel(5), 
            fontface = "bold", 
            force = 2, 
            segment.alpha = 0.5, 
            box.padding = unit(.5, "lines"), 
            color = "black", 
            if (sub.ID.all == TRUE) { 
              aes(axis.data.X, axis.data.Y,  
                  label = sub.ID.var)} 
            else { 
              aes(axis.data.X, axis.data.Y,  
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                  fill = factor(sub.ID.repel$grp), #NEEDS WORK 
                  label = sub.ID.var)} 
          )} 
      } + { 
        if(exists("tit.var") == FALSE) {tit.var = "Woah, such graph!"} 
        if(exists("Xax.var") == FALSE) {Xax.var = ""} 
        if(exists("Yax.var") == FALSE) {Yax.var = ""} 
        if(exists("tit.var")==TRUE&exists("Xax.var")==TRUE&exists("Yax.var")==TRU
E){ 
          labs(title = tit.var,x = Xax.var,y = Yax.var) 
        } 
      } + { 
        if(exists("annote.opt") == FALSE) annote.opt = FALSE 
        if(annote.opt)annote.obj 
      } + { 
        if(exists("elip.fill.leg") == FALSE) {elip.fill.leg = "legend"} 
        if(hex.mode.on == FALSE) { 
          scale_fill_manual( 
            name = "", 
            labels = c(lab.var), 
            guide = elip.fill.leg, 
            values = alpha(c(col.fill),alpha.fil.var)) 
        } 
      } + { 
        if (exists("sub.scale.opt") == FALSE) {sub.scale.opt = FALSE} 
        if (sub.scale.opt == TRUE) { 
          scale_color_viridis(aes(axis.data.X, axis.data.Y, color = sub.scale.var
), option = "D", alpha = 1, discrete = sub.scale.dis) 
        } else { 
          scale_colour_manual( 
            name = "", 
            guide = "legend", 
            labels = c(lab.var), 
            values = alpha(c(col.fill),alpha.col.var)) 
        } 
      } 
  } 
  # STRESS LABEL - ADD OPT. FOR LOCATION + COLLISION DETECTION 
  if (exists("stress.opt") == FALSE) {stress.opt = FALSE} 
  if (stress.opt == TRUE) { 
    range.x <- ggplot_build(plot.out.PCoA)$layout$panel_ranges[[1]]$x.range 
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    range.y <- ggplot_build(plot.out.PCoA)$layout$panel_ranges[[1]]$y.range 
    sts.anot <- list() 
    sts.anot[[1]] <-  annotate("label",  
                               x = min(range.x),  
                               y = max(range.y), 
                               hjust = 0.1, 
                               alpha = .4, 
                               fontface = "bold", 
                               fill = "white", 
                               label = paste0("Stress = ", stress.var)) 
    plot.out.PCoA <- plot.out.PCoA + sts.anot 
  } 
  #LIMIT EXTRACTION FOR DENSITY PLOT CONFIGURATION 
  #DENSITY PLOTS 
  if (exists("axis.density.opt") == FALSE) {axis.density.opt = FALSE} 
  if (axis.density.opt == TRUE){ 
    range.x <- ggplot_build(plot.out.PCoA)$layout$panel_ranges[[1]]$x.range 
    range.y <- ggplot_build(plot.out.PCoA)$layout$panel_ranges[[1]]$y.range 
    if (exists("axis.density.grp") == FALSE) {axis.density.grp <- grouping.var.ma
in} 
    if (exists("axis.density.col") == FALSE) {axis.density.col <- col.fill} 
    if (exists("axis.density.X") == FALSE) {axis.density.X <- axis.data.X} 
    if (exists("axis.density.Y") == FALSE) {axis.density.Y <- axis.data.Y} 
    xdensity <- ggplot(GG.data.in, aes(axis.density.X, y = ..scaled.., fill = axi
s.density.grp)) +  
      geom_density(alpha=.5) +  
      scale_fill_manual(values = axis.density.col) + 
      scale_x_continuous(limits = range.x, expand = c(0,0)) + themeBW.var + theme
.var + 
      scale_y_continuous(breaks = c(0,0.5,1.0), 
                         labels = c("     ","   0.5","   1.0")) + 
      theme(legend.position = "none",  
            axis.text.x = element_blank(), 
            axis.title.y = element_text(size = rel(0.8)), 
            panel.grid.minor = element_blank(), panel.grid.major = element_line(s
ize = rel(.5))) + 
      labs(x = NULL, y = "Density") 
    ydensity <- ggplot(GG.data.in, aes(axis.density.Y, y = ..scaled.., fill = axi
s.density.grp)) +  
      geom_density(alpha=.5) +  
      scale_fill_manual(values = c(axis.density.col)) + 
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      scale_x_continuous(limits = range.y, expand = c(0,0)) + themeBW.var + theme
.var + 
      scale_y_continuous(breaks = c(0.0,0.5,1.0), 
                         labels = c("","0.5","1.0")) + 
      labs(x = NULL, y = "Density") + 
      theme(legend.position = "none",  
            #TMP 
            axis.text.y = element_blank(), 
            axis.title.x = element_text(size = rel(0.8)),  
            panel.grid.minor = element_blank(), panel.grid.major = element_line(s
ize = rel(.5))) +  
      coord_flip() 
    blankPlot <- ggplot()+geom_blank(aes(1,1))+ 
      theme(plot.background = element_blank(),  
            panel.grid.major = element_blank(), 
            panel.grid.minor = element_blank(),  
            panel.border = element_blank(), 
            panel.background = element_blank(), 
            axis.title.x = element_blank(), 
            axis.title.y = element_blank(), 
            axis.text.x = element_blank(),  
            axis.text.y = element_blank(), 
            axis.ticks = element_blank(), 
            axis.line = element_blank()) 
    if (is.list(guide.var) == TRUE){ 
      if (is.null(guide.var) == FALSE){ 
        main.legend <- get_legend(plot.out.PCoA) 
      } 
    } 
    main.plot <- plot.out.PCoA + theme(legend.position = "none") 
    main.title <- ggdraw() + draw_label(tit.var, fontface = "bold", size = rel(20
)) 
    if (exists("fig.config") == FALSE){fig.config <- "traditional"} 
    if (fig.config == "traditional") { 
      panels.internal <- plot_grid(ncol = 2,  
                                   nrow = 2,  
                                   main.plot + theme(plot.title = element_blank()
),  
                                   ydensity, xdensity, NULL, rel_heights = c(1,0.
25,1), rel_widths = c(1,0.25,1)) 
      if (is.list(guide.var) == FALSE){ 
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        if (is.null(guide.var) == TRUE) { 
          panels.external <- panels.internal 
        } 
      } 
      if (is.list(guide.var) == TRUE){ 
        if (is.null(guide.var) == FALSE) { 
          panels.external <- plot_grid(main.legend, panels.internal, rel_widths =
 c(.1,1))  
        } 
      } 
    } 
    if (fig.config == "neat") { 
      if (is.list(guide.var) == FALSE){ 
        if (is.null(guide.var) == TRUE) { 
          panels.internal <- plot_grid(ncol = 2,  
                                       nrow = 2,  
                                       xdensity, 
                                       blankPlot, 
                                       main.plot + theme(plot.title = element_bla
nk()),  
                                       ydensity,  
                                       rel_heights = c(0.9,0.2), rel_widths = c(0
.9,0.2), 
 scale = c(1,1,1,20)) 
          panels.external <- panels.internal 
        } 
      } 
      if (is.list(guide.var) == TRUE) { 
        if (is.null(guide.var) == FALSE) { 
          panels.internal <- plot_grid(ncol = 2,  
                                       nrow = 2, 
                                       xdensity + theme(plot.margin = unit(c(0.5,
0,0,0),"lines")), 
                                       main.legend, 
                                       main.plot + theme(plot.title = element_bla
nk(), 
                                                         plot.margin = unit(c(0,0
,0,0),"cm")),  
                                       ydensity + theme(plot.margin = unit(c(0,0.
5,0,0),"lines")),  




                                       rel_heights = c(0.2,1.0), rel_widths = c(1
.0,0.2), scale = c(1,1,1,1)) 
          panels.external <- panels.internal 
        } 
      } 
    } 
    plot.out.d <- plot_grid(main.title, panels.external, ncol = 1, rel_heights = 
c(0.1, 1)) 
    plot.out.PCoA <- plot.out.d 
  } 
  return(plot.out.PCoA) 
}fdatish 
